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“Business Report 2002” and the “Financial Report 2002”.
Together, they constitute the reference document filed
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The ANDROMEDA study was stopped on 
January 16, 2003 on the advice of the independent
committee monitoring the tolerability data. 
This study evaluated the tolerability of dronedarone 
in high-risk patients suffering from serious heart failure. 
As of February 12, 2003, on the favorable
recommendation of the independent tolerability data
monitoring committees, the two pivotal efficacy studies
EURIDIS and ADONIS are continuing their evaluation of
dronedarone in patients with atrial fibrillation.
In accordance with the authorization granted by the
Annual General Meeting and the Board of Directors on
May 22, 2002 to purchase and sell the company's shares
in the light of market conditions, Sanofi-Synthélabo has
continued the share purchase plan initiated in 2002. 
As of February 28, 2003, this figure rose to 38.6 million
shares, 5.26% of the capital, of which 24.7 million shares
were acquired under the share purchasing plan.
Marketing approval granted by the U.S. health
authorities for Eligard 30 mg (“four month” formulation
of leuproreline acetate in subcutaneous injection) in the
treatment of advanced prostate cancer in February 2003.
Subsequent to filing in December 2002, the U.S. 
health authorities granted priority review to Arixtra“ 
in March 2003 for a new indication: the prolonged
prophylaxis of deep-vein thrombosis in patients who have
undergone hip fracture surgery.
Following publication by Bristol–Myers Squibb of its
restated consolidated financial statements for the years
1999 - 2002, Sanofi-Synthélabo confirmed on 
March 12, 2003 there were no changes in the Group
accounts, established in accordance with French
accounting principles, nor in the growth prospects
communicated on February 18, 2003. 
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The story began
Creation of Sanofi by Elf Aquitaine, through the takeover 
of the Labaz pharmaceutical company.
L’Oréal took over Synthélabo, created in 1970 by the merger
of two French pharmaceutical companies, Dausse 
(founded in 1834) and Robert & Carrière (founded in 1899).
Sanofi launched its first major product on the market:
Ticlid®.
Synthélabo launched two major products on the French
market: Stilnox® and Xatral®.
Synthélabo launched Stilnox® in the United States 
under the trade name Ambien®. As of 1994,
Stilnox®/Ambien® became the leading medicine in the
treatment of insomnia (IMS data).
Sanofi made a significant entrance into the U.S. 
market through the acquisition of Sterling Winthrop, 
the pharmaceutical unit of Eastman Kodak.
In 1997, Sanofi launched its first major product in the U.S.
market, Avapro®, followed by Plavix® in 1998.
Two leaders of the French pharmaceutical industry
At that time, Sanofi was the 2nd pharmaceutical group in
France, Synthélabo the 3rd. Sanofi was majority-held by Elf
Aquitaine, currently a subsidiary of TotalFinaElf and
Synthélabo was majority-held by L’Oréal.
The merger was decided at the end of 1998.
The year of the merger 
Following the merger, which took place on May 18, 1999,
the new Group refocused on its core business,
pharmaceuticals. Sanofi divested its non-strategic activities 
in the Beauty, Veterinary and Diagnostics businesses. 
TotalFinaElf and L’Oréal are the reference shareholders 
of the new group.
Strength through unity
Sanofi and Synthélabo combined their resources to expand
the presence of the new Group worldwide, notably in 
the U.S., and to concentrate R&D efforts on high-potential
products.
Over three years, the sales of the three flagship products,
Stilnox®/Ambien®/Myslee®, Plavix®/Iscover® and
Aprovel®/Avapro®/Karvea® progressed strongly. 
This strategy paid off, and today Sanofi-Synthélabo 
is the 2nd pharmaceutical group in France, 7th in Europe, 
and among the top 20 worldwide.
”The American years“
The expansion of the affiliate Sanofi-Synthélabo Inc., 
the doubling of the sales force, the contribution of the U.S.
market to Group sales and earnings - all these factors 
justified the decision to list company shares on 
the New York Stock Exchange on July 1, 2002. 
The U.S. health authorities granted six marketing approvals 
in 2002, confirming our strong presence in the world’s
leading pharmaceutical market.
Sanofi-Synthélabo celebrates its 30th anniversary
HISTORY IN THE MAKING
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Four areas of expertise
Sanofi-Synthélabo is specialized in four therapeutic areas
 Cardiovascular disease/Thrombosis
 Disorders of the Central Nervous System
 Internal Medicine 
 Oncology
Worldwide dimension 
Present in more than 100 countries.
In Europe, the Group has an affiliate in every country. 
In the United States, it operates through its affiliate, two alliances and licensing agreements. 
In Japan, its products are marketed via joint ventures and licensing agreements.
Innovative and productive R&D
52 compounds in development, including:
 23 in Phase II or III clinical trials
 29 in preclinical or Phase I clinical trials
Sanofi-Synthélabo’s R&D, focused on the Group’s key areas of expertise, is supported 
by state-of-the-art technology.
2ndpharmaceutical group in France
7thpharmaceutical group in Europe
among the top 20 pharmaceutical 
groups worldwide
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 2002 was a very good year. Which aspects of this
year were particularly important for you?
Without wishing to appear overly optimistic, I cannot deny
that we are satisfied with our performance in 2002. 
For several years now, we have posted sales growth well
into double-digits and this performance is reflected in our
profits. In 2002, our consolidated earnings per share rose
by 28.7% before exceptional items and goodwill
amortization, one of the highest growth rates within the
pharmaceutical industry, and we exceeded our objectives.
If we look back, we can see that our net profit has steadily
increased, practically tripling over the last three years.
This achievement is all the more remarkable in that 
the economic environment was far from favorable 
during the entire year.
In contrast to previous years, we were penalized by
fluctuations in foreign exchange rates. This cost us
2.5 points with regard to our consolidated sales growth.
In addition, we had to absorb the impact of the stock-
reducing measures taken by our U.S. partner Bristol-Myers
Squibb who distribute two of our flagship products, 
Plavix® and Avapro®, and which limited our sales in 
the U.S. despite a substantial increase in prescriptions. 
Finally, in common with the entire pharmaceutical industry, 
we continued to be affected by measures taken to curb
healthcare expenditure in Europe, and by the economic
crisis in Latin America.
Despite all these unfavorable factors, our sales progressed
by 14.8% on a reported basis, thanks to the performance
of our flagship products and also the taking back of rights
to Ambien® in the U.S. 
This shows that, even in challenging times, our company 
is capable of achieving its objectives and meeting 
its commitments to shareholders.
 Apart from the flagship products, 
how is the portfolio performing?
The growth rates of our flagship products, in terms of
developed sales on a comparable basis, are indeed
spectacular: +32% for Plavix®, +19% for
Aprovel®/Avapro®, +26% for Stilnox®/Ambien®/Myslee®;
but the wealth of our portfolio does not rest solely 
on their performance. 
Jean-François Dehecq
ALL the CONDITIONS
for our CONTINUED
GROWTH are met
“
”
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The year 2002 saw the launch of two new medicines
which are likely to become new flagship products within
the next few years. Arixtra® took off slowly due to its
restricted initial indication for the prophylaxis of deep-vein
thromboses following major orthopedic surgery, 
but its potential is considerable. Apart from its remarkable
efficacy, Arixtra® has the merit of being a 100% synthetic
product, a characteristic ensuring a high degree of purity
and safety. Its vocation is to replace current products of
animal origin, as that is the long-term trend observed in
the pharmaceutical industry. 
As for Eloxatin®, its clear therapeutic benefits led to its
approval in the U.S. within an exceptionally short time.
Four months after its launch, Eloxatin® had already 
attained sales of 116 million euros on the U.S. market 
and promises to become the reference treatment for
colorectal cancer worldwide.
 2001 was an “American” year. 
Did this effort pay off?
We were determined to succeed in penetrating the U.S.
market and we have achieved our objective. In 2002, 
sales of our products increased by 32% in the U.S.
according to the IMS, outperforming the market 
more than three-fold. We doubled our sales force in 2002,
following the taking back of full rights to Ambien® in April,
and launched four medicines during the year. In other
words, we are now firmly established in the U.S., 
the world’s leading pharmaceutical market. 
We took advantage of this economic visibility to apply 
for a listing of Sanofi-Synthélabo shares on the New York
Stock Exchange in July. 
 What about the Group’s global market presence?
Our international expansion has been rapid and, above all,
well balanced: our growth exceeds that of the market in
practically all countries worldwide. 
In Europe, we gained market share in all countries except
Italy, where severe measures taken by the health authorities
affected us considerably. 
WE were determined to
SUCCEED in penetrating
the U.S. MARKET, 
and we have ACHIEVED
our objective
“
”
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In other countries, our growth remained buoyant. In Japan,
our performance was bolstered by the launch of our hypnotic
Myslee® (zolpidem), ranking second in its market within 
two years. 
Today we enjoy direct presence in all markets worldwide,
with the exception of Japan, where we market our
products through joint ventures with major partners. 
We will continue to optimize these cooperative
agreements, while at the same time setting up 
our own marketing systems during the coming years.
This rapid international development justifies the priority
given to our R&D: our patented products and new
compounds provide the momentum driving our expansion.
 Certain observers have criticized Sanofi-
Synthélabo for its lack of visibility in the medium
term. How strong is the R&D pipeline?
With 52 compounds in development in our research
portfolio, including 23 in an advanced phase and 9 new
compounds entering development in 2002, we possess
quite a remarkable pipeline, particularly for a company 
of our size. Of course, not all these products will reach 
the market, but if we simply apply the statistics of the
pharmaceutical industry, we have a very good chance 
of being able to submit new filings for innovative
medicines in the medium term.
Our R&D is our strength, and our earnings enable us to
pursue our efforts. In 2002, our R&D expenditure once
again increased by almost 20% at comparable exchange
rates. Relative to our size, our R&D portfolio is one of the
most fertile in the pharmaceutical industry. All our major
compounds, Plavix®, Aprovel®, Arixtra®, Eloxatin®, Xatral®
and Ambien®, benefit from an intense Life Cycle
Management program designed to extend their clinical
indications and boost sales. We also ensure the
development of a backup compound as a potential
successor for each major product. 
These efforts have paid off. In 2002, we experienced an
exceptional year with six new marketing approvals in 
the U.S., representing a remarkable performance in an
environment where – as all pharmaceutical companies
agree – it is more and more difficult to obtain marketing
approval for new products.
 How do you view the current environment of the
pharmaceutical industry, the rise of generics and,
in particular, the generic challenges to Plavix®? 
In 2002, the pharmaceutical industry was affected by 
an uncertain economic environment worldwide. It also
suffered, for the first time in its history, from the impact 
of loss of patent protection for medicines with sales
amounting to several billion dollars, and the increasing
number of attacks on the patents of medicines marketed 
OUR R&D portfolio
is one of the  
MOST FERTILE 
“
”
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in the U.S.. In addition, the efforts of various countries 
to curb their healthcare expenditure show no sign of 
diminishing and this policy naturally favors generics.
As regards Plavix®, which has been challenged by two
generic manufacturers, legal action is still continuing. 
We have full confidence in the strength of Plavix® patents.
With respect to generics, it is clear that we cannot hope 
for profitable prices for new innovative products without
the development of low-cost generics for products which
are no longer protected by patents. Our portfolio of new
products certainly shows that we are less affected by 
this situation than some of our competitors.
 What are your prospects for 2003?
Barring major adverse events, our prospects remain
excellent for 2003. We expect to see continued double-
digit growth of the same order of magnitude as that
registered in 2002 and, assuming one-to-one parity
between the euro and the dollar, a growth in consolidated
earnings close to 20% per share before exceptional items
and goodwill amortization. 
In the longer term, all the conditions for our continued
growth are met and our strategic products will sustain 
their progression. 
The pharmaceutical industry will remain a sector where
innovation takes precedence over all other factors. 
The industry will continue to experience strong growth in
the long term, in view of the currently unmet therapeutic
needs, the progressive aging of the world’s population, 
the increasing demand in industrial countries and 
the necessity to find ways of facilitating access to
medicines in the countries of the southern hemisphere.
These are the challenges that the worldwide
pharmaceutical industry must face. As far as we are
concerned, at this start of 2003, the year in which 
we celebrate our 30th anniversary, all the Group’s
employees are ready and determined to meet them.
The INDUSTRY
will continue to experience
STRONG GROWTH
in the LONG TERM
“
”
Jean-François Dehecq
Chairman and Chief Executive Officer
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Our business activity
Consolidated sales(2)
(in millions of euros)
Developed sales*(2)
(in millions of euros)
Consolidated sales(2)
of the three flagship products
(in millions of euros)
Developed sales*(2)
of the three flagship products 
(in millions of euros)
Consolidated sales(1) by geographic area 
EUROPE
+11.8%
Developed sales*(1) by geographic area
57.7%
19.6% 22.7%
45.6%
17.8%
36.6%
2002 Consolidated sales: 7,448 million euros
+12.8% on a comparable basis(1) and +14.8% on a reported basis
2002 Developed sales: 9,585 million euros
+14.5% on a comparable basis(1)
OTHER COUNTRIES
+10.3%
UNITED STATES
+17.5%
OTHER COUNTRIES
+14.9%
UNITED STATES
+18.5%
EUROPE
+11.4%
2000 5,963
2001 6,488
2002 7,448
2000 7,508
2001 8,746
2002 9,585
Plavix®
Aprovel®/
Avapro®
Stilnox®/
Ambien®/
Myslee®
Plavix®
Aprovel®/
Avapro®
Stilnox®/
Ambien®/
Myslee®
2000 1,279
2001 2,033
2002 2,587
2000 665
2001 924
2002 1,068
2000 920
2001 1,215
2002 1,455
2000 437
2001 705
2002 987
2000 300
2001 423
2002 562
2000 582
2001 786
2002 1,424
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Our earnings Our resources
Consolidated sales by therapeutic area
(in millions of euros)
Operating profit
(in millions of euros)
Research & Development expenditure 
(in millions of euros)
2000
2001
2002
Net profit attributable to the Group 
before exceptional items and
goodwill amortization
(in millions of euros)
Operating profit by geographic area 
(excluding non-allocated costs: 1,322 million euros)
Global workforce: 32,436 people
by geographic area
at December 31, 2002
66.2%42%
13%
45%
22.7%
11.1%
Employees by activity
at December 31, 2002
20.5% 34%
20.7%
24.8%
ONCOLOGY
404
OTHER
304
4
.1
%
39.0%
32.3%
19.2%
5.4%
Another year of strong growth for Sanofi-Synthélabo,
with sales up throughout the world, continued growth
of major strategic products and net earnings which have
almost tripled in three years.
*Developed sales include sales consolidated by Sanofi-Synthélabo, plus sales
generated under the agreements with Bristol-Myers Squibb on
Plavix®/Iscover® (clopidogrel) and Aprovel®/Avapro®/Karvea® (irbesartan),
with Fujisawa on Myslee® (zolpidem), with Pharmacia on Ambien®
(zolpidem) for 2000 and 2001 figures, with Organon on Arixtra®
(fondaparinux sodium), as they have been communicated to us 
by our partners.
(1) Change on a comparable basis, at constant group structure 
and exchange rates
(2) On a reported basis
OTHER COUNTRIES
+15%
OTHER COUNTRIES
7,363
OTHER
6,660
PRODUCTION
8,043
INTERNAL MEDICINE
1,427
CENTRAL NERVOUS SYSTEM
2,409
UNITED STATES
+36%
EUROPE
+14%
UNITED STATES
3,595
MARKETING/
SALES FORCE
11,015
RESEARCH
AND DEVELOPMENT
6,718
EUROPE INCLUDING FRANCE
21,478
CARDIOVASCULAR/THROMBOSIS
2,904
1,577
2,106
2,614
945
1,031
1,218
2000
2001
2002
961
1,376
1,758
2000
2001
2002
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Providing a return on investment to shareholders through 
strong and steady growth in profits and in the dividend, 
and raising the share profile in the world's great financial markets:
in 2002 Sanofi-Synthélabo achieved these two essential strategic
objectives. 
 2002 unfolded in a difficult stock market climate, marked by geopolitical uncertainties
and a strong downtrend across all equity markets. At the start of the year, 
Sanofi-Synthélabo shares were affected by the announcement of the U.S. filing
of two abbreviated new drug applications (aNDA) for generic versions of Plavix®.
 Sanofi-Synthélabo made its entrance on the New York Stock Exchange (NYSE) 
on July 1, 2002. 
Dictated by the growth of the Group in the United States, where 45% of its operating
profit is now generated, this decision raises the Group's financial profile in America 
to the height of its commercial reputation. It facilitates access to the share for many more
investors in the world's leading financial market. 
Sanofi-Synthélabo shares are listed on the NYSE in the form of American Depositary
Receipts (ADRs), each representing half a share. Because no new shares were issued 
at the time of the listing, the listing had no impact on earnings per share. 
A N O F I - S Y N T H E L A B O
S T O C K  E X C H A N G E  I N F O R M AT I O N
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Sanofi-Synthélabo shares are included in the main
benchmark indices:
 The CAC 40 French pan-sector index
 The Dow Jones Euro Stoxx 50
European pan-sector index 
 The Dow Jones Stoxx Pharma
European sector index
 The NYSE International 100 
American pan-sector index 
 The NYSE World Leaders 
American pan-sector index
Share particulars
Par value of the share: 2 euros
Trading: continuous, eligible for the SRD 
deferred settlement service in Paris 
and for PEA share savings schemes
Euroclear France code: 12057
ISIN code: FR0000120578
NYSE listing code: SNY
Euronext Paris listing code: SAN
Reuters code: SASY.PA
Bloomberg code: SNYNF
Trends in the share price
220
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100
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2000 2001 2002
75
July
2002 
August
2002
September
2002  
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2002
November
2002
December
2002
80
85
90
95
105
110
100
Sanofi-Synthélabo in Paris on the Euronext Premier Marché 
Base 100 at December 30, 1999
Sanofi-Synthélabo on the New York Stock Exchange 
Base 100 at June 28, 2002
Sanofi-Synthélabo
STOXX Pharma
SNY
DOW JONES
CAC 40
Euro STOXX 50
Monthly volume 
of shares
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* Based on the total number of voting rights published following the Annual General Meeting of May 22, 2002, i.e. 1,064,540,103
** Shares held through Sanofi-Synthélabo's company share savings plan mutual fund. 
TotalFinaElf and L'Oréal have entered into a shareholders' agreement for an initial term of six years commencing
December 2, 1998 (see Financial Report, page 105)
PUBLIC
50.75%
EMPLOYEES**
1.36%
TREASURY SHARES
0%
EMPLOYEES**
1.05%
S T O C K  E X C H A N G E  I N F O R M AT I O N
Share ownership
 As of December 31, 2002, the share capital of Sanofi-Synthélabo amounted to 1,464,735,014 euros, divided into
732,367,507 shares with a par value of 2 euros.
 As of December 31, 2002, Sanofi-Synthélabo held 30.4 million of its own shares, representing 4.15% of the capital, of which
16.4 million shares (2.24% of the capital) were acquired in the light of market conditions in accordance with the authorization
granted by the Annual General Meeting and the Board of Directors on May 22, 2002, and 14 million shares (1.91% of the capital)
intended for stock option purchase plans. As of February 28, 2003, the total number of shares held by the company rose to 
38.6 million shares (5.26% of the capital). (see Financial Report, page 106)
Shares Voting rights*
Ownership of Sanofi-Synthélabo shares as of December 31, 2002
Shareholder information at a glance
Sanofi-Synthélabo provides a return for shareholders through the steady growth in its consolidated net income, 
coupled with a payout ratio of about 35%.
1999 2000 2001 2002
Number of shares as of December 31 731,143,218 731,441,746 732,005,084 732,367,507
Share price (in euros)
• High 46.35* 71.00 86.50 84.30
• Low 34.72* 34.70 52.60 49.78
• Last 41.34 71.00 83.80 58.25
Market capitalization as of December 31
(in millions of euros)
30,225 51,932 61,342 42,660
Ranking in CAC 40 
by market capitalization 15 8 4 3
* From May 25, 1999
PUBLIC
38.03%TOTALFINAELF
24.52%
TOTALFINAELF
33.74%
L’OREAL
26.87%
L’OREAL
19.53%
TREASURY SHARES
4.15%
A N O F I - S Y N T H E L A B OS
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Information on the company's prospects is based on estimates regarded as realistic by the company as of the date of publication. Fulfillment of such estimates 
is subject to the risks and uncertainties of the markets, and may be considerably affected by a number of factors, including the success of research and development
programs, the company's ability to defend its intellectual property rights, the intensity of competition, governmental constraints or the occurrence of litigation.
Investors and holders of securities issued by the company may obtain free copies of documents filed by Sanofi-Synthélabo with the Commission 
des Opérations de Bourse in France at www.cob.fr and with the Securities and Exchange Commission in the U.S. at www.sec.gov, or directly from 
Sanofi-Synthélabo at www.sanofi-synthelabo.com. 
(1) Before exceptional items and goodwill amortization
(2) Pro-forma data
(3) To be proposed at the Annual General Meeting on May 19, 2003
(4) In accordance with ordinary law, coupons detached from the company's shares become time-barred five years from the date they fall due for payment.
Dividends invalidated by the five-year rule are forfeited to the State.
(5) In the case of individual shareholders, 50% of the net dividend. For corporate shareholders, the tax credit rate has been progressively reduced in the last
three years. It was 40% in 1999, 25% in 2000, 15% in 2001, and 10% in 2002.
(6) Means the sum of the net dividend and the tax credit in the case of individual shareholders.
(7) Based on a tax credit of 50% and on the most recent share price (Euronext Paris).
Outlook for 2003
Barring major adverse events and assuming an exchange rate of 1 euro to the dollar, Sanofi-Synthélabo’s 2003 sales figures 
point to continuing strong growth in earnings per share of around 20% (before exceptional items and goodwill amortization).
The factors supporting this growth will be:
 growth in consolidated net sales comparable with the 2002 figure;
 anticipated good performance of the three flagship products: Plavix ®, Aprovel ®, Stilnox ®;
 development of Eloxatin® sales in the U.S. after launch in August 2002
 continued good performance of the rest of the portfolio, in particular Depakine ®, Solian ® and Xatral ®.
Research and Development efforts will continue at a high level, notably through the Phase III clinical trials on rimonabant,
dronedarone, idraparinux and zolpidem MR. The strong R&D portfolio, along with sound positions for all products, give 
the Group confidence in its ability to develop its business activities and its earnings. 
Consolidated earnings(1) per share (in euros) Net income payout ratio(1) (%)
Net dividend per share (6) (in euros) Total rate of return (7)
0.32
0.16
0.66
0.33
0.84(3)
0.42
1999 2000 2001 2002
0.22
0.44
0.48
0.99
1.26
0.66
Total return(4)
Tax credit (5)
0.851999 (2)
1.312000
1.882001
2.422002
37.41999 (2)
33.62000
35.12001
34.7 (3)2002
1.161999 (2)
0.932000
1.182001
2.162002
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Group publications 
Sanofi-Synthélabo has the following documents available
on request. They are also posted on its website: 
 All press releases,
 The Annual Report, given out to shareholders attending
the Annual General Meeting, which has reference
document status with the COB (Commission des
Opérations de Bourse) for 2002, and the interim report,
 The U.S. Form 20-F, filed with the SEC (Securities and
Exchange Commission),
 Presentations to financial analysts, institutional investors
and journalists on publication of earnings,
 The Letter to Shareholders, sent to all registered
shareholders at least every six months,
 The Shareholder's Guide, available from mid-2003,
 The financial calendar.
Our website
www.sanofi-synthelabo.com
Set up in 1999, the Sanofi-Synthélabo website 
at www.sanofi-synthelabo.com contains all the information
required to find out about and monitor the activities of the
Group: a description of the main research areas, progress
reports on clinical trials, sales trends, etc. 
Go to the "Finance" section to consult the full range of 
financial and stock market data needed by investors (share 
prices, capital, reports, etc). Items are regularly updated. 
The Group's various publications are available on-line, 
as are audio webcasts concerning financial information.
From the "Finance" section it is also possible to:
 communicate directly with the Investor Relations 
department by e-mail,
 order the Group's financial publications.
H A R E H O L D E R  I N F O R M A T I O NS
On the corporate website, 
you can e-mail directly to the Investor
Relations Department and order 
all the Group’s financial publications..
Sanofi-Synthélabo believes in the need for transparent communication,
and regularly provides comprehensive and easily-accessible
information to individual and institutional shareholders, analysts
and journalists. Corporate Communications, based in Paris, 
has a network of communication managers in more than 
40 countries. The Investor Relations department, based in Paris 
and now with a branch in New York, doubled its staff in 2002. 
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Finding out more 
about the Group 
For individual shareholders, the Annual General Meeting 
is an opportunity to find out about the Group's strategy.
Once a year, before the Annual General Meeting, 
Sanofi-Synthélabo sends shareholders a questionnaire 
so that they can give their opinions on issues that 
are of concern to them and suggest subjects for inclusion
on the agenda of the Annual General Meeting. This regular
procedure enables shareholders to play an active role 
in the life of the Company if they wish to. 
Information meetings for institutional investors, financial
analysts and journalists take place twice a year in Paris and
London when full-year and interim results are published. 
Sanofi-Synthélabo meets institutional investors throughout
the year by organizing road shows, notably in the United
States and Europe.
Wednesday, January 22 n Press release: 
2002 sales
Tuesday, February 18 n Press release: 
2002 earnings
Thursday, April 24 n Press release: 
2003 first-quarter sales
Monday, May 19 n Annual General Meeting
Wednesday, July 23 n Press release: 
2003 first-half sales
Tuesday, September 2 n Press release: 
2003 first-half earnings
Wednesday, October 22 n Press release: 
2003 9-month sales
Financial 
calendar 
for 2003:
Contacting the Group
If you are individual shareholders institutional investors journalists
or analysts
By telephone toll-free: +33 800 07 58 76
Paris: +33 1 53 77 45 45
Paris: +33 1 53 77 40 76 
New York: +1 212 551 42 93
By fax +33 1 53 77 42 96
Paris: +33 1 53 77 42 96
Paris: +33 1 53 77 41 74
New York: +1 212 551 49 10
Sanofi-Synthélabo Sanofi-Synthélabo Sanofi-Synthélabo
Investor Relations Investor Relations Media Relations 
By mail
Department
r
Department
r
Department
174 Avenue de France 174 Avenue de France 174 Avenue de France
75013 Paris 75013 Paris 75013 Paris
90 Park Avenue
New York, NY 10016
By e-mail relations-actionnaires@sanofi-synthelabo.com investor-relations@sanofi-synthelabo.com media-relations@sanofi-synthelabo.com
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The Board of Directors
As of December 31, 2002, the Board of Directors 
is composed of 12 members: 
 the Chairman and Chief Executive Officer,
 four directors proposed by TotalFinaElf and four directors
proposed by L’Oréal (reference shareholders), 
 three independent directors. 
The appointment of a new independent director, 
Mr Gérard Van Kemmel, President for Europe, 
Middle East and Africa at Novell will be submitted 
for ratification at the Annual General Meeting of
shareholders on May 19, 2003.
Directors are appointed for a period of five years.
Appointments are renewed by rotation. The number 
of directors over 70 years old cannot exceed a third 
of the directors in office. 
According to the bylaws, each director must be the legal
owner, in his/her own right, of at least one share
throughout his/her term of office. As of December 31, 2002,
individual Board members held a total of 273,756 shares. 
 In accordance with the law of May 15, 2001 on the new economic regulations, 
the statutes of the company were modified at the Annual General Meeting on 
May 22, 2002, so that the Board of Directors could decide whether or not the 
functions of Chairman of the Board and Chief Executive Officer should be separated.
At its meeting on May 22, 2002, the Board of Directors decided that these two functions
should not be separated and Jean-François Dehecq was appointed Chairman and Chief
Executive Officer.
 As proposed by the Chairman and Chief Executive Officer, the Board of Directors appointed
Gérard Le Fur Senior Executive Vice President at its meeting on December 11, 2002.  
O R P O R A T E  G O V E R N A N C EC
Since the merger in May 1999, the Board of Directors 
of Sanofi-Synthélabo has set up three specialist committees
entrusted with advising and assisting the Board in its decisions. 
It has adopted a charter defining the rights and duties of Board
members, along with committee composition and functioning.
K e y  e v e n t s  i n  2 O O 2
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Board of Directors:
Directors:
 René Barbier de la Serre, aged 62
Director ! from May 1999 to 2004
Director of Crédit Lyonnais and Schneider Electric
Member of the Supervisory Board of Compagnie
Financière Saint Honoré and Pinault-Printemps-Redoute
 Robert Castaigne, aged 56
Director from February 2000 to 2004 
Chief Financial Officer, TotalFinaElf SA
Chairman and Chief Executive Officer, Total Chimie 
and Total Nucléaire
Director of Atofina, Compagnie Générale 
de Géophysique and Elf Aquitaine
 Pierre Castres Saint Martin, aged 67
Director from May 1999 to 2004
Chairman of the Supervisory Board 
of Groupe Marc de Lacharrière
Director of Fimalac and SEB
 Jean-François Dehecq, aged 63
Director from May 1999 to 2004 
Chairman and Chief Executive Officer, Sanofi-Synthélabo
Director of Air France and Péchiney
 Thierry Desmarest, aged 57
Director from February 2000 to 2004 
Chairman and Chief Executive Officer,
TotalFinaElf SA and Elf Aquitaine 
Member of the Supervisory Board 
of AREVA and L'Air Liquide
 Lord Douro, aged 57
Director ! from May 2002 to 2007
Chairman, Richemont Holdings UK (United Kingdom)
Chairman, Framlington Group (United Kingdom)
 Elf Aquitaine
Director from May 1999 to 2004
Represented by Jean-Paul Léon, aged 65
 Pierre-Gilles de Gennes, aged 70
Nobel Prize for Physics (1991)
Director ! from May 1999 to 2004
Director of the Ecole Supérieure de Physique 
et de Chimie Industrielles de Paris
Director of Rhodia
 Hervé Guérin, aged 61
Director from May 1999 to 2004
Chairman of the Supervisory Board of Human Health
Investments (H2i)
 L'Oréal
Director from May 1999 to 2004
Represented by Michel Somnolet, aged 63
Vice-President, General Management, 
Administration and Finance, L'Oréal
Director of L’Oréal
 Lindsay Owen-Jones, aged 57
Director from May 1999 to 2004
Chairman and Chief Executive Officer, L’Oréal
Director of BNP Paribas and Gesparal
Vice President and member of the Supervisory Board 
of L’Air Liquide
 Bruno Weymuller, aged 54
Director from May 1999 to 2004
Executive Vice President, Strategy and Risk Assessment,
Total Fina Elf SA
Director of Elf Aquitaine
Observers: 
participating in the meetings of the Board with 
a consultative role
 Régis Dufour
 René Sautier
All the appointments and functions of the members of the Board of Directors
and of the Senior Executive Vice President in companies in France and elsewhere,
during the financial year 2002, are detailed in the Management Report.
! Independent director
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Activity of the Board 
of Directors in 2002
In 2002, the Board of Directors met four times, 
with an overall attendance rate of directors above 80%.
The meeting agendas principally focused on the following
points:
 February 18, 2002:
. review of consolidated and parent company 
financial statements,
. allocation of profits,
. management report,
. notice to the Annual General Meeting,
. planned 100% incorporation of affiliates,
. planned listing on the New York Stock Exchange (NYSE).
 May 22, 2002: 
. Management organization,
. appointment of Lord Douro (independent director) 
to the audit committee, 
. delegations to the Chairman and Chief Executive Officer,
. stock option plan,
. decision to apply for listing of the Company on the NYSE.
 August 30, 2002:
. review of financial statements for the first 
half of 2002,
. review of progress in Research and Development programs,
 December 11, 2002: 
. appointment of a Senior Executive Vice President,
. forecast for the financial year 2002,
. review of the budget for 2003,
. compensation of corporate officers, 
. pensions plan.
Compensation of directors  
The compensation paid to Board members in 2002 
consisted exclusively of attendance fees (1): the attendance
fees paid to each Board member in 2002, which were
allocated to them in the financial year 2001, amounted to
365,500 euros. The attendance fees paid to each Board
member in 2002 are detailed in the Management Report.
(Financial Report 2002, page 14)
Attendance fees allocated to Board members for 
the financial year 2002 amounted to 456,250 euros.
(1) apart from the compensation of the Chairman and Chief Executive
Officer detailed below, page 21.
Specialist committees 
Since 1999, the Board of Sanofi-Synthélabo has set up 
specialist committees entrusted with assisting the Board in its
deliberations and decisions. Their members are chosen from
among the directors and appointed by the Board.
Audit committee  
The audit committee currently comprises:
 René Barbier de la Serre !
 Lord Douro !
 Michel Somnolet
 Bruno Weymuller
The audit committee, entrusted with continuously evaluating
the application and efficacy of the company's financial
control and risk assessment procedures, is specifically
responsible for examining:
. annual financial statements and interim financial statements
for the first half of the year,
. control procedures,
. the appropriateness of accounting policies,
. internal audit programs and actions,
. the annual report of major litigations,
. any issue likely to have a material financial or accounting impact,
. proposed appointments of statutory auditors.
The committee can undertake any visits and interviews
relevant to the accomplishment of its assignments. It may
ask to interview those involved in the preparation and
control of financial statements, in particular the statutory
auditors.
The audit committee met five times during 2002. 
The meeting agendas principally focused on the following
points:
 February 18, 2002:
. review of consolidated and parent company 
financial statements,
. proposed dividend,
. planned listing on the New York Stock Exchange
 March 11-12, 2002:
. presentation of the note of reconciliation of the financial
statements with US GAAP in preparation for listing on the
New York Stock Exchange,
. first draft of the Form 20F required by the Securities and
Exchange Commission.
O R P O R A T E  G O V E R N A N C EC
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 May 16-17, 2002:
. presentation of the final version of the Form 20F,
. timetable for listing operations
 August 29, 2002:
. review of interim financial statements for the first half 
of 2002,
. update on exchange risk management and examination 
of off balance sheet commitments.
 December 5, 2002:
. organization and functioning of internal audit, 
. presentation of the procedure for preparing the Group’s
financial statements for 2002,
. statutory auditors' fees and duties.
Compensation and appointments committee 
As of December 31, 2002, this committee comprises:
 René Barbier de la Serre !
 Thierry Desmarest
 Lindsay Owen-Jones
The role of the compensation and appointments 
committee is to:
. formulate recommendations and proposals concerning
the compensation of corporate officers and the granting
of options to purchase or to subscribe for shares,
. examine the allocation of attendance fees between the
directors and, where appropriate, observers,
. assist the Board in selecting new directors,
. advise the Chairman on the selection of key senior 
executives and their compensation.
The compensation and appointments committee met three
times during 2002. 
The meeting agendas principally focused on the following
points:
 February 18, 2002:
. establishment of attendance fees,
. special report on stock options.
 May 22, 2002:
. proposed stock option plan and granting of stock options.
 December 11, 2002 :
. the issues of independent directors, appointment of a
Senior Executive Vice President and company organization,
. compensation of the Chief Executive Officer, the Senior
Executive Vice President and the principal senior executives, 
. pensions plan.
Scientific committee
As of December 31, 2002, the Scientific committee 
comprises:
 Pierre-Gilles de Gennes !
 Jean-François Dehecq.
The role of the Scientific committee is to:
. inform the Board of technological advances likely to have
an impact on the Company's activities,
. provide advice on Research and Development orientations,
. contribute to solving any technical problem confronting
the Company.
The Scientific committee met on October 28, 2002 
and reviewed all the Group's Research and Development
programs.
Directors' Code
Sanofi-Synthélabo has drawn up a code for directors specifying the rights and duties of the members of the Board 
and its committees.
 The Board requires that, over and above the obligations contained in the bylaws, each director must hold at least five hundred
Company shares.
 When a director attends and votes at Board meetings, he/she represents all the shareholders and must act 
in the Company's corporate interests.
 Each Director must make every effort to attend meetings of the Board and of any committees of which he/she is 
a member. He/she must devote the necessary time to examining the matters submitted to him/her.
 Each Director must inform the Board of any conflict of interest, even potential, and may not become involved personally
in undertakings competing with Sanofi-Synthélabo without first informing the Board and obtaining its authorization.
 Each Director must abstain from trading in the Company's shares if he/she possesses insider information.
Considering the listing of Sanofi-Synthélabo on both the Paris and New York stock exchanges, the charter governing 
the Board and its committees is being revised to take into account changes in corporate governance regulations in France
and in the U.S. (Bouton report, Sarbanes Oxley Act).
! Independent director 
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Jean-François Dehecq
Chairman and Chief 
Executive Officer
Nicole Cranois
Senior Vice President
Corporate Communications
Jean-Pierre Kerjouan
General Counsel
Senior Vice President
Legal Affairs
Jean-Claude Leroy
Senior Vice President
Strategy
Jean-Claude Armbruster
Senior Vice President
Corporate Human
Resources
Gérard Le Fur
Senior Executive 
Vice President 
Executive Vice President
Scientific AffairsHanspeter Spek
Executive Vice President
Operations 
Marie-Hélène Laimay
Senior Vice President
Chief Financial Officer
Pierre Lepienne
Executive Vice President 
Corporate Affairs
Gilles Lhernould
Senior Vice President
Industrial Affairs
Christian Lajoux
Senior Vice President
Europe
Gordon Proctor
Senior Vice President
Intercontinental
X E C U T I V E  C O M M I T T E EE
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The compensation of the Chairman and Chief Executive Officer,
the Senior Executive Vice President, and the other members
of the Executive Committee is set after taking into
consideration the practices of the leading French 
and European industrial companies and the opinion 
of the compensation and appointments committee.
In addition to base compensation, Executive Committee members
receive variable compensation, which is determined by the
actual performance and growth of the business areas for
which the manager concerned has responsibility. This variable
compensation may reach over half the base compensation.
Stock options may be granted in addition to compensation.
The total compensation paid to the twelve members of the
Sanofi-Synthélabo Executive Committee during the financial
year 2002 was 7.5 million euros, including 1.9 million euros for
the Chairman and Chief Executive Officer (base compensation:
0.9 million, variable compensation: 1 million) and 
1.3 million euros for the Senior Executive Vice President
(base compensation: 0.64 million, variable compensation: 
0.68 million). 
On May 22, 2002, the Board of Directors of Sanofi-Synthélabo
granted 3,111,850 share purchase options to 1,162 beneficiaries
at a price of 69.94 euros per share. These beneficiaries included
the twelve members of the Executive Committee of Sanofi-
Synthélabo who received a total of 423,000 options of which
145,000 were granted to the Chairman and Chief Executive
Officer and 70,000 to the Senior Executive Vice President.
Each option entitles the holder to purchase one share. These
options can be exercised on or after May 23, 2006.
As of December 31, 2002, the members of the Executive
Committee held 1,848,000 options to purchase or to subscribe
for shares, of which 530,000 were held by the Chairman and
Chief Executive Officer and 287,000 by the Senior Executive
Vice President (see summary table below). 
Additional information concerning the option plans to
purchase or to subscribe for shares, in accordance with the
Commission des Opérations de Bourse regulations, is provided
in the 2002 Financial Report, under “financial, administrative
and legal additional information” - administration and
management bodies - stock options page 109.
Compensation of Executive Committee members 
and attribution of stock options
Current options to purchase or to subscribe for shares*
Options granted
Date of plan(s) 1993 1994 1995(1) 1996(1) 1997 1998 1999 2000 2001 2002 TOTAL
Total number
364,000 379,600 1,498,000 1,492,800 1,382,080 1,496,400 716,040 4,292,000 2,936,500 3,111,850 17,669,270of options granted
- Executive Committee 0 - 268,560 158,000 236,000 247,200 36,400 472,000 431,000   423,000 2,272,160
- of which J.-F. Dehecq - - 44,000 44,000 60,000 80,000   - 160,000 145,000   145,000 678,000
- of which  G. Le Fur - - 26,400 26,400 32,000   40,000   - 75,000 70,000   70,000 339,800
Expiry date 12/2013
10/2014 09/2002 09/2003 09/2004 12/2005 
03/2019 05/2010 05/2011 05/2012
to 12/2014 to 12/2015 to 04/2016 to 10/2017 to 06/2018
Purchase/ 
6.36
5.86 8.50 8.56 19.73 28.38 
38.08 43.25 64.5 69.94subscription price (in €) to 6.1 to 10.26 to 14.56 to 21.46 to 34.95
Options exercised in 2002
Date of plan(s) 1993 1994 1995(1) 1996(1) 1997 1998 1999 2000 2001 2002 TOTAL
Number of options
3,000 45,000 399,316 180,802 205,380 13,520 NA NA NA NA 847, 018exercised in 2002
- Executive Committee 0 0 31,500 24,400 60,000 0 NA NA NA NA 115,900
- of which J.-F. Dehecq - - 0 0 60,000 0 NA NA NA NA 60,000
- of which G. Le Fur - - - - - - - NA NA NA 0
Number of options
10,400 25,000 63,600 704,055 1,133,100 1,468,880 710,320 4,225,600 2,907,900 3,102,650 14,351,505outstanding
- Executive Committee 0 0 22,000 46,400 170,000 247,200 36,400   472,000   431,000   423,000 1,848,000
- of which J.-F. Dehecq - 0 - 0 0 80,000 - 160,000   145,000   145,000 530,000
- of which G. Le Fur - - - - 32,000 40,000 - 75,000   70,000   70,000 287,000
(1) In 1995 and 1996, there were option plans both to purchase shares and to subscribe for shares.
(2) Including 514,925 subscription options and 13,836,580 purchase options.
* Plans for which options were exercised during 2002, including those closed during the year
(2)

 Research and Development: 
sustained momentum
 Medicines: 
our portfolio gets stronger and stronger
 Global development: 
strong international presence
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The discovery of innovative medicines has been the source of 
the Group's expansion during the past 30 years, backed by more
than 6,700 Sanofi-Synthélabo R&D staff and a budget of over 
1 billion euros. Cardiovascular Disease/Thrombosis, disorders 
of the Central Nervous System, Oncology and Internal Medicine:
the Group's areas of expertise represent major public health
challenges. The Group's R&D efforts also encompass certain 
rare but severe diseases.
4 products in the field of Oncology registered in the United States
2 major extensions of indications in the U.S.
and in Europe for two flagship products, Plavix® and Aprovel®
9 new compounds in clinical development
52 products in development, 
including 23 at an advanced stage
In 2002, Sanofi-Synthélabo saw a significant increase in
the number of new clinical trials intended to support
marketing approval submissions for its compounds at an
advanced stage of development (Phase III), and to obtain
extensions in the indications of its marketed products
K e y  e v e n t s  i n  2 0 0 2
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Preclinical Phase I Phase IIa Phase IIb Phase III Launched / LCM
SSR 126517 
SSR 128429
SSR 182289
SR 123781
SSR 149744
SL 65.0472
SR 121463
dronedarone
idraparinux 
Arixtra®
Aprovel®
Plavix®
SSR 125047
SSR 125543
SSR 149415
SSR 180575
SSR 240612
SSR 411298
SSR 482073
SSR 146977
SSR 181507
SSR 591813
SR 57667
SR 57667 SL 65.0155
SR 58611
SL 65.1498
eplivanserin
osanetant
saredutant
xaliproden
rimonabant
zolpidem MR
Stilnox®
SSR 97193
SSR 126768
SSR 150106
SSR 161421
SSR 240600
SSR 241586
SSR 125180
SSR 125329
SR 146131
SR 147778
SR 48692
SR 140333
saredutant
rimonabant
fumagillin
pleconaril
Xatral® OD
SSR 250411
SR 271425
CEP7055
SR 48692
IDD3
SR 31747
tirapazamine
Eloxatin®
Fasturtec®
Cardio-
vascular/
Thrombosis
Central
Nervous
System
Oncology
Internal
Medicine
Research and Development portfolio in 2002
As of January 31, 2003
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New submissions 
and marketing approvals 
in 2002
In 2002, Sanofi-Synthélabo's Research and Development
efforts in its four areas of expertise culminated in the filing
of four new marketing approval submissions in the United
States, Europe and Japan, the granting of four marketing
approvals in the U.S. and one in Europe, and two major
extensions of indication in the U.S. and Europe.
CARDIOVASCULAR / THROMBOSIS
Arixtra®
fondaparinux sodium
Following the United States in December 2001 and Europe
in March 2002, over 30 countries, including Australia,
Canada, Brazil, South Korea and Switzerland have
authorized the marketing of Arixtra® for the prevention 
of deep-vein thrombosis and pulmonary embolism
following major orthopedic surgery.
An application for extension of the indication to prolonged
prophylaxis of deep-vein thrombosis and pulmonary
embolism after hip fracture was filed in December 2002 
in the U.S. and Europe.
Plavix®
clopidogrel
An extension of the indication to include acute coronary
syndrome was granted in the U.S. in February and 
in Europe in June. 
Aprovel®
irbesartan
An extension of the indication to nephropathy induced 
by type 2 diabetes was granted in Europe in June and 
in the U.S. in September.
A marketing approval application for the treatment of
hypertension was filed in Japan in October.
CENTRAL NERVOUS SYSTEM 
Depakine chrono®
sodium valproate
A marketing approval application was filed in Europe 
for the treatment of bipolar disorders.
Depakine chronospheres®
sodium valproate
Marketing approval for the treatment of epilepsy 
was obtained in France, Portugal and Finland.
INTERNAL MEDICINE
Xatral® O.D.
alfuzosin
Following the “approvable letter” received at the end 
of 2001, the results of additional studies requested by
the Food and Drug Administration (FDA) to obtain 
the indication of symptomatic treatment of benign
prostatic hyperplasia were submitted in December 2002.
E S E A R C H  &  D E V E L O P M E N TR
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Cardiovascular/Thrombosis department: angiogenesis program.
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ONCOLOGY
Fasturtec®/Elitek®
rasburicase
Marketing approval for the treatment of hyperuricemia
related to chemotherapy in children was granted by the
FDA in July.
After receiving marketing approval in Europe in 2001,
Fasturtec® was granted marketing approval in 16 other
countries, including Australia, New Zealand and
Switzerland, in 2002.
Eloxatin®
oxaliplatin
Marketing approval for the second-line treatment of
colorectal cancer was granted in the U.S. in August 2002, 
46 days after the application was filed.
Submission of a marketing approval application for the first-
line treatment of metastatic colorectal cancer is planned in
2003. Eloxatin® is under license from Debiopharm.
Eligard®
leuprolide acetate
Marketing approval for the treatment of prostate cancer
was granted by the FDA in January for the one-month
formulation and in July for the three-month formulation.
Eligard® is under license from Atrix.
Portfolio changes
in 2002
9 new products entered Preclinical or
Phase I clinical development:
SSR 241586
NK2/NK3 antagonist
(Internal Medicine)
SSR 128429
factor IIa and Xa inhibitor
(Cardiovascular/Thrombosis)
SSR 126768
oxytocin receptor antagonist
(Internal Medicine)
SSR 97193
ferroquine
(Internal Medicine)
SSR 161421
A3 receptor antagonist
(Internal Medicine)
SSR 482073
PBR ligand
(Central Nervous System)
SSR 250411
cytotoxic agent
(Oncology)
CEP 7055
angiogenesis inhibitor
(Oncology)
IDD3 -Uvidem
“cell drug”
(Oncology)
The last two compounds were co-developed with
Cephalon (CEP7055) and Immuno-Designed
Molecules (IDD3).
Development of the following products 
was stopped:
SR 27897 (Oncology)
SL 251188 (Central Nervous System)
SL 251131 (Central Nervous System)
SR 144190 (Central Nervous System)
SL 651708 (Cardiovascular/Thrombosis)
SSR 69071 (Internal Medicine)
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CARDIOVASCULAR / THROMBOSIS
Idraparinux sodium
Treatment and secondary prevention of thromboembolic
events, and prevention of thromboembolic events
associated with atrial fibrillation
Initiation of Phase III studies
Like Arixtra®, idraparinux sodium belongs to the synthetic
oligosaccharide family. Idraparinux sodium is an injectable
synthetic pentasaccharide, selectively inhibiting coagulation
factor Xa. Its potency and long duration of action permit 
a therapeutic regimen comprising only one injection per
week in humans.
The Phase IIb study PERSIST, comparing idraparinux with
anti-vitamin K in the treatment of venous thrombosis was
completed in 2002 and results were published in
September. These permitted selection of a dose of 2.5 mg
and justified the initiation of two Phase III trials:
- in the treatment and secondary prevention of venous
thromboembolic events in patients suffering from deep-vein
thrombosis or pulmonary embolism (the VAN GOGH
program);
- in the prevention of thromboembolic events associated
with atrial fibrillation (the AMADEUS program).
These programs will start in early 2003 
and will include over 10,000 patients.
Dronedarone
Atrial fibrillation
Continuation of Phase III studies
The prevention of cardiac arrhythmia is one of Sanofi-
Synthélabo’s areas of excellence, with Cordarone®
(amiodarone) remaining the reference treatment 
to this day. With dronedarone, a potential successor to
Cordarone® the Group's objective is to propose a new
treatment presenting at least equivalent efficacy with
improved tolerability.
The first indication developed for dronedarone is the
prevention of recurrence of the most common cardiac
rhythm disorder: atrial fibrillation. The usual treatment for
acute atrial fibrillation is an external electric shock to the
heart. To avoid recurrences, which are extremely common,
this is generally followed by medicinal anti-arrhythmic
treatment.
Phase III studies for this highly promising compound
were initiated in 2002. The program comprises:
- two efficacy studies on the prevention of recurrences in
patients who have already experienced atrial fibrillation:
EURIDIS (Europe) and ADONIS (North and South
America, Australia, South Africa).
- a tolerability study in high-risk patients suffering from
heart failure and impaired ventricular function:
ANDROMEDA. 
The ANDROMEDA study was stopped in January 2003 after
the enrollment of 627 patients out of the 1,000 planned. This
was decided on the advice of the committee monitoring the
tolerability data, following an interim tolerability analysis
indicating a higher potential risk of death in the group
treated with dronedarone. A new protocol will be envisaged
after detailed analysis of all the data collected.
This interruption does not mean that development of
dronedarone has been stopped. On the favorable
recommendation of the steering committees and
tolerability data monitoring committees concerned, the
efficacy studies EURIDIS and ADONIS are continuing in
accordance with the planned protocol. Enrollment totaling
1,245 patients was completed in August 2002.
E S E A R C H  &  D E V E L O P M E N TR
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Four major therapeutic areas
R e s e a r c h  &  D e v e l o p m e n t
29
CENTRAL NERVOUS SYSTEM
Xaliproden
Alzheimer's disease
Completion of Phase IIb
Alzheimer's disease is a neurodegenerative disorder 
leading to progressive cognitive deterioration, 
behavioral problems and functional decline, 
culminating in dementia. Alzheimer's disease, 
the prevalence of which increases with age, is the most
common cause of dementia in elderly subjects. Worldwide,
approximately 22 million patients suffer from various 
forms of dementia, two-thirds of which correspond to 
the Alzheimer type. The prevalence of this disease 
could double within the next 25 years. Alzheimer's 
disease is a major public health problem. 
Current treatments are purely symptomatic. 
Due to its neurotrophic and neuroprotective properties, 
xaliproden could be the first treatment capable of 
slowing the progression of the disease. This non-peptide
compound activates the synthesis of endogenous
neurotrophins. Its efficacy has been demonstrated in vitro
and in vivo in numerous models of central or peripheral
neurodegeneration, as a curative or prophylactic treatment. 
It is orally active as a single daily dose.
Phase IIb studies, completed in 2002, confirmed 
the tolerability of xaliproden in elderly subjects with
Alzheimer's disease. A Phase III international development
program focused on this disease will be initiated in 2003.
Xaliproden
Amyotrophic lateral sclerosis
Marketing approval application withdrawn
In 2002, Sanofi-Synthélabo decided to withdraw 
its European marketing approval application for 
xaliproden in the treatment of amyotrophic lateral 
sclerosis. This rare neurological disease is caused by
degeneration of the motor neurons responsible 
for muscle function. It results in progressive paralysis,
leading to invariably fatal respiratory failure. 
The marketing approval application, based on 
two Phase III trials versus placebo, was filed in 2001.
The results of these two pivotal clinical trials evaluating
xaliproden at a dose of 1 or 2 mg, either alone or in
combination with riluzole, in patients suffering from
amyotrophic lateral sclerosis, showed that the compound
was well tolerated, and that it had a beneficial effect on
respiratory function and the conditions of survival.
However, the interpretation of the positive effect on
respiratory function was complicated by the extent of the
survival benefit which was smaller than the studies were
powered to detect. These results were not considered
sufficiently robust to meet the regulatory requirements 
for marketing approval.
Sanofi-Synthélabo will continue to supply xaliproden to
patients suffering from amyotrophic lateral sclerosis
currently treated in Europe and elsewhere in the world in
the context of ongoing long-term studies, as envisaged in
the protocol and in conformity with the procedures defined
by the national regulatory authorities.
Aqueous coatings for capsules have replaced organic mixtures.
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Osanetant
Schizophrenia
Continuation of Phase IIb
Sanofi-Synthélabo designed an original study protocol,
known as a Metatrial, to evaluate the therapeutic activity
of four compounds possessing novel mechanisms of action
in patients with schizophrenia. Osanetant, an NK3 receptor
antagonist, showed an activity and an efficacy profile 
close to those of haloperidol, combined with very good
tolerability. Clinical investigation was continued in 2002.
In contrast, the Phase IIb study evaluating the potential of
osanetant in severe depression proved non-conclusive.
After six weeks of treatment, no significant difference 
was observed between the active treatments tested,
including paroxetine, and placebo. 
SR58611
Depression
Phase IIb
SR58611 is a beta3 adrenergic receptor agonist. These
substances stimulate neuronal activity in a specific region
of the prefrontal cortex and could give rise to a new class
of antidepressants.
In a Phase IIa trial in patients suffering from severe,
recurrent depression, SR58611 was observed to be superior
to fluoxetine and was very well tolerated. In a Phase IIb
study comparing SR58611 to paroxetine, the efficacy 
of SR58611 and its tolerability profile were sufficiently
encouraging to warrant the initiation of a Phase III
program in depression. Two trials designed to support 
a marketing approval application for SR58611 in 
the treatment of depression will start in 2003.
Rimonabant
Smoking cessation
Continuation of Phase III
Rimonabant, a CB1 endocannabinoid receptor antagonist, 
is in development for the treatment of obesity (see Internal
Medicine). In 2002, the results of a 10-week Phase IIa trial
in smoking cessation showed that rimonabant resulted in
smoking cessation rates superior to those achieved with
placebo. Patients receiving rimonabant also lost weight, 
an appreciable advantage, in contrast to placebo-treated
patients ceasing to smoke, who gained weight.
In view of these results, and after agreement of the FDA, 
a large-scale Phase III program including almost 
6,000 patients was initiated in 2002 in Europe and 
the United States, with the aim of obtaining a marketing
approval for rimonabant as a smoking cessation aid and 
for long-term maintenance of abstinence from smoking.
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Central Nervous System department: research into eating disorders.
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INTERNAL MEDICINE
Rimonabant
Obesity
Continuation of Phase III
Obesity is defined by elevation of the body mass index
(BMI), calculated by comparing the weight and 
the height of patients (in kilograms/m2). Obesity is
currently recognized to be a major risk factor, 
particularly for cardiovascular diseases and diabetes. 
The prevalence of this disease has reached alarming
proportions in the United States and Europe. In the U.S., 
in 1999-2000, 30% of the adult population were obese
(BMI > 30) and more than 60% were "overweight" 
(BMI > 25). Recent studies have demonstrated that 
obesity leads to a significant reduction in life expectancy,
the risk appearing as soon as subjects were "overweight"
and worsening with increase in BMI. This disquieting
epidemiological situation makes obesity a major public
health problem, affecting the young adult population 
and even, to an increasing extent, adolescents.
The research and development studies conducted by
Sanofi-Synthelabo on rimonabant open up completely 
new and extremely encouraging prospects with regard to
elucidation of the mechanisms regulating appetite and
metabolism, likely to lead to an effective and safe
treatment of obesity with long-term activity. 
Rimonabant, the only selective CB1 endocannabinoid
receptor antagonist currently in clinical trials in humans,
has an original pharmacological profile demonstrated in
animals and confirmed in humans by the positive results
obtained in Phase IIa and IIb clinical studies. Rimonabant
appears to intervene at the heart of central appetite-
regulating systems by counteracting endogenous
cannabinoids (endocannabinoids), such as anandamide.
The crucial aspect of this mode of action is that it induces
not only a quantitative regulation of calorie consumption, 
but also a qualitative regulation of nutrition by specifically
diminishing appetite for fatty foods or foods with an
excessive sugar content. Weight reduction is significant
and the tolerability profile is very good.
Phase III trials on rimonabant in the long-term treatment
of obesity, initiated in 2002, have enrolled over 
6,000 patients. Two large two-year trials are ongoing in
the U.S. and Europe. Patient enrollment is complete. 
Two other clinical trials, each including close to 
1,000 patients, are designed to demonstrate the efficacy of
rimonabant in obese patients suffering from diabetes or
dyslipidemia, disorders aggravating the cardiovascular risk
factors associated with obesity. Patient enrollment for 
these trials is progressing according to plan.
ONCOLOGY
Tirapazamine
Non-small cell lung cancer, in combination 
with cisplatin and vinorelbin
Continuation of Phase III
Tirapazamine is an anticancer agent which is not directly
cytolytic, but promotes the destruction of resistant 
hypoxic cells. This innovative mechanism of action 
is likely to reduce the risk of relapse. Phase III trials on
tirapazamine in non-small cell lung cancer will be
completed by the end of 2003. Clinical studies in 
other indications such as head and neck cancers, in
particular pharyngolaryngeal cancers, are ongoing.
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Multiple research approaches
To identify promising compounds that will be proposed 
for development, Sanofi-Synthelabo teams employ 
a wide range of approaches differing in both nature 
and objectives.
A project-based organization
The constraints of speed, cost and quality have led to 
an overall project-based organization within 
the Development Department, extending throughout
compound development from the Preclinical phase 
to the granting of new indications for medicines already 
marketed. This organization ensures the consistency 
and continuity of development, promotes optimal use of
resources and shortening of timelines, and permits 
the transmission of expertise encompassing all activities
from research to marketing, which are necessary to obtain
marketing approval.
Partnerships
Joint projects with biotechnology companies and other
pharmaceutical companies permit Sanofi-Synthélabo
Research to gain access to new technologies 
and methodologies and to expand or strengthen existing
areas of research.
In functional genomics
- The joint project initiated in 1999 with Genfit (Lille,
France) was confirmed in 2002. The objective of this
project is to study inflammatory phenomena affecting 
the arterial wall, which could lead to the discovery 
of new and original biological targets for the treatment 
of atherosclerosis.
- The joint project with Genoway (Lyon, France) provides
access to specific know-how concerning the study of
mouse embryonic stem cells which should permit the
construction of screening tools by genetic modifications,
either in a cellular environment, or in entire organisms.
This program forms part of a larger partnership, with 
the French Ministry of Industry, the Institut National 
de la Recherche Agronomique (INRA – French National
Agronomic Research Institute) and the Institut National
de Recherche en Informatique et en Automatique 
(INRIA – French National Institute for Research 
in Computer Science and Control).
- The joint project with Lifespan (Seattle, U.S.) provides
access to a data base permitting the localization 
and validation of the function of 300 receptors 
coupled with G proteins that have already been identified 
in the human genome.
In molecular screening 
- The joint project with CEREP (Rueil-Malmaison, France),
initiated in 1997, has been extended. This contract envisages
the synthesis of chemical libraries expanding the Group's
chemical potential and the screening of these libraries on
new biological targets of interest. The discovery of novel lead
compounds active on the selected targets has permitted 
the implementation of a program of chemical optimization.
E S E A R C H  &  D E V E L O P M E N TR
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R&D organization 
at Sanofi-Synthélabo
Aqueous film coating of pills helps protect the environment by eliminating
volatile organic compounds escaping into the atmosphere.
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In the search for new 
development candidates
 The research and development agreement concluded
with Mitsubishi-Pharma Corp. (Tokyo, Japan) in 1998,
with the aim of identifying new neuroprotective agents
for the treatment of neurodegenerative diseases, 
has been renewed up to the end of 2003.
 A research and development agreement was concluded in
December 2001 with Cephalon (West Chester, United
States), providing access to a new compound, CEP 7055, 
an angiogenesis inhibitor with the potential to become an
anti-cancer agent, and also to a research program designed
to identify new compounds acting by this mechanism.
Sanofi-Synthélabo has accepted to co-promote with
Cephalon all compounds successfully developed by
Cephalon, in accordance with the agreement in the U.S.,
Canada and Mexico. Sanofi-Synthélabo has exclusive
marketing rights for these medicines in Europe and other
countries, except Japan. Sanofi-Synthélabo shares
development costs with Cephalon and will pay royalties 
on sales of developed medicines.
 The collaboration with Organon (Oss, The Netherlands),
in the area of oligosaccharides with antithrombotic 
activity, is continuing. This collaboration has already led
to the development of Arixtra® and idraparinux.
 In January 2002, Sanofi-Synthélabo and IDM (Paris, France)
signed a cooperation agreement in cell immunotherapy for
the development and marketing of immunological
treatments for cancers. A first product, Uvidem®, targeting
melanoma, is currently in Phase II clinical development.
Under the terms of this agreement, Sanofi-Synthélabo has
priority in choosing up to 20 cellular therapy programs from
the range of products developed by IDM. IDM is responsible
for preclinical development. Where an option is exercised,
Sanofi-Synthélabo will finance the clinical development 
and will possess the worldwide marketing rights for 
the compounds selected if the clinical trials are successful, 
in return for paying royalties to IDM on the sales of 
these medicines.
 Impact Malaria: in the context of this initiative, three
cooperative R&D programs were begun in 2002.
The principal stages of 
clinical development
It usually takes ten to fifteen years from the time 
a compound is discovered to the time the
corresponding medicine is marketed. This long
journey is punctuated by a series of mandatory
stages, each of which is crucial: 
, Preclinical phase: devoted to pharmacological and
toxicological studies on various animal species.
, Phase I: on the basis of the results of the Preclinical
phase, the health authorities authorize studies in
humans. Phase I studies are conducted on healthy
volunteers to obtain information on tolerability,
dosage, pharmacokinetics and interactions 
with other medicines.
, Phase IIa: using the doses determined in Phase I,
this phase aims to evaluate the pharmacological
and therapeutic activity of the compound on 
a small number of patients. 
, Phase IIb: now the objective is to demonstrate
clinical activity on a larger and more varied
population and to determine the optimal dose.
, Phase III: the clinical efficacy of the compound is
tested on a large patient population (generally
between 3,000 and 5,000 volunteers) in order to
demonstrate therapeutic superiority and good
tolerability. These trials always involve comparisons
with control groups, either treated with the
standard reference medication for the disease
concerned, or receiving an inactive compound
known as a placebo. 
Altogether, Phases IIb and III usually take from 
three to five years. A marketing approval application,
including the results of all the studies, is then
submitted to the authorities. Their reply is generally
received within six months to two years.
Complementary clinical studies may be initiated 
after completion of Phase III. Some of these, 
known as Phase IIIb trials, are designed to
demonstrate the efficacy of the compound 
in new therapeutic indications. Others, designated
Phase IV trials, are related to pharmacovigilance,
monitoring the efficacy and tolerability of the new
medicine after its market launch.
M e d i c i n e s
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For the third consecutive year, sales showed strong growth in 2002,
exceeding that of the market. This performance was due to 
the success of our flagship products, the launch of new medicines
and the overall strength of our portfolio.
New indications for Plavix® and Aprovel®/Avapro®
Launch of Arixtra® in the United States and Europe, 
Launch of Eloxatin®‚ Eligard® and Elitek® in the United States
Rapid granting of a product license for Eloxatin® in the U.S.
on the basis of clinical trial results
Commercial success of Plavix® with a 40%* increase in 
consolidated sales in 2002
Plavix® patents challenged by two generic manufacturers in the U.S. 
Success of Myslee® (zolpidem) in Japan
no. 2 on the market within two years.
our portfolio gets stronger and stronger 
* on a reported basis
K e y  e v e n t s  i n  2 0 0 2
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The 15 leading products
Cardiovascular/Thrombosis
Consolidated sales
Principal products Compounds Indications (in millions of euros)
2000 2001 2002
Plavix®/Iscover® clopidogrel Atherothrombosis 437 705 987
Aprovel®/Avapro®/Karvea® irbesartan Hypertension 300 423 562
Fraxiparine® nadroparin calcium Thrombosis 255 297 324
Cordarone®/Ancaron® amiodarone Arrhythmia 156 162 162
Tildiem® diltiazem Angina, hypertension 154 152 141
Ticlid® ticlopidine Thrombosis 235 205 137
Corotrope®/Primacor®/Milrila® milrinone Heart failure 180 237 127
Kerlone®/Kerlong® betaxolol Hypertension, angina 77 82 77
Central Nervous System
Consolidated sales
Principal products Compounds Indications (in millions of euros)
2000 2001 2002
Stilnox®/Ambien®/Myslee® zolpidem Insomnia 582 786 1424
Depakine® sodium valproate Epilepsy 211 243 267
Solian® amisulpride Schizophrenia 93 116 135
Aspégic® and derivatives* lysine acetylsalicylate Fever, pain 100 100 108
Dogmatil®/Dogmatyl® sulpiride Psychosomatic disorders 134 124 78
Internal Medicine
Consolidated sales
Principal product Compound Indication (in millions of euros)
2000 2001 2002
Xatral® alfuzosin
Benign prostatic
hyperplasia
120 148 182
Oncology
Consolidated sales
Principal product Compound Indication (in millions of euros)
2000 2001 2002
Eloxatin® oxaliplatin Colorectal cancer 141 196 389
* Including sales for Kardegic®, a product classed by the IMS in the cardiovascular therapeutic sector.
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hypertension
Hypertension is one of the most common diseases,
affecting approximately 20% of the adult population
worldwide. 
Generally asymptomatic, it induces severe damage of
target organs and, for this reason, is known as the "silent
killer". It is manifested by elevation of one or both arterial
pressure values beyond the thresholds associated with the
onset of complications. These concern the heart, with
damage to coronary arteries leading to myocardial
infarction and the brain, where there is a risk of stroke,
but also affect the entire vascular system, the kidneys 
and the eyes.
On the basis of large epidemiological studies, normal
blood pressure is defined as 140/90 mmHg for the
majority of people. However, this threshold is lowered
when the risk of complications is increased by the
presence of other diseases, such as diabetes, which
doubles the risk, or proteinuria, an abnormal amount of
protein in the urine, leading to renal impairment.
The guidelines published by the World Health
Organization and professional bodies recommend 
a complete assessment of the risk profile of each
hypertensive patient to enable an individually 
adapted treatment.
Certain concomitant diseases or impairments of "target
organs" are sometimes silent and therefore necessitate
specific research investigations. For this reason, 
the American Diabetes Association (ADA) recommends 
an annual evaluation of incipient renal impairment 
in diabetics. This is characterized by microscopic
proteinuria, known as microalbuminuria. If renal
impairment is confirmed, the ADA recommends 
initiating treatment with an angiotensin receptor
antagonist, particularly in patients with type 2 diabetes.
Aprovel®/Avapro®
irbesartan
Hypertension
2002: new indication in Europe and the United States
for the treatment of kidney disease in patients
with hypertension and type 2 diabetes
Launched in 1997, Aprovel® belongs to the most recent
class of anti-hypertensive medications: angiotensin II
receptor antagonists (AIIRAs), which are poised to become
the leading treatment for this disorder in terms of market
share. Highly potent and very well-tolerated, AIIRAs act 
by blocking the effect of the hormone responsible for
blood vessel contraction, thereby enabling blood pressure
to return to normal. Aprovel®/Avapro® alone or combined
with a diuretic, hydrochlorothiazide, under the name 
Co-Aprovel®/Avalide® achieves blood pressure control 
in close to 90% of patients with optimized therapeutic
tolerability. 
Aprovel® is currently available in more than 80 countries,
including the U.S. under the name Avapro® according to
agreements with Bristol-Myers Squibb. The product 
has also been submitted for approval in Japan.
In 2002, Aprovel® was granted a new indication in Europe
and the U.S. for the treatment of diabetic nephropathy, 
on the basis of the PRIME program. This clinical program
demonstrated that irbesartan protected diabetic
hypertensive patients from the progression of renal
impairment, at both early and more advanced stages of
the disease. The importance of these results, demonstrated
for the first time in this population, led the American
Diabetes Association (ADA) to recommend the use of
angiotensin receptor antagonists as first-line treatment 
for renal disease in patients with type 2 diabetes.
Two new, large-scale trials have now been initiated to
demonstrate the ability of irbesartan to protect 
the cardiovascular system against a frequent complication
of hypertension, ventricular hypertrophy, and to prevent
recurrences of atrial fibrillation episodes:
E D I C I N E SM
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- The I-PRESERVE trial evaluates the benefit of irbesartan
in the treatment of a specific but frequent form of heart
failure, known as heart failure with preserved systolic
function or diastolic heart failure. In this case, the
contractile capacity of the ventricles is preserved, but
ventricular filling is disturbed. I-PRESERVE is the largest
study conducted to date in this disease. Started in 2002,
it is currently in an active stage of patient enrollment.
- The ACTIVE trial, due to start in 2003, will evaluate 
the efficacy of irbesartan, combined with clopidogrel, 
in preventing cardiovascular complications in patients
suffering from atrial fibrillation.
These two trials will enroll a total of 15,000 patients 
and should be completed in 2006.
Cardiac rhythm disorders
Cardiac rhythm disorders can arise both in the atria, with
supraventricular rhythm disorders, and in the ventricles,
with ventricular rhythm disorders. Both kinds of rhythm
disorder generally have an organic cause and therefore
tend to recur. 
Patients concerned may present various symptoms –
palpitations, malaise, loss of consciousness, etc. – and
even heart failure. Certain types of cardiac rhythm
disorder may lead to death, sometimes sudden death.
The prevalence of atrial fibrillation – the most common
supraventricular rhythm disorder - is 1% in the general
population, but this increases with age. Over the age of
65, prevalence is more than 8%.
Cordarone®/Ancaron®
amiodarone
Cardiac rhythm disorders
2002: publication of the CAT study in the medical
journal “Circulation”, 03.26.02, pages 1453-58
Thirty-six years after receiving its first product license,
Cordarone® remains the reference anti-arrhythmic agent for
the treatment and prevention of cardiac rhythm disorders.
Cordarone® is effective against potentially life-threatening
supraventricular rhythm disorders. 
Two studies, AMIOVIRT and CAT, published in 2002,
showed that Cordarone® is as effective as the implantation of
a defibrillator in preventing sudden cardiac death in patients
with idiopathic dilated cardiomyopathy. Cordarone® has a
good cardiac safety profile and only exceptionally induces the
complications potentially associated with the use of anti-
arrhythmics, such as “torsades de pointes”, a potentially fatal
cardiac rhythm disorder, or ventricular insufficiency.
However, its effects on thyroid function restrict its use. 
Cordarone® is available in more than 126 countries, including
the U.S, where it is licensed to American Home Products, 
and Japan, where it is marketed under the trade name
Ancaron® through a joint venture with Taisho.
The identification of tablets 
and capsules make them 
unique worldwide.
M e d i c i n e s
38
Angina
Angina results from an imbalance between myocardial
oxygen demand and supply due to the narrowing 
of one or more of the coronary arteries, the arteries 
nourishing the heart. Angina is an incapacitating 
and life-threatening disease.
The usual treatment comprises control of cardiovascular
risk factors and prescription of one or more anti-anginal
agents, such as nitrate derivatives, beta-blockers and
calcium antagonists, as well as platelet anti-aggregants.
Sanofi-Synthélabo has medicines in each of these
therapeutic classes.
Tildiem® 
diltiazem
Angina, hypertension
Among calcium antagonists, Tildiem® is considered a
reference treatment for angina. It increases oxygen supply
to the myocardium through coronary vasodilatation while
simultaneously reducing oxygen needs by decreasing heart
rate and lowering peripheral arterial resistance. Tildiem®
therefore exhibits good anti-anginal efficacy, combined
with a good safety profile. 
The prolonged release formulations of Tildiem®
LP 200/300 mg provide 24-hour protection against
ischemia with a single daily dose. This convenience 
of use improves both compliance, and tolerability.
Furthermore, a meta-analysis showed that these
formulations permit consistent regulation of heart rate: 
the faster the heart rate initially, the more this is slowed by
Tildiem®. A study conducted in 1999 showed that the
profile of release of Tildiem® LP 200/300 mg is unique 
in its therapeutic class. 
The NORDIL study of morbidity and mortality associated
with hypertension showed that diltiazem was as effective
as diuretics and beta-blockers - the reference treatment -
in reducing cardiovascular complications. These results
emphasize the value of treating hypertension with Tildiem®
LP 200/300 mg. 
Tildiem® LP 200/300 mg is marketed in most 
European countries.
Kerlone®/Kerlong®
betaxolol
Hypertension, angina
A cardioselective beta-blocker, Kerlone® is marketed not only 
in Europe but also in the U.S., through a joint venture with
Pharmacia, and in Japan under the name Kerlong®, 
through a joint venture with Mitsubishi. A recent clinical trial,
BETACAR, showed the ease of administration of Kerlone®
in the treatment of patients with an altered cardiac function.
Heart failure
Related to a defect in the pumping function of the left
ventricle, heart failure passes through various stages of
seriousness. Accompanied by breathlessness, edemas 
and various types of effusion, the most severe forms 
may render everyday activities practically impossible. 
The prevalence of heart failure is between 0.3% 
and 2%, increasing almost exponentially with age.
Corotrope®/Primacor®/Milrila® 
milrinone
Heart failure
Corotrope® combines positive inotropic properties,
increasing the contractile force of the heart, with a
vasodilatory action. It constitutes an effective treatment 
for advanced forms of heart failure. It is also a treatment
for certain less advanced forms that have been abruptly
decompensated by a dietary change or intercurrent
disease. Corotrope® is marketed in several European
countries, in the U.S. under the name Primacor®, 
where the patent came into the public domain in May
2002, and in Japan under the name Milrila® through
a joint venture with Yamanouchi.
Atherothrombosis
Atherothrombotic events constitute the major cause of
morbidity and premature death in industrial countries.
Every year, in Europe and the U.S., 3.4 million people
experience an acute coronary event and 1.2 million
experience an ischemic stroke, both of which are related
to impaired or blocked blood circulation. In addition, 
16.8 million people present signs of peripheral arterial
disease, an arterial disorder of inflammatory origin.
E D I C I N E SM
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All these symptoms are manifestations of the same
underlying disease - atherothrombosis.
Atherothrombosis is the formation of a coagulated mass 
of blood, known as a thrombus, in a vessel affected by
atherosclerosis. Atherosclerosis is common to numerous
cardiovascular diseases and gives rise to lesions on the
internal wall of the artery in the form of plaques. These
are likely to be disseminated in the vascular system. 
A thrombus is formed when an atheromatous plaque
becomes unstable and breaks up, exposing components
such as collagen to the circulating blood and thereby
leading to platelet adhesion at the site of the lesion.
The thrombus may spread and eventually obstruct the
vessel to the extent that it impairs or blocks blood
circulation, leading to acute ischemia and causing tissue
damage. The final consequence may be a fatal or non-
fatal cardiovascular event, such as stroke, acute coronary
syndrome (unstable angina, myocardial infarction with
or without Q-wave, vascular death) or peripheral 
arterial disease.
Plavix®
clopidogrel
Atherothrombosis
2002: extension of the indication to acute coronary
syndrome, based on the results of the CURE trial
Plavix®, a platelet adenosine diphosphate receptor
antagonist, is indicated for the prevention of
atherothrombotic events in patients presenting a history of
recent myocardial infarction, recent ischemic stroke or
documented peripheral arterial disease. Plavix® is the only
medicine indicated for the secondary prevention of
atherothrombosis, irrespective of the location of the arteries
initially affected, whether heart, brain or lower limbs.
The results of the CAPRIE study, the largest phase III 
study ever conducted with close to 20,000 patients
enrolled, support the broad indication for Plavix®. 
CAPRIE demonstrated the superior efficacy of Plavix®
relative to acetylsalicylic acid (ASA), with at least equally
good safety.
Launched in 1998, Plavix® is marketed in over 
75 countries. In the U.S., the product is commercialized
through the alliance with Bristol-Myers Squibb (see page
36 of the Financial Report for details of the alliance). 
In Japan, where it is being developed in partnership 
with Daiichi, the file submission is planned for the 
end of 2003.
The year 2002 was marked by three major events:
- on the basis of the results obtained in the CURE trial,
completed in 2001, the U.S. and European health
authorities approved an extension of the Plavix®
indications to acute coronary syndrome. This new
indication was incorporated in the guidelines of the
American Heart Association and the American College of
Cardiology in March 2002 and in those of the European
Society of Cardiology in September 2002.
The CURE trial demonstrated that clopidogrel, on top of
standard therapy including acetylsalicylic acid (ASA),
reduced the risk of atherothrombotic events (myocardial
infarction, stroke, death from cardiovascular cause) by
20% with only a 1% increase in the rate of major
hemorrhages and provided significant short- and long-
term benefit in patients presenting with an acute
coronary syndrome. With more than 12,000 patients
enrolled, CURE is the largest trial ever conducted in
patients presenting with unstable angina or non-Q-wave
myocardial infarction. 
- the results of the CREDO trial, announced in November
2002, confirmed the therapeutic value of Plavix® in the
short- and long-term prevention of atherothrombotic
events in patients having undergone coronary
angioplasty, with or without stenting. CREDO, conducted
in more than 2,000 patients, demonstrated the benefit of
prolonged use of clopidogrel: the risk of atherothrombotic
events (myocardial infarction, stroke and cardiovascular
death) was reduced by 27% after one year. 
- the CHARISMA trial started in September 2002 with 
the enrollment of the first patients. The objective of 
this study is to demonstrate the value of using Plavix® 
on top of existing treatments in the primary prevention
of cardiovascular events in patients at risk. CHARISMA
will include 15,000 patients. 
Pharmaceutical forms depend on the composition of the medicine.
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Other major studies are designed to support the long-term
use of Plavix® ‚ by providing complementary data 
- MATCH in the treatment of high-risk patients having
recently experienced a stroke or transient ischemic attack.
Enrollment of the planned 7,600 patients is complete.
- CLARITY and COMMIT in patients with acute 
myocardial infarction.
- CAMPER in patients with peripheral arterial disease, 
who have undergone angioplasty or bypass surgery.
- ACTIVE in the prophylactic treatment of patients 
with atrial fibrillation.
In total, this major clinical program on clopidogrel will include
more than 100,000 patients.  
Ticlid®
ticlopidine
Thrombosis
Ticlid® is indicated for the prevention of coronary or
cerebrovascular ischemic events in patients at risk (following
an initial ischemic stroke or transient ischemic attack, or
symptomatic peripheral arterial disease). In combination 
with ASA, Ticlid® is the standard prophylactic treatment
against the risk of thrombosis (reocclusion of the dilated
artery) in patients who have undergone coronary angioplasty
with insertion of a stent. Ticlid® is marketed in over 
75 countries. In the U.S., it is licensed to Roche. In Japan,
where it is marketed under the brand name Panaldine®, 
it is licensed to Daiichi.
Venous thrombosis
Deep-vein thrombosis is triggered by coagulation factor
abnormalities, lesions of the vascular wall and venous
stasis, which are most likely to occur during prolonged
immobilization.
The risk of thrombosis is particularly high after surgical
operations, notably major orthopedic surgery such as hip
or knee replacement, and especially hip fracture. In the
absence of treatment, it occurs in 40% to 50% of patients
undergoing hip replacement, and in 70% to 80% of
patients undergoing total knee replacement. Venous
thrombosis may be manifested locally by pain or edema
affecting the leg. However, venous thromboembolism
often occurs without any apparent clinical sign and the
patient remains ignorant of the disease. This may also
have more dramatic consequences, such as pulmonary
embolism, with fatal outcome. 
Current standard prophylaxis for thrombosis is low
molecular weight heparin which reduces frequency 
by a factor of 2 to 3.
Fraxiparine®
nadroparin calcium
Venous and arterial thrombosis 
Fraxiparine® is an injectable low molecular weight heparin.
Launched in 1986, it is marketed in more than 100 countries,
excluding the U.S. and Japan. 
The indications of Fraxiparine® have expanded over the years.
Initially indicated for the prevention of venous thromboembolic
disease, this antithrombotic is currently indicated for the
treatment of venous thromboembolism and the treatment of
acute coronary syndromes.
Fraxodi®, a curative treatment for venous thromboembolic
disease administered as a once-a-day injection, was launched
in France in 1998. It is now marketed in most countries in
Europe and Latin America. This regimen permits shorter
hospital stays, facilitates outpatient treatment and enhances
patient recovery.
The indication of Fraxiparine® for the treatment of the acute
phase of unstable angina in association with ASA has also 
been granted in the majority of countries.
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Arixtra® is administered using a safety syringe
which protects the person giving the injection.
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Arixtra®
fondaparinux sodium
Venous thrombosis
Arixtra® was launched in the U.S. and in Europe in 2002 
in its first clinical indication, the prevention of venous
thromboembolism (VTE) including deep vein thrombosis
and pulmonary embolism in patients who have undergone
major orthopedic surgery of the lower limbs, a high-risk
situation. Arixtra®, a totally synthetic compound, has
entered the market of low molecular weight heparins,
which are animal sourced. Co-developed by Sanofi-
Synthélabo and Organon (Akzo Nobel), Arixtra® represents
a major advance in the prevention of venous thrombo-
embolism. It is the first agent in a new class of
antithrombotics: selective inhibitors of coagulation factor
Xa. Arixtra® interrupts a key step in the coagulation
cascade, preventing the formation of blood clots. A
product of sugar chemistry, Arixtra® is a totally synthetic
compound, a characteristic conferring a high degree of
purity. For both these reasons, this product constitutes 
a major technological and therapeutic advance. 
Its development potential promises to be substantial.
In this indication, Phase III trials including over 
7,000 patients demonstrated a major clinical benefit
relative to the reference low molecular weight heparin.
Arixtra® diminishes the risk of a thromboembolic event 
by 55%, irrespective of the type of orthopedic surgery
performed and the characteristics of the patient, without
increasing the risk of clinically important bleeding. For
patients undergoing surgery for hip fracture, the risk of
deep-vein thrombosis is reduced from 20% to 8%. The
safety profile of the two treatments is similar. Granted
product license approval in the U.S. in December 2001 
for the prevention of venous thromboembolic events after
orthopedic surgery, after an expedited review, Arixtra® was
launched in February 2002. In Europe, Arixtra® received
marketing approval for this same indication in March 2002
and was launched on the first European markets in April. In
Japan, the product is under development in Phase IIb/III.
From launch to the end of 2002, Arixtra® was included in
more than 750 formularies in some of the most prestigious
U.S. and European centers. The process of inclusion in
formularies is slow, but is an essential prerequisite for use
of the product in hospital centers. In December 2002, the
Food and Drug Administration modified the summary of
product characteristics for Arixtra®. This new version
provides an improved description of its profile. Sanofi-
Synthélabo rapidly initiated a life cycle management
program for Arixtra® which will cover all segments 
of the market:
- the value of prolonged prophylaxis of 30 days versus
five to nine days: the result of the Penthifra Plus study
established that Arixtra® administered for 28 days could
significantly reduce the rate of venous thromboembolic
events after surgery for hip fracture, the orthopedic
surgery operation carrying the highest risk. 
At the end of 2002, an application was submitted to 
the United States Food and Drug Administration (FDA)
and to the European Agency for the Evaluation of
Medicinal Products (EMEA). The FDA granted expedited
review status to this application on the basis that Arixtra®
is the only product indicated for hip fracture patients, 
and in view of the results of the Penthifra Plus trial,
- treatment of venous thromboembolism: completed in
2002, the MATISSE program on 4,400 patients
demonstrated that Arixtra® is as well tolerated and at
least as effective as existing standard therapies - low
molecular weight heparins and unfractionated heparin -
for the treatment of deep vein thrombosis and
pulmonary embolism respectively,
- prevention of venous thrombosis in other types of
surgery, such as abdominal surgery (PEGASUS and
APOLLO programs),
- prevention of venous thromboses in medical patients at
high risk of venous thromboembolic events who have not
undergone surgery (ARTEMIS program),
- acute coronary disease (unstable angina, coronary
angioplasty, myocardial infarction): the initial efficacy
results were confirmed by the Phase IIb PENTUA trial.
These were presented at the Scientific Sessions of the
American Heart Association in November 2001, and
provide grounds for expecting a good benefit/risk ratio
compared to existing therapies.
Arixtra® is marketed jointly by Sanofi-Synthélabo and
Organon in the U.S., Canada and Mexico, and by Sanofi-
Synthélabo alone in Europe and the rest of the world,
excluding Japan.
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Insomnia
Insomnia is usually defined as a complex of generally
unsatisfactory sleep - difficulty in falling asleep, waking
up during the night, waking up too early in the morning,
impression of non-restorative sleep – and daytime
consequences such as mood changes, problems of
attention, alertness and memory, and difficulties in
concentrating. Depending on the definition used and the
method employed for collecting epidemiological data, 
an average of 20% to 30% of the general population
report having suffered from insomnia at some time. 
If left untreated, insomnia may become chronic, a
condition demonstrated to favor the onset of depressive
states. In addition, recent epidemiological surveys have
shown that the social costs of insomnia, with absenteeism
and reduced professional productivity as well as the public
health costs of hospitalization and more frequent use of
medications, justify its early treatment.
Surveys have also shown that both patients and physicians
tend to considerably underestimate both the existence of
this disorder and the need to treat it.
Stilnox®/Ambien®/Myslee®
zolpidem
Insomnia
2002: Myslee® no. 2 in Japan
Launched in almost 100 countries,
Stilnox®/Ambien®/Myslee® is the world’s leading 
hypnotic. Chemically and pharmacologically distinct 
from benzodiazepines, Stilnox®/Ambien®/Myslee®
is distinguished by its selective binding exclusively 
to receptors mediating hypnotic activity. As a result, 
it induces sleep that is qualitatively close to natural 
sleep and devoid of certain side effects which are
characteristic of the benzodiazepine class as a whole. 
Stilnox®/Ambien®/Myslee® induces sleep rapidly and its
action persists for 6 to 8 hours. It is well tolerated and
allows the patient to awake with a reduced risk of impaired
attention, alertness or memory lapses throughout the day.
The risk of dependence is minimal when the product is
used at the recommended dosage and duration of use.
Thanks to an extensive program of eight clinical trials on
6,000 patients, Stilnox®/Ambien®/Myslee® is the only
product demonstrated to be suitable for use “as needed”,
according to the requirements of each individual. This
mode of administration avoids systematic intake of a
hypnotic for patients who do not suffer from insomnia
every night. It is consequently an effective and safe option,
reassuring for both patients and their physicians. 
Stilnox®/Ambien®/Myslee® is also probably the best 
studied hypnotic in the world: data on its efficacy and
safety have been generated from 140 clinical trials
including over 80,000 patients from all continents, 
and on an experience of 15 years, representing to date
more than 8 billion nights of treatment since the product
was launched. 
Two key events marked the year 2002:
- in the U.S., Sanofi-Synthélabo successfully took back all
rights to Stilnox®/Ambien®/Myslee® as of April. 
Thanks to the efforts of its sales force, the U.S. affiliate
succeeded in achieving sales of 1.2 billion euros 
(+26.6%) by the end of 2002.
- Myslee® has achieved high market penetration in Japan.
Marketed since December 2000 through a joint venture
with Fujisawa, the product has already become 
the second leading hypnotic on the market. With an
18.5% market share in terms of sales, Japan is the
country with the second-highest sales of zolpidem.
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Epilepsy
Epilepsy is a frequent, chronic neurological disorder,
affecting approximately 1% of the population worldwide.
Children under 10 years old and the elderly are those
most frequently affected.
Epilepsy is characterized by repeated spontaneous seizures
resulting from an excessive discharge of cerebral neurons.
The characteristics of these seizures and their
repercussions, which include physical injury, loss of self-
confidence and even decreased autonomy, their origin, 
the presence or absence of associated symptoms and 
the quality of response to treatments make this 
a heterogeneous disorder.
Our understanding of epilepsy is improving with recent
progress in genetics and cerebral electrophysiology, and
also thanks to new techniques of functional cerebral
imaging. It is crucial to facilitate access to care, including
diagnosis, treatment and counseling. With adequate
treatment, the great majority of epileptic patients can
continue to live normal, productive and fulfilling lives.
Depakine®
sodium valproate
Epilepsy
2002: new pharmaceutical formulation approved
Depakine® is a broad-spectrum antiepileptic which has
been successfully prescribed for over 30 years.
Numerous clinical trials, as well as long years of experience
have abundantly shown that Depakine® is effective in all
types of epileptic seizure and epileptic syndrome, and is
generally well tolerated. Depakine® consequently remains 
a reference treatment for epilepsy worldwide. Furthermore,
in contrast to findings sometimes reported with other 
anti-epileptic agents, Depakine® does not induce
paradoxical aggravation of seizures.
The Chrono® form (prolonged release formulation) permits
once-daily administration in most cases, a criteria favoring
improved compliance with treatment and overall care of
the patient. Depakine® is available in a wide range of
formulations, permitting its adaptation to all types of
patients. A new pharmaceutical form, facilitating the use of
Depakine® particularly in children and the elderly, has
already been authorized for marketing in several European
countries and will be launched within the next few years.
Depakine® is marketed in over 100 countries, including the
U.S., where it is licensed to Abbott.
Chemical library: identifying compounds 
from our chemical resources.
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Neurotic and psychosomatic
disorders
Patients suffering from these disorders present a variety of
somatic complaints, associated with psychological distress.
It is estimated that these somatic complaints are the main
reason prompting 30% to 40% of patients to consult 
a physician.
Clinical investigations generally fail to reveal any organic
cause. The management of these patients is problematic,
with a frequent risk of self-medication, as well as a high
rate of prescription of complementary tests.
Dogmatil®/Dogmatyl®
sulpiride
Neurotic and psychosomatic disorders
At low doses, Dogmatil® 50 mg is used in numerous
countries for the symptomatic treatment of neurotic
and/or psychosomatic disorders. Its specific mechanism of
action on central and peripheral dopaminergic receptors
permits rapid improvement of the psychic state of the
patient as well as relief of functional symptoms in patients
who are difficult to treat.
At higher doses, Dogmatil® 200/400 mg is also 
proposed for the treatment of psychotic states. Its good
cardiovascular and neurological safety profile makes it
particularly suitable for the treatment of elderly patients.
Dogmatil® is available in over 90 countries, including
Japan, where it is marketed under the name Dogmatyl®
through a joint venture with Fujisawa.
Schizophrenia
A particularly severe and incapacitating disorder,
schizophrenia affects approximately 1% of the population.
It generally first appears during adolescence or early
adulthood. In the majority of cases, the disease follows 
a chronic course, necessitating long-term treatment 
and often recourse to hospitalization.
Two principal types of symptoms are distinguished, 
which may coexist or appear at different stages of this
progressive disease, acute or chronic: 
- positive symptoms, notably delusions and hallucinations,
most often occur during the acute phases,
- negative symptoms, characterized by introversion and an
incapacity for action, appear very early on or during the
chronic phase of the disease and lead to the progressive
social isolation of the patient.
Solian®
amisulpride
Schizophrenia
2002: launches in 12 countries worldwide, including
Australia, Belgium and Spain
This antipsychotic agent has an atypical pharmacological
profile. Its originality consists in its capacity to act
selectively on D3/D2 dopaminergic receptors and its dual
pre- and post-synaptic activity. Furthermore, its preferential
action on the limbic system confers excellent neurological
safety.  
Solian® is effective for all symptoms of schizophrenia, both
positive and negative, irrespective of the phase of the
disease, whether acute or chronic. At doses of 400 mg to
800 mg per day in patients with positive symptoms and
associated depressive symptoms, and at the optimal daily
dose of 100 mg in patients with dominant negative
symptoms, Solian® demonstrates both efficacy and very
good safety.
Solian® is available in the principal European markets and
worldwide in a total of 51 countries.
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Aspégic®
lysine acetylsalicylate
Fever, pain
Aspégic® is a salicylate with the original property of total
and immediate solubility. This characteristic confers both
very rapid efficacy as an analgesic, antipyretic and 
anti-inflammatory agent. 
Aspégic® is marketed in certain countries in Europe, 
Africa and the Middle East.
Internal Medicine
Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is the most common
benign tumor in men. Both the frequency of this condition
and the problems it engenders increase with age. 
The resulting urinary symptoms consequently affect 
22% of men aged 50-59 years, but up to 45% of men
aged 70-80 years.
By 2004, the aging of the population will result in an
increase in the number of patients affected by this
condition to over 55 million men. This number will
continue to rise to reach 60 million men in 2009. 
In addition, the rising expectations of this senior
population in terms of quality of life will lead to 
a 50% increase in the number of patients treated 
between now and the end of the decade.
The need is great, as both the diagnosis and the treatment
of this condition could be still further improved. A recent
survey, MSAM-7 (Multinational Survey of the Aging
Male), was conducted in seven countries: (United States,
France, Italy, United Kingdom, Spain, Germany and 
the Netherlands) in 14,000 men over 50 years old. 
This revealed that only 20% of men suffering from
moderate symptoms, and 43% of those with severe
symptoms, were receiving treatment. 
The urinary problems associated with benign prostatic
hyperplasia, not correlated with prostate volume, may
have a considerable effect on the patients’ quality of life.
They result, for example, in urgent and frequent needs to
urinate, causing substantial inconvenience particularly
when experienced during the night. 
Although benign in the majority of cases, untreated BPH
may in the long term trigger serious complications such as
acute urinary retention, and necessitate an emergency
surgical operation. This complication arises in 10% of
men aged 70 years within a period of five years.
The same survey, MSAM-7, also demonstrated the link
between urinary problems resulting from benign prostatic
hyperplasia and sexual dysfunction. Irrespective of age 
or other concomitant pathological conditions, men over 
50 years old presenting severe urinary symptoms 
due to BPH have a four-fold higher risk of developing
sexual problems.
Xatral®
alfuzosin
Benign prostatic hyperplasia
2002: launch of Xatral® OD
Alfuzosin was discovered by Sanofi-Synthélabo research
and marketed for the first time in France in 1988 under
the trade name Xatral®, administered at 2.5 mg three
times daily. Constantly improved since then, its optimal
pharmaceutical form, Xatral® OD (10 mg once daily) has
now been granted a product license in 70 countries and 
is marketed in 14 European countries and in more than 
35 other countries. 
In the U.S., the product filing for alfuzosin entered the
final phase of review in 2002 and the product should be
available during the course of 2003. This launch will
provide a substantial opportunity for growth: the U.S.
market alone represents 36% of worldwide sales of
medications for BPH, with sales of close to a billion euros
and a 19% annual growth rate.
Xatral® belongs to the alpha1-blocker class. It was the 
first product of this class to be indicated uniquely and
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specifically for the treatment of symptoms of benign
prostatic hyperplasia, and the first product capable of
acting selectively on the urinary system. Due to this clinical
uroselectivity it is immediately effective, with no need for
dose titration, and shows good tolerability, particularly
cardiovascular. Active from the first dose, it provides rapid
and lasting symptom relief and significantly improves
patients’ quality of life.
Besides relieving symptoms, the results of major clinical
trials completed in 2002 have demonstrated the original
contribution of Xatral® to the treatment of this condition
and the prevention of its complications.
- The results of the first phase of the ALFAUR trial notably
showed that Xatral® doubles the probability of a restored
capacity to urinate normally after an episode of acute
urine retention in conjunction with catheter insertion.
These are the first published results of an original
development program to demonstrate the capacities of
Xatral® to prevent the principal complication of benign
prostatic hyperplasia: acute urinary retention. Filings 
for extension in this indication have been submitted 
in the principal European countries.
- The preliminary results of another large international trial
on more than 800 patients have provided evidence that
Xatral® preserves sexual function in patients suffering 
from BPH.
Oncology
Colorectal cancer
Colorectal cancer is the third most frequent cancer
worldwide, with one million new cases diagnosed and
close to 500,000 deaths per year, and represents a major
public health problem. This disease is particularly common
in western countries. Colorectal cancers are hereditary in 
5% to 10% of cases, but otherwise their etiology is
generally explained in terms of behavioral factors such as
nutrition, excessive calorie intake and sedentary lifestyle. 
For localized forms of the disease, curative treatment is
based on surgery. However, the risk of relapse often
justifies the use of adjuvant chemotherapy.
For metastatic forms, chemotherapy has demonstrated 
its efficacy in halting or slowing tumor progression and
prolonging patient survival.
Eloxatin®
oxaliplatin
Colorectal cancer
2002: marketing approval in the U.S.
Eloxatin® is a new-generation platinum agent, the only one
with demonstrated activity in colorectal cancer. Its recent
introduction in the treatment of metastatic colorectal
cancer has led to major progress:
- prolonging median survival to 20 months when used as
first-line treatment; 
- enabling a significant proportion of patients with isolated
hepatic metastases to undergo surgical resection, 
due to the rapid and substantial reduction in the size of
these metastases with treatment. Eloxatin® consequently 
gives these patients the hope of substantially prolonged
survival. 
Eloxatin® was granted marketing approval in the U.S. in
2002 after a particularly rapid review by the Food and
Drug Administration. This was achieved on the basis of the
results of a large U.S. trial conducted on patients in relapse
after an initial treatment. Treatment with the combination
oxaliplatin + 5-fluorouracil (5-FU) succeeded in delaying
disease progression and demonstrated a clinical benefit in
terms of pain reduction, weight gain, and improvement of
general status. 
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Survival benefit with first-line treatment was also
demonstrated by one of the largest randomized trials ever
conducted in metastatic colorectal cancer. These data were
presented at the annual congress of the American Society
of Clinical Oncology (ASCO) in May. In this study,
conducted with the support of the U.S. National Cancer
Institute, oxaliplatin + 5-FU (Folfox regimen) was shown 
to be more effective and better tolerated than 
irinotecan + 5-FU (IFL regimen). The prolongation of
median survival of patients receiving oxaliplatin led to
premature discontinuation of the trial and the proposal to
treat all patients still enrolled in the trial with the
oxaliplatin-based regimen. A product filing for first-line
treatment will be submitted in the U.S. in 2003.
Already marketed in 60 countries, Eloxatin® plays a major
role in the development of new therapeutic strategies in
metastatic colorectal cancer. In view of its tolerability,
Eloxatin® is also being developed as an adjuvant treatment
for non-metastatic colorectal cancer, to prevent relapse
in patients whose recovery has not been achieved by
surgery alone. 
Its activity in colorectal cancer has also encouraged
specialists to explore the value of Eloxatin® in the
treatment of other tumors, particularly tumors of the
digestive system such as pancreatic cancer, but also 
ovarian and breast cancers, as well as certain 
hematological cancers.
Tumor lysis syndrome
While modern chemotherapies cure more and more
leukemias and lymphomas, particularly in children, the
need to prevent and manage their side effects is a major
preoccupation of the medical community.
These side effects may be serious, and even potentially
fatal. In certain types of cancer, the very rapid destruction
of the tumor by chemotherapy leads to a massive release
of uric acid that may overwhelm the kidneys’ capacity 
for elimination. Uric acid is poorly soluble and may
crystallize in the kidneys. Tumor lysis syndrome may
therefore lead to acute renal failure, sometimes
necessitating dialysis and inducing substantial morbidity.
At the very least, it imposes a delay in chemotherapy
administration, adversely affecting its efficacy. 
Fasturtec®/Elitek®
rasburicase
Tumor lysis syndrome
2002: market launch in Europe and the U.S.
Fasturtec®/Elitek® is a recombinant enzyme produced by
genetic engineering. Within less than four hours, 
it converts uric acid into highly soluble allantoin, 
easily eliminated in the urine, thereby avoiding tumor lysis
syndrome. Administered before or at the same time as
chemotherapy, Fasturtec®/Elitek® allows clinicians to
administer anticancer treatment in optimal conditions
without delays or dose reductions. 
Fasturtec®/Elitek® is the first biotechnology product entirely
discovered and developed by Sanofi-Synthélabo and
manufactured in its state-of-the-art manufacturing unit 
in Labège, France. Authorized for marketing in Europe 
in February 2001 (1.5 mg form), it was launched in the
first European countries in May 2001.
2002 saw:
- in Europe, marketing authorization of the 7.5 mg form 
in April and launch of the product in all countries,
- in the U.S., granting of a product license in July and
market launch in the following month.
The results of three clinical trials including 490 adult
patients, presented at the congress of the American
Society of Hematology in December, provided additional
evidence of the reliability and efficacy of Fasturtec®/Elitek®
in adults and in children.
Fasturtec®/Elitek® is also in clinical development in Japan. 
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- The CHARISMA trial will evaluate the benefit of the
combination clopidogrel + ASA in the prevention of
serious vascular events in more than 15,000 at-risk
patients. The trial started in September 2002.
- The ACTIVE trial in patients with atrial fibrillation, will
start in April 2003, with a planned enrollment of 
15,000 patients. 
A pediatric indication is in development following 
a written request from the FDA, and will permit a 
six-month extension of patent protection in the U.S. 
for all indications of Plavix®.
Finally, a product filing for clopidogrel, developed in
partnership with Daiichi, is scheduled to be submitted 
in Japan at the end of 2003.
Plavix®
clopidogrel
On the basis of the landmark trials CAPRIE and CURE, 
Plavix® has become the worldwide reference treatment 
for secondary prevention in patients suffering from
atherothrombosis, including acute coronary syndrome.
Sanofi-Synthélabo has implemented a vast program of
clinical trials designed to better define the therapeutic
benefit of Plavix®‚ in various patient populations at risk of
atherothrombosis and its most severe complications.
- The CREDO trial, presented at the annual scientific
sessions of the American Heart Association in November
2002, showed the importance of a prolonged treatment
of one year after stent placement in subjects presenting
with acute coronary artery disease.
- The COMMIT trial, in acute myocardial infarction,
currently includes almost 30,000 patients. Completion of
the trial is scheduled in 2004 with over 40,000 patients.
- The MATCH trial in patients experiencing a transient
ischemic attack or ischemic stroke completed patient
enrollment in April 2002, with 7,600 patients.
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Life Cycle Management of pharmaceuticals
A pharmaceutical product goes through several growth phases before reaching 
its full potential. 
The rate of progression depends on the drive for innovation and the resources 
allocated to this end.
“Life Cycle Management” consists in exploring new properties and new indications 
of a medicine already on the market. An original Life Cycle Management program 
can meet new medical needs which are unmet or insufficiently satisfied. 
It provides opportunities for innovation and progress which are at least as great as 
the launch of a new product.
The following examples provide graphic illustrations of this.
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Aprovel®
irbesartan
In addition to its development in hypertension, the post-
launch clinical development of irbesartan has been focused
on demonstrating its protective effect on target organs: 
the kidneys, the heart, the blood vessels and the brain.
This strategy’s originality rests on designing and
implementing innovative studies for diseases which 
are either insufficiently explored or for which there 
exists an unsatisfied medical need.
- The PRIME program has shown the renal protective
effect of irbesartan in early and late stages of diabetic
renal disease.
- The I-PRESERVE study explores the benefits of irbesartan
treatment in heart failure patients with preserved systolic
function.
- The ACTIVE-i study will explore the potentially beneficial
effects of irbesartan in atrial fibrillation as well as the
overall protection of the cardiovascular system.
Arixtra®
fondaparinux sodium
Prevention of deep-vein thrombosis 
and pulmonary embolism
Marketed in Europe and the U.S
Deep-vein thrombosis (DVT) results from three types of
risk: coagulation factor abnormalities, vascular injuries 
and increase in venous stasis, notably during prolonged
immobilization. They most frequently occur in the lower
limbs. The risk is highest after major orthopedic surgery: 
in 40% to 50% of patients undergoing elective hip
replacement, and in 70% to 80% of those undergoing
total knee replacement. The chief complication of DVT
is the migration of blood clots located in the lower limbs to
the lungs, where they trigger pulmonary embolism (PE), 
a potential cause of sudden death.
DVT and PE are therefore two expressions of a single
disease, venous thromboembolism (VTE). The third most
frequent cardiovascular disease after myocardial infarction
and stroke, VTE has an annual incidence of between 
2 and 3 per 1,000 inhabitants of western countries. 
Every year, VTE affects approximately two million
Americans, of whom at least 60,000 die as a result of
pulmonary embolism. VTE represents an annual cost 
of at least 2.9 billion dollars in the U.S. alone.
An original compound co-developed by Sanofi-Synthélabo
and Organon (Akzo Nobel), Arixtra® (fondaparinux
sodium) is the first entirely synthetic agent selectively
inhibiting a key enzyme in the coagulation process, factor
Xa. In contrast, other available treatments, low molecular
weight heparins (LMWH) and unfractionated heparin
(UFH), are of animal origin as they are obtained from the
intestinal mucosa of pigs, and act on multiple targets in 
the cascade of reactions involved in coagulation. 
The synthetic origin of Arixtra® and its selectivity of 
action ensure a high degree of purity and safety of use. 
In view of these two characteristics, it constitutes a real
technological and therapeutic advance.
Arixtra® in the prophylaxis of venous thromboembolism
Arixtra® has been extensively investigated in the
prophylaxis of VTE following major orthopedic surgery on
the lower limbs. In the four phase III trials conducted in
patients undergoing reconstructive surgery after hip
fracture or surgery for hip or knee replacement, Arixtra®
achieved a significant overall reduction of more than 
55% (p < 0.001) in the rate of venous thromboembolic
events, with a safety profile similar to that the reference
low molecular weight heparin.
A double-blind trial versus placebo conducted recently in
prolonged prophylaxis in patients undergoing hip fracture
showed that Arixtra®, administered for four weeks, resulted
in a reduction of 96% in the incidence of thromboembolic
complications (p < 0.001), combined with very good
tolerability. These results formed the basis for an 
extension of indication filing in Europe and in U.S. 
in December 2002.
Arixtra® in the curative treatment of venous
thromboembolism
Currently, the initial treatment of patients presenting a
documented DVT consists in the subcutaneous
administration of LMWH at a dose adapted to body
weight, usually as two daily injections for approximately
two weeks. In patients with PE, the initial treatment
remains the intravenous administration of unfractionated
heparin at an adjusted dose for the same duration. In both
these conditions, it is essential to administer a potent and
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rapidly acting antithrombotic during the acute phase,
followed by a treatment with vitamin K antagonist for 
3 to 6 months as secondary prophylaxis.
For methodological reasons, DVT and PE are studied
separately in clinical trials, but certain patients can suffer
from both disorders simultaneously. No currently available
product is capable of effectively and safely treating both
conditions with the same dosage regimen.
The MATISSE clinical trial program conducted by Sanofi-
Synthélabo and Organon on 4,400 patients with DVT or
PE was completed in 2002. The results of the MATISSE
trials represent a new advance in the demonstration of 
the efficacy and safety of Arixtra®. Administered
subcutaneously once daily at a fixed dose (7.5 mg),
Arixtra® is at least as effective and well tolerated as
treatments usually employed in the initial therapy of DVT
and PE, besides being easier to use. A filing for these new
indications will be submitted to health authorities in 2003
on the basis of the results of the MATISSE trials.
Arixtra®: other ongoing developments
The clinical development program for Arixtra® is continuing
in the prophylaxis of VTE in general surgery (PEGASUS and
APOLLO trials) and in medical patients (ARTEMIS trial). 
The results of these studies are expected in 2003.
A large-scale clinical program in arterial thrombosis is in
preparation, with over 25,000 patients planned. It will be
focused on the prevention of cardio-ischemic complications
in patients presenting an acute coronary syndrome. 
These clinical trials will be initiated in 2003.
zolpidem MR 
Sleep disorders
Phase III
Although numerous effective hypnotic treatments are
currently available on the market, led by Sanofi-
Synthélabo’s Stilnox®/Ambien®/Myslee® (zolpidem), they
do not meet the expectations of all insomniac patients. 
The problems of falling asleep and the quality of
awakening are satisfactorily addressed, but providing he
patient taking zolpidem with an even more restorative
sleep for the second half of the night is still an issue.
With this in mind, Sanofi-Synthélabo has developed a
formulation allowing the progressive release of zolpidem 
in the organism – zolpidem MR – which diminishes the
duration and number of awakenings during the second
half of the night without increasing residual sedative
effects when the patient awakes, a major advantage 
of zolpidem.
Two Phase III trials are ongoing, one in adults under 
65 years for which enrollment is completed and one in
elderly subjects. These trials are evaluating the hypnotic
properties of zolpidem MR, particularly with regard to
sleep maintenance. This Phase III program is completed,
among other trials, by two studies designed to
demonstrate the absence of residual effects on awakening.
The patent protecting the specific dissolution profile of
zolpidem MR was obtained on February 4, 2003 in the U.S.
Sanofi-Synthélabo’s objective is to submit the product filing
for zolpidem MR in the second quarter of 2004, in the U.S.
and then in Europe, i.e. 18 months before the patent
protecting the active ingredient of Ambien® falls into 
the public domain in the U.S.
E D I C I N E SM
our portfolio gets stronger and stronger 
M e d i c i n e s
51
Xatral®
alfuzosin
Benign prostatic hyperplasia (BPH) 
and acute urinary retention (AUR)
Marketed in Europe; product filing submitted 
in the U.S. for BPH
Benign prostatic hyperplasia
Xatral®‚ is marketed in this indication in Europe, and 
a new drug application (NDA) has been submitted 
in the U.S. Clinical development in benign prostatic
hyperplasia will be started in Japan in March 2003.
Acute urinary retention
Acute urinary retention is a frequent and severe
complication of benign prostatic hyperplasia, generally
culminating in surgery, the complications of which are all
the more frequent in that the operation is often performed
as an emergency. A clinical development program has been
implemented in Europe and the U.S. to assess the
therapeutic value of Xatral®‚ in the long-term prevention of
an initial episode of acute urinary retention in patients with
benign prostatic hyperplasia of an acute episode 
in conjunction with urinary drainage.
Eloxatin®
oxaliplatin
Metastatic colorectal cancer
Marketed
In 2002, Eloxatin® was granted a product license 
in the U.S. for the second-line treatment of patients 
with metastatic colorectal cancer. 
The results of a clinical trial studying the efficacy of
oxaliplatin in association with 5-FU in the first-line
treatment of colorectal cancer were presented at the
congress of the American Society of Clinical Oncology 
(ASCO) in 2002. This trial demonstrated a survival
advantage (p< 0.002) in patients treated with 
oxaliplatin + 5-FU, in comparison to those receiving the
reference treatment, irinotecan + 5-FU. 
These results will be submitted to the FDA in 2003 
in support of a supplementary new drug application
(SNDA) for Eloxatin® in the U.S.
The Arixtra® syringe was awarded the “User safety” prize in 2003.
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Spurred by the quality of medicines coming from its research,
Sanofi-Synthélabo continues to strengthen its international presence
and gain market share throughout the world.
This performance is represented by double-digit growth in both
consolidated and developed sales, up by 12.8%(1) and 14.5%(1)
respectively, confirming the trend established in recent years.
+17.5% (1) in the United States
+11.8% (1) in Europe
+10.3% (1) in other countries
Growth in consolidated sales reached double digits in all major areas.
All regions grew more rapidly than their respective markets. 
The United States, the world’s leading pharmaceutical market worldwide,
generated 37% of developed sales and 45% of the Group’s profits
Sanofi-Synthélabo is intensifying its efforts in Japan, the second leading pharmaceutical
market worldwide, to derive full benefit from its partnerships and to strengthen its 
direct presence.
(1) Growth based on comparable group structure and at constant exchange rates.
K e y  e v e n t s  i n  2 0 0 2
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Sales figures by geographic area in 2002
Consolidated sales Market Main product launches
(in millions of euros) Variation(1) share(2) in 2002
Europe including: 4 297 +11.8% 3.9%(3) -
France 1 546 +8.0% 7.9% Fasturtec®, Arixtra®
Germany 634 +7.0% 2.9%(4) Arixtra®
Italy 444 +3.6% 2.9% Fasturtec®, Plavix®
Spain 358 +21.7% 2.9% Solian®, Fasturtec®
United Kingdom 287 +7.9% 2.9% Arixtra®, Fasturtec®
Belgium 163 +21.9% 5.1% Fasturtec®, Solian®, Fraxodi®
Hungary 101 +23.7% 6.4% -
Greece 100 +37.8% 3.9% Arixtra®, Solian®
Turkey 98 +41.5% 2.5% Xatral OD®
Switzerland 92 +18.8% 3.8% Arixtra®, Fasturtec®
Scandinavia 91 +24.3% 1.5%(5) Arixtra® (Sweden, Finland, Norway 
and Denmark) Solian® (Denmark)
Portugal 88 +12.6% 3.7% Arixtra®
Poland 82 +15.7% 2.7% -
Netherlands 69 +26.6% 2.2%(4) Arixtra®
Czech Republic 41 +15.8% 3.8% Fasturtec®
Austria 35 +19.9% 1.8% Arixtra®
United States 1 689 +17.5% 1.8%(6) Arixtra®, Eloxatin®, Eligard®,
Elitek®
Other countries including: 1462 +10.3%
Asia/Middle East 423 +27.0% Solian®, Arixtra® (Australia)
Solian®, Xatral® OD (South Korea)
Latin America 327 +3.6% 1.9%(7) Arixtra® (Mexico and Colombia)
Japan 312 -0.7%
Africa 200 +6.5%
Eastern and Central Europe 116 +7.3%
(1) Growth based on comparable group structure and at constant exchange rates
(2) Sources IMS/GERS, 12-month Moving Annual Total December 2002
(3) 18 countries, retail market (excluding Czech Republic, Denmark, Sweden and Finland)
(4) IMS data adjusted to reallocate parallel imports to the company of origin
(5) Excluding Finland
(6) Determined on a basis of sales consolidated by Sanofi-Synthélabo and those generated through alliances in the U.S.
(7) Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela
Sales, market shares and growth in IMS/GERS data mentioned in the text of this Report on pages 53 to 63, correspond to annual figures at end December 2002 
at constant exchange rates, valued at “direct from manufacturer” prices 
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EUROPE
Consolidated sales: 4,297 million euros
Growth in sales
Source: IMS/GERS 12-month Moving Annual Total December 2002
Consolidated sales and growth in millions of
euros
Source: Sanofi-Synthélabo 2001 sales figures and growth on 
a comparable basis
All European countries, with varying degrees of intensity
and resources, are committed to a policy of curbing
healthcare expenditure. In 2002, the regulatory
environment was strengthened noticeably in two principal
markets. In Italy, cost-containment measures introduced in
September 2001 exerted their full effect in 2002 and were
accompanied in April by a 5% cut in all medicine prices. In
Germany, retail pharmacists were authorized to substitute
up to 5.5% of their sales with products imported from
countries with lower prices. The net result of these
measures was a decrease in prices.
Driven by the 15 leading products in the portfolio, which
showed growth of 17%, consolidated sales by Sanofi-
Synthélabo progressed by 12% to reach 4,297 million
euros. The Group gained market share in all countries
except Italy. A sustained effort with regard to patented
products enabled most affiliates to achieve a growth rate
exceeding that of their respective markets. Affiliates in the
United Kingdom, Denmark, Finland, Turkey, Austria and
Slovakia progressed twice as fast as their markets, while
those in Belgium, Poland, Switzerland, Sweden, Norway,
and the Netherlands outpaced the market by a factor of
three or more.
Recently introduced products showed strong growth. 
Sales of Plavix® rose by 50%(1)without any increase 
in price. Aprovel®/Avapro®/Karvea® (irbesartan) became 
the second ranking product in its class and the leading
antihypertensive in France. 
The ongoing launches of Fasturtec® and Arixtra®, 
both high technology products, herald promising results in
the coming months, though they did not significantly
affect performance in 2002. 
(1) Source IMS 12-month Moving Annual Total December 2002: 16 European
countries, hospital and retail
France
Consolidated sales: 1,546 million euros
Growth: +8.0%
Market share: 7.9%
Product launches in 2002: Fasturtec®, Arixtra®
The second half of the year was marked by a sharp
acceleration in the prescription of generics by physicians or
their substitution by pharmacists. In addition, the law on
social security system financing, passed in autumn 2002 for
the year 2003, represents a break with the previous legal
framework. It schedules the introduction of a system of
reference prices for medicines likely to be subject to
generic competition, and envisages the progressive
cessation of reimbursement of medicines which have
insufficient “medical benefit”. The positive aspect of these
measures is that they include mechanisms to facilitate
market access for innovative products, which are currently
being implemented. The law banks on a provisional
increase in health insurance expenditure of 5.3% in 2003,
compared to 3% in 2002. 
Sanofi-Synthélabo sales growth in France (source: GERS)
exceeded that of the market, with contrasting progression
by activity: 
- sales of ethical products, representing over 80% of total
sales, progressed slightly faster than those of the
affiliate’s other activities, notably boosted by sales of 
2001 2002
+11%
+8%
+10%
+12%
Market
Sanofi-Synthélabo
2001 2002
+12%3,843
4,297
v
L O B A L  D E V E L O P M E N TG
s t r o n g  i n t e r n a t i o n a l  p r e s e n c e
G l o b a l  D e v e l o p m e n t
55
the flagship products Plavix®, Aprovel®/Co-Aprovel®
and Eloxatine®,
- retail sales of generics progressed at the same rate as
those of the affiliate as a whole, whereas hospital generic
sales progressed twice as fast. These performances were
in line with the overall market development, 
- consumer health (OTC) sales stagnated in the context 
of a national market in regression. 
Within the ethical sector, the following points 
are noteworthy:
- extremely rapid progression of the Cardiovascular
portfolio, driven by Plavix® and Aprovel®,
counterbalanced by a regression of older products
subjected to generic pressure. Plavix® and Aprovel‚ are
promoted jointly with Bristol-Myers Squibb but all sales
are registered by Sanofi-Synthélabo. Plavix® is continuing
to progress very rapidly. Aprovel® became leader of the
angiotensin II receptor antagonist class in the summer
and is also the leading medicine in the antihypertensive
market as a whole in terms of market share, 
- vigorous growth of the Oncology portfolio, stimulated by
the progression of Eloxatine®. The initial results of 
the launch of Fasturtec® were positive. In contrast, 
the regression of Maxomat® was disappointing,
- limited progression of the Central Nervous System
portfolio due to loss of momentum in much of the
product range, despite the significant increase 
in sales of its leading products: Solian®, Stilnox®
and Depakine®/Depakote®.
- similar slowdown in the Internal Medicine portfolio,
despite the performances of Xatral® and Inipomp‚ which
achieved remarkable progression,
- finally, regression of the Thrombosis portfolio, pending
the expected renewal of growth from Arixtra® (launched
in December 2002).
Germany
Consolidated sales: 634 million euros
Growth: +7.0%
Market share: 2.9%
Product launch in 2002: Arixtra®
Major decisions designed to curb healthcare expenditure 
were taken in Germany in 2002: it was recommended that
pharmacists make up to 5.5% of total pharmaceutical sales
from parallel imported products and they were authorized to
substitute generics for medicinal products which are no longer
under patent protection. The latter measure affected important
products such as Depakine® and Cordarone®, as well as Stilnox®,
for which patent protection expired in 2001 in Germany.
In this challenging context, the affiliate nevertheless posted
growth slightly exceeding that of its market, if parallel imports
are included. This result was due to the success of strategic
products such as Plavix®, Eloxatin®, Aprovel® and Uroxatral®,
which progressed very strongly.
Italy
Consolidated sales: 444 million euros
Growth: +3.6%
Market share: 2.9%
Product launches in 2002: Fasturtec®, Plavix®
The Italian market was greatly penalized by a series of
decisions taken by the health authorities to reduce healthcare
expenditure: 
- right of generic substitution of non-patented products.
Enacted in September 2001, this measure affected the sales
of Ticlid®, Tildiem®, Deursil® and Sucralfin®,
- overall 5% price cut in April 2002,
- implementation of a decentralized policy giving regions 
a discretionary role with regard to the reimbursement 
and distribution of medicinal products,
- withdrawal of reimbursable status for Deniban® (amisulpride),
- hospital resale to the public of certain products purchased
by hospital pharmacies.
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Plavix®, launched in 2002, is not yet reimbursed.
Negotiations have been resumed with the health
authorities on the basis of the new indication of Plavix®
for acute coronary syndrome, obtained at the European
level. A final decision is expected in 2003.
The very good performance of the leading medicines –
Aprovel®, Eloxatin®, Fraxiparine®, Xatral® and Stilnox® –
nevertheless enabled the affiliate to maintain its positions.
Spain
Consolidated sales: 358 million euros
Growth: +21.7%
Market share: 2.9%
Product launches in 2002: Solian®, Fasturtec®
Due to parallel exports, the growth in consolidated sales
does not fully reflect the performance achieved nationally.
Domestic sales progressed by 12% (source: IMS), in an
internal market expanding by 10%. Plavix®, Aprovel® and
Eloxatin® achieved excellent performances. In contrast, the
loss of patent protection of Stilnox® adversely affected the
performance of this product.
Solian®, launched in May 2002, and Arixtra®, launched in
February 2003, were both granted the status of
reimbursable products. Seven months after its launch,
Solian® achieved 5% market share.
United Kingdom
Consolidated sales: 287 million euros
Growth: +7.9%
Market share: 2.9%
Product launches in 2002: Arixtra®, Fasturtec®
The dramatic development of parallel imports in the United
Kingdom necessitates differentiation between the affiliate’s
own sales and those of Sanofi-Synthélabo products 
within the country. For example, an estimated 85% 
of Aprovel® sales and 60% of Plavix® sales came from
parallel imports in 2002. 
On the basis of IMS data, sales in the U.K. continued 
to grow considerably faster than the market: 22% versus
10%. This progress was driven by four major products,
Plavix®, Aprovel®, Eloxatin® and Xatral®. 
The highly favorable opinions issued by the National
Institute for Clinical Excellence (NICE) on Eloxatin® and
Solian® are noteworthy. This official recommendation 
from one of the national authorities should benefit
prescriptions in 2003. 
Belgium
Consolidated sales: 163 million euros
Growth: +21.9%
Market share: 5.1% 
Product launches in 2002: Fasturtec®, Solian®, Fraxodi®
After implementing a reference price system in June 2001, 
the Belgian health authorities once again penalized products 
no longer protected by patents by diminishing their
reimbursement rate. Tildiem® 60 mg (the non-delayed 
release form), Ticlid®, Dogmatil® and Cordarone® were 
among the products affected.
The Belgian affiliate nevertheless achieved an excellent
performance, driven by the success of Plavix® and Aprovel®.
Aprovel® is now the leading AIIRA with a 26% market share. 
In contrast, sales of Stilnox® were slowed by the introduction 
of generics.
Recent launches provided further growth. Fraxodi® effectively
strengthened sales of Fraxiparine®. Eloxatin® got off to a very
good start in its first year of reimbursement and Solian®
captured a 7% market share in the fourth quarter of 2002.
Information systems - user support team.
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Hungary
Consolidated sales: 101 million euros
Growth: +23.7%
Market share: 6.4%
The change in government postponed until 2003 the
second stage of price increases for products with high sales
volumes and low prices, which was initially scheduled 
for mid-2002.
The portfolio as a whole generated sales growth slightly
exceeding that of the market. The key event this year was
the acquisition of a new manufacturing facility in Veres,
with a capacity of 40 million units. This site increased the
Group’s industrial capacity in Hungary to 100 million units.
This expansion will enable the production of Aprovel®,
Fraxiparine® and the first batches of Arixtra®.
Greece
Consolidated sales: 100 million euros
Growth: +37.8%
Market share: 3.9%
Product launches in 2002: Arixtra®, Solian®
In Greece, the introduction of new compounds remains
challenging. Concerned with reducing healthcare
expenditure, the health authorities continue to align prices
with the lowest found within the European Union, and the
time taken to grant reimbursable status to new compounds
is particularly long. 
The affiliate overcame these obstacles, thanks to the
therapeutic advantages of the products launched over the
last three years, and to highly focused marketing efforts.
Sales progressed faster than the market.
Aprovel® has become the leading product in its category
and has the second highest market share of all 
anti-hypertensives. Plavix® sales have doubled. Eloxatin®
is already used by half of the patients suffering from
colorectal cancer, even though it is not yet reimbursed.
Fasturtec®, in the year of its launch, attained a high 
rate of penetration in pediatric cancer treatment centers.
Stilnox® has a 60% market share and Xatral® has 19%.
Turkey
Consolidated sales: 98 million euros
Growth: +41.5%
Market share: 2.5%
Product launch in 2002: Xatral® OD
The Turkish market was affected in 2002 by 
30% inflation in retail prices and substantial delays 
in payments by the Social Security system.
Despite these challenges, the affiliate flourished during 
this year, with sales growing more than twice as fast as 
the market. This result was principally due to Plavix®,
Aprovel® and Fraxiparine®.
A team in the Impact Malaria project.
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- in Norway, where the use of new medicines continues to
progress, sales posted a sharp increase thanks to
Aprovel®, second in its market, Plavix®, despite limited
reimbursement, and Eloxatin®. 
- in Denmark, recovery of the affiliate was confirmed.
Aprovel®, Plavix®, Xatral® and Stilnoct® all showed
substantial growth rates.
Portugal
Consolidated sales: 88 million euros
Growth: +12.6%
Market share: 3.7%
Product launch in 2002: Arixtra®
In February 2002, the price of Aprovel® was reduced by
7%. Portugal is preparing to adopt a reference price
system in 2003.
The year 2002 was nevertheless satisfactory, with sales
growth exceeding market expansion by three points (IMS).
Sales of Aprovel®, Eloxatin® and Xatral® progressed steadily.
With almost 23% of the AIIRA market, Aprovel® was 
the second-ranking product in its category in December,
and in third position among antihypertensive treatments 
as a whole.
The granting of the acute coronary syndrome indication 
for Plavix® at European level permitted resumption 
of negotiations for its reimbursement, with hope of 
success in 2003.
Switzerland
Consolidated sales: 92 million euros
Growth: +18.8%
Market share: 3.8%
Product launches in 2002: Arixtra®, Fasturtec®
A new law considerably modified conditions for the
distribution of medicines in 2002, with regard to both
hospital and retail sectors. Products with high added value
such as Arixtra® should benefit from the new system. 
On the other hand, retail pharmacists are now authorized
to substitute generics for branded products.
The success of Aprovel®, leader in the AIIRA market, and
of Plavix® substantially enhanced the results of the Swiss
affiliate. Eloxatin® and Stilnox®, leaders in their respective
markets in terms of market share, as well as Xatral Uno®,
also contributed.
For the second year running, the affiliate achieved the
strongest growth among the top ten pharmaceutical
companies, achieving a growth 3.5 times greater than 
that of the market.
Scandinavia
Consolidated sales: 91 million euros
Growth: +24.3%
Market share: 1.5% (excluding Finland)
Product launches in 2002: Arixtra® in Sweden, Finland,
Norway and Denmark,
Solian® in Denmark
2002 was a good year in all Scandinavian countries, with
rapid progression of sales, exceeding market growth by a
factor of two to three. 
- in Sweden, a new system implemented in October 2002
separated pricing policy from the reimbursement process.
This system also makes generic substitution compulsory.
The affiliate’s performance was driven by the major
medicines Plavix®, Aprovel®, Xatral® and Stilnoct®, 
despite their already high market shares. 
- in Finland, there was a trend towards increased 
use of recently introduced medicines. Xatral® once daily,
launched in 2001, benefited from this trend, its sales
doubling within a year. Sales of Plavix® remained modest,
pending approval of reimbursement in its new indications.
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Poland
Consolidated sales: 82 million euros
Growth: +15.7%
Market share: 2.7%
With the prospect of entry into the European Union,
Poland implemented a new law in October 2002
concerning marketing approval, pricing, reimbursement
and the promotion of medicines. 
However, the reimbursement of innovative medicines,
blocked since 1998, has still not been included in 
these new regulations.
As a result, the affiliate was still without the most recent
compounds and concentrated its efforts on the other
products in the portfolio. Fraxiparine®, boosted by 
the launch of Fraxodi®, Depakine®, Xatral® and Stilnox®
all progressed strongly. 
Netherlands
Consolidated sales: 69 million euros
Growth: +26.6%
Market share: 2.2%
Product launch in 2002: Arixtra®
Aprovel® continued to lead the portfolio, attaining a
market share of 20.5% by December 2002.
Partially reimbursable since 2001, Plavix® achieved 
rapidly accelerating sales. Eloxatin® tripled its sales 
and Xatral® OD was also a success.
Czech Republic
Consolidated sales: 41 million euros
Growth: +15.8%
Market share: 3.8%
Product launch in 2002: Fasturtec®
The Czech Republic faced a difficult and competitive
environment, including pressure on reimbursement levels
for Solian® and Deniban®, which will take effect in 2003.
Despite these challenges, the affiliate succeeded in
maintaining an overall growth rate slightly higher than
that of its market. Fraxiparine®, Eloxatin®, Depakine®
and Stilnox® progressed strongly.
Austria
Consolidated sales: 35 million euros
Growth: +19.9%
Market share: 1.8%
Product launch in 2002: Arixtra®
Since October 1st, 2002, medicine reimbursement 
has been determined on the basis of pharmacological,
medical and economic criteria. If necessary, pharmaceutical
companies can appeal against decisions to a special
independent commission.
Plavix®, Eloxatin® and Fraxiparine® boosted the affiliate’s
sales growth to twice that of the market.
Medical marketing team, Latin America.
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UNITED STATES
Consolidated sales: 1,689 million euros
Developed sales: 3,505 million euros
Product launches in 2002: Arixtra®, Eloxatin®, Eligard®,
Elitek®
Sales growth
(1) Sales generated directly by Sanofi-Synthélabo in the U.S. 
(Source: IMS, 12-month Moving Annual Total December 2002)
(2) Sales generated directly by Sanofi-Synthélabo and through 
alliances in the U.S. 
(Source: IMS, 12-month Moving Annual Total December 2002)
Sales in millions of euros
(Source: Sanofi-Synthélabo, 2001 sales and variations on a comparable basis)
Despite slowing growth relative to 2001, the U.S. market
continued its expansion in 2002 (+12%). Sanofi-
Synthelabo continued to outperform the market, with
growth of 32% in developed sales (IMS – November 2001,
calculated on the basis of four weeks’ sales).
In 2002, the budgetary repercussions of the slowing U.S.
economy led to a major debate on health care expenditure
in the U.S. in 2002. The different states, partially
responsible for managing the Medicaid and Medicare
programs, all strengthened their pressure on medicine
prices, with requests for rebates, higher co-payments and
the creation of a “preferred medicines” status. Private
insurance organizations also continued to exert pressure on
prices. Also in 2002, increasing promotional restrictions
have come into effect through recommendations from the
Pharmaceutical Research and Manufacturers 
of America (PhRMA). 
The Group’s products are marketed in various ways:
- by the affiliate, Sanofi-Synthelabo Inc.,
- through an alliance with Bristol-Myers Squibb for Plavix®
and Avapro® - these sales are not consolidated by 
Sanofi-Synthélabo,
- through a 50-50 alliance with Organon for Arixtra®,
- through licensing agreements, for Cordarone®, 
Depakine® and Ticlid®, among others.
In 2002, both consolidated and developed sales showed a
progression of 18%. This performance was achieved
despite the decision of our partner Bristol-Myers Squibb to
reduce wholesalers’ stocks of Plavix® and Avapro®, and the
arrival of generics due to the expiry of Primacor® patent
protection. It also reflects the initial effects of the 100%
reacquisition of rights to Ambien® in April 2002 and the
subsequent marketing efforts. Developed sales of Ambien®
progressed by 27% to 1,208 million euros. In total, the
U.S. currently accounts for almost a quarter of the Group’s
worldwide consolidated sales and over a third of its
developed sales.
Flagship products were clearly the principal driving force
for growth. Despite the stock-reducing operation
mentioned above, developed sales of Plavix® increased by
23% to 1,565 million euros, while those of Avapro®
remained at the same level as last year at 373 million
euros. Prescriptions of these two products increased by
33% and 13% respectively*. Plavix® benefited from the
extension of its indication to acute coronary syndrome, 
on the basis of the CURE trial, and Avapro® from the
approval of its supplementary new drug application
(SNDA) for the renal protection of hypertensive patients
suffering from diabetes, on the basis of the PRIME
program. The attack on the patent protecting Plavix®
by two generic companies was met by a vigorous
counterattack launched jointly by Sanofi-Synthélabo 
and Bristol-Myers Squibb. 
2001
+18%1,437
2,958
2002
1,689
3,505 
v
+18%
v
Consolidated
Developed
U.S. Market Sanofi-
Synthélabo(1)
Presence(2)
+12%
+21%
+32%
* IMS NPA plus, 12-month Moving Annual Total December 2002.
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Arixtra® was launched in February through a 50/50 alliance
with Organon. Despite an extremely complex and
challenging environment, this product was successfully
introduced into a significant number of hospital
formularies.
The year 2002 ended on a very positive note, with sales 
of 116 million euros attained by Eloxatin® only four months
after its launch for the second-line treatment of colorectal
cancer. Sanofi-Synthélabo was also granted a product
license for two presentations of Eligard® for the treatment
of advanced prostate cancer (under license from Atrix) as
well as a marketing approval for Elitek® in the treatment 
of chemotherapy-related hyperuricemia in children. 
Both these products were launched in 2002.
OTHER COUNTRIES
Consolidated sales: 1,462 million euros
Asia/Middle East
Consolidated sales: 423 million euros
Growth: +27.0%
Product launches in 2002: Solian® and Arixtra®
in Australia, 
Solian® and Xatral®
in South Korea,
Supported by Plavix®, Aprovel®, Stilnox®, Eloxatin®
and Xatral®, sales growth in the Asia-Pacific region
continued at a rapid rate, significantly higher than that of
the different markets, particularly in Australia and South
Korea. This result is all the more impressive in that it was
achieved in a context of healthcare cost containment,
notably in Hong Kong.
Sanofi-Synthélabo increased its presence in the region. 
An affiliate was created in Indonesia in partnership 
with Combiphar, and the Group took a 100% stake in 
its affiliate in India. 
- In Australia, sales reached 97 million euros (+29%). 
The affiliate registered the strongest growth in the market. 
- In Taiwan, sales totaled 44 million euros. The growth of
Plavix® and Aprovel®, now on the formularies of almost
all medical centers, was very strong. Growth of Stilnox®
and Eloxatin® was curbed by generic competition.
Marketing and medical teams were strengthened..
- In South Korea, a strategic market, sales increased by
61.9% to 72 million euros, despite the policy of
restricting healthcare expenditure. The market share of
the affiliate more than doubled. The Group is examining
opportunities for external growth.
- In the Philippines, sales reached 41 million euros 
(+18%). Lactacyd®, a consumer health (OTC) product,
remained the affiliate’s leading product.
- In China, the policy of healthcare cost restriction is
continuing, strengthened by a fall in the price of generics.
With sales of 39 million euros (+18%), the Group is now
established in this country. 
- In the Middle East, the Group’s activity is progressing
strongly, principally in Saudi Arabia. Total sales reached
65 million euros (+31%). A scientific unit was set up in
Egypt to strengthen the Group’s presence in this major
market.
Latin America
Consolidated sales: 327 million euros
Growth: +3.6%
Product launches in 2002: Arixtra® in Mexico 
and Colombia
This region of the world experienced a series of major crises
in 2002, affecting Argentina, Brazil and Venezuela
successively. All currencies lost value relative to the euro.
Foreseeing the consequences of this unfavorable economic
situation and concerned with protecting its profitability, 
the Group chose to reduce the stocks of its products 
held by wholesalers in Mexico and Brazil.
In the region as a whole, the growth in sales according to
IMS data increased by 16%, exceeding market growth 
(+13%) by three points.
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The following four countries accounted for more than 
80% of the total sales of the region.
- In Mexico, after a very strong progression in 2001, sales
of the affiliate were stable at 111 million euros, due to
the reduction in stocks, and did not reflect the increased
market growth of our products (+17% - IMS). Arixtra®
was launched in the second half of 2002, in partnership
with Organon.
- In Brazil, the affiliate’s sales were stable for the same
reason, remaining at 88 million euros, whereas the
market progression of our products was +11% (IMS), 
a performance in line with overall market growth.
- In Colombia, the affiliate strengthened its presence in 
an expanding market. Sales reached 44 million euros 
(+11%) and the year 2002 saw the launch of Arixtra®.
- In Venezuela, the very strong progression in sales to 
22 million euros permitted gains in market share.
Japan
Consolidated growth: 312 million euros
Growth: -0.7%
In a challenging operating environment, characterized 
by a sluggish market, the affiliate posted growth of 9%, 
not counting the licensing-out of Panaldine® (ticlopidine) 
to Daiichi.
This performance was attained thanks to a range of
initiatives that are already bearing fruit. Launched at the
end of 2000, the hypnotic Myslee® (zolpidem), marketed 
in partnership with Fujisawa, achieved sales of 62 million
euros in 2002 (IMS) and held an 18.5% market share by
the end of the year. Myslee® has already become the
second leading treatment in its category and should
become the market leader in 2003 or early 2004. 
At the same time, Sanofi-Synthélabo is actively pursuing
its strategy of development in Japan, the world’s second
largest pharmaceutical market. This goal is being met in
several ways: the Group is strongly reinforcing existing
joint ventures and optimizing their management, while
preparing for a direct presence and continuing to closely
examine all opportunities for external growth.
Product license applications are being submitted in rapid
succession: the submission of an application for irbesartan
in the fourth quarter of 2002 will be followed by those 
for clopidogrel in 2003 and fondaparinux sodium in early
2004. To enhance the Group’s profile and to draw the
attention of prescribers to its products, the development of
local clinical trials is being intensified: patient enrollment
for a Phase III trial on clopidogrel in stroke is now
complete; patient enrollment for two Phase IIb trials on
fondaparinux sodium is progressing on schedule; Phase I
trials on rasburicase have been completed, and Phase II
trials on rimonabant and dronedarone have started.
Consumer health customer service.
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Africa
Consolidated sales: 200 million euros
Growth: +6.5%
Overall growth in Africa masked contrasting situations
among the different countries.
- In Algeria, consolidated sales reached 52 million euros,
up by 14%.
- In Morocco, overall sales amounted to 80 million euros, 
a growth rate of 2%.
- In Tunisia, business activity progressed appreciably 
in parallel with market growth to attain sales of
15 million euros.
- South Africa maintained its impetus with a 20% increase
in sales, still driven by the very good performances of
Stilnox®, Plavix® and Depakine®. Taking into account the
negative impact of the devaluation of the rand, net sales
were slightly down at 20 million euros.
- In other African countries, business activity was slowed
by political instability and economic disruptions affecting
several countries within this zone. Sales amounted to 
33 million euros, representing very slight growth, notably
due to opening of new markets in East Africa.
Central and Eastern Europe
Consolidated sales: 116 million euros
Growth: +7.3%
In contrast to other Eastern European countries, sales in
Russia were flat. The Russian market was disrupted by 
the imposition of VAT on pharmaceutical products and 
the introduction of a new certification system. Despite
sustained growth of the flagship products, overall
development of activity was curbed by the stabilization of
sales of No-Spa®, which remains the leading product both
for the affiliate and in the Russian market.
The overall situation in Romania remains precarious in view
of the size of the national debt and the chronic delays in
payments to hospitals by social security systems, affecting
distribution. The affiliate experienced strong growth,
notably due to Plavix®, recommended in the context 
of a national program to combat stroke.
In the Baltic countries, growth slowed as a result of
economic difficulties affecting social security systems. In
Lithuania, the development of Plavix® sales suffered from
the introduction of prescription quotas affecting 
the medical community. In Latvia, the bankruptcy of 
the Health Insurance Fund had severe repercussions on the
entire distribution system during the first half of the year.
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The pharmaceutical industry is controlled by extremely
exacting national and international rules and regulations.
These directly affect both development and strategy.
The main objective of Sanofi-Synthélabo, along 
with other pharmaceutical companies, is to launch
innovative products worldwide as quickly as possible,
within the framework of the constraints imposed by the
administrative authorities to obtain regulatory approval.
A strictly controlled industry
Because the pharmaceutical industry directly affects 
human health and lives, it is strictly controlled at every
stage of its operations on both national and international
levels. Numerous regulations cover the implementation of
preclinical and clinical trials, establishing the modes of
evaluation for tolerability and efficacy which are needed
for the approval of a New Chemical Entity and determining 
the modes of manufacture, packaging, labeling and
marketing of medicines. These regulatory constraints 
are intended to evaluate whether an active ingredient 
can eventually become a medicine, as well as 
the amount of time and the investment necessary 
for such a development.
Each regulatory authority can impose its own conditions,
refusing to grant authorization or requiring complementary
studies, even if the product concerned has been registered
in another country.
The time required to obtain marketing approval varies 
from country to country and can be lengthy. In many
cases, notably in Japan and in several member states of 
the European Union, negotiations on price or on
reimbursement rates with the regulatory authorities 
can extend the procedure significantly.
The United States and the European Union have worked
hard with Japan to harmonize the registration document 
to be submitted, entitled a Common Technical Document
(CTD). Within the European Union, requests made to 
the European Agency for the Evaluation of Medicinal
Products in accordance with the centralized procedure,
make it possible to obtain marketing approval which is
valid for all E.U. member states. This procedure 
is obligatory for all biotechnology products and 
is optional for other active ingredients. 
Under another procedure, the mutual recognition
procedure, once an initial authorization is granted by 
a member state, approval can be requested in other E.U.
countries. Requests for authorization on a national level 
are reserved for products which are intended to be
marketed only in the country concerned, or for 
extensions to existing national product licenses. 
In the U.S., New Drug Applications (NDA) are filed 
with the Food and Drug Administration (FDA).
Generally speaking, files submitted for marketing 
approval are supported by clinical trial results which show 
the quality, tolerability and efficacy of the medicine. 
All indication extensions are the subject of a new filing, 
in both the U.S. and Europe. Once marketing approval 
is obtained, the proprietor of the medicine must indicate
cases of undesirable side effects and must submit periodic
reports. For certain medicines, the regulatory authorities
can demand complementary post-approval trials to
evaluate long-term effects or certain specific conditions 
of use. The manufacturing facilities must be approved 
and are periodically inspected by the regulatory
authorities. In addition, manufacturing facilities 
which are located outside the U.S. and export 
products to the U.S. market must be approved by 
the FDA and are subject to periodic inspections. 
In most countries, manufacturers of pharmaceutical
products must respect Good Manufacturing Practice
(GMP) in order to be approved.
How Sanofi-Synthélabo’s global business functions
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Direct marketing and
partnerships: 
strategies adapted to 
the countries concerned
Sanofi-Synthélabo markets and promotes its
pharmaceutical products through its affiliates and
representative offices. Global marketing strategy is adapted
by the various Group affiliates to the needs of their local
markets. The Group’s worldwide sales force now counts
more than 10,000 people, including 4,900 in Europe and
more than 2,000 in the U.S. where the number of medical
sales representatives has doubled in two years.
Certain Sanofi-Synthélabo products are marketed through
alliances. Sanofi-Synthélabo has formed two major
alliances for the marketing of three of its products.
- The first with Bristol-Myers Squibb (BMS) for the marketing 
of Aprovel®/Avapro® and Plavix®.
- The second with Organon, a subsidiary of Akzo Nobel, 
for the marketing of Arixtra®.
The nature of these agreements, whether co-marketing,
exclusive marketing or co-promotion, vary according to 
the territories concerned. The alliances are detailed 
in note C-1 of the consolidated financial statements
presented on pages 36 and 37 of the financial report.
Counterbalancing this, Sanofi-Synthélabo has built its
presence in the U.S. in April 2002 through the acquisition
from its partner Pharmacia of its interest in the Lorex joint
venture. This joint venture marketed zolpidem under the
name Ambien® on the U.S. market.
In Japan, Sanofi-Synthélabo markets its products mainly
though alliances or licensing agreements with other
companies. The most important of these have been
concluded with Fujisawa for Myslee®, Dogmatil®
and Pimperan®; with Daiichi for Ticlid®; with Taisho 
for Cardarone®; with Mitsubishi for Kerlone®
and with Yamanouchi for Corotrope®.
Other agreements strengthen the presence of Sanofi-
Synthélabo, e.g. via alliances in certain countries such as
Slovenia, China and Vietnam.
A crucial issue: 
industrial property
The protection of patents and trademarks is of utmost
importance. Sanofi-Synthélabo’s policy is to protect them
throughout the whole world.
Patents on individual products last for twenty years as from 
the date of patent submission: this protection can be extended
in certain countries. The degree of protection varies in
accordance with the existing legislation in each country. 
Is some countries, including E.U. member states, the U.S. 
and Japan, many Sanofi-Synthélabo products can also benefit
from five to ten years of marketing exclusivity. This period of
exclusivity can protect a product from generic competition
even if there is no more patent protection. In all cases, Sanofi-
Synthélabo is vigilant regarding the activities of its competitors
and systematically attacks infrigements of patents and
trademarks. 
Sanofi-Synthélabo possesses more than 9,000 patents
throughout the world, and has obtained licenses for 
around 30 patents. These patents cover active ingredients,
pharmaceutical formulations, product manufacturing processes,
intermediate chemical compounds used in manufacturing or
therapeutic indications. 
Product patent expiry can lead to significant competition 
from generic products, along with a considerable drop in sales
figures. If some products like Cordarone® and Dogmatil® no
longer benefit from patent protection, others such as Tildiem®
and Depakine® continue to be protected through their
formulation. The principal patents for milrinone expired in the
U.S. in May 2002, where it was sold under the name
Primacor®. Plavix® is protected in the U.S. by five patents listed
in the Orange Book, expiring respectively in 2003, 2011, 2014
and 2019; in Europe, the patents expire in 2003, 2013 and
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2019. Aprovel® is protected in the U.S. until 2011 and in
Europe until 2012. The principal patents for Stilnox® expire
between 2002 and 2006, in 2006 for the U.S. and Japan.
Arixtra® benefits from marketing exclusivity in the U.S. until
2006 and in Europe until March 2012.
In the U.S. and Canada, generic drug manufacturers have filed
Abbreviated New Drug Applications for generic versions of
Plavix®, challenging the validity of certain Sanofi-Synthélabo
patents for clopidogrel. 
Sanofi-Synthélabo considers that its patents are valid and
intends to defend them vigorously. Despite the fact that the
situation is gradually improving, thanks to international
agreements, the absence of recognition for industrial property
rights poses difficulties in certain countries.
Competition 
and pricing pressure
Sanofi-Synthélabo is currently the second pharmaceutical
group in France, the seventh in Europe and among 
the top twenty worldwide. Market shares by geographic
zone are detailed in the Global Development section,
pages 53 to 63 of this Report; the description of different
medicines is on pages 34 to 51.
The pharmaceutical industry is highly competitive. 
This competition exists between pharmaceutical companies
in the development of new patented medicines, 
between compounds patented by different pharmaceutical
companies for identical therapeutic indications and
between original products and considerably cheaper 
bio-equivalent generics once patent protection expires. 
Patented products which are launched on the market 
enter into direct competition with other products
developed for the same therapeutic indications. 
This is particularly the case with Aprovel®, Eloxatin®
and Arixtra®, which have to face competition from other
products which have recently appeared on the market 
or are currently in last phases of development 
by other companies. Aprovel® is in direct competition with
Cozaar® from Merck and Diovan® from Novartis, Eloxatin®
with Campto®/Camptosar® from Aventis/Pharmacia.
Arixtra® competes with the low molecular weight 
heparins, notably Lovenox® from Aventis.
When a pharmaceutical product loses its patent protection,
it generally has to face competition from generic products.
For example, since Primacor®’s U.S. patent protection
expired in May 2002, it has faced direct competition 
from generics which has led, as forecast, to a significant
drop in sales for this product. This competition from
generic products is constantly growing, due to increasingly
stringent national policies to limit healthcare expenditure,
and there are more and more attempts by generic
manufacturers to challenge patent protection. 
(see page 89 of the Financial Report)
The normal effect of competition is to influence prices. 
In addition, the aim of controlling healthcare expenditure
at a national level leads to a hardening of market
conditions in most countries where Sanofi-Synthélabo 
is present. Agreed or mandatory price reductions, ceilings
on promotional expenditure and/or profits, difficulties of
access to medicine reimbursements or rate reductions,
seeking the best price/efficacy ratio, etc. – the mechanisms
implemented vary from one country to another but the
spirit is the same. These measures can entail considerable
price differences between markets. Accentuated by
currency fluctuations, these variations can be exploited by
parallel importers who obtain branded products on the
markets with the lowest prices to sell them on the markets
with the highest prices.
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Investments - Principal sites
Investments are detailed in note D6 of the consolidated
financial statements, presented on page 41 of the 
Financial Report.
The main administrative centers are located in Paris.
Sanofi-Synthélabo owns or rents offices, R&D centers 
and manufacturing facilities throughout the world.
In 2002, Sanofi-Synthélabo spent 423 million euros,
mainly to increase its manufacturing capacity for 
new products.
Sanofi-Synthélabo considers that its manufacturing
facilities and R&D centers are sufficient for the Group’s
needs in the near future.
The table below lists the main manufacturing, distribution,
R&D and administrative sites. Sanofi-Synthélabo also 
has other sites throughout the world which serve local 
and regional markets.
Chemical and pharmaceutical manufacturing
Aramon, France 
Sisteron, France
Ambarès, France
Tours, France
Notre-Dame de Bondeville, France
Quetigny, France
Riells, Spain
Fawdon, U.K.
Ujpest, Hungary
Csanyikvolgy, Hungary
Verès, Hungary
R&D
Montpellier, France
Toulouse, France
Great Valley, PA, U.S.
Bagneux, France(1)
Chilly-Mazarin, France(1)
Porcheville, France
Alnwick, U.K.
Principal sites
Distribution
Chilly-Mazarin, France
Amilly, France
St. Loubès, France
Administration
Sanofi-Synthélabo
174 Avenue de France,
Paris, France
Sanofi-Synthélabo
74-82 Avenue de Raspail
Gentilly, France
Sanofi-Synthélabo Inc.
90 Park Avenue
New York, NY, U.S.
(1) These buildings were constructed under leasing agreements, under the terms of which Sanofi-Synthélabo pays the rental fees and can exercise an option
to purchase when the leasing agreements expire. Sanofi-Synthélabo finances the cost of repairs, taxes and other costs for the duration of the leasing
agreement. The leasing agreements are listed as debit in the consolidated accounts.
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We can distinguish three key steps in pharmaceutical
production: active ingredient synthesis (chemical
manufacturing), product formulation (pharmaceutical
manufacturing), and distribution. Each stage of the process
is conducted under strictly controlled conditions defined by
specific regulations. 
Sanofi-Synthélabo’s industrial strategy is based on an
absolute requirement for safety, ensuring market supply by
investing in manufacturing capacity, and constantly striving
for quality in medicine production. 
This requirement has led the Group to develop and
manufacture most the active ingredients used in 
its products. Equally in the interests of safety, 
the objective of Sanofi-Synthélabo is to obtain official
authorization for two production units in the manufacture
of each key active ingredient and each finished product.
The Group similarly has the policy of ensuring several
sources of supply for its raw materials. 
Chemical manufacturing
The three chemical manufacturing units located in Aramon
and Sisteron in France, and in Ujpest in Hungary, 
produce most the active ingredients used by Sanofi-
Synthélabo. All three sites have been approved by 
the U.S. Food and Drug Administration (FDA), 
testifying to their high level of manufacturing quality.
The investments made during recent years have enabled
the Group to respond to strong growth in demand 
and to introduce increasingly efficient modes of synthesis.
Gains in productivity and organizational rationalization
have led to an appreciable reduction in costs.
In 2002, the Andromeda building on the Sisteron site 
was inaugurated, assuring, in liaison with Scientific 
Affairs, the chemical development of new compounds
under optimal conditions. In parallel, the Aramon site 
has completed the necessary preparations for 
ISO 14001 certification.
How Sanofi-Synthélabo produces its medicines
Safer medicines thanks to constant efforts to improve quality
L O B A L  D E V E L O P M E N TG
s t r o n g  i n t e r n a t i o n a l  p r e s e n c e
G l o b a l  D e v e l o p m e n t
69
Pharmaceutical Distribution
Safety in terms of market supply also necessitates
optimization of the distribution process. The year 2002 
saw improvement of the supply chain organization,
through joint efforts with European affiliates. 
Major investments, implementation of computerized
systems, and the introduction of standard indices, 
have made it possible to manage this chain more
effectively at a worldwide level, improving supply flows
and reducing costs, while respecting quality standards. 
Conclusion
Safety, quality, cost control, productivity and social
dialogue on the basis of shared managerial principles: such  
were the strategic goals set by Industrial Affairs in 2002.
Pursuit of these goals resulted in a significant improvement
in our performance in 2002, which will continue into 2003.
Pharmaceutical manufacturing
Pharmaceutical manufacturing in Europe is currently
ensured by a complex of six manufacturing facilities 
in France, two in Spain, one in Italy, one in the U.K., 
one in Poland and three in Hungary. These sites are both
specialized and complementary. This organization ensures
the necessary capacity to meet to demand while providing
several alternative manufacturing sources for each of 
the major products.
The acquisition in July 2002 of a new factory in Hungary,
located a few kilometers from Ujpest, will strengthen
manufacturing potential. An ambitious investment 
program has already been initiated.
Our manufacturing facilities conform to international
quality norms required by the pharmaceutical industry. 
In 2002, our efforts to optimize quality enabled us to
successfully pass the various tests necessary for 
certification by the FDA and the European Agency 
for the Evaluation of Medicinal Products (EMEA).
Through our manufacturing facilities located outside
Europe (in Latin America with factories in Brazil, Mexico
and Colombia, in Asia with factories in China, Korea and
Vietnam, or in Africa with factories in Morocco) local
markets also benefit from our industrial expertise.

U R  R E S P O N S I B I L I T YO
 Our responsibility as a pharmaceutical group 
 The dynamics of continuous progress: 
a methodology for our HSE policy
 Our social responsibility 
 Our corporate responsibility: 
to inform and communicate
The difficulty encountered by the most vulnerable countries
in gaining access to medicines constitutes an unacceptable
situation. The pharmaceutical industry is conscious of 
the critical human and social importance of this issue, 
and is cooperating in the search for solutions. 
In this context, it must reconcile two imperatives: to reduce
the price of medicines to reach a cost level accessible to
patients in impoverished countries, while at the same time
ensuring respect of intellectual property rights. 
If this latter objective is not achieved, the pharmaceutical
industry will no longer be able to support the financial cost
of an ambitious research policy, the basis of its existence.
The "Impact Malaria" project initiated by Sanofi-Synthélabo
Facilitating access to medicines
two years ago is consistent with this view. Its aim is 
to provide the populations most affected with the means 
of combatting a major disease: malaria. Approximately 
300 million cases of infection per year worldwide lead to 
2.7 million deaths annually. 
90% of those contracting the disease live in Africa. 
The great majority of them are children.
Thanks to the efforts of the Group's scientists and a
dedicated team, the first products will be available in 2003.
(They will be distributed according to a specific program 
in order to guarantee that they are actually used by 
the targeted populations). Local production of these drugs
within Africa is currently under review.
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For thirty years, Sanofi-Synthélabo has been meeting a crucial need:
safeguarding health through the development of safe and effective
medicines consistent with ethical principles. The Group now intends
to expand this goal by responding to two of the major challenges 
of our time: the combat against rare but severe diseases and access
to medicines in the most impoverished countries.
The first products developed in the Impact Malaria project, designed to 
combat this disease which is endemic in developing countries, should be made available in 2003.
Fumagillin, in development for the treatment of intestinal diarrhea of parasitic origin, 
was included in the European Union list of orphan drugs in February 2002.
K e y  e v e n t s  i n  2 0 0 2
U R  R E S P O N S I B I L I T Y  A S  O
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Integrating ethical concerns
into clinical studies  
All clinical studies are performed in accordance with Good
Clinical Practices, and in close cooperation with health
authorities, to ensure scrupulous respect of ethical
principles: evaluation of the benefit/risk ratio, complete
patient information and patient's consent to participate
in the study.
Limiting animal
experimentation 
For ethical, scientific and legal reasons, animal
experimentation constitutes an essential step in research
prior to clinical studies in humans. These experiments are
subject to strict regulations, both national and international.
Going beyond the compulsory norms, Sanofi-Synthélabo has
developed an "International code for the use of laboratory
animals". Its objectives include: reducing to a minimum the
number of animals used in studies, taking care to prevent
any suffering, and developing alternative methods.
Targeting rare diseases
The Group considers that it has a moral obligation to focus
not only on widespread diseases, but also on severe diseases
that are rare and either untreated or poorly treated, 
even though the sales potential of drugs indicated for
these diseases is low.
A specific R&D effort has already culminated in the launch
of Fasturtec® (rasburicase) in 2001, for prevention 
of the increase in blood uric acid levels during
chemotherapy of acute leukemia. This complication may
develop in children.
Other compounds are also in development, including
fumagillin, designed to combat intestinal diarrhea 
of parasitic origin in patients with immune deficiency.
Fumagillin was included on the European Union list 
of orphan drugs on February 4, 2002
Defining and applying clear
bioethical rules 
Discoveries in genetics and molecular biology have already
led to major therapeutic advances and will continue 
to do so. They have also obliged society as a whole, 
and particularly the medical  community and the
pharmaceutical industry, to draw up clear and transparent
rules with regard to gene therapy, genetic modification 
and the use of human tissues and embryos. In particular,
it is indispensable to control the origin and use of stem cells.
With the aim of developing innovative medicinal products,
Sanofi-Synthélabo is studying the mechanisms of
differentiation of adult stem cells. However, the Group 
has no program on embryonic stem cells. 
Ensuring the quality 
and safety of medicines 
This is the most crucial imperative for a pharmaceutical
group. At Sanofi-Synthélabo, 1,600 employees,
corresponding to 5% of the workforce, are dedicated to
the continuous monitoring of drug quality. They intervene
in all areas of activity and in all affiliates worldwide.
Selecting suppliers
Whether purchasing raw materials or active ingredients,
marketing its medicinal products, or contracting out clinical
trials, Sanofi-Synthélabo requires its partners to respect rules
ensuring quality, safety, environmental protection and ethics
identical to those the Group imposes on itself. This criterion 
is crucial in the selection of its suppliers and external
contractors.
! The Group also publishes a Sustainable Development Report, detailing the actions described above.
Identifying the hazards
Scientific expertise in the service of health
The prevention of chemical and biological risks necessitates
a thorough and constantly updated knowledge of 
the intrinsic hazards of the materials handled on our sites. 
Our scientists place their expertise at the service of 
the Group's employees, assessing the risks of exposure 
to biological or toxicological hazards from the stage 
of research and development of new compounds.
COVALIS: 
committee for the prevention of chemical risks
Created in 1993, Covalis, Sanofi-Synthélabo's internal
exposure limits committee, comprises a multidisciplinary
team of experts in industrial toxicology, industrial hygiene 
and toxicovigilance, physicians, legal experts, representatives
of research facilities and delegates from chemical synthesis
and pharmaceutical manufacturing units.
This committee evaluates physical, chemical and toxicological
properties and the consequent hazards of all chemical 
and pharmaceutical substances handled on the Group's
various sites.
The Covalis committee also draws up  the toxicological
study program and interprets the results. Finally, it classes
the substances in five categories according to their
potential hazard by inhalation and through contact with
the skin, and defines the limits of occupational exposure
that should  be respected in the workplace.
All these data are communicated to all facility directors 
and HSE coordinators, enabling them to assess the risks 
at each workstation and to determine the appropriate
means for their prevention: standard operating procedures,
collective or personal protective equipment. This system 
is implemented by all employees in all research, chemical
and pharmaceutical activities.
Covalis experts also analyze the data of toxicovigilance
collected by the Occupational Physicians. All clinical events
occurring after exposure of an employee to 
a substance are taken into account in revising, if necessary,
the defined hazard level of the substance.
TRIBIO: 
committee for the prevention of biological risks 
Exposure to pathogenic biological agents demands a different
type of expertise, as scientific issues are complicated by
bioethical questions. The objective of the Tribio expert
committee is to anticipate biological risks in order to better
prevent them.
Equally multidisciplinary, the Tribio committee evaluates 
and classifies biological agents (micro-organisms, cell cultures,
tissues or blood of animal or human origin) used in R&D. 
It unites physicians, biologists, veterinary surgeons, HSE
coordinators and a legal expert. Its activity has three facets:
 Biosafety to define a strategy for assessing and preventing
biological risks,
 Biovigilance to assure feedback on the effects of any
contamination,
 Bioethics to verify that research projects conform with legal
requirements.
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In the service of life and health, Sanofi-Synthélabo has adopted 
an ambitious program to protect the safety and health 
of its employees, to guarantee the safety of its industrial sites, 
and to respect the environment.
The Group sees this constant effort to respond to these major
challenges as a driving force for internal progress and a key
advantage in its relationships with partners and clients.
HE DYNAMICS OF CONTINUOUS PROGRESS:   T
a methodology for  our  HSE pol icy
O u r  R e s p o n s i b i l i t y
75
The Tribio committee lists all the biological agents to which
the Group's employees may be exposed and classifies these
according to various criteria: pathogenicity, biological stability,
mode of propagation, route of contamination, and existence
of an effective prophylactic or curative treatment. It informs
employees about the nature of the risks, preventive measures,
personal protective equipment, and personal hygiene
measures and participates in training courses organized 
in this area.
Process safety: a laboratory dedicated 
to risk evaluation
At the service of all Sanofi-Synthélabo facilities, the PCP
(Physicochemical Process unit) is a laboratory created 
to respond to the Group's need for expertise in evaluating
the inherent hazards of processes. In this laboratory, 15
scientists analyze and quantify the intrinsic hazards of
processes and products, and conduct studies on the
explosive potential of powders and the stability of products
and other materials. All projects concerning process
development must be submitted to the PCP. 
The experimental data generated by its studies are used 
to define the scale of safety structures in industrial
facilities. They also form the basis for information
documents supplied to external contractors. The PCP
networks with other organizations, in particular European
authorities, with which it is currently investigating runaway
reactions, and universities.
Assessing occupational 
and environmental risks 
Once all the potential hazards associated with products,
procedures, processes and equipment have been evaluated,
the risks are assessed in the context of normal and impaired
functioning. Particular attention is paid to the road safety
risks to which medical sales representatives are exposed.
Assessing work stations
All work stations or projects related to research, development
or industrial production are assessed with regard to:
 Occupational exposure to the substances used 
(in relation to their physicochemical, toxicological,
thermal. characteristics, etc),
 Safety of the procedures and processes employed 
in laboratories, pilot plants of chemical development
units and manufacturing areas,
 Environmental impact.
From R&D to industrial manufacturing, each phase 
in the life cycle of the medicine is this way subjected 
to Health, Safety and Environment appraisal. Every project
has an HSE file compiled on the basis of the Covalis 
and Tribio committee assessments and the studies
of the Physicochemical Process laboratory.
Managing change
This assessment of work stations and products is
complemented by a procedure known as "Hazard Vetting"
which re-assesses risks prior to any change in a product,
procedure, installation or item of equipment. Conducted
by the unit manager, the scientist responsible for the R&D
study and the HSE coordinator, its aim is to evaluate 
all the repercussions of this change: requirements not 
only for technical adaptations, but also for new risk
prevention and protection procedures, as well as changes
in the operating procedure and further training.
Assessing major risks
The danger of major accidents, and the risks associated
with exposure to these, is subjected to a specific analysis 
to identify the possible scenarios, define the "Safety
Important" factors and verify that the appropriate
equipment is available to deal with these.
Seveso classified chemical sites apply this methodology
through the implementation of a safety management
system (SMS). This major risk assessment methodology,
applicable to chemical sites, is currently being extended 
to the Group's other industrial activities.
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Controlling risks
Once the dangers have been identified and the risks assessed,
it is possible to develop preventive measures, secure 
the necessary specific capital investments and install collective
and personal protection equipment. These actions are
accompanied by training programs designed to incorporate
the safety reflex into all professional activities. This approach
is implemented systematically in all our facilities worldwide.
The HSE Department, within the Group's Strategy & Risk
Assessment Department, is supported by a worldwide
network of HSE coordinators and occupational physicians
who assist the line managers, provide expertise, and monitor
the application of HSE policy through the continuous
progress management system.
Throughout the world, the Group applies a set of internal
directives (rules to be applied immediately) and standards
(results to be achieved, measured by performance indices).
Guidelines are available to help line managers apply 
the directives and achieve the objectives defined by 
the standards.
Training to integrate safety into work practices
All Group employees on industrial and R&D sites benefit from
compulsory general training courses run by the HSE
coordinator. These are complemented by specific job-related
training courses assured by the line management.
In all facilities, managers and operators must participate 
in training courses focused on the prevention of exposure 
to chemical risks. These are based on the multimedia module
prepared by the Group entitled "Health at Work - Hazardous
Substances".
Managers also receive training in HSE management and risk
prevention. These courses are based on 18 standards 
of application concerning the topics of HSE organization 
and management, the risk prevention system, safety in the
workplace, industrial hygiene and workstation organization. 
Capital investments
Specific capital investments are allocated to risk prevention
and employee protection, as well as to environmental
protection, reduction of natural resource use, development 
of clean manufacturing processes and waste reduction 
and recovery. 
These permit, for example, the provision of personal 
or collective protection equipment, containment techniques,
and installation of fail-safe systems on machines. They also
permit the installation of incinerators reducing gaseous
emissions and new water treatment technologies, as well as
the development of closed circuit cooling systems.
Because its aims are improvement and constant progress, the HSE management system is not a rigid one.
HE DYNAMICS OF CONTINUOUS PROGRESS:   T
a methodology for  our  HSE pol icy
HSE Policy
 Objectives
 Guiding principles
 Directives, Standards, GuidesManagement Reviews
 Group Management  
 Scientific Affairs
 Industrial Affairs
Application
 Plans and programs
 Continuous management
 Projects
Monitoring
Performance measurement
 HSE Indicators
 Self-assessments
 Audits
.
.
.
.
.
HSE Organization
 HSE Directorate: Expertise
and Missions
 HSE Network: Coordinators,
physicians
 HSE Committees: COVALIS, 
TRIBIO
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Monitoring performances
and organizing feedback 
on experience
Indices and  balance sheets 
A set of indices permits the consolidation of safety and
environmental protection indices for all the Group's facilities
worldwide. For each individual facility, these indices constitute
a balance sheet serving as the basis for orientating HSE
initiatives and permitting the implementation of corrective
actions to remedy any discrepancies noted between current
status and the objective to be achieved.
Audits  
The HSE Department conducts internal audits to verify the
application of HSE policy, directives and internal standards,
as well as conformity with regulations. Audits performed
by external bodies complete this internal check.
The recommendations resulting from the audits form the
basis of action plans which are then monitored by tracking
the appropriate indices. 
Feedback of experience
The Groupe systematically elicits feedback on experience to
draw the lessons from all discrepancies, incidents or accidents
occurring at a local level.
This information regularly leads to revision of internal
standards and is taken into account in the annual progress
action plans (PASS).
Health Safety and Environment Policy
The Health Safety Environment policy is based on eight guiding principles 
which define a framework of actions with respect to both 
our Group employees and external partners. It is applied to all of our activities.
1. The Health, Safety and Environment policy is an integral part of the general policy of
the Group.
2. The management and the employees of the group apply this policy at all levels. Each
person is aware of their role and their personal responsibilities with regard to the
prevention of accidents, risks to health or damage to the environment.
3. In all places in which the group operates it respects the applicable laws and the
regulations, applies expert recommendations and uses the best industrial practices.
4. Sanofi-Synthélabo operates management systems relating to safety, health at work
and protection of the environment adapted to each of its activities. These systems
are assessed periodically, by measurement of the results obtained, by defining
objectives for progress and by implementing action plans called PASS with associated
control systems. This process depends on basic understanding, learning from
experience, working together and training.
5. Every development project and every product launch will be subjected to a safety,
health and environmental risk assessment integrating all the scientific and technical
knowledge of the Group. Such projects will be developed using the best available
technology to take stewardship of the product or project throughout its life cycle.
6. Sanofi-Synthélabo takes care to economise on natural resources, to minimise the
residual impact of atmospheric emissions, of effluents or of waste in all its industrial
activities in order to preserve the natural environment.
7. With regard to its suppliers, contractors or sub-contractors, Sanofi-Synthélabo aims
to promote the application of the rules of safety and protection of the environment,
and considers the adoption of these rules as a criterion to be applied to suppliers,
contractors or sub-contractors.
8. Sanofi-Synthélabo has a constructive attitude of transparency and dialogue with
regard to third parties with respect to its safety, health and environmental protection
policy, its achievements and its commitment.
THE HSE ANNUAL PROGRESS ACTION PLAN:  PASS
Every year, all facility directors are expected to define the overall goals of an action plan 
designed to achieve progress in Health-Safety-Environment practices: PASS. This plan takes 
into account both Group policy and the specific activity of each facility. Each sector manager 
then draws up his own specific action plan consistent with these overall goals of the facility.
Finally, the various departmental PASS plans are consolidated into the PASS plan for the facility.
PASS covers four areas:  Workplace accident prevention
 Industrial hygiene practice
 Improvement of working conditions
 Environmental protection 
The objectives are clearly identified and quantified so that they can be measured. The actions are planned on a department by
department basis and the necessary means and resources defined. Once finalized, the PASS is presented to the facility's Health
and Safety Committee, and communicated to all employees and then to the Group's HSE Department.
Throughout the year, PASS objectives are regularly assessed: progress is checked monthly by the sector line managers 
and every three months by the facility director.
Relations with partners
Sanofi-Synthélabo does not limit itself solely to an internal
perception of its health, safety and environmental
responsibilities. The Group also implements a chain of
vigilance involving its suppliers and contractors, such as
contract manufacturers and transporters of hazardous
materials, extending throughout the manufacturing
process.
We request these partners to take into account our HSE
requirements and provide them with all useful information
available on our products and procedures. Assessment
visits are regularly conducted on their sites.
H.S.E.
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Employee numbers and changes by geographic area in 2002
Africa
1,264
+22.7%
Latin
America
2,482
-2.6%
North
America
3,861
+11.7%
Europe 
(excluding France)
9,274
+6.9%
Eastern and
Central Europe
450
+6.4%
China/Japan
616
+11.6%
WORLD 32,436 people +6.1%
France
12,204
+2.6%
Asia/Australasia
2,285
+15.2%
Sanofi-Synthélabo believes that its economic performance 
and its corporate social policy should be mutually enriching. 
All affiliates apply this principle and adapt it to their 
specific culture, history, activities and markets. 
Employment expanded worldwide, resulting in a
6.1% growth in the total workforce, 
The Group set out the fundamental principles of its social policy and facilitated adaptation
of this policy by affiliates worldwide whilst 
respecting the specific local context. 
K e y  e v e n t s  i n  2 0 0 2
U R  S O C I A L  R E S P O N S I B I L I T Y  O
During 2002, Sanofi-Synthélabo continued its expansion
in all the zones where it is present. 
As a result of the growth in its sales, the Group 
was able to achieve one of its priority objectives: 
"to expand its workforce throughout the world". 
The workforce accordingly increased by 6.1%, 
from 30,571 employees in 2001 to 32,436. 
This growth in the workforce reflected both 
the strengthening of sales forces in all countries 
and the development of our activities in four countries:
Indonesia, Egypt, Algeria and Hungary. 
A total of 5,297 employees were recruited, 
including both permanent contracts and fixed-term
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Workforce changes in 2002
Total: 32,439 people
20.5%
34%
20.7%24.8%
Creating employment
throughout the world
MANUFACTURING
8,043
OTHER
6,660
MARKETING/
SALES FORCE
11,015
R&D 
6,718
contracts, of whom 1,939 joined the sales force. 
For all positions, including management, priority is given
to candidates from the particular country concerned,
whenever the local labor market permits. 
A total of 4,089 employees departed in 2002, 
due to retirement, internal mobility between the various
affiliates of the Group, resignation, etc., including 
762 redundancies. In 2002, the Group emphasized 
the need for decentralized recruitment , as this is key 
to understanding the local situation. 
Gender equity is respected: 1,759 women and 1,705 men
were recruited on permanent contracts in 2002. 
The Group's employees currently comprise equal numbers
of men and women. This balance applies to all socio-
professional categories, including management positions. 
Promoting 
international mobility 
Sanofi-Synthélabo is committed to respecting local identities
and cultures and to privileging internal mobility. This policy
means that the Group recruits employees from the country
concerned whenever possible. However, it is also important to
provide opportunities for professional development, exchange 
of expertise between countries, and the cultural intermingling
indispensable to the force and cohesion of a multinational
Group. In this spirit, Sanofi-Synthélabo has implemented a
policy coordinating mobility of its managers between its various
affiliates worldwide. A total of 73 employees benefited from
this policy in 2002. 
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Fostering career development
Sanofi-Synthélabo takes care to recruit employees according to
their skills , their  adaptability to change and their commitment
to the Group’s fundamental values , notably concern for
performance, audacity, creativity and respect for others. 
For new employees, this approach is one of the keys  building
a dynamic career and  real professional satisfaction. 
Annual career development interviews give each employee 
the opportunity to discuss future career plans with line
managers. Already implemented in Europe and North 
America, systematic interviews are being progressively
extended to the rest of the world.
In the second half of 2002, a project was initiated to strengthen
the Group’s guiding principles of career development. The focus
of this project brings together two distinct philosophies. 
One philosophy aims to help each employee become 
“your own career manager” by facilitating progression 
and mobility: the publication of job offers in each country 
is already moving in this direction, but the Group's ambition
goes beyond this. 
The other philosophy is based on the need to create 
a pro-active system for managing "exceptional human
resources and hopes for the future", corresponding
respectively to experts and promising young employees.
Experts  clearly need a mode of career management
different to that of line managers, to acknowledge their
contribution to the Group's performance and maintain 
their motivation intact.
This project is scheduled to culminate, by the end of 2003, 
in an improvement in information systems and a strengthening
of the career development process. It will contribute significantly
to increasing the Group's competitive advantage.
Building skills to ensure
continued employment 
1,149,814 hours of training in 2002
In 2002, the total number of training courses provided by 
the Group reached 1,149,814 hours worldwide, corresponding
to an average of five days for each employee concerned. 
Over 80% of the Group's employees were able to increase
their skills, develop new know-how, prepare for career changes
and build employability  by learning to adapt rapidly to
change. 
The worldwide implementation of career development
interviews will continue to permit optimal adjustment of 
the proposed training courses both to the Group's needs 
and to each employee's personal plans for the future. 
In addition, the Group has created a module to welcome new
managers recruited worldwide and to facilitate their
integration. 
The first session provided an opportunity for more than 
60 managers, from all the countries in which the Group 
is present, to meet in Paris for three days. This module has also
been adapted to suit each individual job and country so every
newly recruited employee can gain a better insight into the
Group, its history, its activities, and the fundamental values
guiding its actions.
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Compensating performance
Sanofi-Synthélabo makes a point of compensating performance
while preserving internal equity and respecting our need to be
competitive. Each country adapts this principle according to local
practices and realities, with the objective of setting the average
salary levels above the market median for its activity. 
Apart from the base salary, the Group has implemented individual
and collective compensation systems which recognize the successes
of each employee or work team, and everyone’s contribution  to
the Company's performance. These systems are adapted according
to the country and the local legislation.
Ensuring the social
protection of employees
worldwide
In 2002, the Group carried out an inventory and an
evaluation of the employee benefits policies of each of its
affiliates.
Wishing to put  economic performance at the service of
social performance, the Group adopted the principle of a
"Sanofi-Synthélabo minimum" with regard to the
reimbursement of costs related to health care, pensions,
death and invalidity.  This will be defined according to the
care available and the regulations applicable in each country
and will complement the local coverage  systems. It will be
applied irrespective of age, sex, state of health or the nature
of the post. 
This policy, all the more ambitious in that it must respect
economic constraints, will be implemented progressively
worldwide within the next five years.
Encouraging dialogue  
Sanofi-Synthélabo gives priority to  social dialogue in all countries,
both with employee representatives and with the entire workforce.
All employees need to be aware of the Company's challenges and
objectives, and should also have  the possibility of discussing with
their managers. This approach enables all employees to focus their
efforts on a common goal and will give meaning to their daily
professional activities.
Designed as a forum for information and discussion concerning 
the Group's strategic orientations, the European Industrial Relations
Committee was created in December 2001. It represents over
20,000 employees in all the European countries in which the Group
is present. The Committee comprises 29 representatives and 
5 observers, originating from the fifteen European Union member
countries and the first six candidate member countries, and meets
twice a year.
In March 2002, the Committee elected a seven-member office
team, comprising five nationalities: German, British, Spanish, Italian
and French. This first meeting involved an exchange of information
on the budget, results and future of the Group. 
At its second meeting, in September 2002, the Committee's
agenda was focused principally on the Group's research objectives
and organization.
Contributing to the insertion
of disabled employees
In all sites or facilities, particular attention is paid to any work
situations likely to lead to health problems, and these risks are
addressed by specific studies and ergonomic measures.
Employees  who have accidents outside work are supported in
their efforts to pursue their professional activity whenever
possible.
Disabled persons are also incorporated within the Group as
trainees or employees, under agreements with various
organizations, to facilitate their professional integration. In
France, the Group played a major role for the second year
running in the National Handicap Week organized in November
2002. It has also assumed the presidency of the "Trampoline"
association, comprising  25 major French companies of
international dimensions. The objective of this organization 
is to develop training programs  for handicapped students 
to aid their future professional integration, and also to help
them ensure  that the job they envisage is consistent with their
abilities and to encourage them in their choice. In this way,
"Trampoline" has enabled approximately 450 trainees to be
employed by various companies, including Sanofi-Synthélabo.
Exploratory chemistry: creation and synthesis of new compounds.
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A commitment to growth and a policy of transparency require 
active external and internal communication. Sanofi-Synthélabo’s
relationship with all its partners is based on respect for cultural
diversity and provision of frank and thorough information, 
and the Group communicates on all its major pharmaceuticals 
throughout their development.
U R  C O R P O R AT E  R E S P O N S I B I L I T YO
to  inform and communicate
 information campaign focused on the listing on 
the New York Stock Exchange in July 2002,
 preparation of Sanofi-Synthélabo’s 30th anniversary in January 2003,
 development of the Group’s web site, now accessible in three languages,
 international media communications on the Group’s
major pharmaceuticals.
Listing on the NYSE: corporate campaign.
K e y  e v e n t s  i n  2 0 0 2
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With the constant aim of increasing the Group’s visibility
and accessibility, Sanofi-Synthélabo’s communication policy
targets four key audiences: 
- the medical community, principally interested in 
the major medicines emerging from its R&D,
- the financial community, comprising shareholders,
institutional investors and financial analysts,
- the general public, through regular risk prevention
campaigns focused on major diseases, 
- and the Group’s 32,436 employees, who are interested in
having an overall view of company strategy and keeping
up to date with the progress of its Research and
Development on the different continents.
Increasing 
Sanofi-Synthélabo’s 
visibility worldwide
Building the Group’s image across the world implies
providing comprehensive information within the shortest
possible time. The Group has dedicated considerable
resources to reaching its various audiences rapidly.
Besides Corporate Communications, located in the head
office, a network of communication managers in the
different sites and countries enables the Group to
disseminate information worldwide in real time in more
than 20 languages and, whenever appropriate, to adapt
this information to specific local contexts. 
The web site, which was revised in 2002, can now be
consulted in three languages: English, French and Spanish,
and its content has been considerably developed. Providing
information on the Group’s international presence, 
R&D approaches, descriptions of targeted diseases, stock
exchange information and financial reports, key events,
human resources, health and safety, environmental
protection, humanitarian commitment, etc., the new web
site design emphasizes the major challenges facing the
Group, providing a full picture of its activity, and includes
career opportunities. Content is continuously updated. 
The affiliates have designated areas to develop their own
communication, coordinated with that of the Group.
Major events in the life of the Group were also
communicated in more than 30 press releases in 2002. 
The listing of the company shares on the New York Stock
Exchange provided the occasion for a major corporate
identity campaign, principally in New York, which received
the “Top Com d’Or” award from France’s communication
professionals.
Creating a link 
between employees
The same concern for facilitating access to information applies
to internal communication.
A bimonthly magazine, The Blue Dolphin, is published in 
20 languages and has a circulation of 20,000. It is distributed
to all the Group’s employees worldwide. This magazine covers
events and challenges, with content that includes financial
results, progress of clinical trials, new product launches,
marketing efforts, industrial investments, environmental
protection and humanitarian actions. Besides providing
information, it contributes to creating a genuine Group spirit
based on shared values. The affiliates have pages for local
news in their national editions of the magazine.
Some affiliates also have intranets accessible to all employees
and designed to facilitate rapid and reliable communication.
The Group’s listing on the New York Stock Exchange on 
July 1, 2002 was marked by a particular internal
communication effort, with the publication of a special issue
of The Blue Dolphin with a print run of 25,000 copies. 
All the Group’s employees were able to witness this event 
as it happened, via a worldwide satellite transmission. 
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Informing the medical
community
The Group regularly reports the results of clinical trials
conducted on compounds originating from its R&D or on
medicines which are already marketed. This information 
is targeted at the international medical community 
and the media.
In 2002, the principal communications concerned:
Plavix® (clopidogrel)  
 Updated recommendations of the American Heart
Association/American College of Cardiology and the
European Cardiology Society concerning acute coronary
syndrome.
 Results of the CREDO (Clopidogrel for Reduction of
Events During Observation) trial demonstrating the long-
term (one-year) efficacy of Plavix® combined with
acetylsalicylic acid versus placebo combined with
acetylsalicylic acid in patients having undergone
percutaneous coronary intervention.
 Present and future role of Plavix® in the long-term
prophylaxis of ischemic stroke: implementation of the
MATCH trial, for which the last patient was enrolled in
April 2002.
Eloxatin® (oxaliplatin)
 The N9741 trial, coordinated by the North Central
Cancer Treatment Group (NCCTG), the results of which
were announced at the American Society of Clinical
Oncology (ASCO) congress in May 2002.
Arixtra® (fondaparinux sodium)
 Results of the Penthifra Plus trial: prolonged prophylaxis
of deep-vein thrombosis liable to lead to pulmonary
embolism in patients operated for hip fracture.
 Results of the Matisse PE and Matisse DVT trials in the
treatment of pulmonary embolism and deep-vein
thrombosis respectively. 
Aprovel®/Avapro® (irbesartan)
 Role of irbesartan in renal and cardiovascular protection.
 Presentation of the I-PRESERVE trial: evaluation of the
potential effect of irbesartan in reducing mortality and
cardiovascular morbidity in patients with heart failure.
 Partnership with the International Diabetes Federation.
Stilnox®/Ambien®/Myslee® (zolpidem)
 The Per-Sleep trial - performance and sleep: 
role of sleep in athletic performance: study conducted
during the “Tour de France” Yacht Race in 2002.
 The Sle-ep trial on sleep and epidemiology:
35,000 questionnaires collected in 11 countries, 
one of the largest surveys ever undertaken in this area.
 The “Holidays and Sleep” survey: 
results of a Gallup poll in the U.S. conducted on 
1,000 members of the general public. 
 “As needed” administration: new data. 
U R  C O R P O R AT E  R E S P O N S I B I L I T YO
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Supporting the Federation for Brain Research.
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Informing the general public
about risk prevention with
regard to major diseases
Sanofi-Synthélabo is committed to helping safeguard
public health within its areas of expertise. This is achieved
through information campaigns focused on risk prevention,
conducted in partnership with health care professionals
and patient associations.Numerous initiatives were
organized in 2002: 
 the OPAL program, conducted with the French Stroke
Association, to inform and support stroke victims and
their families, and provide further training to physicians
and healthcare personnel;
 the “Out of the Shadows – Overcoming the stigma”
project under the aegis of the International Bureau for
Epilepsy, the International League against Epilepsy and
the World Health Organization and supported by an
unrestricted educational grant from Sanofi-Synthélabo, 
to reduce the social prejudices associated with this
disease in African countries;
 the SOLEDUC program, to better inform patients 
and their families about schizophrenia, to improve
understanding of treatment, to increase the degree 
of compliance, and to illustrate the complexity 
of mental illnesses;
 the Meeting and Information Center program,
implemented in cooperation with the National Anti-
Cancer League and the Institut Gustave Roussy, to
respond to the need of patients and their families to talk
to others. Complementing the relationship established
between patients and physicians, this provides the
psychological and moral support which is often essential
to continue fighting against this disease;
 the International Sleep Day program, designed to raise
public awareness of sleep disorders, their impact on
quality of life and their treatment. Sleep Days are an
integral part of the worldwide program focusing on sleep
and health, initiated by the World Health Organization.
Conveying the Group’s
social commitment 
Humanitarian actions and social commitment have been core
elements of the Group’s philosophy since it was founded. 
The values of respect for others and social commitment to
which Sanofi-Synthélabo subscribes are embodied in this 
policy of striving to help those in need. This sense of
responsibility is strongly supported by the Group’s employees
and contributes to reinforcing team spirit.
In the interests of efficacy and legitimacy, Sanofi-Synthélabo
focuses these initiatives on its areas of expertise. Priority is
given to actions promoting access to treatment, and
improvement in health and quality of life. Conducted
throughout the world, these initiatives involve partnerships
with associations or bodies devoted to those most
disadvantaged, and children in particular. The Group’s expertise
and voluntary work naturally complement its financial support
to charitable associations and humanitarian organizations.
Sanofi-Synthélabo’s actions are pursued over the long term.
Some of the main associations supported by the Group over
the years:
Fédération pour la Recherche sur le Cerveau, Culture à
l’Hôpital, L’Envol pour les Enfants Européens, UNICEF, Mécénat
Chirurgie Cardiaque, PlaNet Finance, Fraternité Universelle,
Ligue Nationale contre le Cancer and the Fondation de la 2ème
Chance.
The Impact Malaria project.
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The year 2002 also saw the inauguration of the Impact Malaria
program. The objective of this program is to provide the most
impoverished populations in Africa with the means of obtaining
effective antimalarial treatment in locations often devoid of any
primary care structure. Malaria is still a major disease today:
some 300 million cases of infection are recorded each year
worldwide, leading to 2.7 million deaths annually, for the most
part children.
The Group’s actions to improve health and quality of life 
are strongly supported by its affiliates, as illustrated by 
the following examples:
- the U.S. supports “The Dream Factory” association, helping
to make the dreams of chronically ill children come true, 
- Germany aids the association “Die Kleinen Patienten”,
providing entertainment for hospitalized children.
- Brazil, in partnership with UNICEF, has contributed to helping
46,000 children living among refuse dumps to attain better
living conditions, enabling them to return to school, providing
food grants, medical and psychological care.
- Greece supports the “Will to overcome” association, restoring
a smile to the faces of children hospitalized in pediatric
oncology units by organizing a painting competition,
- Egypt also helps children suffering from cancer through the
“Association of the Friends of the National Cancer Institute”,
- South Korea supports the “Korean Foundation for Aid to
Children with Leukemia”,
- South Africa helps the “Farranani” association, educating
poor children,
- India aids the Italian association CESVI, combating child
poverty and malnutrition,
- and finally, Hungary supports the association “Polgari
védelemert alapituaroy”, which provides assistance in
catastrophes by conveying medical supplies and 
transporting victims. 
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A N O F I - S Y N T H E L A B OS
S I M P L I F I E D  A C C O U N T S
Sanofi-Synthélabo simplified consolidated balance sheets 
In millions of euros
ASSETS 12/31/01 12/31/02 LIABILITIES 12/31/01 12/31/02
Fixed assets 2,296 2,899 Shareholders’ equity 5,768 6,035
Deferred income taxes 471 484 Minority interests 21 17
Inventories, accounts Other long-term liabilities 1,063 796
receivable & other current
assets 2,911 2,988
Cash, short term investments Account payable & other
& deposit 4,289 3,088 current liabilities 2,711 2,195
Financial debt 404 416
Total assets 9,967 9,459 Total liabilities and equity 9,967 9,459
Sanofi-Synthélabo consolidated statements of income 
In millions of euros 2001 % of sales 2002 % of sales Change
Net Sales 6,488 100 7,448 100 +14.8%
Cost of goods sold (1,253) (19) (1,378) (19) +9.9%
Gross profit 5,235 81 6,070 81 +16.0%
Research and Development expenses (1,031) (16) (1,218) (16) +18.1%
Selling and general expenses (2,306) (36) (2,428) (33) +5.3%
Other operating income and charges 208 3 190 3 -8.7%
Operating profit 2,106 32 2,614 35 +24.1%
Intangibles (amortization and impairment) (68) (129)
Financial income 102 85 -16.7%
Income before tax and exceptional items 2,140 33 2,570 35 +20.1%
Exceptional items 281 4 10
Income taxes (842) (13) (746) (10) -11.4%
Income from equity investees net 14 20
Goodwill amortization (7) (8)
Minority interests (1) (87) (1)
Net income 1,585 24 1,759 24 +11.0%
Exceptional items and goodwill amortization (209) (3) (1)
Net income before exceptional items 
and goodwill amortization 1,376 21 1,758 24 +27.8%
Weighted average shares outstanding 731,711,225 727,686,372
Earnings per share before exceptional items and
goodwill amortization basic and diluted in euros 1,88 2,42 +28.7%
This Business Report was designed and published by:
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In 2002, Sanofi-Synthélabo significantly outperformed the pharmaceuticals market in terms of growth. Consolidated net sales
for the year were 7,448 million euros, an increase of 14.8% on a reported basis and 12.8% on a comparable basis (before the
impact of changes in Group structure and movements in exchange rates). Growth was driven by a fine performance from the
three flagship products, Plavix®, Aprovel® and Stilnox®, which between them generated consolidated net sales of 2,973 million
euros, up 32.1% on a comparable basis. Operating profit was 2,614 million euros, 24.1% higher than in 2001, giving 
operating margin of 35.1% compared with 32.5% in the previous year.
This rise in operating profit was achieved:
 despite the negative impact of euro exchange rates. At 2001 exchange rates, operating profit would have been 30.1% higher
than in 2001;  
 thanks to strong growth in sales of the Group's top 15 products (up 20.1% on a comparable basis) and to an improvement
in production costs;
 and thanks to improved sales force productivity;
 without affecting the high level of R&D spend, which at 1,218 million euros was 18.1% higher than in the previous year and
represented 16.4% of net sales;
 and despite the impact of the reduction in American wholesaler inventories of Plavix® and Avapro® by Bristol-Myers Squibb
from March 2002. 
Net income was 11.0% higher than in 2001 at 1,759 million euros. Exceptional items were minimal in 2002 at 10 million euros,
against 281 million euros in 2001. Net income before exceptional items and goodwill amortization was 1,758 million euros. This
was 27.8% higher than in 2001, and represented 23.6% of net sales, compared with 21.2% in the previous year. Earnings per
share before exceptional items and goodwill amortization was 2.42 euros, 28.7% higher than the 2001 figure of 1.88 euros.
Other highlights of 2002 included the following:
 On April 16, 2002, Sanofi-Synthélabo acquired the 51% interest in Lorex Pharmaceuticals held by Pharmacia, enabling the
Group to recognize all the profits generated by Ambien® in the United States.
 A new indication was obtained in the United States and Europe for Plavix®/Iscover® in the treatment of patients suffering
from acute coronary syndrome (unstable angina or non Q-wave myocardial infarction).
 An extension of indication was obtained in  the United States and Europe for Aprovel®/Avapro® in the treatment of 
diabetic nephropathy in patients with high blood pressure and type 2 diabetes.
 Arixtra® was registered in Europe, and launched in the United States and some European countries, in the prevention of
venous thrombo-embolic events in patients undergoing major orthopedic surgery to the lower limbs, such as surgery of hip 
fracture and hip or knee replacement.
 In the United States, Eloxatine® was launched in the second-line treatment of colorectal cancer, Elitek® (rasburicase) in the 
management of plasma uric level associated with chemotherapy in pediatric patients, and Eligard® (1-month and 3-month 
formulations) in the treatment of advanced prostate cancer.
 Sanofi-Synthélabo defended the industrial property rights of Plavix® in the United States, working closely with Bristol-Myers
Squibb to bring patent infringement proceedings against Apotex and Dr Reddy Laboratories, after these companies filed
abbreviated new drug applications with the FDA for generics of Plavix®.
 A new patent was registered in Europe and the United States protecting the crystalline polymorphic form 2 of clopidogrel
(Plavix®/Iscover®). This new patent protects the form currently marketed worldwide, and runs until 2019.
 Sanofi-Synthélabo was admitted to listing on the New York Stock Exchange (NYSE), where since July 1, 2002 the Group's shares
have been listed in the form of American Depositary Receipts (ADRs), with each ADR representing one-half of an ordinary share.
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 Under the authority granted by the General Meeting of May 22, 2002 to buy the company's shares in the light of market 
conditions, the Group initiated a share repurchase program. Under this program, the Group held 16.4 million of its own
shares as of December 31, 2002, equivalent to 2.24% of the share capital.
Business review 
DEVELOPED SALES
Developed sales include Sanofi-Synthélabo consolidated sales and sales generated under the agreements with Bristol-Myers Squibb
for Plavix®/Iscover® (clopidogrel) and Aprovel®/Avapro®/ Karvea® (irbesartan), with Fujisawa for Stilnox®/Myslee® (zolpidem), and
with Organon for Arixtra® (fondaparinux). Our partners provide us with details of invoiced sales. These are used to determine 
developed sales, which are an indicator of the worldwide market presence of the products. 
Based on data provided to us as of the date of the meeting of the Board of Directors, developed sales for 2002 were 9,585 million
euros, an increase of 14.5% on a comparable basis.
The 3 flagship products, Plavix®, Stilnox® and Aprovel®, posted total developed sales of 5,110 million euros in 2002, up 27.3% on 
a comparable basis. These products now account for 53.3% of developed sales, compared with 48.0% in 2001.
A significant feature of 2002 was the policy initiated by Bristol-Myers Squibb, starting in March 2002, of reducing inventories 
of Plavix® and Avapro® held by American wholesalers.
Developed sales of the 3 flagship products
2001 sales 2001 sales 2002 sales Change (%)
(in millions of euros) reported comparable reported comparable reported
Plavix®/Iscover®
Europe 520 531 754 +42.0% +45.0%
United States 1,333 1,270 1,565 +23.2% +17.4%
Other countries 180 156 268 +71.8% +48.9%
Sub-total 2,033 1,957 2,587 +32.2% +27.3%
Aprovel®/Avapro®/Karvea®
Europe 388 397 512 +29.0% +32.0%
United States 392 374 373 –0.3% –4.8%
Other countries 144 127 183 +44.1% +27.1%
Sub-total 924 898 1,068 +18.9% +15.6%
Stilnox®/Ambien®/Myslee®
Europe 143 146 139 –4.8% –2.8%
United States 1,004 954 1,208 +26.6% +20.3%
Other countries 68 60 108 +80.0% +58.8%
Sub-total 1,215 1,160 1,455 +25.4% +19.8%
Total: 3 flagship products 4,172 4,015 5,110 +27.3% +22.5%
Total developed sales 8,746 8,368 9,585 +14.5% +9.6%
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Over the full year, developed sales of Plavix®/Iscover® came to 2,587 million euros, a rise of 32.2% on a comparable basis.
In the United States, invoiced sales reached 1,565 million euros, up 23.2% on a comparable basis. Demand continued to grow
at a fast pace, with cumulative prescription volumes to end December up 35% (IMS retail+mail order). There was also 
a favorable price effect. In Europe and the other countries, sales rose by 48.8% on a comparable basis in 2002.
Developed sales of Aprovel®/Avapro®/Karvea® came to 1,068 million euros in 2002, a rise of 18.9% on a comparable basis. 
In the United States, invoiced sales amounted to 373 million euros, a decline of 0.3% on a comparable basis. Demand rose, with
cumulative rolling prescription volumes to end December up 13% (IMS retail+mail order). There was also a favorable price
effect. In Europe and the other countries, sales rose by 32.6% on a comparable basis in 2002. 
Worldwide developed sales of Stilnox®/Ambien®/Myslee® reached 1,455 million euros over the full year, an increase of
25.4% on a comparable basis. 
In the United States, the product registered annual sales of 1,208 million euros, an increase of 26.6% on a comparable basis.
Demand remained very strong throughout the year, with cumulative prescription volumes to end December up 19% (IMS
retail+mail order). There was also a favorable price effect. In Europe and the other countries, sales rose by 19.9% in 2002 on
a comparable basis, thanks to the product's success in Japan, where it had market share of 16% at end November 2002.
Consolidated financial statements
The consolidated financial statements of Sanofi-Synthélabo and its subsidiaries (the "Group") have been prepared in accordance
with Rule 99-02 of the Comité de la Réglementation Comptable ("CRC") issued April 29, 1999, applicable with effect from 
January 1, 2000.
The accounting policies and methods used are identical to those applied in the preparation of the financial statements for the
year ended December 31, 2001, except for the new CRC Rule 2000.06 on liabilities, implemented by Sanofi-Synthélabo with
effect from January 1, 2002.
CONSOLIDATED NET SALES
Consolidated net sales amounted to 7,448 million euros in 2002, 14.8% higher than the 2001 figure of 6,488 million euros on
a reported basis. On a comparable basis, the increase was 12.8%. Changes in Group structure, which had a net favorable
impact of 4.5 percentage points on consolidated net sales growth, mainly comprised the change from 49% to 100% 
consolidation of the sales of Lorex Pharmaceuticals in the United States, the change from full consolidation to 51% proportionate
consolidation of the Sanofi-Synthélabo-Fujisawa joint venture in Japan in 2002, and the deconsolidation of Ela Medical with effect
from May 1, 2001. Currency fluctuations had a net unfavorable impact of 2.5 percentage points on sales growth in 2002. This
included 0.8 of a point due to the fall in the US dollar against the euro, 0.5 of a point due to the fall in the Japanese yen against
the euro, and 1 point due to the depreciation of Latin American currencies. 
Consolidated sales by geographical region
2001 2001 2002 Change (%)
consolidated consolidated consolidated
net sales net sales net sales comparable reported
(in millions of euros) reported comparable reported
Europe 3,877 3,843 4,297 +11.8% +10.8%
United States 1,098 1,437 1,689 +17.5% +53.8%
Other countries 1,513 1,325 1,462 +10.3% –3.4%
Total 6,488 6,605 7,448 +12.8% +14.8%
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 In Europe, net sales amounted to 4,297 million euros, an increase of 11.8% on a comparable basis and 10.8% on a reported
basis. This strong level of growth in Europe during 2002 was achieved in spite of measures taken to contain healthcare costs in
Italy and Germany. Europe accounted for just under 58% of total consolidated net sales in 2002, compared with 60% in 2001.
 Net sales reached 1,689 million euros In the United States, a rise of 17.5% on a comparable basis and 53.8% on a reported basis.
Eloxatine®, launched on August 30, 2002, had registered sales of 116 million euros by end December, offsetting the impact of
the arrival on the market of generics of Primacor® (Corotrope®). The very marked growth in reported sales, achieved in spite of the
falling dollar, was due to the fact that 100% of Ambien® sales have been consolidated with effect from January 1, 2002, compared
with 49% in 2001. The United States accounted for 23% of total consolidated net sales in 2002, compared with 17% in 2001.
 In the other countries, net sales totaled 1,462 million euros, up 10.3% on a comparable basis but 3.4% lower on a reported basis.
Very good growth in Asia canceled out the negative effect of the economic and monetary crisis in Latin America. The decline
in reported sales reflected the change from 100% to 51% consolidation of Sanofi-Synthélabo-Fujisawa in Japan, and the 
weakness of the yen and some Latin American currencies. The “other countries” accounted for 19% of consolidated net sales
in 2002, compared with 23% in 2001.
Consolidated net sales by product
Consolidated net sales generated by the Group's top 15 products rose by 20.1% on a comparable basis to 5,100 million euros,
and accounted for 68.5% of total consolidated net sales, against 64.3% in 2001.
This strong growth was driven by a very fine performance from the 3 flagship products, Plavix®, Aprovel® and Stilnox®, 
combined sales of which were 32.1% higher on comparable basis than in the previous year at 2,973 million euros. They now
account for 39.9% of total net sales, against 34.1% in 2001, on a comparable basis.
2001 2001 2002 Change (%)
(in millions of euros) reported comparable reported comparable* reported*
Product Indication
Stilnox® Insomnia 786 1,135 1,424 +25.5% +81.3%
Plavix® Atherothrombosis 705 697 987 +41.5% +39.8%
Aprovel® Hypertension 423 419 562 +34.0% +32.8%
Eloxatine® Colorectal cancer 196 194 389 +101.3% +99.2%
Fraxiparine® Thrombosis 297 294 324 +10.1% +8.9%
Depakine® Epilepsy 243 240 267 +11.0% +9.8%
Xatral® Benign prostatic hyperplasia 148 147 182 +24.3% +23.1%
Cordarone® Arrhythmia 162 157 162 +3.1% –0.1%
Tildiem® Angina, hypertension 152 151 141 –6.9% –7.4%
Ticlid® Thrombosis 205 205 137 –33.2% –33.2%
Solian® Schizophrenia 116 115 135 +17.2% +16.7%
Corotrope®/
Primacor® Heart failure 237 226 127 –43.5% –46.1%
Aspégic® and 
related products Fever, pain 100 101 108 +6.7% +7.6%
Dogmatil® Psychosomatic disorders 124 86 78 –9.0% –37.2%
Kerlone® Hypertension, angina 82 81 77 –5.0% –6.9%
Total for the top 15 products 3,976 4,248 5,100 +20.1% +28.3%
Other products 2,512 2,357 2,348 –0.4% –6.5%
Total 6,488 6,605 7,448 +12.8% +14.8%
* These percentages are calculated on the basis of figures that have not been rounded.
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Stilnox®/Ambien® is the Group's no.1 product in terms of consolidated net sales, and no.4 in terms of comparable-basis growth.
The difference between the growth achieved by Stilnox®/Ambien® on a comparable basis (25.5%) and on a reported basis
(81.3%) was mainly due to the fact that Lorex Pharmaceuticals was 100% consolidated in 2002, as opposed to 49% previously.
  Consolidated net sales of Plavix® rose by 41.5% on a comparable basis to 987 million euros. Growth was maintained at a very
high level thanks to the new indication obtained in 2002 and to the inclusion of the product in recommended cardiology therapy lists.
 Consolidated net sales of Aprovel® came to 562 million euros, a rise of 34.0% on a comparable basis. This underlines the success
of the product, especially in Europe where it has become no.2 in its class.
 Consolidated net sales of Eloxatine® were 389 million euros, a rise of 101.3% on a comparable basis. This very high figure reflects
the successful launch of Eloxatine® on the American market on August 30, 2002, coupled with strong growth for the 
product in Europe and the other countries. 
 Consolidated net sales of Arixtra® totaled 9.1 million euros. Penetration was slower than expected, in a narrow indication. The
program to extend indications is proceeding as planned, with the filing at end 2002 of an extension of indication in long-term
prophylaxis of venous thrombo-embolic events after orthopedic surgery.
 Net sales of the other products in the portfolio were virtually unchanged in 2002 at 2,348 million euros, a fall of just 
0.4% on a comparable basis.
Consolidated net sales by therapeutic area
Cardiovascular/Thrombosis sales reached 2,904 million euros (39% of Group net sales) in 2002, an increase of 10.6% on a reported
basis and 12.4% on a comparable basis. The main growth driver was the boom in sales of Plavix® and Aprovel®, offsetting
lower sales of Ticlid® and Primacor® (a product now exposed to competition from generics in the United States).
Central Nervous System sales came to 2,409 million euros (32.3% of Group net sales) in 2002, a rise of 33.1% on a reported
basis and 15.4% on a comparable basis. The 100% consolidation of Stilnox® in the United States had a very favorable impact
on reported sales growth.
Internal Medicine sales were 1,427 million euros (19.2% of Group net sales), down 2.6% on a reported basis but up 2.0% on
a comparable basis. 
Oncology sales totaled 404 million euros (5.4% of Group net sales), an increase of 94.2% on a reported basis and 96.1% on
a comparable basis. This strong growth was due to a doubling of Eloxatine® sales in 2002.
Sales of other products fell by 7.9% on a comparable basis and 20% on a reported basis to 304 million euros. The difference
between reported and comparable figures was mainly due to the divestiture of Ela Medical in 2001.
The table below shows a split of consolidated net sales by therapeutic area:
2001 2001 2002 Change (%)
(in millions of euros) reported comparable reported comparable reported
Cardiovascular/thrombosis 2,625 2,583 2,904 +12.4% +10.6%
Central Nervous System 1,810 2,087 2,409 +15.4% +33.1%
Internal Medicine 1,465 1,399 1,427 +2.0% –2.6%
Oncology 208 206 404 +96.1% +94.2%
Other 380 330 304 –7.9% –20.0%
Total 6,488 6,605 7,448 +12.8% +14.8%
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GROSS PROFIT 
Gross profit rose by 16% to 6,070 million euros. Gross margin was 81.5% in 2002, an improvement of 0.8 of a percentage point
relative to the previous year.
This improvement reflects a number of positive factors, including:
 productivity gains in the industrial cost of goods sold, giving an improvement of 0.6 of a point;
  strong growth in sales of the top 15 products (28.3% on a reported basis) and an improved product mix, representing 
a further gain of 0.6 of a point.
These factors were partially canceled out by:
  slower growth in royalty income, due to the inventory reduction program implemented in the United States by Bristol-Myers
Squibb for Plavix® and Avapro®, which had a negative impact of 0.4 of a point on gross margin.
The 100% consolidation of the Lorex Pharmaceuticals joint venture had no impact on the change in the gross margin rate
between 2001 and 2002. 
At 2001 exchange rates, gross margin would have been 82.1%.
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses totaled 1,218 million euros (16.4% of consolidated net sales), an increase of 18.1% 
relative to 2001. At 2001 exchange rates, the increase would have been 20.4%.
The increase in research and development expenses reflects the substantial investment being made by the Group in its four areas
of expertise (Cardiovascular/Thrombosis, Central Nervous System, Immuno-Oncology and Internal Medicine). 
The marked acceleration in R&D spend during 2002 was due in particular to:
  ongoing major clinical trials programs aimed at obtaining new indications for products already on the market (Plavix®, Aprovel®,
Arixtra®, Eloxatine® and Xatral®), or covering new molecules: rimonabant (obesity, nicotine withdrawal), dronedarone 
(atrial fibrillation), tirapazamine (non-small-cell lung cancer) and zolpidem MR, the new formulation of Stilnox®/Ambien®.
  collaboration agreements signed in 2001 and 2002:
- with IDM in cellular immunotherapy, for the development and marketing of immunological treatments in oncology, 
with exclusive marketing rights;
- with Cephalon, for the development and marketing of angiogenesis inhibitors.
SELLING AND GENERAL EXPENSES  
Selling and general expenses totaled 2,428 million euros, 5.3% higher than in 2001. At 2001 exchange rates, the increase
would have been 8%. In the United States, the full effect was felt during 2002 of the reinforcement of the sales force at end
2001 in anticipation of the takeover by the Group of all promotion of Ambien® with effect from January 1, 2002, and of the
launch of Arixtra®. The cost of deploying these extra sales resources was recognized in the final quarter of 2001. 
The Group responded to the economic and monetary crisis in Latin America by adjusting its sales resources in the region. In Europe,
the Group's strong presence helped stimulate sales growth.
Overall, 2002 saw an improvement in the productivity of medical sales representatives in all regions. Marketing spend 
continued to rise, in support of the main products in the Group's portfolio.
OTHER OPERATING INCOME/EXPENSE
Other operating income and expense mainly comprise transfers of profits in respect of joint operations with partners under
collaboration agreements relating to product marketing and development, recorded as adjustments to operating profit.
This line showed net income of 190 million euros for the year ended December 31, 2002, compared with 208 million euros for
the previous year. 
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The three main factors underlying this change were:
 rapid growth in European sales of Plavix® and Aprovel®, which led to a significant increase in the profits generated in this
region and hence in the amount of profit passed on by Sanofi-Synthélabo to Bristol-Myers Squibb;
 reductions in Plavix® and Aprovel® inventories by Bristol-Myers Squibb in the United States, which slowed growth in profits
in the United States, and hence reduced the amount of profit passed on by Bristol-Myers Squibb to Sanofi-Synthélabo;     
 the elimination in 2002 of the share of Lorex profits passed on to Pharmacia, following the buyout by Sanofi-Synthélabo of
the rights in the joint venture. In 2001, the amount of profit passed on to Pharmacia was 14 million euros.
OPERATING PROFIT
Operating profit amounted to 2,614 million euros, 24.1% higher than the 2001 figure of 2,106 million euros. At 2001 exchange
rates, the increase would have been 30.1%. 
Operating margin was 35.1% in 2002, against 32.5% in 2001.
The table below shows the main components of operating profit for 2001 and 2002:
2001 2002 2001/2002
As % As % Change (%)(in millions of euros) of sales of sales
Net sales 6,488 100% 7,448 100% +14.8%
Cost of goods sold (1,253) (19.3%) (1,378) (18.5%) +10.0%
Gross profit 5,235 80.7% 6,070 81.5% +16.0%
Research and 
development expenses (1,031) (15.9%) (1,218) 16.4% +18.1%
Selling and general expenses (2,306) (35.5%) (2,428) 32.6% +5.3%
Other operating income/expense 208 3.2% 190 2.6% -8.7%
Operating profit 2,106 32.5% 2,614 35.1% +24.1%
In geographical terms, operating profit advanced strongly in all regions. 
The table below shows a split by region for 2001 and 2002:
2001 2002 Change (%) 
(in millions of euros)
Europe 1,427 1,633 +14.4%
United States 1,311 1,781 +35.9%
Other countries 456 522 +14.5%
Unallocated costs (1,088) (1,322) +21.5%
Total operating profit 2,106 2,614 +24.1%
The United States reported a 35.9% increase in operating profit before unallocated costs, accounting for 45.2% of the Group
total in 2002, against 41.0% in 2001.
The main factors underlying this increase were:
 The recognition of 100% of the profits of the Lorex joint venture with effect from January 1, 2002, and the fine performance
of Ambien® in the American market.
 The launch of Eloxatine®, which offset the fall in sales of Primacor® following the launch of generics in May 2002.
In the two other regions (“Europe” and “Other countries”) operating profit growth substantially outpaced sales growth year on year.
Unallocated costs, which advanced by 21.5%, mainly comprise fundamental research and worldwide development of 
pharmaceutical molecules, and part of the cost of support functions. The main reason for the rise in these costs in 2002 was 
a substantial increase in Research and Development expenses during the year.
INTANGIBLES – AMORTIZATION AND IMPAIRMENT
Amortization and impairment of intangibles rose from 68 million euros in 2001 to 129 million euros in 2002. This increase was
mainly due to the amortization of the United States rights to Avapro® (acquired from Bristol-Myers Squibb in October 2001)
and to Ambien® (acquired from Pharmacia on April 16, 2002 when Sanofi-Synthélabo increased its interest in the Lorex
Pharmaceuticals joint venture to 100%).
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FINANCIAL INCOME/EXPENSE
Net financial income fell from 102 million euros in 2001 to 85 million euros in 2002.
This reflects three factors:
 a provision for impairment of 46 million euros taken against treasury shares held in connection with stock option plans, solely
to cover the shortfall between the average acquisition price of the shares and the average listed stock market price of the shares
during December 2002 (57.10 euros);
 a reduction in net income on the investment of surplus cash caused by a fall in interest rates (1.1 percentage point lower on
average), similar average amounts of surplus cash having been invested in both years;
 net gains arising on hedging transactions, which were boosted by the fall in the dollar relative to the euro (net gain of 
47 million euros, compared with a net gain of 5 million euros in 2001).
INCOME BEFORE TAX AND EXCEPTIONAL ITEMS
Income before tax and exceptional items amounted to 2,570 million euros, an increase of 20.1% relative to 2001. At 2001 exchange
rates, the increase would have been 23.3%.
EXCEPTIONAL ITEMS
Exceptional items for the period showed a net gain of 10 million euros, compared with a net gain of 281 million euros in 2001.
The 2002 net gain mainly comprised gains on disposals of short-term investment securities in the United States. The 2001 
figure included the capital gain of 158 million euros arising on the sale of Sanofi-Synthélabo's interest in Laboratoires de Biologie
Végétale Yves Rocher, plus the disposal of a number of activities and products. 
INCOME TAXES
Income taxes fell by 96 million euros, from 842 million euros in 2001 to 746 million euros in 2002. The effective tax rate
(income taxes as a percentage of net income before tax) was 34.8% for the year ended December 31, 2001 and 28.9% for
the year ended December 31, 2002.
Changes in the effective tax rate were due to:
 in France, the impact of reduced-rate taxation (mainly on royalties) and of a cut in the corporate income tax rate;
 the impact of the revaluation of the Group's contingent tax positions, resulting in a net reversal of 53 million euros of provisions
following finalization of the main tax audits in the first half of 2002;
 the impact of the full consolidation of the Lorex joint venture, a tax-transparent entity for which the "Income taxes" line includes
only the charge attributable to the Group.
The effective tax rate for the first half of 2002, which included the impact of the second and third factors mentioned above, was 26%.
The rate for the second half of the year was 32%.
INCOME FROM EQUITY INVESTEES
The share of net income from equity investees for the year ended December 31, 2002 amounted to 20 million euros, mainly
comprising the share of 2001 profits to which Sanofi-Synthélabo is entitled via its interest in the Yves Rocher group.
MINORITY INTERESTS
Minority interests totaled 87 million euros in the year ended December 31, 2002. These mainly comprise the share of profits from
the Lorex Pharmaceuticals joint venture reverting to Pharmacia in respect of the period from January 1, 2002 through April 16,
2002. Because Lorex Pharmaceuticals is a tax-transparent entity, the "Minority interests" line does not include the related tax.
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NET INCOME
Consolidated net income was 1,759 million euros, 11% higher than the 2001 figure of 1,585 million euros.
Consolidated net income before exceptional items and goodwill amortization was 1,758 million euros, an increase of 27.8%
compared with the previous year. At 2001 exchange rates, the increase would have been 31.2%. Earnings per share was 
2.42 euros, compared with 1.88 euros for 2001, a rise of 28.7%.
CONSOLIDATED STATEMENT OF CASH FLOWS
Operating cash flow before changes in working capital reached 2,260 million euros in 2002, 30.5% up on the 2001 figure
(1,732 million euros).
Working capital needs rose by 584 million euros, compared with a decrease of 86 million euros in the year ended December
31, 2001. This change was due mainly to an increase in income taxes paid, both for 2001 and on account for 2002, and to 
payment arrangements relating to joint operations with the Group's partners. Working capital needs directly related to 
operations rose in line with sales, by a total of 173 million euros.
Total investments were 1,435 million euros, compared with 619 million euros in 2001. The 2002 figure includes the purchase
of Pharmacia's interest in the Lorex joint venture, payment of the balance of the consideration for additional rights to Avapro®
in the United States, and capital expenditure.
Proceeds from disposals of assets, net of income taxes, came to 22 million euros, compared with 492 million euros in 2001.
Dividends paid to Sanofi-Synthélabo shareholders totaled 473 million euros, an increase of 49.2% on the 2001 figure of 
317 million euros.
The movement in other financial investments comprised:
- share repurchases totaling 207 million euros in connection with stock option plans (these shares are included under short-term
investments in the balance sheet);
- the implementation of the share repurchase program authorized by the General Meeting and the Board of Directors on May
22, 2002, which resulted in the net purchase of 16,411,795 shares for a total amount of 963 million euros (these shares are
netted off consolidated shareholders' equity in the balance sheet).
After all these cash flows, the amount of cash and cash equivalents (defined as liquid assets, excluding treasury shares classified as
short-term investments) shown in the statement of cash flows fell by 1,340 million euros during the year ended December 31, 2002.
CONSOLIDATED BALANCE SHEET
The balance sheet total was 9,459 million euros as of December 31, 2002, 508 million euros lower than as of December 31, 2001.
The consolidated balance sheet showed shareholders' equity of 6,035 million euros as of December 31, 2002, an increase of 
267 million euros relative to December 31, 2001.
Balance sheet items showing material movements relative to December 31, 2001 were as follows:
Assets:
 Intangible assets increased by 486 million euros, mainly due to the purchase of the rights to Ambien® arising from the 
acquisition of the remaining 51% of the Lorex Pharmaceuticals joint venture from Pharmacia on April 16, 2002.
Liabilities:
 Provisions and other long-term liabilities fell by 267 million euros due to the reclassification as short-term items of liabilities
relating to operations with joint venture and alliance partners; the application of new French accounting rules on liabilities; the
reversal of provisions recorded in the opening balance sheet but no longer required; and the reassessment and utilization of
provisions shown in the balance sheet at the end of the previous financial year.
 Other current liabilities fell by 395 million euros, due mainly to payment during 2002 of the balance of the income tax 
liability for the previous year and to a reduction in taxes payable in respect of the 2002 financial year as a result of payments
on account linked to the tax charge for the year.
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The Group had a net year-end cash position of 2,672 million euros, compared with 3,885 million euros as of December 31, 2001,
after taking account of 623 million euros of treasury shares held in connection with stock option plans.
OFF BALANCE SHEET COMMITMENTS
The Group does not use off balance sheet vehicles. All the Group's operations are reflected in the consolidated financial statements.
All the Group's material off balance sheet commitments are identified and disclosed in the consolidated financial statements.
OUTLOOK
In 2003, sales and profits should show further strong growth, driven by:
 the fine performance expected from the three blockbusters Plavix®, Stilnox® and Aprovel®;
 growth in sales of Eloxatine® in the United States, following the launch on August 30, 2002; 
 continuing strong performances from the rest of the portfolio, especially Depakine®, Solian® and Xatral®.
Investment in Research and Development will be maintained at a high level, in particular via phase III clinical trials  
of rimonabant, dronedarone, idraparinux and zolpidem MR.
An impressive research pipeline, plus the solid positions of all our products, give the Group confidence in its capacity to expand
its business and deliver earnings growth.
Sanofi-Synthelabo parent company
The main features of the Sanofi-Synthélabo parent company financial statements for the year ended December 31, 2002 
are as follows:
BALANCE SHEET
The balance sheet total as of December 31, 2002 was 8,980 million euros, compared with 7,967 million euros at end December
2001. On the assets side, the balance sheet included long-term investments (investments in and advances to subsidiaries and
affiliates) of 3,976 million euros, representing 89% of total fixed assets (4,530 million euros). Current assets (4,429 million
euros) mainly comprised amounts receivable from Group companies (1,182 million euros as of December 31, 2002) and short-
term investments and deposits (2,856 million euros as of December 31, 2002, against 4,083 million euros at end December 2001). 
On the liabilities and equity side, shareholders' equity amounted to 7,055 million euros, or 78% of the balance sheet total. 
The movement in current liabilities reflects the payment in 2002 of the balance of tax payable in respect of the 2001 financial
year (281 million euros), and the recognition of an accrued liability relating to a license agreement (392 million euros).
STATEMENT OF INCOME
Operating profit for the year ended December 31, 2002, was 396 million euros, compared with 521 million euros in 2001.
This reduction was mainly due to an increase in research services carried out for Sanofi-Synthélabo (802 million euros in 2002,
against 657 million euros in 2001). The société en participation (silent partnership) involved in chemicals activities was wound
up on December 31, 2001, and consequently the line "Share in profits/losses of joint venture partnerships" showed no income
in 2002. 
Net financial income came to 793 million euros, compared with 561 million euros in 2001, and mainly comprised dividends received
from subsidiaries (674 million euros).
Exceptional items showed a net gain of 327 million euros, against a net gain of 581 million euros in 2001. In 2002, the main excep-
tional items were reversals of provisions relating to vendor's guarantees of liabilities and to developments in tax litigation. 
After an income tax charge of 193 million euros, net income for the year ended December 31, 2002 was 1,323 million euros,
compared with 1,442 million euros for the previous year.
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ACQUISITION OF PARTICIPATING INTERESTS
During the year, Sanofi-Synthélabo acquired 1,811,940 shares in Sanofi-Synthélabo A.E. (Greece) and 1,500,000 shares in
Sanofi Torrent (India), in both cases taking its interest to 100%.
Additional information
SHARE CAPITAL
The share capital as of December 31, 2002 amounted to 1,464,735,014 euros, divided into 732,367,507 shares all entitled to
dividend in respect of the 2002 financial year except the own shares and including the issuance of 362,423 new shares as a result
of the exercising of stock options.
SANOFI-SYNTHÉLABO VOTING RIGHTS AND SHARE OWNERSHIP
Share ownership of Sanofi-Synthélabo as of December 31, 2002
Shares Voting rights
Number % Number %*
TotalFinaElf 179,586,513 24.52 359,173,026 33.74
L’Oréal 143,041,202 19.53 286,082,404 26.87
Treasury shares 30,376,375 4.15 – –
Employees 7,659,036 1.05 14,460,072 1.36
Public 371,704,381 50.75 404,824,601 38.03
Total 732,367,507 100.00 1,064,540,103 100.00
* Based on the total number of voting rights published subsequent to the Ordinary General Meeting of May 22, 2002, i.e. 1,064,540,103
During the year, the interest held by TotalFinaElf, both directly and indirectly via Elf Aquitaine and its subsidiary Valorisation et
Gestion Financière, fell from 26.07% of the capital and 34.90% of voting rights as of December 31, 2001 to 24.52% of the
capital and 33.74% of voting rights as of December 31, 2002.
As required by article L.233-7 of the Commercial code, State Street Bank and Trust declared on several occasions between
November 22 and December 16, 2002 that it had alternately passed above then below the legal threshold of 5% of the 
company's capital, on behalf of its clients. On December 16, 2002, State Street Bank and Trust declared that as of that date it
held 36,638,351 of the company's shares, representing 5.00% of the capital.
No company controlled by Sanofi-Synthélabo owns any Sanofi-Synthélabo shares.
DIVIDENDS IN RESPECT OF THE LAST THREE FINANCIAL YEARS
Year Net dividend Tax already paid Total Tax already paid Total
paid to the French income to the French income
(euros) Treasury (euros) Treasury (tax credit)(1) (euros)
(tax credit: 50% rate) (euros)
(euros)
1999 0.32 0.16 0.48 0.13 0.45
2000 0.44 0.22 0.66 0.11 0.55
2001 0.66 0.33 0.99 0.10 0.76
(1) Rate: 15% in 2001, 25% in 2000 and 40% in 1999.
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PROPOSED DIVIDEND IN RESPECT OF THE 2002 FINANCIAL YEAR
The Board of Directors will propose to the General Meeting of May 19, 2003 that a net dividend of 0.84 euro per share be declared
in respect of the year ended December 31, 2002, representing a rise of 27.3% relative to the 2001 dividend of 0.66 euro.
TRANSACTIONS RELATING TO STOCK OPTION PLANS
On May 22, 2002, the Board of Directors of Sanofi-Synthélabo granted 3,111,850 options to purchase shares to 1,162 grantees 
at a price of 69.94 euros per share.
The tables provided in note D12.6 to the consolidated financial statements show for each outstanding plan the date of grant, 
the total number of options granted, the exercise date and the exercise price.
During 2002, 362,423 new Sanofi-Synthélabo shares were subscribed for by grantees of stock options, at prices of between 10.26 and
14.56 euros, increasing shareholders' equity by 4.2 million euros.
As of December 31, 2002, 514,925 options to subscribe for shares were outstanding, representing a potential increase of 7.5 million
euros in shareholders' equity.
During 2002, a total of 847,018 shares were subscribed for or purchased by grantees of stock options. 
The information required by article L.225-184 of the Commercial code is contained in a special report of the Board of Directors.
EMPLOYEE SHARE OWNERSHIP
As required by article L.225-102 of the Commercial code, it is disclosed that as of December 31, 2002, employees of the 
company and of related companies owned 7,659,036 Sanofi-Synthélabo shares, representing 1.05% of the share capital, via the
"Actions Sanofi-Synthélabo" mutual fund set up in connection with the Group employee savings plan.
AUTHORIZATION TO BUY AND SELL THE COMPANY'S SHARES ON THE STOCK MARKET
During the year ended December 31, 2002, the Company used the authorizations given on May 22, 2001 and May 22, 2002
to buy the company's shares on the stock market, in order to allocate shares to the stock option plan of May 22, 2002 and 
in the light of market conditions.
A total of 19,550,679 shares were bought at an average price of 60.57 euros per share. Trading costs on these purchases
amounted to 3,320,064 euros excluding taxes, or 0.17 euros per share.
During the same period, 484,595 shares were sold to grantees of stock options at an average price of 14.49 euros per share,
and 109,000 shares were sold on the market at an average price of 59.29 euros.
At end December 2002, the company held 13,964,580 treasury shares classified under "Short-term investments" and 
16,411,795 treasury shares classified under "Long-term investments" at a total gross value of 1,666,642,026 euros, 
representing 4.15% of the share capital. Of these shares, 13,836,580 were allocated to pre-existing stock option plans.
AUTHORIZATIONS TO ISSUE SECURITIES WITH OR WITHOUT PREEMPTIVE RIGHTS
No use has been made since the General Meeting of May 22, 2002 of the authorizations allowing the Board of Directors to
issue, at its sole discretion, securities leading to an increase in the company's share capital with or without preemptive rights.
REMUNERATION OF CORPORATE OFFICERS
Total remuneration paid to Mr Jean-François Dehecq, Chairman and Chief Executive Officer, by Sanofi-Synthélabo: 
1,902,885 euros comprising a fixed component of 902,885 euros and a variable component of 1,000,000 euros.
Total remuneration paid to Mr Gérard Le Fur, Senior Executive Vice-President, by Sanofi-Synthélabo: 1,326,312 euros comprising
a fixed component of 643,373 euros and a variable component of 682,939 euros (including 182,939 euros in respect of 2001).
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Remuneration of other members of the Board of Directors 
The table below shows attendance fees for each member of the Board of Directors in respect of the year ended December 31,
2001, as paid in 2002 either to the Board member in question or to the main company in which he holds office.
Names Total in thousands of euros
Mr Robert Castaigne 29.24
Mr Pierre Castres St Martin 29.24
Mr Pierre-Gilles de Gennes 30.28
Mr René Barbier de la Serre 55.35
Mr Thierry Desmarest 30.28
Elf Aquitaine 29.24
Mr Hervé Guérin 29.24
L’Oréal 33.42
Mr Lindsay Owen-Jones 38.64
Mr Bruno Weymuller 33.42
Mr Régis Dufour (Observer) 14.62
Mr René Sautier (Observer) 12.53
Employee data
Employee data are consolidated at group level on the basis of data for subsidiaries included in the scope of consolidation.
EMPLOYEE HEADCOUNT
Registered employees  
Total Europe incl. France USA Other countries
Registered employees: Dec 31, 2002 32,436 21,478 12,204 3,595 7,363
Split by type of contract
• permanent 30,621 20,536 11,591 3,595 6,490
• fixed-term 1,815 942 613 0 873
Split by gender
• Female 16,339 11,112 6,434 1,861 3,366
• Male 16,097 10,366 5,770 1,734 3,997
Split by category
• managers 7,772 5,526 4,003 1,032 1,214
• other 14,189 11,107 6,830 307 2,775
• sales force 10,475 4,845 1,371 2,256 3,374
The total number of registered employees as of December 31, 2002 was 6.1% higher than at the previous year-end (30,571), 
an increase of 1,865 employees.
Of these 1,865 new employees, around 680 came from additions to the scope of consolidation (Indonesia, Egypt, Algeria, and the
acquisition of a site in Hungary).
Other increases in employee headcount related mainly to the sales force (China, Europe excluding France, and the United States).
The activities with the highest number of employees are the sales force (34% of the total) and research (21% of the total).
Most of the Group's employees (66% of the total) are located in Europe.
The gender split is 50/50 male/female.
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Changes in employee headcount
Registered employees: Dec 31, 2002 Total Europe incl. France USA Other countries
Total number of new recruits 5,297 2,958 1,647 733 1,606
•  permanent contracts 3,464 1,689 775 733 1,042
– of which female 1,759 826 368 423 510
– of which male 1,705 863 407 310 532
•  fixed-term contracts 1,833 1,269 872 0 564
Total number of leavers 4,089 2,244 1,326 361 1,484
•  permanent contracts 2,609 1,063 371 361 1,185
•  fixed-term contracts 1,480 1,181 955 0 299
Total number of dismissals 762 338 144 41 383
• for personal reasons 640 255 110 40 345
• redundancies 122 83 34 1 38
The recruitment ratio (permanent and fixed-term contracts combined) was 16% in 2002, the same as in 2001. By zone, the ratio
was 22% in the “Other countries” zone, 14% in the Europe zone (13% in France) and 20% in the United States, where there
was a major campaign to recruit over 2,000 medical representatives in 2001. 
Of the permanent contract employees recruited in 2002, 51% were female and 49% male.
WORKING TIME ORGANIZATION
Working time
Total Europe incl. France USA Other countries
Theoretical average 
annual working hours 1,703 1,629 1,547 1,856 1,865
Part-time
• Number of registered 
employees at Dec 31, 2002 1,516 1,476 1,278 0 40
• Full time equivalent* 1,192 1,169 1,041 0 23
Temporary agency staff
• Number of hours 2,547,265 1,638,340 891,234 23,433 885,492
• Full time equivalent* 1,497 1,001 576 13 483
*Full time equivalent = hours paid / theoretical hours.
Part-time staff account for 5% of registered employee headcount worldwide. 
Total overtime worked in France, paid at uplifted rates and recorded in the payroll in the year ended December 31, 2002,
amounted to 3,989 hours.
Absenteeism
Total Europe incl. France USA Other countries
Total number of days' absence 343,928 271,574 155,004 15,500 56,854
Split by reason
• Sick leave 203,970 168,332 107,746 8,889 26,749
• Accidents 
(industrial or while travelling) 8,034 6,665 3,657 103 1,266
• Maternity leave 75,455 55,071 24,572 3,956 16,428
• Other* 56,469 41,506 19,029 2,552 12,411
Rate of industrial accidents** 4,1 4,6 4,5 2,4 3,7
* Other includes family events, unpaid leave, parental leave, sabbatical leave, etc.
** Rate of industrial accidents (based on Health, Safety & Environment data): number of industrial accidents requiring more than one day's absence
from work occurring in a 12-month period, per million hours worked. These data are consolidated across virtually all Group companies 
(97% of total employee headcount). 
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Training
Total Europe incl. France USA Other countries
Number of employees receiving training 26,288 17,699 10,021 3,170 5,419
Total number of training hours 1,149,814 718,796 341,719 129,253 301,765
Total number of health, safety 
and environment training hours* 303,896 285,634 51,289 1,897 16,365
* Health, safety and environment training hours relate solely to industrial sites (chemicals, pharmaceuticals, distribution) and research sites.
Training concerned 83% of the average workforce in 2002. The total number of training hours is equivalent to 5 days of 
training per employee during the year 2002.
Subcontracting
Sanofi-Synthélabo aims to handle the bulk of its core business in-house. However, like all industrial groups, it outsources some
of its functions, and consequently makes use of subcontractors to provide specialist services or additional capacity. In order to
minimize stockout, quality, safety, environmental, ethical and citizenship risks, procurement of subcontracted services is 
handled by a network of trained buyers, and in-house risk management teams are involved in the supplier selection process.
HUMANITARIAN ACTIVITIES
Not-for-profit organizations founded or supported by Sanofi-Synthélabo
Sanofi-Synthélabo has been investing in humanitarian activities since 1986, with a particular emphasis on children in need. In more than
100 countries, we express our commitment and solidarity in areas that reflect our core business in health. We provide humanitarian
organizations with financial, technical and human resources to help them solve problems relating to health, social deprivation, disease 
prevention, social exclusion and childhood trauma, through effective and sustainable international programs.
EMPLOYEE INFORMATION: FRANCE, 2002
Remuneration
Individual remuneration
(in euros)
Average annual basic gross salary* 38,322
Minimum annual gross salary after 1 year's service 18,000
* Average annual basic gross salary: average of December 2002 basic salaries multiplied by the number of months' pay for full-time, 
permanent staff employed from January 1 through December 31, 2002.
Effective January 1, 2002, there was a collective pay rise of 2%, supplemented in some cases by individual pay rises.
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Collective remuneration
(in millions of euros)
Statutory profit-sharing scheme
2001 entitlement paid in 2002 50.6
% of total payroll 10.3%
Group voluntary profit-sharing scheme*
2001 entitlement paid in 2002 23.7
% of total payroll 4.8%
* In addition, specific individual company profit shares were paid in 2002.
Industrial relations
The five trades unions with nationwide representation in France (CFTC, CFDT, CFE-CGC, CGT, CGT-FO) are all present within
the Sanofi-Synthélabo Group in France. 
31 collective agreements signed or amended since the merger of Sanofi and Synthélabo in 1999 remained in force within the
Group in 2002. The main areas covered are welfare and healthcare costs; top-up pensions; trade union rights; the Group
employee savings scheme; training; mobility; and health/safety/working conditions/environment…
In 2002, an agreement was signed on the implementation of a mediation procedure relating to moral or sexual harassment within
the Sanofi-Synthélabo Group.
Following the agreement reached in 2001 on the establishment of a European Works Council, the Council met twice in 2002.
It is made up of 34 representatives from European Union countries and from six EU candidate countries.
Disabled employees
Number of disabled employees: 289 (excluding those indirectly employed via subcontracting)
Sanofi-Synthélabo has a Disabled Persons Program, helping Group companies implement an employment policy for employees
whose health has been impaired. There are two objectives: to allow disabled employees to continue working through 
preventive measures and by adapting their jobs and organizational structures, and to recruit new disabled employees.
Pre-recruitment initiatives have been developed, including intern programs and work experience under apprenticeship or 
qualification contracts for both young people and adults.
Redundancy programs
There was no restructuring within the Group's French operations during 2002. In the event of a site closure or relocation, the
Group provides a range of support packages intended to minimize the impact on the employees affected. These support 
packages reflect the Group's continuing commitment to uphold the principles and values that have always underpinned 
its human resources policy, by keeping redundancies to a minimum and ensuring that everyone has help in finding new 
employment.
The Group's concern for the safety and the physical and moral welfare of children is reflected by its application of ILO conventions
no. 138 (1973) and no. 182 (1999).
Sanofi-Synthélabo participates in regional employment initiatives via specially-formed not-for-profit and other organizations.
In the same spirit, the Group has for more than 15 years operated a "spin-off unit" for employees who wish to set up their 
own business.
In all the countries in which it operates, Sanofi-Synthélabo operates integration policies which strive to preserve local identities
and cultures. For example, nationals of the host country are favored for recruitment and promotion, including for 
management posts, subject to the constraints of the local labor market.
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Environmental data
Environmental data are consolidated at Group level from data for industrial units and research centers. No figures are given for changes
or comparatives because 2002 is the first year that this report has been produced, as a result of the enactment of the NRE law.
CONSUMPTION, WASTE AND POLLUTION
Water used for production and thermal purposes is supplied mainly from available groundwater, mostly in France. Consumption
is reduced by installing closed loop cooling systems and by accurate monitoring of usage.
m3 2002
Water 6,430,892
Energy is used for processes, air conditioning of buildings in line with pharmaceutical good manufacturing practices (GMP), and
the operation of environmental protection installations. Compared with other industries, the pharmaceutical industry generally
does not require large amounts of energy.
mWh (megawatt hours) 2002
Gas 408,156
Electricity 374,005
Liquid hydrocarbons 20,218
Other (steam) 115,201
These data do not include energy used for work-related travel by our medical reps or for transporting goods to and from our sites.
RAW MATERIALS
Of our raw materials, solvents – used mainly for synthesizing our active ingredients – are the resource with the greatest potential 
secondary effects for the environment. Reprocessing (where possible) and thermal utilization are promoted in order to cut consumption
of non-renewable raw materials. The criteria for selection or replacement include the reduction of any adverse effects on safety, health
and the environment. 
Tonnes used* 2002
Solvents 48,444
* "Tonnes used" includes solvents reprocessed at Group factories. This means that the amount bought in from outside is a smaller figure.
EMISSIONS, EFFLUENTS AND DEPOSITS
Emissions of Volatile Organic Compounds (VOC) from our synthesis and manufacturing of pharmaceuticals have been 
declining for several years. In particular, our research and development staff are developing solvent-free processes, while our
technical staff are installing solvent vapor recovery or thermal oxidation systems at Aramon, Ambarès, Budapest and Sisteron.
Tonnes 2002
VOC 1,736
The combustion of natural gas and small quantities of liquid hydrocarbons releases carbon dioxide into the air (direct 
emissions). Electricity consumption involves emissions at the premises of our electricity suppliers (indirect emissions), which are
calculated using Greenhouse Gas Protocol Initiative data.
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Not included in this total are emissions due to steam purchased externally, our medical rep vehicle fleet and the transport of
our goods. The effect of other greenhouse gases is not significant.
Equivalent tonnes (1) of CO2 2002
Fuel 79,485
Power generation 72,032
Industrial effluent discharge is processed either by our water treatment units or by municipal treatment works under agreements
with their operators. The main environmental impact of our effluents is COD (Chemical Oxygen Demand). Use was made of
innovative technologies (membrane bioreactors) or more traditional technologies (biological and physico-chemical stations).
Tonnes 2002
COD 481
The nitrogen contained in industrial effluents also has an environmental impact. 
Tonnes 2002
N2 31.6
The Group has no landfill sites or slurry spreading areas at its units. One of our units regularly reinjects its aqueous liquid 
effluents under license at great depth, the corresponding tonnage has not being accounted for in this report.
WASTE
We would highlight the very high level of utilization of hazardous wastes, either by recycling or reprocessing, or in the form 
of energy.
Two exceptional events this year have led to an increase in tonnage. The main one involves the incineration of liquid effluents
from one of our factories during a period when the water treatment unit was malfunctioning, a decision taken in order to 
minimize the impact on the natural environment. 
Where incineration treatment infrastructures are not available, a very small and constantly-declining proportion of wastes 
continues to be disposed of at agreed landfills.
Hazardous, tonnes (1) 2002
Recycled (utilized) 57,939
Incinerated (not utilized) 1,754
Total 59,693
Three-quarters of non-hazardous wastes are now reused, recycled or thermally utilized.
Non-hazardous, tonnes (1) 2002
Utilized 21,342
Processed (not utilized) 6,254
Total 27,596
(1) figures are provided in metric tons
SOIL
We have instituted a long-term program of preventive monitoring and study of topsoils and sub-soils at our sites, with ten
sites involved this year.
SPECIFIC PROTECTION OF NATURAL ENVIRONMENTS
Only one of our sites is located in an area where there is specific protection of the natural environment: Csanyikvölgy in
Hungary. Its activities are slightly polluting to the environment and it is specifically monitored in this connection.
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ENVIRONMENTAL EVALUATION AND CERTIFICATION
Two sites – the Alnwick research center in the UK and the Veresegyhaz pharmaceutical factory – have been granted ISO 14001
environmental certification.
Three other sites in France have just obtained a favorable recommendation in their certification audits: Aramon (chemicals), 
Amilly (pharmaceuticals) and Labège (research).
REGULATORY COMPLIANCE
An environment law watch is organized and carried out for all industrial and scientific activities in France. Subsidiaries in other
countries which carry out industrial or scientific activities also organize and carry out their own environment law watch.
An audit program is used to evaluate the effectiveness of this watch and to assess compliance with applicable administrative
and regulatory provisions.
Over the 2000-2002 period, all sites were subjected to an audit, either a general health safety and environment audit or 
a specific environmental, health & safety or fire protection audit, except for two sites with fewer than 100 staff.
EXPENDITURE INCURRED IN MONITORING AND CONTROLLING THE IMPACT OF THE COMPANY'S
ACTIVITIES ON THE ENVIRONMENT
Investment with an industrial health, safety, working conditions, process safety or environmental dimension amounted to 
23 million euros in 2002. In addition, new developments are designed with built-in preventive mechanisms, the associated 
investment being impossible to quantify specifically.
Expenditure on health, safety and environment, comprising HS&E personnel costs, consumables, energy, labor, waste 
processing and recycling, environmental taxes, studies and audit services, totaled 40 million euros in 2002.
GROUP HSE DEPARTMENT
The HSE (Health-Safety-Environment) department comprises 14 experts in environmental technologies, industrial safety, 
industrial toxicology, safety at work, fire safety, industrial risks, life sciences and work-related medicine. The department is
active at all the Group's sites. It is responsible for formulating HSE policy and general objectives, managing and coordinating
implementation, maintaining and developing competencies and reporting overall performances to divisional heads using reports
and audits. It is supported by: 
 59 HSE officers on site, implementing central guidance and directives.
 57 other officers at the largest sites, completing our Group HSE management services.
 9 full-time or part-time company doctors employed by the Group, and interprofessional doctors providing medical services
on site. They are assisted in their work by company nurses.
 3 European sites classified as SEVESO II, which also have their own first-aid personnel and equipment. 
Finally, each site has instituted and maintains its own emergency plan setting out the risks incurred and the internal and 
external resources to be mobilized or called upon as a result.
AMOUNT OF PROVISIONS AND GUARANTEES RELATING TO ENVIRONMENTAL RISKS
Detailed assessments of topsoil and subsoil pollution risks were carried out at 3 sites or former sites which are to be cleaned up.
In association with other corporate site-users, we also participated in an in-depth investigation and preliminary works at 
a former hazardous waste dump. In all, 21 million euros were provided for cleanup costs.
AMOUNT OF COMPENSATION
We were not ordered to pay any compensation of an environmental nature through the enforcement of any judicial decision
in 2002.
OBJECTIVES SET FOR FOREIGN SUBSIDIARIES
The programs, resources and results of foreign subsidiaries are included in the above report.
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Directorships and other positions held by members of the Board of
Directors and the Senior Executive Vice-President in all companies
in France and abroad during the year ended December 31, 2002
René Barbier de la Serre
in France :
 Director of Crédit Lyonnais, Sanofi-Synthélabo and Schneider
Electric
 Member of the Supervisory Board of Compagnie Financière
Edmond de Rothschild Banque (subsidiary of Compagnie
Financière Saint Honoré), Compagnie Financière Saint-
Honoré and Pinault-Printemps-Redoute
 Observer of Fimalac and Nord-Est
abroad:
 Chairman of Tawa UK Ltd (United Kingdom)
 Delegated Director of Harwanne Compagnie de Participations
Industrielles et Financières SA (Switzerland)
 Member of the Supervisory Board of Euronext NV
(Netherlands)
Robert Castaigne
in France :
 Chief Financial Officer of TotalFinaElf SA
 Chairman and Chief Executive Officer of Total Chimie and
Total Nucléaire (subsidiary of Total Chimie)
 Director of Atofina (subsidiary of Elf Aquitaine), Compagnie
Générale de Géophysique, Elf Aquitaine, Eramet, Hutchinson
(subsidiary of Total Chimie) and Sanofi-Synthélabo
abroad:
 Director of Omnium Insurance & Reinsurance Company Ltd
(Bermuda), Petrofina (Belgium), Total Nigeria Ltd (Nigeria),
TotalFinaElf, Exploration Norge AS (Norway), TotalFinaElf,
Exploration Holdings UK (United Kingdom) and TotalFinaElf
Exploration UK (United Kingdom)
Pierre Castres Saint Martin
in France :
 Chairman of the Supervisory Board of Groupe Marc de
Lacharrière
 Director of Fimalac (subsidiary of Groupe Marc de
Lacharrière), SEB and Sanofi-Synthélabo
 Member of the Supervisory Board of Arc International
Jean-François Dehecq
in France :
 Chairman and Chief Executive Officer of Sanofi-Synthélabo
 Director of Air France, Finance et Management, Société
Financière des Laboratoires de Cosmétologie Yves Rocher
and Péchiney
 Permanent representative of Sanofi-Synthélabo as Director
of Sanofi-Synthélabo Recherche (subsidiary of Sanofi-
Synthélabo)
abroad:
 Chairman and Director of Sanofi-Synthelabo Daiichi
Pharmaceuticals Co Ltd (Japan)
 Director of Sanofi-Synthelabo Inc. (United States) and
Fujisawa Sanofi-Synthelabo (Japan)
Thierry Desmarest
in France :
 Chairman and Chief Executive Officer of TotalFinaElf SA
and Elf Aquitaine (subsidiary of TotalFinaElf SA)
 Director of Sanofi-Synthélabo
 Member of the Supervisory Board of Areva and L'Air Liquide
Lord Douro
in France:
 Director of Sanofi-Synthélabo
abroad:
 Chairman of Richemont Holdings UK (United Kingdom)
 Chairman of Framlington Group (United Kingdom)
 Director of Compagnie Financière Richemont AG 
(Switzerland) and GAM Worldwide (United Kingdom) 
ELF AQUITAINE
in France:
 Director of Elf Aquitaine Exploration Production France, Elf
Exploration Production, Elf Hydrocarbures Chine, Elf
Neftegaz, Elf Petroleum Irak, Elf Petroleum Iran, Elf Union
Océane, Eurotadia International, Safrep, Sanofi-Synthélabo,
Sofrea, TotalFinaElf E & P Syrie and TotalFinaElf Lubrifiants
abroad:
 Director of Elf Aquitaine Algérie (Algeria), TotalFinaElf 
E & P Congo (Congo), Elf Gabon (Gabon), GPL (Gabon),
Reachim SA (Luxembourg), SAR (Senegal), SIR (Côte
d'Ivoire), Sogara (Gabon), Sonara (Cameroon) and
TotalFinaElf E & P (Cameroon)
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represented by Jean-Paul Léon
in France:
 Director of Société Financière des Laboratoires de
Cosmétologie Yves Rocher
 Permanent representative of Elf Aquitaine as Director of
Sanofi-Synthélabo
Pierre-Gilles de Gennes
Nobel Prize for Physics (1991)
in France:
 Professor at the Collège de France
 Director of the Ecole Supérieure de Physique et Chimie
Industrielles de Paris
 Director of Rhodia and Sanofi-Synthélabo
 Member of the Supervisory Board of L'Air Liquide
Hervé Guérin
in France:
 Chairman of the Supervisory Board of Human Health
Investments (H2i)
 Director of Ethypharm SA and Sanofi-Synthélabo
Gérard Le Fur
in France:
 Executive Vice-President – Scientific Affairs
 Senior Executive Vice-President of Sanofi-Synthélabo
 Chairman and Chief Executive Officer of Sanofi-Synthélabo
Recherche (subsidiary of Sanofi-Synthélabo)
abroad:
 Director of Sanofi-Synthélabo Inc. (United States)
L’ORÉAL
in France:
 Director of Cospar, Ecopar, Genfa, Laboratoires Galderma,
Parfums Guy Laroche, Regefi, Sanofi-Synthélabo and
Semercli
abroad:
 Director of Biotherm (Monaco), L'Oréal Hong Kong (Hong
Kong) and Sofamo (Monaco)
represented by Michel Somnolet
in France:
 Vice-President of L'Oréal in charge of General Management,
Administration and Finance 
 Chairman of Regefi
 Director of L'Oréal
 Permanent representative of L'Oréal as Director of Sanofi-
Synthélabo
abroad:
 Chairman and Director of Geral Inc. (United States)
 Director of L'Oreal USA Inc. (United States)
 Member of the Supervisory Board of L'Oréal Maroc 
(Morocco)
Lindsay Owen-Jones
in France:
 Chairman and Chief Executive Officer of L'Oréal
 Director of BNP Paribas, Gesparal and Sanofi-Synthélabo
 Vice-Chairman and Member of the Supervisory Board of
L'Air Liquide
abroad:
 Chairman and Director of L'Oreal USA Inc. (United States)
and L'Oreal UK Ltd (United Kingdom)
 Director of Galderma-Pharma (Switzerland)
Bruno Weymuller
in France:
 Executive Vice-President, Strategy and Risk Assessment of
TotalFinaElf SA
 Director of Elf Aquitaine and Sanofi-Synthélabo
 Member of the Supervisory Board of Technip-Coflexip
Observers
Régis Dufour
in France:
 Chairman of Mercure Pharmacie (mutual fund)
 Member of the Supervisory Board of Chevrillon Associés
 Observer of Sanofi-Synthélabo
René Sautier
in France:
 Observer of Sanofi-Synthélabo
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Fees charged to the Group for services provided by the statutory
auditors and by member firms of their networks (year 2002)
PricewaterhouseCoopers Ernst & Young
€ '000 % € '000 %
Audit
• Statutory audit, certification, examination 
of individual company financial statements 
and consolidated financial statements 2,757 2,527
- France 1,602 1,273
- Other countries 1,155 1,254
• Related engagements 164 659
Sub-total 2,921 83% 3,186 84%
Other services 
• Legal, tax, employee-related 548 527
- France - 69
- Other countries 548 458
• Information technology - -
• Internal audit - -
• Other 43 92
Sub-total 591 17% 619 16%
TOTAL 3,512 100% 3,805 100%
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Report of the statutory auditors on the consolidated 
financial statements
Year ended December 31, 2002
In compliance with the assignment entrusted to us by your shareholders' meeting, we have audited the accompanying 
consolidated financial statements of Sanofi-Synthelabo presented in euros for the year ended December 31, 2002.
These consolidated financial statements are the responsibility of the Board of Directors. Our responsibility is to express an 
opinion on these financial statements based on our audit.
We conducted our audit in accordance with French auditing standards. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial
statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as
well as evaluating the overall consolidated financial statements presentation. We believe that our audit provides a reasonable
basis for our opinion.
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Sanofi-
Synthelabo and its subsidiaries as of December 31, 2002, and the results of their operations for the year then ended, 
in accordance with principles generally accepted in France.
Without qualifying our opinion, we draw attention to note B2 to the consolidated financial statements, which present the
impact on the consolidated financial statements of the change in accounting method resulting from the application, with effect
from January 1, 2002, of the new CRC rule 2000-06 on liabilities.
We have also reviewed the information contained in the Directors’ report. We have nothing to report with respect to the 
fairness of such information or its consistency with the consolidated financial statements.
Paris, February 18, 2003
The Statutory Auditors
PricewaterhouseCoopers Audit Ernst & Young Audit
Jacques Denizeau Jean-Christophe Georghiou Dominique Thouvenin Valérie Quint
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Consolidated balance sheets
Before appropriation of profit
ASSETS
Note December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Intangible assets, net D.2
Goodwill  134 141 82
Other intangible assets  1,161 668 319
1,295 809 401
Property, plant and equipment D.3
Gross 1,989 1,630 1,417
Accumulated depreciation  (594) (401) (200)
Net 1,395 1,229 1,217
Long-term investments
Investments in/advances to equity investees  D.4 109 100 86
Investments in/advances 
to non-consolidated companies  D.5 27 110 274
Other long-term investments  73 48 67
Total fixed assets  2,899 2,296 2,045
Deferred income taxes  D.11 484 471 397
Inventories D.7 823 805 737
Accounts receivable  D.8 1,311 1,566 1,234
Other current assets  D.9 854 540 553
Short-term investments and deposits  D.10 2,944 4,166 2,672
Cash 144 123 207
Total assets 9,459 9,967 7,845
The accompanying notes on pages 31 to 60 are an integral part of the consolidated financial statements.
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Consolidated balance sheets
Before appropriation of profit
LIABILITIES AND SHAREHOLDERS’EQUITY
Note December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Shareholders' equity D.12
Share capital  1,465 1,464 1,463
(December 31, 2002: 732,367,507 shares; 
December 31, 2001: 732,005,084 shares; 
December 31, 2000: 731,441,746 shares)
Additional paid in capital and reserves 2,971 2,736 1,886
Net income for the period 1,759 1,585 985
Cumulative translation adjustment (160) (17) (30)
Total shareholders' equity  6,035 5,768 4,304
Minority interests 17 21 28
Long-term debt  D.13 65 119 121
Provisions and other long-term liabilities  D.14 786 1,053 1,130
Deferred income taxes D.11 10 10 4
Accounts payable  596 717 667
Other current liabilities D.15 1,599 1,994 1,300
Short-term debt D.16 351 285 291
Total liabilities and shareholders’equity  9,459 9,967 7,845
The accompanying notes on pages 31 to 60 are an integral part of the consolidated financial statements.
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Consolidated statements of income 
Note Year ended Year ended Year ended
(in millions of euros) Dec. 31, 2002 Dec. 31, 2001 Dec. 31, 2000
Net sales D.28 7,448 6,488 5,963
Cost of goods sold (1,378) (1,253) (1,442)
Gross profit  6,070 5,235 4,521
Research and development expenses (1,218) (1,031) (945)
Selling and general expenses (2,428) (2,306) (2,016)
Other operating income/(expense), net 190 208 17
Operating profit  D.28 2,614 2,106 1,577
Intangibles – amortization and impairment (129) (68) (35)
Financial income/(expense), net  85 102 18
Income before tax and exceptional items 2,570 2,140 1,560
Exceptional items D.22 10 281 46
Income taxes  D.23 (746) (842) (611)
Net income before income from equity investees, 
goodwill amortization and minority interests  1,834 1,579 995
Income from equity investees, net 20 14 8
Goodwill amortization (8) (7) (4)
Net income before minority interests 1,846 1,586 999
Minority interests D.24 (87) (1) (14)
Net income 1,759 1,585 985
Weighted average shares outstanding 727,686,372 731,711,225 731,232,525
Earnings per share, basic and diluted (in euros) 2.42 2.17 1.35
Net income  1,759 1,585 985
Exceptional items and goodwill amortization, 
net of income taxes and minority interests (1) (209) (24)
Income before exceptional items and goodwill 
amortization, net of income taxes 
and minority interests 1,758 1,376 961
Earnings per share before exceptional items and 
goodwill amortization ,basic and diluted (in euros) 2.42 1.88 1.31
The accompanying notes on pages 31 to 60 are an integral part of the consolidated financial statements.
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Consolidated statements of cash flows 
Note Year ended Year ended Year ended
(in millions of euros) Dec. 31, 2002 Dec. 31, 2001 Dec. 31, 2000
Net income  1,759 1,585 985
Minority interests  87 1 14
Share in undistributed earnings of equity investees (20) (14) (8)
Depreciation and amortization  379 301 241
Gains on disposals of fixed assets,  net of income taxes (9) (216) (28)
Provisions, long-term deferred taxes and other 64 75 91
Operating cash flow before changes in working capital 2,260 1,732 1,295
– Dividends received from equity investees 11 – –
– (Increase)/decrease in inventories (78) (105) 31
– (Increase)/decrease in accounts receivable  (18) (235) (125)
– Increase/(decrease) in accounts payable (77) 70 10
– Change in other operating assets and liabilities (net) (422) 356 (12)
Net cash provided by operating activities (A) 1,676 1,818 1,199
Acquisitions of property, plant & equipment and intangibles D.6 (1,403) (565) (372)
Acquisitions of investments (32) (54) (93)
Total investments  (1,435) (619) (465)
Proceeds from disposals of fixed assets, net of income taxes 22 492 81
Net change in loans, long-term advances 
and other investing cash flows 4 14 (5)
Net cash used in investing activities (B) (1,409) (113) (389)
Issuance of Sanofi-Synthélabo shares  D.12 4 7 3
Capital contribution from minority shareholders 5 – –
Dividends paid:
– to Sanofi-Synthélabo shareholders  (473) (317) (231)
– to minority shareholders of subsidiaries (3) (6) (10)
Additional long-term borrowings 1 9 –
Repayments of long-term borrowings (9) (12) (29)
Net change in short-term borrowings 54 (1) (21)
Acquisitions of treasury shares (1,170) (163) (183)
Net cash used in financing activities (C) (1,591) (483) (471)
Impact of exchange rates on cash and cash equivalents (D) (16) 3 1
Net change in cash and cash equivalents (A) + (B) + (C) + (D)  (1,340) 1,225 340
Cash and cash equivalents, beginning of period  B.10 3,805 2,580 2,240
Cash and cash equivalents, end of period B.10 2,465 3,805 2,580
The accompanying notes on pages 31 to 60 are an integral part of the consolidated financial statements.
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Consolidated statements of shareholders’equity 
Number of Share Additional Cumulative Total
shares capital paid in capital translation
(in millions of euros) and reserves adjustment
Balance December 31, 1999 731,143,218 1,462 2,131 (15) 3,578
Dividend paid out of 1999 earnings
(0.32 € per share) - - (231) - (231)
Issuance of shares on exercise of share options 298,528 1 2 - 3
Net income for year ended December 31, 2000 - - 985 - 985
Adjustments relating to the merger (note D.12.4.) - - (16) - (16)
Movement in cumulative translation adjustment - - - (15) (15)
Balance, December 31, 2000 731,441,746 1,463 2,871 (30) 4,304
Dividends paid out of 2000 earnings 
(0.44 € per share) – – (317) – (317)
Issuance of shares on exercise of stock options 563,338 1 6 – 7
Net income for year ended December 31, 2001 – – 1,585 – 1 585
Adjustments related to the Sanofi-Synthélabo 
merger (note D.12.4.) – – 176 – 176
Movement in cumulative translation adjustment – – – 13 13
Balance, December 31, 2001 732,005,084 1,464 4,321 (17) 5,768
Dividends paid out of 2001 earnings
(0.66 € per share) – – (473) – (473)
Issuance of shares on exercise 
of stock options 362,423 1 3 – 4
Net income for year ended December 31, 2002 – – 1,759 – 1,759
Adjustments related to the Sanofi-Synthélabo
merger (note D.12.4.) – – 59 – 59
Change in accounting method 
(note D.12.3.)  – – 24 – 24
Repurchase of shares (note D.12.5.)  – – (963) – (963)
Movement in cumulative translation adjustment – – – (143) (143)
Balance, December 31, 2002  732,367,507 1,465 4,730 (160) 6,035
The accompanying notes on pages 31 to 60 are an integral part of the consolidated financial statements.
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A. BASIS OF PREPARATION 
The consolidated financial statements of Sanofi-Synthélabo and its subsidiaries (the "Group") have been prepared in accordance
with Rule 99-02 of the Comité de la Réglementation Comptable ("CRC") issued April 29, 1999. Under the option allowed by
this rule, acquisitions of companies occurring prior to 2000 have not been restated.
The accounting policies and methods used are identical to those applied in the preparation of the financial statements for the
year ended December 31, 2001, except for the new CRC Rule 2000-06 on liabilities, implemented by Sanofi-Synthélabo with
effect from January 1, 2002.
Use of estimates
The preparation of financial statements requires management to make estimates and assumptions that may affect the reported
amounts of assets, liabilities, revenues and expenses in the financial statements, and the disclosures of contingent assets and
liabilities as of the balance sheet date. Examples include provisions for returns, bad debts, product claims reserves, inventory 
obsolescence and length of product life cycles, provisions associated with restructuring activities, income tax exposures, 
environmental liabilities, estimated useful lives of goodwill and intangible assets and fair values of derivative financial instruments.
Actual results could vary from these estimates. 
Accounting for the May 18, 1999 merger
In 1999, Sanofi and Synthélabo merged by absorption into Sanofi-Synthélabo, a separate legal entity. The effective date of the
merger for accounting purposes was July 1, 1999.
The excess of the acquisition cost of the shares (including transaction-related expenses) over the book value of net assets 
acquired, calculated using the Group's accounting policies, was accounted for as follows:
 In consolidation, revaluations were recorded in the balance sheets of the companies to adjust the book value of their 
separately identifiable assets and liabilities to their value to the Group based on a valuation carried out as of June 30, 1999,
which took into account restructuring costs and was subsequently adjusted as of December 31, 1999 and finalized as of
December 31, 2000. 
 The remaining excess of cost over the adjusted book value of net assets acquired was deducted from consolidated shareholders'
equity, in accordance with Bulletin 210 issued by the Commission des Opérations de Bourse ("COB"). In compliance with
CRC Rule 99-02, this accounting treatment was not adjusted for the new rules that became effective as of January 1, 2000.
B. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
B.1. Basis of consolidation
The consolidated financial statements include the accounts of Sanofi-Synthélabo and subsidiaries which it controls, using the
full consolidation method. The existence of effectively exercisable or convertible potential voting rights is taken into account
in determining whether control exists. 
Companies in which Sanofi-Synthélabo and outside shareholders exercise joint control over significant financial and operational
policies are accounted for using the proportionate consolidation method. For such companies, the Group recognizes in its financial
statements its share of assets and liabilities, revenues and expenses, and cash flows on the same lines as used for 
fully-consolidated subsidiaries, in proportion to the percentage interest held by the Group. 
Notes to the consolidated financial statements
Year ended December 31, 2002
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The Group defers recognition of its share of the margin generated by the purchase of products from within the Group until 
such products are resold to independent third parties. However, if it is probable that the loss on a transaction will result in a 
reduction in the net realizable value of such products or in other-than-temporary impairment, the loss is recognized immediately
in the Group's financial statements.
Companies over which Sanofi-Synthélabo exercises significant influence are accounted for under the equity method.
All material intercompany balances and transactions have been eliminated in the consolidated financial statements.
The Group's share of post-acquisition profits or losses is taken to the statement of income, and post-acquisition movements in
the acquired company's reserves are taken to consolidated reserves. Profits or losses arising on transactions with consolidated
companies or equity investees are eliminated in proportion to the percentage interest held by the Group in the company, until
the assets are resold to an independent third party.
A list of companies included in the consolidation is presented in section E. of the notes to the consolidated financial statements.
Companies are consolidated from the date on which control (exclusive or joint) or significant influence is transferred to the
Group, and are excluded from consolidation from the date on which the Group transfers control or significant influence. 
B.2. Change in accounting method
Pursuant to the new CRC Rule 2000-06, which became effective as of January 1, 2002, the Group reviewed all its liabilities as
of that date for compliance with the new rule.
The impact of applying this new rule was an adjustment to shareholders' equity of 24 million euros net of income taxes.
Adoption of CRC Rule 2000-06 had no material impact on net income for the years presented.
B.3. Foreign currency translation
Each foreign subsidiary measures its results in the currency that is most representative of its economic environment 
(the functional currency).
a) Accounting for transactions in foreign currencies in individual company accounts
Fixed assets and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate
prevailing at the date of acquisition.
All amounts receivable or payable in foreign currencies are translated using the exchange rate prevailing at the balance sheet
date or, where hedging instruments have been contracted in the market, at the hedged rate. The resulting gains and losses are
recorded in the statement of income. However, foreign exchange gains and losses arising from the translation of capitalizable
advances made to consolidated subsidiaries are reflected directly in the "Cumulative translation adjustment" line in shareholders'
equity.
b) Foreign currency translation of the financial statements of foreign subsidiaries
All assets and liabilities are translated into euros using the exchange rate of the subsidiary's functional currency prevailing at the
balance sheet date. The statements of income are translated using a weighted-average exchange rate for the period. The resulting
translation difference is shown as a separate component of shareholders' equity and is recognized in the statement of income when
the subsidiary is sold. By exception to this general rule, when a subsidiary operates in a hyper-inflationary environment with 
inflation exceeding 100% over a three-year period, fixed assets and inventories are translated using the exchange rate 
prevailing at the date of acquisition. Related statement of income items, such as depreciation expense, are translated using the
same exchange rate as for the corresponding asset, and the resulting translation adjustment is recorded in the statement of income
under "Financial income/(expense), net."
B.4. Goodwill
When the Group acquires control of a company, the separately identifiable assets and liabilities of the acquired company are
included in the consolidated balance sheet at their fair value to the Group at the date of first consolidation. The excess of the
purchase price, including transaction-related expenses, over the fair value of the Group's share of the identifiable assets and 
liabilities as of the acquisition date is recorded as goodwill.
33
C o n s o l i d a t e d  f i n a n c i a l  s t a t e m e n t s
Goodwill is amortized over periods which do not exceed 40 years. Individual amortization periods are determined after considering
the nature of the acquired business and the geographical location in which the acquired company operates. Goodwill is subject
to an impairment review when events or circumstances indicate that an impairment might exist. Such events or circumstances
include significant changes liable to have an other-than-temporary impact on the substance of the original investment.
B.5. Other intangible assets
Patents are amortized over the shorter of the period of legal protection or their estimated useful life.
Licenses are amortized over the shorter of the duration of the agreement or their estimated useful life.
Trademarks, leasehold rights and other intangible assets are recorded at their acquisition cost and are amortized on a straight-line
basis over their estimated useful lives, net of any provision for impairment if deemed necessary. Provisions for impairment are
measured on the basis of the same objective criteria that were used for the initial valuation.
Rights to pharmaceutical products that are acquired from third parties prior to receipt of regulatory approval to market the products
are expensed immediately as research and development expenses. However, amounts attributable to patents or other intellectual
property rights relating to molecules are capitalized if they have a market value. In such cases, they are amortized on a straight-line
basis over their estimated useful lives, net of any provision for impairment if their value in use is less than net book value.
B.6. Impairment of intangible assets
The value of intangible assets is reviewed regularly once a risk of impairment has been identified. The impairment review
involves a comparison of the net book value of the asset with the future cash flows from the asset.
Future cash flows are estimated by Group management on the basis of the medium-term plans for each business activity.
If net book value exceeds the value of the undiscounted cash flows, a provision for impairment is recorded equal to the difference
between the discounted cash flows and net book value. The discounting rate used is determined with reference to the risks inherent
in the business activities in question and to the economic situation in the country in which they operate.
B.7. Property, plant and equipment
Property, plant and equipment are recorded at acquisition cost to the Group or estimated value on the date of first consolida-
tion and are depreciated on a straight-line basis over their estimated useful lives.
Interest charges incurred on the financing of property, plant and equipment during the construction period are capitalized.
Leased assets are recorded as a fixed asset with a related liability when the terms of the lease effectively transfer the risks and
rewards of ownership of the asset to the Group.
Property, plant and equipment are depreciated over the following estimated useful lives:
Buildings 20 years
Plant and equipment 8 to 10 years
Other tangible fixed assets 4 to 10 years
B.8. Investments in/advances to non-consolidated companies
Investments in and advances to non-consolidated companies are recorded at acquisition cost. A provision for impairment is
recorded when the value in use to the Group as of the balance sheet date is less than acquisition cost, after taking account of
various factors including the share held in the company's net assets, its future earnings prospects, its position in the market, and,
if listed, the current market price.
B.9. Inventories
Inventories are valued at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method
or the first-in, first-out method. Returned goods are recorded at the standard cost of the accounting period in which the return
occurs. Expected returns are provided for at the end of the accounting period based on the Group's past experience.
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B.10. Short-term investments and deposits
Short-term investments are valued at the lower of cost or market value. They include treasury shares held in connection with stock
option plans. Treasury shares held in connection with stock option plans are allocated to these plans over the term of the plan,
and are valued at the lower of acquisition cost or exercise price of the related option. Provisions recorded to reduce the carrying
amount of treasury shares to the expected proceeds to be received on exercise of the options are charged to the statement of
income. A provision for impairment is recorded if their stock market value, taken as the average of the last 20 listed market
prices preceding the balance sheet date, is less than acquisition cost. This calculation is performed separately for each plan.
Cash and cash equivalents in the statement of cash flows comprise all liquid assets, including petty cash, bank accounts, short-
term deposits with an original maturity of three months or less and short-term investment securities other than treasury shares.
B.11. Revenue recognition
The Group derives the majority of its revenues from the sale of pharmaceutical products. Revenue is recognized when all of the
following criteria are met: persuasive evidence exists of agreement between the parties; delivery has occurred or services have
been rendered; and the price is fixed or determinable. Revenue from product sales is recognized when the risk and rewards of
ownership pass to the customer. Licensing income is reflected in gross profit over the period during which it is earned. Sales of
pharmaceutical product rights are recorded as exceptional income upon disposal of the rights, when no further obligation exists
and there is no continuing commitment on the part of the Group. Non-refundable up-front payments received in respect of
research and development and/or marketing agreements are recognized immediately in the statement of income.
Provisions for discounts, rebates to customers and product returns are recorded at the time the related sales are recognized, and
are classified as adjustments to consolidated net sales.
B.12. Cost of goods sold
Cost of goods sold consists primarily of the industrial cost of goods sold, licensing income and charges, distribution costs, and 
specific government levies related to the pharmaceuticals sector paid in certain countries.
B.13. Research and Development
Research and development costs are expensed as incurred.
B.14. Other operating income/(expense), net
"Other operating income/(expense), net" relates primarily to profit sharing arrangements with partners under joint venture and
alliance agreements. The effects of these profit sharing arrangements are reflected in operating profit (note C.).
B.15. Intangibles – amortization and impairment
"Intangibles – amortization and impairment" includes all amortization and impairment relating to intangible assets other than
software and goodwill. Amortization of software is reflected in operating profit.
B.16. Financial income/(expense), net
"Financial income/(expense), net" comprises interest received and paid and foreign exchange gains and losses. It excludes
commercial discounts, which are recorded as a reduction of consolidated net sales.
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B.17. Exceptional items
Exceptional items consist of gains and losses on disposals of tangible and intangible fixed assets and of long-term investments,
costs associated with strategic restructuring programs, and significant costs or provisions relating to litigation.
B.18. Income taxes 
Income taxes include current and deferred taxation of consolidated companies.
Withholding taxes on intra-group and third-party royalties are recorded as current taxes.
Provision is also made for unrecoverable taxes payable on distributions of reserves by subsidiaries, unless such distributions 
are not probable.
The Group accounts for deferred taxes using the liability method, whereby deferred income taxes are recognized on:
  differences between the tax and carrying amounts of assets and liabilities; and
 tax loss carryforwards.
Deferred tax assets and liabilities are calculated using enacted tax rates applicable for the years during which the temporary 
differences are expected to reverse. A provision is recorded when it is more likely than not that the realization of the deferred
tax assets will not occur.
In accordance with CRC Rule 99-02, deferred taxes are presented using a net position for each fiscal entity, aggregated as 
an asset or a liability in the consolidated balance sheet.
B.19. Employee benefits
Sanofi-Synthélabo's pension and retirement benefit commitments are recognized as liabilities on the basis of an actuarial 
estimate of the potential rights vested in employees and retirees as of the balance sheet date, net of the valuation of funds 
available to meet these obligations.
This estimate is prepared annually, and takes into account assumptions regarding life expectancy, staff turnover, salary 
inflation, and discounting of the amounts payable.
Other post-employment benefits (healthcare and life insurance) granted by Group companies to their employees are also 
recognized as liabilities on the basis of an actuarial estimate of the potential rights vested in employees as of the balance sheet date.
Actuarial gains and losses less than 10% of the higher of the future obligation or the market value of invested funds are 
not recognized.
B.20. Financial instruments  
The Group applies a hedging policy based on the use of diversified, liquid financial instruments to reduce its exposure to risks
arising from fluctuations in exchange rates and interest rates and to protect operating margins. Derivative financial instruments
are entered into only with counterparties having a high credit rating. The Group does not require collateral with respect to
these transactions.
Derivative instruments used to meet the Group's hedging objectives may include forward foreign currency exchange contracts,
foreign currency options and interest rate swaps. These instruments relate to assets and liabilities existing at the balance 
sheet date and, in some cases, to commitments related to future transactions as determined from the Group's annual 
forecasting process.
Gains and losses arising on hedging transactions are calculated and recognized symmetrically with the recognition of gains and
losses on the hedged item. Gains and losses arising from the mark-to-market at the balance sheet date of instruments not 
qualifying as hedges are recognized in the statement of income.
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B.21. Earnings per share
Basic earnings per share and basic earnings per share before exceptional items and goodwill amortization are calculated using the
weighted average number of shares outstanding during the accounting period, adjusted on a time-weighted basis from the
acquisition date to reflect the number of Sanofi-Synthélabo shares held by the Group and acquired in order to stabilize the share
price. In the event of a stock split or bonus issue of shares, earnings per share and earnings per share before exceptional items
and goodwill amortization for prior periods are adjusted accordingly.
Diluted earnings per share and diluted earnings per share before exceptional items and goodwill amortization are calculated
assuming (i) the exercise of all outstanding options and warrants and (ii) the conversion of any financial instruments giving access
to the capital, after taking account of the theoretical impact of these transactions on the Group's net income. 
C. ALLIANCES
C.1. Alliance agreements with Bristol-Myers Squibb ("BMS")
Two of the Group's leading products were jointly developed with BMS: the anti-hypertensive agent irbesartan
(Aprovel®/Avapro®/Karvea®) and the atherothrombosis treatment clopidogrel (Plavix®/Iscover®).
Sanofi-Synthélabo is paid, as inventor of the two molecules, a royalty on all sales generated by these products. This royalty is
recorded as a reduction in cost of goods sold.
As co-developers of the products, Sanofi-Synthélabo and BMS each receive equal development royalties from their two licensees,
which have been responsible, since 1997, for marketing the products using their local distribution network, composed of the 
affiliates of both groups. These licensees operate in two separate territories: (i) Europe, Africa and Asia, under the operational
management of Sanofi-Synthélabo; and (ii) the rest of the world (excluding Japan), under the operational management of BMS.
In Japan, Sanofi-Synthélabo has granted a license to BMS and Shionogi, a Japanese pharmaceutical company. 
The products are marketed in different ways in different countries.
Co-promotion consists of a pooling of sales resources under a single brand name. Co-promotion is preferably achieved through
contracts or through appropriate tax-transparent legal entities. Each partner records directly its share of taxable income.
Co-marketing consists of separate marketing of the products by each local affiliate using its own name and resources under dif-
ferent brand names for the product.
In certain countries of Eastern Europe, Africa, Asia, Latin America and the Middle East, the products are marketed on an exclusive
basis, either by Sanofi-Synthélabo or by BMS.
In the territory managed by Sanofi-Synthélabo, operations are recognized by the Group as follows:
(i)  Co-promotion is used in most of the countries of Western Europe and Asia (excluding Japan) for both products, and in Portugal
for irbesartan (Aprovel®/Avapro®/Karvea®). The legal entities used are partnerships ("sociétés en participation") or other 
tax-transparent entities, which are majority-owned by and under the operational management of the Group. Sanofi-Synthélabo
recognizes all the revenue associated with the sale of the drugs, as well as the corresponding expenses. The share of net income
reverting to BMS subsidiaries is recorded in "Other operating income/(expense), net".
(ii) Co-marketing is used in Germany, Italy, Spain and Greece for both products, and in Portugal for clopidogrel (Plavix®/Iscover®).
Sanofi-Synthélabo recognizes revenues and expenses generated by its own operations.
(iii) In Eastern Europe, Africa, Asia and the Middle East, where products are marketed exclusively by Sanofi-Synthélabo, the Group
recognizes revenues and expenses generated by its own operations.
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In the territory managed by BMS, operations are recognized by the Group as follows:
(i) Co-promotion is used in the United States and Canada through entities which are majority-owned by and under the operational
leadership of BMS. Sanofi-Synthélabo does not recognize revenues; rather, it invoices the entity for its promotion expenses, accounts
for royalties in gross profit and records its share of net income in "Other operating income/(expense), net".
(ii) Co-marketing is used in Brazil, Mexico, Argentina, Colombia and Australia. Sanofi-Synthélabo recognizes revenues and expenses
generated by its own operations.
(iii) In certain other countries of Latin America, where products are marketed exclusively by Sanofi-Synthélabo, the Group
recognizes revenues and expenses generated by its own operations.
The presentation of these transactions in the Sanofi-Synthélabo financial statements, in accordance with the legal nature of the agreements,
results in the inclusion of Sanofi-Synthélabo's share of the results of operations in its consolidated operating profit and consolidated
income before tax and exceptional items.
C.2. Alliance agreements with Pharmacia-Searle
Through December 29, 2001: 
The hypnotic drug zolpidem (Ambien®) was sold in the US through the Lorex Pharmaceuticals joint venture ("Lorex"), owned
49% by Sanofi-Synthélabo and 51% by Pharmacia-Searle. This joint venture was accounted for under the proportionate
consolidation method, as the two groups had signed an agreement under which they exercised joint control over financial and
operational policy. Sanofi-Synthélabo also received royalties from Lorex, the non-Group portion of which was accounted for
as an addition to gross profit.
Under the profit-sharing agreement, Sanofi-Synthélabo was entitled to 40% of the profits in 2000 (against 60% for Pharmacia-
Searle). The percentage rose to 47% in 2001 and to 49% from January 1 through April 15, 2002. The difference between the
net income of Lorex and the share to which Sanofi-Synthélabo was contractually entitled was recorded in the statement of
income on the line "Other operating income/(expense), net".
The profit-sharing agreement also provided for the acquisition by the Group of the 51% interest owned by Pharmacia-Searle
on April 16, 2002. 
As from December 30, 2001:
On December 30, 2001, the partners signed an amendment to the profit-sharing agreement pursuant to which Pharmacia-Searle
transferred control of Lorex Pharmaceuticals to Sanofi-Synthélabo as of that date. Consequently, the Lorex Pharmaceuticals balance
sheet was fully consolidated as of December 31, 2001. In 2002, the Group fully consolidated the Lorex Pharmaceuticals 
statement of income with effect from January 1. Pharmacia-Searle retained its 51% interest in Lorex Pharmaceuticals' net
income until April 16, 2002, on which date Sanofi-Synthélabo exercised its rights to acquire Pharmacia-Searle's interest. These
rights are shown as intangible assets in the balance sheet at a value of 697 million dollars.
C.3. Alliance agreements with Organon
The alliance with Organon, a subsidiary of Akzo Nobel, covers the worldwide marketing of Arixtra®, which was launched in America
and Europe in 2002. The marketing arrangements vary depending on the region involved:
(i) North America: In the United States, Mexico and Canada, Arixtra® is sold by companies controlled jointly with Organon. Sales
and expenses relating to Arixtra® are recorded using the proportionate consolidation method based on the 50% interest held
by Sanofi-Synthélabo in the joint venture.
(ii) Europe and the rest of the world (excluding Japan): Sanofi-Synthélabo markets and sells Arixtra® in the same way as its
other products, and includes all sales in these countries in consolidated net sales. Sanofi-Synthélabo has an exclusive license
to market Arixtra® in these territories. The royalty paid to Organon on the basis of these sales is accounted for in cost of
goods sold.
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D. DETAILED NOTES TO THE FINANCIAL STATEMENTS
D.1. Changes in the scope of consolidation
Significant changes in 2002
Acquisitions
The three main acquisitions during the period were:
 Acquisition on April 16, 2002 of the 51% interest held by Pharmacia-Searle in the Lorex Pharmaceuticals joint venture 
(note C.2). With effect from this date, Sanofi-Synthélabo has been entitled to 100% of this entity's profits.
 Acquisition on January 1, 2002 of 100% of Institut Médical Algérien.
 The Group also acquired the minority interests held by third parties in two companies in India and Greece.
The acquisitions made during the period resulted in the recognition of goodwill with a gross value of 13 million euros as of 
December 31, 2002.
Divestitures
There were no significant divestitures in the year ended December 31, 2002. 
Change in method of consolidation
The Fujisawa Sanofi-Synthélabo (Japan) joint venture is proportionately consolidated at a rate of 51%, in order to reflect new 
agreements that took effect in 2002. This entity was accounted for using the full consolidation method at a rate of 51% in the
year ended December 31, 2001.
Significant changes in 2001
Acquisitions
Further to an agreement signed by Sanofi-Synthélabo and Pharmacia-Searle on December 30, 2001 (note C.2), the Lorex
Pharmaceuticals balance sheet was fully consolidated as of December 31, 2001.
The table below presents the impact on the Group's balance sheet had Lorex Pharmaceuticals been fully consolidated as of
December 31, 2000.
(in millions of euros) December 31, 2000
Inventories 11
Accounts receivable 118
Other current assets  (44)
Total assets 85
Shareholders' equity  1
Accounts payable  16
Other current liabilities 68
Total liabilities and shareholders' equity 85
The negative impact on other current assets results from the elimination of 100% of the transactions between Lorex Pharmaceuticals
and other Group companies.
On a 100% basis, Lorex Pharmaceuticals generated net sales of 905 million dollars in 2001 and 709 million dollars in 2000, and
net income before taxes of 576 million dollars in 2001 and 420 million dollars in 2000.
In 2001, the Group also acquired the minority interests held by third parties in four companies in Sweden, Turkey, Chile and
Algeria, as well as a majority interest in a company in Colombia. These acquisitions resulted in the recognition of goodwill with
a gross value of 59 million euros as of December 31, 2001.
39
C o n s o l i d a t e d  f i n a n c i a l  s t a t e m e n t s
Divestitures
The three principal divestitures during the period were as follows:
 On February 8, 2001, the Group signed an agreement to sell its Sylachim fine chemicals subsidiary to Dynamit Nobel, 
a subsidiary of the German group MG Technologies. The sale was priced at 99 million euros on an enterprise value basis
(selling price excluding the debt of the divested company). 
 On February 9, 2001, the Group signed an agreement to sell the urological bio-medical devices company Porgès and its
subsidiaries to Mentor Corporation. The sale was priced at 35 million euros on an enterprise value basis (selling price 
excluding the debt of the divested sub-group).
 On March 15, 2001, the Group signed an agreement to sell the cardiological medical devices company Ela Medical and its
subsidiaries to the Snia Group. The sale was priced at 138 million euros on an enterprise value basis (selling price excluding
the debt of the divested sub-group).
Amounts related to these divested businesses reflected in the consolidated balance sheet as of December 31, 2000 are 
shown below:
(in millions of euros) December 31, 2000
Property, plant & equipment and intangible assets 83
Deferred income taxes 3
Inventories 67
Accounts receivable  65
Other current assets 88
Cash and cash equivalents 6
Total assets 312
Shareholders' equity  48
Long-term debt & other long-term liabilities 14
Accounts payable 35
Other current liabilities 103
Short-term debt 112
Total liabilities and shareholders' equity 312
Amounts related to these divested businesses reflected in the consolidated statements of income are summarized below
Year ended Year ended 
(in millions of euros) December 31, 2001 December 31, 2000
Net sales 39 243
Operating profit/(loss) (8) 20
Net income/(loss)  (10) 8
Net income/(loss) before exceptional 
items and goodwill amortization (10) 8
The interest in Laboratoires de Biologie Végétale Yves Rocher was sold at end December 2001 for 316 million euros. The sale 
generated a consolidated net gain for Sanofi-Synthélabo of 125 million euros, recognized in the year ended December 31, 2001.
After this sale, and based on available information, the Group owns 39.1% of Financière des Laboratoires de Cosmétologie Yves
Rocher, a holding company which in turn holds 51.3% of Laboratoires de Biologie Végétale Yves Rocher. Consequently, the
Group had an indirect financial interest of 20.1% in the Yves Rocher group as of December 31, 2001.
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Significant changes in 2000
Acquisitions
In 2000, the Group acquired the minority interests held by third parties in two companies in Poland and Finland. 
These acquisitions resulted in the recognition of goodwill with a gross value of 83 million euros as of December 31, 2000.
Divestitures
There were no significant divestitures in the year ended December 31, 2000.
D.2. Intangible assets
Intangible assets as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Goodwill 153 153 86
Trademarks 53 51 40
Patents, concessions, licenses and other 1,282 697 282
Software 135 103 77
Sub-total – other intangible assets  1,470 851 399
Gross  1,623 1,004 485
Amortization and impairment (328) (195) (84)
Net 1,295 809 401
The increase in the line "Patents, concessions, licenses and other" was principally due to the purchase of the rights to Ambien
in the United States.
Exceptional impairment of an immaterial amount was recognized on the basis of impairment tests carried out as of December
31, 2002 using the method described in note B.6.
D.3. Property, plant & equipment
Property, plant and equipment as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Land 52 50 54
Buildings  611 507 445
Plant and equipment 797 679 578
Fixtures, fittings and other  311 249 205
Fixed assets in progress 218 145 135
Gross 1,989 1,630 1,417
Depreciation and impairment  (594) (401) (200)
Net 1,395 1,229 1,217
Depreciation expense for the years ended December 31, 2002, 2001 and 2000 amounted to 217 million euros, 194 million euros
and 181 million euros respectively. 
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Included in property, plant and equipment are the following balances relating to capitalized leases as of December 31, 2002, 2001
and 2000:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Land 9 9 9
Buildings 105 107 120
Plant and equipment  – – 8
Gross 114 116 137
Depreciation and impairment  (56) (51) (52)
Net 58 65 85
D.4. Investments in/advances to equity investees
Investments in/advances to equity investees as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Yves Rocher group  92 84 73
Other investments and advances 17 16 13
Total 109 100 86
As of December 31, 2002, investments in and advances to equity investees mainly comprised the 39.1% interest in Financière
des Laboratoires de Cosmétologie Yves Rocher, the parent company of the Yves Rocher cosmetics group.  
D.5. Investments in/advances to non-consolidated companies  
As of December 31, 2001 and December 31, 2000, investments in/advances to non-consolidated companies included receivables relating
to operations with joint venture and alliance partners. These items were included in "Other current assets" as of December 31, 2002.
As of December 31, 2000, other investments in/advances to non-consolidated companies related mainly to a direct interest in
Laboratoires de Biologie Végétale Yves Rocher valued at 159 million euros. As described in note D.19, this interest was sold in December
2001 following the exercise by Yves Rocher of its purchase option.
D.6. Acquisitions of property, plant and equipment and intangible assets 
Acquisitions of property, plant and equipment and intangible assets as shown in the consolidated statement of cash flows comprise:
Year ended Year ended Year ended 
(in millions of euros) Dec.31, 2002 Dec. 31, 2001 Dec. 31, 2000
Acquisitions of intangible assets 980 282 119
Acquisitions of property, plant & equipment 423 283 253
Total 1,403 565 372
In 2002, acquisitions of intangible assets mainly comprised the purchase of the rights to Ambien in the United States resulting
from the acquisition of Pharmacia-Searle's 51% interest in Lorex Pharmaceuticals (see note C.2), and payment of the balance
for the rights to Avapro in the United States.
In 2001, they included the payment made in connection with the increase in the Group's share in profits arising from the 
marketing of Avapro in the United States.
In 2000, they comprised acquisitions of pharmaceutical products and buyouts of marketing rights. 
Acquisitions of property, plant and equipment relate mainly to industrial facilities (chemicals and drugs manufacturing) and to
research sites.
The accelerated level of investment in property, plant and equipment in 2002 is related to increases in production capacity for
new products.
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D.7. Inventories
Inventories as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Raw materials  288 305 196
Work in process 144 113 178
Finished goods 474 442 396
Gross 906 860 770
Provision (83) (55) (33)
Net 823 805 737
Given the diversity of the activities carried on by the Group, some products sold within the Group and to third parties may be
classified alternatively as raw materials, work in process or finished goods, depending on the circumstances. The inventory split
shown above uses the classifications adopted by the subsidiary holding the inventory.
The table below shows the movement in inventory provisions for the years ended December 31, 2002, 2001 and 2000:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Balance, beginning of period (55) (33) (4)
Movement in provisions recognized 
in net income for the period (85) (66) (42)
Provisions utilized 53 37 14
Change in scope of consolidation (2) 8 –
Effect of exchange rates  6 (1) (1)
Balance, end of period  (83) (55) (33)
D.8. Accounts receivable
Accounts receivable as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Gross 1,348 1,585 1,246
Provision  (37) (19) (12)
Net 1,311 1,566 1,234
Balances of and movements in provisions for accounts receivable for the years ended December 31, 2002, 2001 and 2000
were not material.
D.9. Other current assets
Other current assets as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Taxes recoverable 335 215 240
Other receivables 462 282 265
Prepaid expenses 57 43 48
Total (net) 854 540 553
Other current assets as of December 31, 2002 include receivables relating to operations with joint venture and alliance partners, shown
in "Investments in/advances to non-consolidated companies" in 2000 and 2001 (see note D.5). The reclassification of these balances
as of January 1, 2002 amounted to 83 million euros.
The balance of receivables relating to operations with joint venture and alliance partners as of January 1, 2001 was 60 million euros.
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D.10. Short-term investments and deposits
Surplus cash is invested in money-market mutual funds and term deposits with counterparties having high credit ratings.
As of December 31, 2002, Sanofi-Synthélabo held treasury shares, mainly allocated to employee stock option plans, with a net
value of 623 million euros. The value of treasury shares held as of December 31, 2001 and 2000 was 462 million euros and 299
million euros respectively. The market value of treasury shares was 813 million euros as of December 31, 2002, compared with
957 million euros as of December 31, 2001 and 635 million euros as of December 31, 2000. These shares are included in "Short-
term investments and deposits".
In the light of the listed market price of the shares in the 20 days preceding the balance sheet date, this line includes a provision
for impairment of 46 million euros as of December 31, 2002.
D.11. Deferred income taxes
Net deferred tax assets as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Deferred income taxes on:
• Consolidation adjustments 237 207 133
• Provision for pensions & 
other employee benefits 35 55 43
• Other non-deductible provisions & other items 202 199 217
Total net deferred tax assets 474 461 393
Deferred tax assets not recognized because of uncertainty as to their future recovery amounted to 243 million euros as of December
31, 2002, compared with 313 million euros as of December 31, 2001 and 361 million euros as of December 31, 2000.
As of December 31, 2002, the Group had total tax loss carryforwards of 97 million euros, which are due to expire as follows:
(in millions of euros) Loss
2003 9
2004 6
2005 3 
2006 13
2007 19
2008 and thereafter 47
Total 97
Use of these tax loss carryforwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are
applied, carryforwards are able to be netted against taxable income generated by other entities in the consolidated tax group.
In certain countries, withholding taxes are paid by the Group when dividends are distributed. Due to local investment needs,
distribution of a portion of these earnings is considered unlikely. No provision has been made for deferred income taxes on this
portion of earnings, which amounted to 1,001 million euros, 652 million euros and 649 million euros as of December 31, 2002,
2001 and 2000 respectively.
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D.12. Shareholders' equity
D.12.1. Share capital
The share capital comprises 732,367,507 shares with a par value of 2 euros per share.
The Group held 30,376,375 treasury shares as of December 31, 2002, 11,419,291 treasury shares as of December 31, 2001 and
8,946,924 treasury shares as of December 31, 2000 respectively. 
D.12.2. Reserves subject to restrictions on distribution
As of December 31, 2002, 591 million euros of the Group's consolidated reserves were non-distributable. Of this amount, 
193 million euros constitutes a legal reserve which is restricted as to distribution. The remaining 398 million euros principally
represents a portion of net long-term gains on disposals whose distribution would be subject to supplementary taxation. 
D.12.3. Changes in accounting method
In application of the new CRC Rule 2000.06, non-compliant provisions amounting to 24 million euros net of taxes were 
reversed by crediting shareholders' equity.
D.12.4. Adjustments to shareholders' equity related to the merger between Sanofi and Synthélabo
As a result of the merger between Sanofi and Synthélabo, positive adjustments of 59 million euros and 176 million euros were made
to shareholders' equity in 2002 and 2001 respectively. A negative adjustment of 16 million euros was made in 2000. 
These adjustments include the portion of provisions recorded in the opening balance sheet no longer required due to favorable changes
in the relevant risks during the period. The 2001 adjustment also included the offset of a portion of the goodwill related to the 
merger (initially recorded as a reduction of equity) against the capital gain on the main businesses divested in that year.
The adjustments are summarized as follows:
(in millions of euros) 2002 2001 2000
Revaluation of assets – – 88
Change in provisions for risks and deferred 
income taxes recorded in the opening balance sheet 59 90 (64)
Allocation of goodwill to divestitures – 34 –
Revaluation of commitments to employees – 52 (40)
Total 59 176 (16)
In 2002 and 2001, the change in provisions for risks and deferred income taxes related mainly to the settlement of tax litigation,
primarily in France and the United States. In 2000, this related mainly to the revaluation of contingent tax positions existing as
of the date of the merger.
D.12.5. Repurchase of shares
The Annual General Meeting of May 22, 2002 authorized the implementation of a share purchase program amounting to 10%
of Sanofi-Synthélabo shares. Under this authorization, the Group proceeded in 2002 with a policy of purchasing its own shares
with a view to holding, selling, transferring or canceling them. Shares purchased are netted off shareholders' equity at purchase
price. Gains and losses on transactions in these shares, net of taxes, are also taken to shareholders' equity. Under this plan, the
Group repurchased 16,520,795 shares in 2002 for 970 million euros.
As at December 31, 2002, the Group held 16,411,795 treasury shares, amounting to 963 million euros.
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D.12.6. Stock-based compensation
Options to subscribe to Group shares
The Sanofi shareholders' meeting of May 21, 1992 authorized a stock option plan, which allows grantees to subscribe to a
fixed number of shares at a pre-determined price over a specified period. Options granted under this plan cliff vested one year
from the date of grant and expired seven years from the date of grant.
Details of the options granted under this plan are presented below (in Sanofi-Synthélabo equivalent shares):
Origin Date of Options Start date Expiration Exercise Options 
grant granted of vesting date price exercised
period (in euros) as of 
12/31/02
Sanofi 09/20/1995 1,056,000 09/21/1996 09/20/2002 10.26 1,025,640
Sanofi 09/18/1996 1,056,000 09/19/1997 09/18/2003 14.56 539,675
The exercise of all of the stock options outstanding at December 31, 2002 would result in an increase of approximately 
7 million euros in shareholders' equity.
Exercise of options under this plan resulted in the creation of 362,423 shares in 2002 (each with a par value of 2 euros per share)
and aggregate proceeds of 4 million euros.
Options to purchase Group shares
The Group has several stock option plans which allow grantees to purchase a fixed number of shares at a pre-determined price over
a specified period. Options generally cliff vest over two to five years from the date of grant and expire seven to twenty years from
the date of grant. Shares acquired under these plans generally may not be disposed of prior to the fifth anniversary of the date of
grant, or prior to the fourth anniversary of the date of grant with effect from the Sanofi-Synthélabo plan of May 24, 2000.
As authorized by the Sanofi-Synthélabo shareholders' meeting of May 18, 1999, the Group may grant options to its employees 
to acquire up to 14,611,740 shares.
Details of the stock purchase options granted under the Group's various plans are presented below (in Sanofi-Synthélabo
equivalent shares):
Origin Date of Options Start date Expiration  Exercise Options
grant granted of vesting date price exercised 
period (in euros) as of
12/31/02
Synthélabo 12/15/93 364,000 12/15/98 12/15/13 6.36 348,400
Synthélabo 10/18/94 330,200 10/18/99 10/18/14 6.01 305,200
Synthélabo 12/15/94 49,400 12/15/99 12/15/14 5.86 49,400
Synthélabo 12/15/95 442,000 12/15/00 12/15/15 8.50 378,400
Synthélabo 01/12/96 208,000 01/12/01 01/12/16 8.56 133,630
Synthélabo 04/05/96 228,800 04/05/01 04/05/16 10.85 114,040
Sanofi 09/22/97 1,120,000 09/23/99 09/22/04 21.46 194,020
Synthélabo 10/14/97 262,080 10/14/02 10/14/17 19.73 49,760
Synthélabo 06/25/98 296,400 06/26/03 06/25/18 28.38 –
Sanofi 12/10/98 1,200,000 12/11/00 12/10/05 34.95 24,720
Synthélabo 03/30/99 716,040 03/31/04 03/30/19 38.08 –
Sanofi-Synthélabo 05/24/00 4,292,000 05/25/04 05/24/10 43.25 –
Sanofi-Synthélabo 05/10/01 2,936,500 05/11/05 05/10/11 64.50 –
Sanofi-Synthélabo 05/22/02 3,111,850 05/23/06 05/22/12 69.94 –
Shares offered under these plans are acquired in the stock market. Consequently, these plans have no impact on shareholders'
equity as of December 31, 2002.
In 2002, the Group repurchased 3,029,884 shares for 214 million euros for allocation under stock option plans.
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Summary of stock-based compensation plans
A summary of the Group stock options outstanding at December 31, 2002, 2001 and 2000, and of changes during those years,
is presented below:
Exercise price (in euros)
Number of options Weighted Aggregate
average per (in millions of euros)
share
Outstanding – January 1, 2000  6,392,174 21.45 137
Granted 4,292,000 43.25 186
Exercised (499,928) 9.76 (5)
Expired/Forfeited (5,200) 19.73 –
Outstanding – December 31, 2000 10,179,046 31.21 318
Granted 2,936,500 64.50 189
Exercised (881,313) 10.98 (10)
Expired/Forfeited (76,260) 43.71 (3)
Outstanding – December 31, 2001 12,157,973 40.64 494
Granted  3,111,850 69.94 218
Exercised  (847,018) 13.27 (11)
Expired/Forfeited (71,300) 36.87 (3)
Outstanding – December 31, 2002 14,351,505 48.63 698
As of December 31, 2002, there were 3,108,635 exercisable options outstanding, with a weighted average exercise price of
24.15 euros per share. As of December 31, 2002, there remained 4,271,390 options available for grant. The following table
summarizes information concerning outstanding and exercisable options as of December 31, 2002:
Outstanding Exercisable
Number Weighted Weighted Number Weighted
of options average average of options average
remaining exercise price exercise price
life (years) per share per share 
Range of exercise prices per share (in euros) (in euros)
From 5.86 to 10.85 euros per share  288,130 12.93 9.16 288,130 9.16
From 14.56 to 28.38 euros per share 1,944,425 4.95 20.50 1,648,025 19.09
From 34.95 to 69.94 euros per share 12,118,950 8.23 54.08 1,172,480 34.95
Total 14,351,505 7.88 48.63 3,108,635 24.15
D.13. Long-term debt (portion due after more than one year)
The Group's long-term debt as of December 31, 2002, 2001 and 2000 comprises:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Capital lease obligations 51 57 65
Other long-term debt 14 62 56
Total 65 119 121
The Group's long-term debt agreements do not contain any covenants which impose significant restrictions on the Group's 
activities, including its ability to pay dividends, acquire or divest other businesses or incur additional borrowings. There are no
specific contractual provisions associated with this debt liable to modify the repayment terms or interest charge.
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The table below presents the maturity of long-term debt as of December 31, 2002, 2001 and 2000:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
2002 – – 8
2003 – 55 55
2004 11 11 9
2005 8 9 8
2006 7 8 6
2007 4 4 5
Thereafter 35 32 30
Total 65 119 121
The table below presents an analysis of long-term debt by interest rate as of December 31, 2002, 2001 and 2000, after taking
into account hedging instruments. The split is based on interest rates at year-end.
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Less than 5% 8 54 54
From 5% to 7.5% 51 53 52
From 7.5% to 10% 6 12 15
Total 65 119 121
Of which:
– fixed rate 15 21 22
– variable rate 50 98 99
The table below presents an analysis of long-term debt by currency as of December 31, 2002, 2001 and 2000, after taking into
account hedging instruments:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Euro 58 110 118
US dollar 2 2 3
Other currencies 5 7 –
Total 65 119 121
The table below summarizes interest paid on the short-term and long-term portion of debt and on credit lines during each
accounting period:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Interest paid 22 18 19
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D.14. Provisions and other long-term liabilities
Provisions and other long-term liabilities as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Provisions for pensions 
and other benefits (D.14.1) 427 474 474
Restructuring provisions (D.14.2)  8 46 61
Other provisions for risks (1) (D.14.3) 347 431 469
Other long-term liabilities (D.14.4) 4 102 126
Total 786 1,053 1,130
(1) ) Of which:
– Environmental remediation risks 21 30 23
– Product risk liabilities 20 25 21
D.14.1. Provisions for pensions and other benefits
The Group and its subsidiaries have a significant number of benefit pension plans covering the majority of their employees. The
specific features (benefit formulas, funding policies and types of assets held) of the plans vary depending on regulations and
laws in the particular country in which the employees are located. Several benefit plans are defined benefit plans and cover besides
employees, certain members of the Board of Directors.
Actuarial valuations of the Group's benefit obligations were computed as of December 31, 2002, 2001 and 2000. 
The calculations incorporate:
 assumptions on staff turnover, life expectancy and salary inflation;
 a retirement age of 60 to 65 for a total working life allowing for full rate retirement rights for French employees, 
and retirement assumptions reflecting local economic and demographic factors specific to foreign employees;
 discounting rates used to determine the actuarial present value of the projected benefit obligations as follows:
– Euro zone plans: 5.25% as of December 31, 2002 and 2001; 5.5% as of December 31, 2000
– US plans: 6.75% as of December 31, 2002; 7% as of December 31, 2001 and 2000 
– UK plans: 5.50% as of December 31, 2002; 5.75% as of December 31, 2001; 6% as of December 31, 2000 
– other plans: 2%-12% as of December 31, 2002; 2.5%-14.5% as of December 31, 2001; 2.5%-15% as of 
December 31, 2000
 Expected long-term rates of return for plan assets ranging from 5% to 10% as of December 31, 2002; 4% to 15% 
as of December 31, 2001; and 5.15% to 15% as of December 31, 2000.
The majority of the fund assets are invested in the United States and the United Kingdom. The long-term rates of return
used are as follows:
–  for American pension plans: 8.5% as of December 31, 2002; 8.75% as of December 31, 2001 and 2000;
–  for UK pension plans: 6.50% as of December 31, 2002 and 2001; 7% as of December 31, 2000.
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D.14.2. Restructuring provisions
The following table summarizes movements in restructuring provisions, classified under "Other long-term liabilities" and "Other 
current liabilities" (note D.15), for each of the years ended December 31, 2002, 2001 and 2000:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Balance, beginning of period 82 149 323
Of which
– classified under "Other long-term liabilities"  46 61 135
– classified under "Other current liabilities"  36 88 188
Charges to provisions recognized 
in net income for the period  1 6 –
Reversals of provisions in application
of CRC Rule 2000-06  (20) – –
Reversals of provisions recorded 
in the opening balance sheet (4) (16) (14)
Provisions utilized (30) (57) (159)
Effect of exchange rates  (2) – (1)
Balance, end of period 27 82 149
Of which:
– classified under "Other long-term liabilities" 8 46 61
– classified under "Other current liabilities" 19 36 88
Following the merger of Sanofi and Synthélabo in 1999, the Group developed a restructuring plan, which consisted of a combi-
nation of actions designed to integrate head offices worldwide, reorganize the sales forces and close or re-size industrial sites
throughout the world. Implementation of these restructuring plans commenced in 1999 and was substantially completed in 2000
and 2001. In France, the restructuring program related to a reduction in workforce was carried out principally through a program
of voluntary early retirement for people aged 55 as of December 31, 1999.
In 2000, the Group revised certain of its previous estimates for restructuring-related activities related to the merger between Sanofi
and Synthélabo. The adjustment consisted of a 14 million euro decrease, comprising an 18 million euro increase for revisions to 
initial plans linked with industrial capacities (in particular employee termination costs) and a 32 million euro decrease for final
assessments of costs to be incurred in connection with other restructuring activities, in particular the retirement or impairment of
tangible assets. Expenses incurred in 2002, 2001 and 2000 and charged against the provision, shown on the line "Provisions 
utilized", relate principally to employee termination costs (11, 56 and 145 million euros respectively), mainly in western Europe.
D.14.3. Other provisions for risks
The table below shows movements in other provisions for risks, including environmental risks and litigation, tax exposures, 
commercial risks, product liability risks and intellectual property risks, for each of the years ended December 31, 2002, 2001 and 2000:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Balance, beginning of period 431 469 302
Charges to provisions recognized 
in net income for the period  88 77 70
Reversals of provisions in application 
of CRC Rule 2000-06  (11) – –
Reversals of provisions recorded 
in the opening balance sheet (32) (96) 63
Provisions utilized  (14) (35) (13)
Reclassifications between accounts  (92) 12 44
Effect of exchange rates (23) 4 3
Balance, end of period 347 431 469
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The Group is involved in a number of legal proceedings and claims. These include commercial and intellectual property 
litigation, tax audits and other matters relating to the normal conduct of its business.
Provisions for tax exposures are recorded if the Group considers that the tax authorities might challenge a tax position taken
by the Group or a subsidiary.
An assessment of these risks has been performed with the assistance of the Group's legal advisers, and provisions have been
recorded where circumstances required.
In 2002, reclassifications mainly comprised the transfer of existing provisions in respect of which payments are due to be made
in 2003, now shown as short-term items under "Other liabilities".
D.14.4. Other long-term liabilities
As of December 31, 2001 and 2000, other long-term liabilities included liabilities on operations with joint venture and alliance
partners, which were included in "Other current liabilities" as of December 31, 2002 (see note D.15).
D.15. Other current liabilities
Other current liabilities as of December 31, 2002, 2001 and 2000 comprise:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Taxes payable  472 597 317
Employee-related liabilities  384 418 352
Restructuring provisions (D.14.2.) 19 36 88
Other liabilities  724 943 543
Total 1,599 1,994 1,300
In 2001, "Other liabilities" included the unpaid portion of the purchase price of acquisitions made in the period, and the impact
of the full consolidation of the Lorex Pharmaceuticals balance sheet.
In 2002, "Other liabilities" also included the reclassification of the balance as of January 1, 2002 of liabilities on operations with
joint venture and alliance partners, amounting to 85 million euros. The balance of such liabilities as of January 1, 2001 was 
89 million euros.
The unpaid portion of the purchase price of acquisitions made in the period, which is included in other liabilities, amounted to
24 million euros as of December 31, 2002 and 170 million euros as of December 31, 2001, and was immaterial as of December
31, 2000.
D.16. Short-term debt
Short-term debt as of December 31, 2002, 2001 and 2000 comprises: 
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Current portion of long-term debt 55 9 12
Other short-term debt 146 156 145
Bank overdrafts 150 120 134
Total 351 285 291
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D.17. Derivative financial instruments
The table below presents the notional amounts of the Group's outstanding derivative financial instruments as of December
31, 2002, 2001 and 2000:
December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000
Interest rate swaps  46 46 46
Currency options – sales of puts (1) 51 24 12
Currency options – sales of calls (2) 758 705 314
Currency options – purchases of puts (3) 448 413 164
Currency options – purchases of calls (4) 90 40 39
Forward foreign currency exchange 
contracts written – financial (5) 1,033 1,016 741
Forward foreign currency exchange 
contracts purchased – financial (6) 131 254 248
(1) including 51 million euros on the Norwegian krone as of December 31, 2002; 18 million euros on the US dollar as of December 31, 2001;
6 million euros on the Swiss franc and 6 million euros on the US dollar as of December 31, 2000.
(2) including 568 million euros on the US dollar and 163 million euros on the yen as of December 31, 2002; 527 million euros on the US 
dollar and 157 million euros on the yen as of December 31, 2001; 220 million euros on the US dollar and 74 million euros on the yen as
of December 31, 2000.
(3) including 321 million euros on the US dollar and 96 million euros on the yen as of December 31,  2002; 326 million euros on the US 
dollar and 77 million euros on the yen as of December 31, 2001; 113 million euros on the US dollar and  43 million euros on the yen as of
December 31, 2000.
(4) including 45 million euros on the US dollar, 19 million euros on the yen and 26 million euros on the Norwegian krone as of December 31,
2002; 16 million euros on the yen, 10 million euros on the US dollar and 9 million euros on the Norwegian krone as of December 31, 2001;
31 million euros on the US dollar and 6 million euros on the yen as of December 31, 2000.
(5) including 798 million euros on the US dollar, 79 million euros on the yen, 60 million euros on the British pound, 26 million euros on the Canadian
dollar, 16 million euros on the Czech koruna and 10 million euros on the Norwegian krone as of December 31, 2002; 812 million euros on
the US dollar, 87 million euros on the yen, 45 million euros on the British pound and 29 million euros on the Canadian dollar as of December
31, 2001; 593 million euros on the US dollar, 83 million euros on the yen, 29 million euros on the British pound and 20 million euros on
the Canadian dollar as of December 31, 2000.
(6) including 68 million euros on the Swiss franc, 33 million euros on the Norwegian krone and 10 million euros on the British pound as of December
31, 2002; 118 million euros on the US dollar, 88 million euros on the Swiss franc, 30 million euros on the Norwegian krone as of December
31, 2001; 103 million euros on the US dollar, 83 million euros on the Swiss franc, 36 million euros on the British pound and 14 million
euros on the yen as of December 31, 2000.
Fair value of financial instruments
The carrying values and estimated fair values of certain of the Group's financial instruments outstanding as of December 31,
2002, 2001 and 2000 are presented below:
2002 2001 2000
Carrying Fair Carrying Fair Carrying Fair 
(in millions of euros) value value value value value value
Long-term debt 
(excluding capital lease obligations)  14 14 62 62 56 56
Forward foreign currency exchange 
contracts – written 23 48 2 23 21 49
Forward foreign currency 
exchange contracts – purchased 1 4 2 3 – (3)
Currency options – sales of puts 1 – – – – –
Currency options – sales of calls 19 3 17 10 8 3
Currency options – purchases of puts 21 36 17 20 8 14
Currency options – purchases of calls 1 2 – 2 – –
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The Group considers that for cash and cash equivalents, accounts receivable, bank overdrafts, accounts payable and other
short-term debt, carrying value is a reasonable estimate of fair value due to their short-term maturities and the readily available
market for these types of instruments.
The following methods and assumptions were used by the Group in estimating the fair values of financial instruments:
  Long-term debt (excluding capital lease obligations) – The carrying value of the Group's variable-rate long-term debt approxi-
mates to fair value. The fair value of long-term fixed rate debt has been estimated based on current interest rates available
for debt instruments with similar terms, degrees of risk and maturities. Substantially all of the Group's long-term debt is
variable rate.
  Forward foreign currency exchange contracts (written and purchased) – The fair value of forward foreign currency exchange
contracts is based on the estimated amount at which they could be settled based on forward market exchange rates.
  Foreign currency option contracts (written and purchased) – The fair value of foreign currency option contracts is obtained
from dealer quotes. These values represent the estimated net amount the Group would receive or pay to terminate 
the agreements.
D.18. Contractual obligations and other commercial commitments
Contractual obligations given
Payments due by period
(in millions of euros) Total Under 1 year 1-5 years Over 5 years 
Long-term debt, excluding capital 
lease obligations (Notes D.13-D.16) 63 49 8 6
Capital lease obligations (including interest) 72 9 29 34
Operating leases 425 70 191 164
Irrevocable purchase obligations  65 60 5 –
Other long-term obligations  202 33 128 41
Total 827 221 361 245
Other commercial commitments given
Commitments by period
(in millions of euros) Total Under 1 year 1-5 years Over 5 years
Credit lines  – – – –
Letters of credit – – – –
Guarantees:
– given 66 37 9 20
– received (60) (60) – –
Repurchase commitments – – – –
Other commercial commitments – – – –
Total 6 (23) 9 20
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Leases
Capital leases
Future minimum payments related to capital leases as of December 31, 2002 totaling 72 million euros and including interest
payments of 15 million euros are scheduled to be made as follows:
(in millions of euros) Interest portion Principal portion Total
2003 3 6 9
2004 3 7 10
2005 2 6 8
2006 1 5 6
2007 1 4 5
2008 and thereafter  5 29 34
Total 15 57 72
Operating leases
The Group leases certain of its properties and equipment used in the ordinary course of business. Future minimum payments under
non-cancelable operating leases as of December 31, 2002 amount to 425 million euros, and are scheduled to be made 
as follows:
(in millions of euros) December 31, 2002
2003 70
2004 63
2005 47
2006 41
2007 40
2008 and thereafter 164
Total 425
Rental expense recognized by the Group for each of the years ended December 31, 2002, 2001 and 2000 amounted to 
87 million euros, 79 million euros and 87 million euros respectively.
Irrevocable purchase obligations
These mainly comprise irrevocable commitments to suppliers of fixed assets.
Other long-term obligations
As of December 31, 2002, these included royalties payable on the marketing of Arixtra under the alliance agreements with NV
Organon in countries other than the United States, Canada, Japan and Mexico. In return for taking over the rights, 
Sanofi-Synthélabo agreed to make phased payments to Organon up to a maximum of 100 million dollars contingent on 
approval of additional indications. Sanofi-Synthélabo also agreed to pay minimum royalties of 75 million dollars. 
In addition, Sanofi-Synthélabo is required to pay minimum royalties of 17 million euros under three pharmaceutical license
agreements.
In 2002, Sanofi-Synthélabo subscribed 20 million euros to a reserved share issue made by IDM. Sanofi-Synthélabo is also 
committed to making an additional investment of 10 million euros in a further share issue. As of December 31, 2002, 
Sanofi-Synthélabo owned 1,700,145 IDM shares, representing 12.7% of the capital. This percentage may change in the future
as a result of this commitment and of the conversion of existing financial instruments giving access to the capital of IDM.  
Guarantees given
These comprise 50 million euros of surety bonds and 16 million euros of real collateral.
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Guarantees received
These mainly comprise surety bonds.
Scope of consolidation
The Group does not use off balance sheet vehicles. All the Group's operations are reflected in the accounts of the companies 
included in the consolidation for each of the periods presented.
There are no commitments other than those disclosed above (notes D.17 and D.18) which are or may become material, except for
those arising under collaboration agreements and contingent additional payments relating to Avapro in the United States as descri-
bed in note D.19.
D.19. Other commitments and contingencies
Additional payments
In connection with the increase of the Group's share in the net income derived from the marketing of Avapro in the United States
(note D.6), the Group may be required to make an additional payment contingent upon the net sales of Avapro in the United
States in 2003. This payment would be made in 2004 based on a percentage applied to the portion of sales over a contractually-
defined threshold.
Research and development collaborations
The Group may be required to make payments to research and development partners under collaboration agreements. These
agreements typically cover multiple products and give the Group the option to participate in development on a product-by-
product basis. When the Group exercises an option with respect to a product, it pays its collaboration partner a fee and receives
intellectual property rights to that product in exchange. The Group is also generally required to fund some or all of the 
development costs for products that it selects and to make payments to its partners when those products reach development milestones.
The Group's principal collaboration agreements are:
 a collaboration agreement with Organon to develop anti-thrombotic oligosaccharides (in continuation of the work that 
resulted in the development of Arixtra®);
 a collaboration agreement with Cephalon for the development of angiogenesis inhibitors, in respect of which the payment for
the first product could reach 32 million dollars;
 an agreement with Immuno-Designed Molecules to develop cellular immunology therapies for cancer, under which IDM
granted Sanofi-Synthélabo 20 development options on current and future research and development programs. For each option
that leads to a commercially marketed product, IDM could receive a total of between 17 and 32 million euros, depending on
the potential of the market, plus reimbursement of the development costs. Contractually, Sanofi-Synthélabo may suspend the
development program for each option exercised at any time and without penalty. In 2002, Sanofi-Synthélabo exercised only
one option, relating to a program for the treatment of melanoma. 
 There are two further contracts relating to research work which could give rise to deferred payments of between 1 and 
4 million euros per molecule.
Because of the uncertain nature of the development work, it is impossible to predict if the Group will exercise an option for a 
product or if the expected milestones will be achieved, or to predict the number of molecules that will reach the relevant milestones.
For this reason, it is impossible to estimate the maximum aggregate amount that Sanofi-Synthélabo will actually pay in the future under
outstanding collaboration agreements. Given the nature of its business, it is highly unlikely that Sanofi-Synthélabo will exercise all options
for all products or that all milestones will be achieved. 
Litigation and claims 
Following the merger of Sanofi and Synthélabo, the Group was in dispute with its co-shareholders in the Yves Rocher Group, who
rejected the registration in the name of the merged entity Sanofi-Synthélabo of the Group's shares in Financière des Laboratoires
de Cosmétologie Yves Rocher and Laboratoires de Biologie Végétale Yves Rocher. They had previously been held by Sanofi. 
Following the expert's conclusions in November 2001, and in accordance with the judgment, Laboratoires de Biologie Végétale
Yves Rocher arranged for the acquisition of the Group's interest in its capital.
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Pursuant to a judgment from the Rennes Appeal Court dated January 10, 2001, Sanofi-Synthélabo remains a shareholder of
Financière des Laboratoires de Cosmétologie Yves Rocher, with an interest of 39.1%. This holding company in turn holds
51.3% of Laboratoires de Biologie Végétale Yves Rocher. Consequently, the Group had an indirect financial interest of 20.1%
in the Yves Rocher group as of December 31, 2001.
During the first six months of 2001, both Sanofi-Synthélabo and Financière des Laboratoires de Cosmétologie Yves Rocher
appealed separately to the highest procedural court in France ("Cour de Cassation") on the appeal judgments.
In addition to the litigation described above, the Group is involved in a number of other legal proceedings and claims (note D.14.3).
Environmental matters
The Group is involved in various stages of investigation and cleanup relating to environmental matters at certain locations.
Whenever identified, the Group's practice is to determine the nature and scope of contingencies related to environmental
remediation activity and obtain and accrue estimates of the cost of remediation. For each period presented, the estimates of
cleanup costs have been accrued. As the Group continues its efforts to ensure compliance with environmental laws and 
regulations, additional contingencies may be identified. The Group does not believe that additional costs that could arise from
environmental remediation activities will have a significant adverse effect on its financial position or results.
D.20. Personnel costs
Personnel costs, which include compensation and other benefits paid to employees leaving the Group during the period, totaled
1,937 million euros in the year ended December 31, 2002, against 1,708 million euros in the year ended December 31, 2001 and
1,541 million euros in the year ended December 31, 2000.
Employee numbers as of December 31, 2002, 2001 and 2000 were 32,436, 30,514 and 29,200 respectively.
Employee numbers by function as of December 31, 2002, 2001 and 2000 were as follows:
December 31, December 31, December 31,
2002 2001 2000
Research and development 6,718 6,273 6,203
Sales force  11,015 10,336 8,636
Production 8,043 7,651 8,288
Other 6,660 6,254 6,073
Total 32,436 30,514 29,200
Remuneration paid to key executive managers of the Group during the year ended December 31, 2002 totaled 7.5 million
euros, compared with 6.2 million euros in the year ended December 31, 2001 for 12 executives and 5.6 million euros in the year
ended December 31, 2000 for 13 executives.
D.21. Foreign exchange gains and losses
The Group recorded a net foreign exchange gain of 48 million euros in 2002, compared with a net gain of 5 million euros in
2001 and a net loss of 25 million euros in 2000. 
D.22. Exceptional items
Exceptional items for the years ended December 31, 2002, 2001 and 2000 comprise:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Net gains on disposals 10 281 46
Other exceptional items – – –
Total 10 281 46
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There were no material disposals in 2002.
In 2001, net gains on disposals related principally to the four major divestitures during the period: Sylachim, Porgès, Ela Medical
and the direct holding in Laboratoires de Biologie Végétale Yves Rocher (notes D.1 and D.5). The gain on these four major 
divestitures included an allocation of part of the goodwill arising on the merger between Sanofi and Synthélabo, which was 
initially offset against consolidated shareholders' equity.
Net gains on disposals in 2000 relate to the sale of minority interests in two listed companies.
D.23. Income taxes  
The Group has opted for tax consolidations in a number of countries, principally France, Germany and the United States.
Pre-tax net income and the corresponding tax charge for the years ended December 31, 2002, 2001 and 2000 break down 
as follows:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Pre-tax net income:
France 1,357 1,317 806
Rest of the world  1,215 1,097 796
Total 2,572 2,414 1,602
Income tax:
France (335) (473) (296)
Rest of the world (411) (369) (315)
Total (746) (842) (611)
The income tax charge for the years ended December 31, 2002, 2001 and 2000 comprises:
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Current taxation  (794) (906) (491)
Deferred taxation 48 64 (120)
Total (746) (842) (611)
Year ended Year ended Year ended
(in millions of euros) December 31, 2002 December 31, 2001 December 31, 2000
Tax on income before goodwill 
amortization and exceptional items (745) (778) (593)
Tax on goodwill amortization 
and exceptional items  (1) (64) (18)
Total (746) (842) (611)
The difference between the effective tax rate and the standard corporate income tax rate applicable in France for each of the
years ended December 31, 2002, 2001 and 2000 is explained as follows:
Year ended Year ended Year ended
(as %) December 31, 2002 December 31, 2001 December 31, 2000
Tax rate applicable in France 35 36 38
Impact of income tax 
at reduced rate in France (4) (3) (4)
Lorex Pharmaceuticals (1) – –
Other (1) 3 4
Effective tax rate before exceptional 
items and goodwill amortization 29 36 38
Impact of exceptional items  – (1) –
Effective tax rate 29 35 38
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As indicated in note C.2, Lorex Pharmaceuticals has been fully consolidated by the Group as from January 1, 2002. Net income
before exceptional items and goodwill amortization therefore includes all the profits and losses of Lorex Pharmaceuticals, inclu-
ding the share of net income reverting to Pharmacia-Searle for the period from January 1, 2002 through April 15, 2002. Because
Lorex Pharmaceuticals is a tax-transparent entity, the "Income taxes" line includes only the charge attributable to the Group.
This has the effect of reducing the effective tax rate by 1.2 points. 
The "Other" line includes the difference between the French tax rate and the tax rate applicable in other countries and, for all
three years, the impact of the revaluation of certain of the Group's tax exposures. 
Income tax payments made by the Group totaled 1,120 million euros in 2002, 449 million euros in 2001 and 378 million euros
in 2000.
D.24. Minority interests
As of December 31, 2002, minority interests mainly comprise the share in the net income of Lorex Pharmaceuticals reverting
to Pharmacia-Searle for the period from January 1, 2002 through April 15, 2002 (see note C.2).
D.25. Related party transactions
Financial relations with the TotalFinaElf and L'Oréal groups existing prior to the merger had mainly ceased by December 31, 1999.
The residual relations had no significant impact in the years ended December 31, 2002, 2001 and 2000.
D.26. Post balance sheet events
As at the date of preparation of its financial statements, the Group is not aware of any post balance sheet events that would signi-
ficantly affect the financial statements as of December 31, 2002.
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D.27. Split of net sales
The Group is not dependent on any single customer or group of customers for its sales. Products are sold throughout the world
to a wide range of customers including pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and
other distributors.
Sales of selected products for each of the years ended December 31, 2002, 2001 and 2000 are as follows: 
Year ended Year ended Year ended
(in millions of euros) Dec. 31, 2002 Dec. 31, 2001 Dec. 31, 2000
Stilnox®/Ambien®/Myslee® 1,424 786 582
Plavix® 987 705 437
Aprovel®/Avapro® 562 423 300
Eloxatine® 389 196 141
Fraxiparine® 324 297 255
Dépakine® 267 243 211
Xatral® 182 148 120
Cordarone® 162 162 156
Tildiem® 141 152 154
Ticlid® 137 205 235
Solian® 135 116 93
Corotrope®/Primacor® 127 237 180
Aspégic® and related products 108 100 100
Dogmatil® 78 124 134
Kerlone® 77 82 77
D.28. Segment information
The Group operates in one significant business segment: the research and development, production and sale of pharmaceuti-
cal products. 
The Group has aggregated all its ethical product lines because they have close similarities in terms of regulatory environment,
production process, distribution methods and customer profile. The Group's generics and OTC activities are not material, and
have been aggregated with its ethical activities.
The Group mainly operates in three geographical segments: “Europe”, “the United States” and “other countries”.
The table below gives net sales, operating profit, total assets and long-lived assets by geographical segment. Net sales and
operating profit are allocated based on the location of the end customer. Total assets and long-lived assets are allocated based
on the location of the subsidiary.
Year ended December 31, 2002
Total Europe USA Other Unallocated
(in millions of euros) countries costs (1)
Net sales 7,448 4,297 1,689 1,462 –
Operating profit 2,614 1,633 1,781 522 (1,322)
Total assets 9,459 6,968 1,814 677 –
Including long-lived assets 2,899 1,715 1,052 132 –
Net sales generated in France and long-lived assets situated in France, where the Group is headquartered, totaled 1,584 million
euros and 1,182 million euros respectively as of December 31, 2002.
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Year ended December 31, 2001
Total Europe USA Other Unallocated
(in millions of euros) countries costs (1)
Net sales 6,488 3,877 1,098 1,513 –
Operating profit 2,106 1,427 1,311 456 (1,088)
Total assets 9,967 7,924 1,321 722 –
Including long-lived assets 2,296 1,558 602 136 –
Net sales generated in France and long-lived assets situated in France, where the Group is headquartered, totaled 1,487 million
euros and 1,096 million euros respectively as of December 31, 2001.
Year ended December 31, 2000
Total Europe USA Other Unallocated
(in millions of euros) countries costs (1)
Net sales 5,963 3,597 888 1,478 –
Operating profit 1,577 1,190 835 440 (888)
Total assets 7,845 6,558 603 684 –
Including long-lived assets 2,045 1,756 177 112 –
Net sales generated in France and long-lived assets situated in France, where the Group is headquartered, totaled 1,507 million
euros and 1,335 million euros respectively as of December 31, 2000.
(1)  Unallocated costs consist mainly of fundamental research and worldwide development of pharmaceutical molecules, and part of the cost of
support functions.
E. LIST OF COMPANIES INCLUDED IN THE CONSOLIDATION FOR THE YEAR ENDED DECEMBER 31, 2002
E.1. Fully consolidated
Financial 
interest %
JV Omnipharma (Pty) Limited South Africa 100
Sanofi-Synthélabo (Pty) Ltd South Africa 100
Synthélabo (South Africa) (Pty) Ltd (2) South Africa 100
Institut Médical Algérien (IMA) Algeria 100
Lichtenstein GmbH Germany 100
Lichtenstein Verwaltungs GmbH Germany 100
Sanofi-Synthélabo GmbH Germany 100
Sanofi-Synthélabo Holding GmbH Germany 100
Sanofi-Synthélabo de Argentina SA Argentina 100
Sanofi-Synthélabo Australia Pty Ltd Australia 100
Sanofi-Synthélabo Gmbh / 
Bristol-Myers Squibb GesmbH OHG (1) Austria 51
Sanofi-Synthélabo GmbH Austria 100
Sanofi-Synthélabo SA/ NV Belgium 100
Sanofi-Synthélabo do Brasil Ltda Brazil 100
Sanofi-Synthélabo Ltda Brazil 100
Sanofi-Synthélabo Canada Inc Canada 100
Sanofi-Synthélabo de Chile Chile 100
Hangzhou Sanofi-Synthélabo 
Minsheng Pharma Co Ltd China 55
Financial 
interest %
Lakor Farmaceutica SA Colombia 85
Pacifico Pharma Colombia 100
Sanofi-Synthélabo de Colombie SA Colombia 100
Sanofi-Synthélabo Korea Co Ltd Korea 100
Sanofi-Synthélabo A/S Denmark 100
Sanofi Winthrop BMS partnership (1) Denmark 51
Sanofi-Synthélabo del Ecuador SA Ecuador 100
Sanofi-Synthélabo SA Spain 100
Synthélabo SA Spain 100
Sanofi Winthrop BMS partnership (1) Finland 51
Sanofi-Synthélabo OY Finland 100
Sanofi Chimie (Ex SaSy 1) France 100
Dakota Pharm France 100
Europar (2) France 100
Francopia France 100
Groupement Fabrication Pharmaceutique France 100
Institut d'édition Sanofi-Synthélabo France 100
Laboratoires Irex France 100
Sanofi Développement Pharma France 100
Sanofi Participation France 100
(1) joint-venture with Bristol-Myers Squibb consolidated using the method described in note C1
(2) deconsolidated during the year
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(1) joint-venture with Bristol-Myers Squibb consolidated using the method
described in note C1
(2) deconsolidated during the year
(3) consolidated during the method described in C2 and D1
Financial 
interest % 
Pharma Bristol-Myers Squibb (1) France 51
Sanofi-Synthélabo France 100
Sanofi-Synthélabo France  France 100
Sanofi-Synthélabo Groupe France 100
Sanofi-Synthélabo OTC France 100
Sanofi-Synthélabo Recherche France 100
Sanofi Winthrop Industries France 100
Secipe France 100
SPI France 100
Synthélabo Biomédical France 100
Sanofi-Synthélabo A.E Greece 100
Sanofi-Synthélabo HK Ltd Hong Kong 100
Sanofi BMS Hong-Kong (1) Hong Kong 51
Chinoin Hungary 99
Sanofi-Synthélabo RT Hungary 100
Sanofi-Synthélabo India Ltd India 100
PT Sanofi-Synthélabo Combiphar Indonesia 70
Sanofi-Synthélabo Ireland Ltd Ireland 100
Inverni Della Beffa Spa Italy 100
Sanofi-Synthélabo OTC Spa Italy 100
Sanofi-Synthélabo Spa Italy 100
Sanofi-Synthélabo Meiji 
Pharmaceuticals Co Ltd Japan 51
Sanofi-Synthélabo 
Taisho Pharmaceuticals Co Ltd Japan 51
Sanofi-Synthélabo Yamanouchi 
Pharmaceuticals KK Japan 51
Sanofi-Synthélabo KK Japan 100
Sanofi-Synthélabo (Malaysia) SDN-BHD Malaysia 100
Sanofi-Synthélabo BMS 
Malaysia partnership(1) Malaysia 51
Laboratoires Maphar Morocco 81
Sanofi-Synthélabo Maroc Morocco 100
Rudefsa Mexico 100
Sanofi-Synthélabo de Mexico SA Mexico 100
Sanofi-Synthélabo AS Norway 100
Sanofi Winthrop BMS 
partnership ANS (1) Norway 51
Sanofi-Synthélabo (NZ) Ltd New Zealand 100
Sanofi-Synthélabo Panama Panama 100
Sanofi-Synthélabo BV Netherlands 100
Sanofi-Synthélabo Polholding BV Netherlands 100
Sanofi-Synthélabo Row BV Netherlands 100
Sanofi Winthrop BMS VOF (1) Netherlands 51
Synthélabo Netherlands BV Netherlands 100
Sanofi-Synthélabo del Peru SA Peru 51
Synthélabo Delagrange del Peru Peru 100
Sanofi-Synthélabo Philippines Inc Philippines 100
Sanofi-Synthélabo Sp Zoo Poland 100
Irex Promocao e Comercializacao
de produtos farmaceuticos Lda Portugal 100
Sanofi-Synthélabo 
Produtos Farmaceuticos SA Portugal 100
Sanofi Winthrop BMS AEIE (1) Portugal 51
Sanofi-Synthélabo Dominican
de la Republica Dominicana Republic 100
Sanofi-Synthélabo sro Czech Republic 100
Laboratoires Irex Sro Czech Republic 100
Financial 
interest %
Sanofi-Synthélabo Ltd United Kingdom 100
Sanofi-Synthélabo UK Ltd United Kingdom 100
Sterwin Medicines Ltd United Kingdom 100
Sanofi BMS (1) Singapore 51
Sanofi-Synthélabo (Singapore) Pte Ltd Singapore 100
Sanofi-Synthélabo Slovakia s.r.o. Slovakia 100
Sanofi Winthrop BMS partnership (1) Sweden 51
Sanofi-Synthélabo AB Sweden 100
Sanofi SA-AG (Genève) Switzerland 100
Sanofi-Synthélabo (Suisse) SA Switzerland 100
Synthélabo Pharma Suisse Switzerland 100
Sanofi-Synthélabo CIS 
& Eastern countries SA Switzerland 100
Fujisawa Sanofi-Synthélabo 
Pharmaceuticals Co Ltd (2) Taiwan 51
Sanofi-Synthélabo Taïwan Limited Taiwan 100
Sanofi-Synthélabo (Thailand) Ltd Thailand 100
Synthélabo (Thailand) Ltd Thailand 100
Sanofi-Synthélabo Adwya SA Tunisia 51
Sanofi-Synthélabo Tunisie Tunisia 70
Sanofi-Synthélabo Ilac. Turkey 100
Sanofi-Dogu BMS ADI 
Ortakligi partnership (1) Turkey 51
Sanofi-Synthélabo Uruguay SA Uruguay 100
Lorex Pharmaceuticals Inc.(3) USA 100
Sanofi-Synthélabo Inc USA 100
Lorex Inc USA 100
Sanocore de Venezuela S.A Venezuela 100
Sanofi-Synthélabo de Venezuela SA Venezuela 100
Sanofi-Synthélabo Vietnam Vietnam 70
E.2. Equity-accounted
CKW Pharma-Extrakt Germany 50
Belgopia SA NV Belgium 49
Alcaliber SA Spain 40
Groupe Yves Rocher France 20
Mediline Ltd (2) Israel 27
Sofarimex Portugal 40
E.3. Proportionately consolidated
Organon Sanofi-Synthélabo 
Canada Partnership Canada 50
Synthélabo Tanabe Chimie France 50
Fujisawa Sanofi-Synthélabo Japan 51
Organon Sanofi-Synthélabo
Mexico SA de CV Mexico 50
Fonda BV Netherlands 50
Fujisawa Sanofi-Synthélabo 
Pharmaceuticals company Limited Taiwan 51
Organon – Sanofi-Synthélabo LLC USA 50
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Consolidated financial summary
Year ended Year ended Year ended 6 months ended
December 31, December 31, December 31, December 31,
(in millions of euros) 2002 2001 2000 1999
Financial position at period-end 
Share capital 1,465 1,464 1,463 1,462
Number of shares in issue 732,367,507 732,005,084 731,441,746 731,143,218
Net sales 7,448 6,488 5,963 2,658
Operating profit 2,614 2,106 1,577 531
Operating cash flow before changes
in working capital 2,260 1,732 1,295 466
Net income before income 
from equity investees, goodwill 
amortization & minority interests 1,834 1,579 995 344
Net income  1,759 1,585 985 342
Net income before exceptional items 
and goodwill amortization 1,758 1,376 961 340
Dividends  473 317 -
Per share data (in euros)
Net income before income from equity 
investees, goodwill amortization 
& minority interests 2.52 2.16 1.36 0.47
Net income 2.42 2.17 1.35 0.47
Net income before exceptional items 
and goodwill amortization  2.42 1.88 1.31 0.47
Dividends (net) 0.66 0.44 -
Reconciliation of US GAAP financial statements
Condensed financial statements prepared under accounting principles generally accepted in the United States (US GAAP), 
and a reconciliation of the financial statements prepared under French GAAP and under US GAAP, will be available on our
website www.sanofi-synthelabo.com when we publish our 20-F document, filed annually with the Securities and Exchange
Commission (SEC).
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Report of the statutory auditors on the parent company financial
statements
Year ended December 31, 2002
In our capacity as statutory auditors, we present below our report on:
• the accompanying annual financial statements of Sanofi-Synthélabo’s management, and for the year ended 
December 31, 2002.
• the specific procedures and disclosures prescribed by law, 
The annual financial statements are the responsibility of the Company’s management. Our responsibility is to express an 
opinion on these financial statements based on our audit.
I. Opinion on the financial statements
We conducted our audit in accordance with French professional standards. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also
includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement’s presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of
December 31, 2002, and the results of its operations for the year then ended, in accordance with French accounting principles.
Without qualifying our opinion, we draw attention to notes 1 and 6 to the financial statements, which present the impact on
the financial statements of the change in accounting method resulting from the application with effect from January 1, 2002
of the new CRC rule 2000-06 on liabilities.
II. Specific procedures and disclosures
We have also carried out the specific procedures prescribed by French law, in accordance with French professional standards.
We have nothing to report with respect to the fairness of information contained in the Directors’ report and its consistency with
the financial statements and other information presented to shareholders concerning the financial position.
In accordance with French law we have ensured that the required information concerning the purchase of investments and 
controlling interests and the names and voting rights of the principal shareholders have been properly disclosed to you in 
the Director’s report.
Paris, February 18, 2003
The Statutory Auditors
PricewaterhouseCoopers Audit Ernst & Young Audit
Jacques Denizeau Jean-Christophe Georghiou Dominique Thouvenin Valérie Quint
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Special report of the statutory auditors on certain 
related-party transactions
Year ended December 31, 2002
In our capacity as Statutory Auditors of Sanofi-Synthélabo, we are required to report on certain contractual agreements with 
certain related parties.
We are not required to ascertain whether any contractual agreements exist but to inform you on the basis of the information
provided to us, of the terms and conditions of agreements indicated to us. It is not our role to comment whether they are
beneficial or appropriate. It is your responsibility, under the terms of article 92 of March 23, 1967 of the Decree, to evaluate
the benefits resulting from these agreements prior to their approval.
We hereby inform you that we have not been advised of any agreement concluded during the year ended December 31, 2002
which would be covered by article L.225-38 of French Company Law (Code de commerce).
In accordance with the March 23, 1967 Decree, we have been provided that the following agreements, approved in prior years
by Synthélabo, merged into Sanofi-Synthélabo on May 18, 1999, remained effective in the year ended December 31, 2002.
A loan and a current account advance which do not bear interest have been made to AO Synthélabo Russia. The balance on
these accounts as of December 31, 2002 was as follows:
Euros
Loan 25,709.15
Current account 574,738.89
We conducted our work in accordance with French professional standards. These standards require that we perform procedures
to verify that the information provided to us is consistent with the necessary documentation from witch it has been extracted.
Paris, February 18, 2003
The Statutory Auditors
PricewaterhouseCoopers Audit Ernst & Young Audit
Jacques Denizeau Jean-Christophe Georghiou Dominique Thouvenin Valérie Quint
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ASSETS
(in millions of euros) 2002 2001 2000
Intangible assets 453 65 126
Tangible fixed assets 101 74 63
Long-term investments 3,976 2,611 2,149
Fixed assets (note 3) 4,530 2,750 2,338
Receivables (notes 4, 15 et 16)
Advance payments to suppliers 1 2 1
Accounts receivable 614 365 306
Other current assets 928 753 1,431
Short-term investments and deposits (note 5) 2,856 4,083 2,619
Cash 30 3 3
Current assets 4,429 5,206 4,360
Deferred charges 19 2 7
Unrealized foreign exchange losses 2 8 5
Total assets 8,980 7,967 6,710
The accompanying notes on pages 70 to 85 are an integral part of the financial statements.
Balance sheet 
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LIABILITIES AND SHAREHOLDERS’ EQUITY
(in millions of euros) 2002 2001 2000
Share capital 1,465 1,464 1,463
Additional paid-in capital 1,578 1,485 1,479
Reserves and retained earnings 2,688 1,717 1,404
Net income for the period 1,323 1,442 630
Special tax-allowable provisions 1 1 3
Shareholders’ equity (note 6) 7,055 6,109 4,979
Provisions for risks and charges (note 7) 239 496 492
Liabilities (notes 4, 15 and 16)
Bank and other debt 777 735 804
Accounts payable 254 207 225
Other current liabilities 624 388 191
Bank overdrafts 15 1 8
Other liabilities 1,670 1,331 1,228
Deferred income 13 20 1
Unrealized foreign exchange gains 3 11 10
Total liabilities and shareholders’ equity 8,980 7,967 6,710
The accompanying notes on pages 70 to 85 are an integral part of the financial statements.
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Statement of income
(In millions of euros) 2002 2001 2000
Operating income (note 8) 1,574 1,180 876
Net sales 273 176 194
Other income 1,301 1,004 682
Operating expenses (note 9) (1,178) (962) (908)
Other purchases and external charges (947) (742) (690)
Taxes other than income taxes (47) (33) (29)
Salaries and social security charges (14) (15) (17)
Depreciations, amortizations and provisions (111) (82) (80)
Other expenses (59) (90) (92)
Share in profits/losses 
of joint venture partnerships (note 10) - 303 183
Operating profit 396 521 151
Net investment income 796 415 746
Changes in provisions, cost transfers (88) 128 (31)
Net foreign exchange gains (losses) (note 11) 85 18 (40)
Net financial income (note 12) 793 561 675
Net income before tax and exceptional items 1,189 1,082 826
Exceptional items (notes 2 and 13) 327 581 (140)
Statutory employee profit-sharing - 1 (6)
Income taxes (notes 2 and 14) (193) (222) (50)
Net income 1,323 1,442 630
The accompanying notes on pages 70 to 85 are an integral part of the financial statements.
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Statement of cash flows
(in millions of euros) 2002 2001 2000
OPERATING ACTIVITIES
Net income 1,323 1,442 630
Depreciation and amortization 53 21 25
Net charge to (write-back of) provisions (*) (140) (65) 289
Gains on disposals of fixed assets (**) 2 (647) (24)
Other items 4 (13) 1
Operating cash flow before changes in working capital 1,242 738 921
(Increase) decrease in working capital (417) 41 (124)
Net cash provided by operating activities 825 779 797
INVESTING ACTIVITIES
Acquisitions of intangible assets and tangible fixed assets (86) (25) (29)
Acquisitions of investments (36) (34) (75)
Long-term loans and advances granted (6) (1) -
Disposals of intangible assets and tangible fixed assets 9 53 24
Disposals of investments 5 382 11
Repayments of long-term loans 
& advances and other investing cash flows - - 4
Net cash provided by/(used in) 
investing activities (114) 375 (65)
FINANCING ACTIVITIES
Issuance of shares 4 7 3
Dividends paid (473) (317) (231)
Change in debt due within less than one year (***) (55) (70) 134
Net change in investments maturing 
within less than one year (***) (378) 690 (119)
Net acquisitions of treasury shares (note 3) (1,170) (****) (****)
Net cash provided by/(used in) 
financing activities (2,072) 310 (213)
Change in cash and cash equivalents (1,361) 1,464 519
Opening cash and cash equivalents 3,624 (2) 2,622 2,103
Closing cash and cash equivalents(1) 2,263 4,086 2,622
(*) excluding write-backs of provisions relating to asset disposals
(**) including write-backs of provisions relating to asset disposals
(***) including current accounts with subsidiaries
(****) net acquisitions of treasury shares: 163 million euros in 2001 and 183 million euros in 2000
(1) As of December 31, 2002, cash and cash equivalents include cash plus short-term investments other than treasury shares. As of December
31, 2001 and 2000, cash and cash equivalents included treasury shares of 462 million euros and 299 million euros respectively. Bank overdrafts
and bank accounts in credit are included in debt due within less than one year.
(2) The difference of 462 million euros between closing cash and cash equivalents related to 2001 and opening cash and cash related to 2002
corresponds to treasury shares, previously included in cash and cash equivalents.
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Notes to the financial statements
INTRODUCTION
 The Extraordinary General Meeting of Sanofi-Synthélabo held on May 22, 2001 approved the merger of the subsidiary
Laboratoires Synthélabo into Sanofi-Synthélabo. Because Sanofi-Synthélabo owned 100% of the shares of this company, 
these shares were cancelled and the merger did not result in the issuance of any new shares.
 On June 30, 2001, Sanofi-Synthélabo transferred the real estate assets of two industrial sites (Amilly and Tours) 
to its subsidiary Sanofi-Winthrop Industrie at a fair value of 27 million euros.
 The Extraordinary General Meeting of Sanofi-Synthélabo held on May 22, 2002 approved the merger of the three 
companies Sasy3, Laboratoires Cèdre and Sanofi Concept into Sanofi-Synthélabo. Because Sanofi-Synthélabo owned 100%
of the shares of these companies, these shares were cancelled and the merger did not result in the issuance of any new shares.
CONSOLIDATION
The Sanofi-Synthélabo Group is consolidated using the equity method in the consolidated financial statements of TotalFinaElf
and L'Oréal.
Note 1: Accounting policies
The financial statements for the year ended December 31, 2002 are presented in accordance with the law and regulations 
in force and with the following basic conventions:
 going concern,
 consistency of method,
 matching of costs and revenues.
The accounting policies and methods used are identical to those applied in the preparation of the financial statements for the
year ended December 31, 2001, except for the new CRC Rule 2000.06 on liabilities, implemented by Sanofi-Synthélabo 
with effect from January 1, 2002.
a) Intangible assets
Concessions, patents, licenses, trademarks, processes, rights and similar assets:
Intangible assets are amortized or written down over their period of legal protection, or over their estimated useful life where
there is no such protection.
b) Tangibles fixed assets
Property, plant and equipment are valued at acquisition cost, comprising purchase price plus incidental costs required to bring
the asset into usable condition.
Depreciation is charged on a straight-line basis. The company makes use of accelerated and exceptional depreciation where 
allowed by the tax authorities. The difference between accounting depreciation and tax depreciation is recorded as a reserve
in the balance sheet on the "Tax depreciation" line under the heading "Special tax-allowable provisions".
Depreciation periods and methods are as follows:
Period Method
Buildings and improvements to land 15-20 years Straight-line
Fixtures, fittings & installations 10-20 years Straight-line
c) Participating interests, other long-term investments, short-term investments
Initial recognition is at acquisition cost, excluding incidental purchase costs. If the fair value as defined under French accounting
rules is less than the book value at the balance sheet date, a provision for impairment is recorded to cover the difference.
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Unlisted participating interests and other long-term investments
Various factors are used to estimate the value of such investments, including current and future earnings prospects, usefulness
to the Group, shareholder’s equity, the prospects for future sale, business conditions, and the criteria used in assessing the 
original investment.
In practice, this rule leads to a distinction being drawn between:
- interests in companies whose activities are carried on almost exclusively within the Group (facilities and service companies).
In such cases, the net book value may under no circumstances exceed the share of shareholder’s equity held;
- interests in companies whose industrial and commercial know-how give them a significant share of a sufficiently profitable 
market. In such cases, the company's market position, customer base and intangible assets may justify the investment being shown
at a net book value in excess of the share of shareholder’s equity held.
Other listed long-term investments and short-term investments
Fair value is calculated by reference to the average quoted price for the last month of the period.
d) Foreign-currency transactions
Foreign-currency income and expenses are recorded at the exchange rate prevailing on the transaction date. Foreign-currency
liabilities, receivables and cash are recorded at the exchange rate prevailing at the balance sheet date. The difference arising from
the restatement of foreign-currency liabilities and receivables at this rate is taken to the balance sheet as an unrealized foreign
exchange gain or loss. A provision for foreign exchange risk is recorded to cover the unrealized foreign exchange losses arising from
the calculation of an overall foreign exchange position on all assets, liabilities and off balance sheet commitments existing at 
the balance sheet date.
Capitalizable advances to subsidiaries made in foreign currencies remain in the balance sheet at face value, converted at the 
historical exchange rate.
Forward purchases and sales of foreign currencies are recorded off balance sheet at the historical exchange rate.
e) Retirement benefit commitments
Sanofi-Synthélabo's pension and retirement benefit commitments are recognized as liabilities on the basis of an actuarial 
estimate of the potential rights vested in employees as of the balance sheet date, net of the valuation of funds available to meet
these obligations.
Commitments to former employees are also recognized as liabilities.
The actuarial estimate of these commitments takes account of:
- the probability that current employees will remain with the Group until retirement, mortality rates, and assumptions on
salary inflation;
- an assumption that retirement will take place at age 60 to 65 after a working life giving entitlement to full pension rights;
- discounting rates used to determine the present value of the commitments. The discounting rate used as of December 31,
2002 was 5.25%.
Note 2: Taxation
Sanofi-Synthélabo has opted for a group tax election as allowed under articles 223 A-Q of the French General Tax Code.
As of December 31, 2002, 25 French subsidiaries more than 95% owned by Sanofi-Synthélabo were included in the group tax
election. The election is effective from 1999 through 2003.
Each company in the group tax election records its own income tax charge. The ultimate tax saving generated by the group tax
election is recorded by the Sanofi-Synthélabo parent company as an exceptional item, including the impact of tax audits on 
the group tax election (see note 13).
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Note 3: Fixed assets
MOVEMENTS IN FIXED ASSETS IN THE YEAR ENDED DECEMBER 31, 2002
Gross values
Opening Mergers Acquisitions Disposals Closing Depreciation, Net
balance (1) and other and other balance amortization book
(in millions of euros) increases decreases & impairment value
Intangible assets 229 14 443 (21) 665 (212) 453
Trading goodwill 19 14 – – 33 (18) 15
Patents 59 – 46 – 105 (63) 42
Trademarks 65 – 1 (1) 65 (39) 26
Other intangible assets 86 – 396* (20) 462 (92) 370
Tangible fixed assets 163 – 59 (29) 193 (92) 101
Lands 13 – 1 (0) 14 – 14
Buildings 135 – 26 (4) 157 (88) 69
Other tangible fixed assets 5 – – – 5 (4) 1
Fixed assets in progress 10 – 32 (25) 17 – 17
Long-term investments 2,727 366 1,055 (25) 4,123 (147) 3,976
Participating interests (2) 2,694 366 53 (15) 3,098 (94) 3,004
Loans/advances 
to participating interests 5 – 12 (2) 15 (8) 7
Other long-term investments (3) 25 – 20 (1) 44 (19) 25
Treasury shares (4) – – 970 (7) 963 (26) 937
Loans 3 – – – 3 – 3
* In accordance with the Tax Instruction of November 26, 1996, Sanofi-Synthélabo has capitalized 392 million euros in respect of royalties payable
over the estimated life of a product, with a matching liability recognized in the balance sheet (see Note 4).    
Depreciation, amortization and impairment
Opening Mergers Acquisitions Disposals Closing
balance (1) and other and balance
(in millions of euros) increases write-backs
Intangible assets 164 10 76 (38) 212
Trading goodwill 5 10 3 – 18
Patents 55 – 9 (1) 63
Trademarks 36 – 3 39
Other intangible assets 68 – 61 (37) 92
Tangible fixed assets 89 7 (4) 92
Buildings 84 – 7 (3) 88
Other tangible fixed assets 5 – – (1) 4
Long-term investments 116 – 68 (37) 147
Participating interests (2) 114 – 17 (37) 94
Loans/advances to participating interests – – 8 – 8
Other long-term investments (3) 2 – 17 – 19
Treasury shares(4) – – 26 – 26
(1) See Introduction.
(2) Details of the movement in participating interests and provisions for impairment are given below.
(3) See notes on Viropharma Inc and IDM below.
(4) Sanofi-Synthélabo shares held by the company itself.
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Viropharma Inc:
As of December 31, 2002, Sanofi-Synthélabo owned 750,000 shares in Viropharma Inc, a company listed on the Nasdaq. These shares
were received in 2001 in connection with the renegotiation of the Pleconaril license agreement, and valued at 19 million euros. In the
light of the average listed stock market price for December 2002, a provision for impairment of 18 million euros has been taken against
these shares.
Immuno-Designed Molecules (IDM):
In 1999, Sanofi-Synthélabo signed a partnership agreement with IDM on the use by IDM of Interleukine 13, a product 
developed by Sanofi-Synthélabo's research teams. In return, Sanofi-Synthélabo received 145,660 shares together with share
warrants. This operation was valued at 0.8 million euros. 
In 2001, Sanofi-Synthélabo and IDM extended this partnership, signing a strategic collaboration agreement whereby IDM
granted Sanofi-Synthélabo 20 development options on its current and future research and development programs. For each option
that leads to a commercially marketed product, IDM could receive a total of between 17 and 32 million euros, depending on
the potential of the market, plus reimbursement of the development costs. Contractually, Sanofi-Synthélabo may suspend the
development program for each option exercised at any time and without penalty. As of December 31, 2002, Sanofi-Synthélabo
had exercised only one option, relating to a program for the treatment of melanoma. 
In 2002, Sanofi-Synthélabo subscribed 20 million euros to a reserved share issue made by IDM. Sanofi-Synthélabo is also 
committed to making an additional investment of 10 million euros in a further share issue. As of December 31, 2002, 
Sanofi-Synthélabo owned 1,700,145 IDM shares, representing 12.7% of the capital. This percentage may change in the future
as a result of this commitment and of the conversion of existing financial instruments giving access to the capital of IDM. 
Sanofi-Synthélabo shares:
During the year ended December 31, 2002, the company used the authorizations to buy its own shares in the market in order
to allocate shares to stock option plans and in the light of market conditions.
A total of 19,550,679 shares were bought at an average price of 60.57 euros per share.
At end December 2002, the company owned:
- 13,964,580 shares classified as short-term investments at a net book value of 623 million euros. In the light of the average
stock market price for December 2002, a provision for impairment of 45.6 million euros was charged to the income statement
during the year. These shares represent 1.91% of the share capital, and include 13,836,580 shares allocated to employee stock
option plans.
- 16,411,795 shares classified as long-term investments at a gross value of 963 million euros, and representing 
2.24% of the share capital. In the light of the average stock market price for December 2002, a provision for impairment of 
25.8 million euros was charged to the income statement during the year.
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Movements in participating interests in 2002
(in millions of euros)
Balance as of January 1, 2002 2,694
Investments during the year 16
Sanofi-Synthélabo A.E. (Greece) 10
Sanofi-Synthélabo (India) Ltd 6
Capital increases by offset of loans/advances 37
Sanofi-Synthélabo (India) Ltd 5
Sanofi Concept 6
Laboratoires Irex 9
Sanofi Développement Pharma 8
Sanofi-Synthélabo Yamanouchi Pharma KK 5 
Others 4
Disposals and other decreases (15)
Europar (7)
Synthélabo South Africa (4)
Sanofi-Synthélabo Philippines inc (4)
Mergers 366 
Impact of the merger of the subsidiaries Laboratoires Cèdre, Sasy3 
and Sanofi Concept into Sanofi-Synthélabo (1)
Balance as of December 31, 2002 (gross) 3,098
(1) See Introduction.
Movement in provisions for impairment of participating interests in 2002
(in millions of euros)
Balance as of January 1, 2002 114
1. Net write-backs during the year (11)
Charges 17
- Sanofi-Synthelabo Panama 1
- Sanofi-Synthélabo Ecuador 5
- Synthélabo Biomédical 3
- Sanofi Développement Pharma 4
- Sanofi-Synthélabo Yamanouchi 4
Write-backs (28)
- Synthélabo Pharma Suisse (1)
- Sanofi-Synthélabo Koréa Co Ltd (25)
- Others (2)
2. Write-backs of provisions relating 
to liquidations, mergers or disposals (9)
- Synthélabo South-Africa (2)
- Europar (5)
- Sanofi-Synthélabo Ilac (Turkey) (2)
Balance as of December 31, 2002 (impairment) 94
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Note 4: Receivables and liabilities by maturity
Gross Impairment Net 1 year  1 year
(in millions of euros)
Receivables
Fixed assets
Loans/advances to participating interests 15 (8) 7 – 7
Other long-term investments 43 (18) 25 – 25
Loans 3 – 3 – 3
Current assets
Advance payments to suppliers 1 – 1 1 –
Accounts receivable 616 (2) 614 609 5
Other receivables 929 (1) 928 916 12
Total 1,607 (29) 1,578 1,526 52
Liabilities
Debt (see note 15) – – 777 775 2
Accounts payable – – 254 254 –
Other current liabilities:
– Tax and employee-related liabilities – – 187 187 –
– Amounts payable to suppliers of fixed assets – – 3 3 –
– Other liabilities * – – 434 112 322
Total – – 1,655 1,331 324
*In accordance with the Tax Instruction of November 26, 1996, Sanofi-Synthélabo has capitalized 392 million euros in respect of royalties
payable over the estimated life of a product, with a matching liability recognized in the balance sheet (see note 3).   
Note 5: Short-term investments
As of December 31, 2002, Sanofi-Synthélabo owned:
– money-market mutual funds totaling 1,579 million euros;
– certificates of deposit totaling 650 million euros;
– short-term bank deposits totaling 3 million euros;
– treasury bills totaling 1 million euros;
– 13,964,580 treasury shares with a net book value of 623 million euros (see note 3).
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Note 6: Movements in shareholders' equity
Number Share Additional Reserves Net Special tax- Total
of shares capital paid-in and  income allowable 
capital retained for the provisions &
earnings period investment 
(in millions of euros) subsidies
Balance as of December 31, 1999
before appropriation of profits 731,143,218 1,462 1,477 1,147 488 5 4,579
Appropriation of 1999 profits 
to reserves and retained earnings – – – 257 (257) – –
Dividends distributed for the period ended 
December 31, 1999 (0.32 euro per share) – – – – (231) – (231)
Issuance of shares on exercise 
of stock options 298,528 1 2 – – – 3
Net income for the year ended 
December 31, 2000 – – – – 630 – 630
Change in special tax-allowable provisions – – – – – (2) (2)
Balance as of December 31, 2000
before appropriation of profits 731,441,746 1,463 1,479 1,404 630 3 4,979
Appropriation of 2000 profits 
to reserves and retained earnings – – – 313 (313) – –
Dividends distributed for the year ended 
December 31, 2000 (0.44 euro per share) – – – – (317) – (317)
Issuance of shares on exercise 
of stock options 563,338 1 6 – – – 7
Net income for the year ended 
December 31, 2001 – – – – 1 442 – 1 442
Change in special tax-allowable provisions – – – – – (2) (2)
Balance as of December 31, 2001
before appropriation of profits 732,005,084 1,464 1,485 1 717 1 442 1 6 109
Appropriation of 2001 profits 
to reserves and retained earnings – – – 969 (969) – –
Dividends distributed for the year ended 
December 31, 2001 (0,66 euro per share) – – – – (473) – (473)
Sasy3 merger (surplus arising on merger) – – 90 – – – 90
Issuance of shares on exercise 
of stock options 362.423 1 3 – – – 4
Change of accounting method (1) – – – 2 – – 2
Net income for the year ended 
December 31, 2002 – – – – 1,323 – 1,323
Balance as of December 31, 2002
before appropriation of profits 732,367,507 1,465 1,578 2,688 1,323 1 7,055
(1) In application of the new CRC Rule 2000.06 on liabilities, non-compliant provisions were reversed by crediting retained earnings.
The share capital comprises 732,367,507 shares with a par value of 2 euros.
The exercise of options relates to plans granted to employees prior to the merger.
The increase in shareholders' equity that would result from the exercise of options still outstanding as of December 31, 2002
would be approximately 7 million euros.
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Note 7: Provisions recorded in the balance sheet
Opening Sasy3 Charge Write-backs Write-backs Change of Closing
balance merger for provision provisions accounting balance
(in millions of euros) the year utilized not utilized method(1)
Provisions for risks and charges
Provisions for miscellaneous risks (2) 425 3 25 (103) (148) (1) 201
Provisions for charges 23 – 7 (19) (1) – 10
Provisions for retirement and early 
retirement benefit commitments 48 – 15 (34) – (1) 28
Total 496 3 47 (156) (149) (2) 239
Charges and write-backs taken to the statement of income: Total
– Operating items 40 (1) – – 39
– Financial items 4 (1) – – 3
– Exceptional items 3 (154) (149) – (300)
Total 47 (156) (149) – (258)
(1) Written back to retained earnings in application of the new CRC Rule 2000-06 on liabilities (see note 6).
(2) This line mainly comprises provisions relating to patent rights litigation, tax audits and vendor's guarantees of liabilities.
Note 8 : Operating income
Net sales 
This line mainly comprises:
– Supply of chemical active ingredients:
During the year, Sanofi-Synthélabo invoiced a total of 123 million euros. 
– Recharged research and development expenses:
Under agreements with the principal French operating subsidiaries on the sharing of the costs and benefits of research and
development expenses relating to future pharmaceutical products, Sanofi-Synthélabo recharges a share of such expenses to its
subsidiaries. For the year ended December 31, 2002, the income generated by such recharges was 77 million euros, 
compared with 118 million euros for the year ended December 31, 2001. The reduction in income is due to the ending of an
agreement between Sanofi-Synthélabo and two of its subsidiaries on December 31, 2001.
– Rent:
Sanofi-Synthélabo owns real estate in France which is let to its subsidiaries, on which it collects rent (29 million euros).
Other income
This mainly comprises royalties collected by Sanofi-Synthelabo from:
– its French and foreign pharmaceutical subsidiaries, to which it has licensed patents, manufacturing know-how and 
trademarks owned by Sanofi-Synthélabo;
– third party companies, to which it has licensed a number of major pharmaceutical products.
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Note 9: Operating expenses
Other purchases and external charges
This line mainly comprises:
– Manufacturing of active ingredients:
Sanofi-Synthélabo subcontracts the manufacturing of active ingredients to a subsidiary. Costs incurred as a result amounted to
62 million euros for the year ended December 31, 2002.
– Research expenses:
Sanofi-Synthélabo, in association with its main operating subsidiaries, assumes responsibility within the Group for research and 
development. It defines strategic priorities, co-ordinates the work, makes investment decisions, and takes out in its own name and at
its own expense all industrial property protection covering products derived from research.
In order to fulfil this role, Sanofi-Synthélabo subcontracts research and development work to those of its subsidiaries that have the 
necessary resources, and if necessary to third parties.
Research expenses amounted to 802 million euros in 2002, compared with 657 million euros in 2001 and 589 million euros in 2000.
Salaries and social security charges
2002 2001 2000
Average number of employees 22 22 26
Remuneration paid to corporate officers holding office as of December 31, 2002 amounted to 3.6 million euros, including 
attendance fees of 0.4 million euros.
Note 10: Share in profits/losses of joint-venture partnerships
Until 2001, this represented Sanofi-Synthélabo's share of the profits from the partnership entity involved in chemicals 
activities. This entity was wound up on December 31, 2001.
Note 11: Management of market risk
Sanofi-Synthélabo operates a centralized foreign exchange risk management system which provides protection from such 
risk for its main subsidiaries at all times.
Gains and losses arising on hedging transactions are calculated and recognized symmetrically with the recognition of gains and
losses on the hedged item.
Outstanding hedging positions at year end are shown in Sanofi-Synthélabo's off balance sheet commitments.
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Note 12: Net financial income
(in millions of euros) 2002 2001 2000
Net investment income 796 415 746
Dividends received 674 277 649
Other portfolio income 19 4 9
Net proceeds from disposals 
of short-term investments 49 48 9
Other interest and similar income (1) 54 86 79
Net change in provisions for impairment of (88) 128 (31)
– participating interests (see note 3) 11 115 (39)
– treasury shares (see note 3) (71) – –
– other long-term investments (2) (17) (2) 1
– loans to subsidiaries (8) 3 –
– other items (3) 12 7 
Net foreign exchange gain/(loss) 85 18 (40)
Total 793 561 675
(1) This line mainly comprises interest received and paid on short-term bank deposits, current accounts and loans arising under the cash 
pooling agreements between Sanofi-Synthélabo and its subsidiaries.
(2) See note 3 on Viropharma Inc.
Note 13: Exceptional items
Exceptional charges amounted to 169 million euros and exceptional income to 496 million euros. The net balance of exceptional
items comprises:
(in millions of euros) 2002 2001 2000
– net change in provisions for risks and charges 300 (77) (155)
– net gain/(loss) realized on mergers 
of Group companies (9) 258 (1) –
– net gain/(loss) realized on disposals 
of long-term investments – 333 (2) 24
– other fixed asset disposals 7 58 –
– net gain on group tax election 
(including impact of tax audits relating 
to the group tax election)  73 17 34
– exceptional restructuring costs – – (78)
– payment received on a license disposal compensation – – 35
– others items (44) (3) (8) –
Total 327 581 (140)
(1) including 237 million euros realized on the merger of Synthélabo Groupe into Sanofi Winthrop Industrie.
(2) including 308 million euros on the disposal of Laboratoires de Biologie Végétale Yves Rocher (see note 18)
(3) including 34 million euros relating to retirement benefit commitments.
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Note 14: Income taxes
As stated in note 2, the annual income tax charge corresponds to the corporate income tax charge specific to Sanofi-Synthélabo.
It breaks down as follows:
(in millions of euros) 2002 2001 2000
Tax on profit before exceptional items           (152) (151) (48)
Tax on exceptional items, plus the impact of tax 
reassessment notices accepted by the company (41) (71) (2)
(193) (222)      (50)
The tax on profit before exceptional items takes into account tax credits and changes in provisions for impairment of 
investments included in net financial income.
Charges regarded as excessive under article 39.4 of the French General Tax Code and not deductible from taxable profits
amounted to 0.1 million euros in 2002.
Increases and reductions in future tax liabilities  
The amount of deferred tax assets not recognized in the parent company financial statements in respect of temporarily non-
deductible provisions was 53 million euros as of December 31, 2002, compared with 55 million euros as of December 31, 2001.
The amount of the deferred tax liability not recognized in the parent company financial statements in respect of deferred charges
was 6 million euros as of December 31, 2002.
Note 15: Transactions with related undertakings
In the table below, a company is treated as related if it is consolidated by the Group using the full consolidation method.
(in millions of euros) 2002 2001 2000
Long-term investments (gross):
– Participating interests 3,088 2,678 2,341
– Loans/advances to participating interests 15 5 57
Receivables (gross):
– Accounts receivable 587 342 287
– Other receivables 598 473 1,201
Liabilities:
– Debt 773 730 800
– Accounts payable 246 187 192
– Other liabilities 2 4 10
– Deferred income 12 – –
Operating expenses:
– Other purchases and external charges (829) (677) (615)
– Other charges (19) (57) (50)
Financial expenses:
– Interest and similar expense (22) (31) (28)
– Exceptional charges on non-capital transactions (2)
Net sales 253 163 172
Other operating income 736 421 496
Share in net income of
joint venture partnerships – 303 183
Financial income 689 318 710
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Note 16: Accrued income and expenses
(in millions of euros) Accrued incomes Accrued expenses
Accounts receivable 297
Other receivables 117
Accounts payable 50
Amounts payable to suppliers of fixed assets 1
Tax and employee-related liabilities 14
Other liabilities 12
Note 17: Off balance sheet commitments
(in millions of euros) < 1 year 1-5 years > 5 years Total
Commitments given:
Surety bonds given to the tax authorities in respect 
of contested tax liabilities relating to Sanofi-Synthélabo 6 – – 6
Guarantees in favor of Group subsidiaries 395 – –  395
Other surety bonds and guarantees 2 – 19 21
Lease - 56 112 168
Currency options including          USD: 568  809 – – 809
JPY:  163
NOK:  51
Others (1)  26 127 40 193
Total 1,238 183 171 1,592
(1) Under the agreements with NV Organon on the marketing of the drug Arixtra in countries other than the United States, Canada, Japan and Mexico,
Sanofi-Synthélabo agreed, in return for taking over the rights, to make phased payments to NV Organon up to a maximum of 100 million
dollars contingent on the approval of additional indications. Sanofi-Synthélabo also agreed to pay minimum royalties of 75 million dollars.
Sanofi-Synthélabo is required to pay minimum royalties of 17 million euros under three pharmaceutical license agreements.
In addition, there are two contracts relating to research work which could give rise to deferred payments between 1 and 4 million euros 
per molecule. Because of the uncertain nature of the research work, it is impossible to predict the number of molecules that will reach the
relevant milestones. For this reason, it is impossible to estimate the maximum aggregate amount that Sanofi-Synthélabo will actually pay. 
Sanofi-Synthélabo is committed to making an additionnal investment of 10 million euros in IDM in a further share issue (see note 3).
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(in millions of euros) < 1 year 1-5 years > 5 years Total
Commitments received:
In return for contract warranty retentions 4 – – 4
Miscellaneous guarantees 1 – – 1
Currency options including USD: 366 539 – – 539
JPY:   115 
NOK:   50
Total 544 –    – 544
Reciprocal commitments:
Forward currency exchange contracts:
– forward purchases, including CHF: 68 125 – – 125
NOK: 33 
GBP: 10 
– forward sales, including USD: 798 1 033 – – 1 033
JPY: 79
GBP: 60
CAD: 26
CZK: 16 
Commitments involving Group subsidiaries:
– export rate guarantees, including USD: 147 309 – – 309
CHF: 34  
GBP: 28  
JPY: 24  
KRW: 17 
CZK: 11 
– import rate guarantees including CHF: 111 191 – – 191
GBP: 36
USD: 28
HUF: 10
Apart from the commitments disclosed above, there are no commitments which are or may become material with the 
exception of those arising under the following collaboration agreements: 
 In 2001, Sanofi-Synthélabo signed a collaboration agreement with IDM. This agreement is described in note 3. Because of the
uncertain nature of the development work, it is impossible to predict if Sanofi-Synthélabo will exercise an option for a product or if
the expected milestones will be achieved. For this reason, it is impossible to estimate the maximum aggregate amount that 
Sanofi-Synthélabo will actually pay in the future under outstanding collaboration agreements. Given the nature of its business, 
it is highly unlikely that Sanofi-Synthélabo will exercise all options for all products or that all milestones will be achieved.
 Sanofi-Synthélabo has signed a collaboration agreement with NV Organon to develop anti-thrombotic oligosaccharides 
(in continuation of the work that resulted in the development of Arixtra).
83
P a r e n t  C o m p a n y  F i n a n c i a l  S t a t e m e n t s
Real estate capital leases relate to administrative and research premises:
(in millions of euros) 2002
Value of assets on signature of lease
Breakdown by balance sheet line:
– land 4    
– buildings 91
Lease payments:
– during the period 9
– cumulative 127
Depreciation that would have been charged if the assets had been acquired outright:
– during the period 5
– cumulative 56
Value of outstanding lease payments as of December 31, 2002:
– until one year 9
– more than one year until five years 26
– more than five years 32
The residual purchase price of the assets will be less than one euro.
Note 18: Note on agreements relating to the Yves Rocher Group
Following the merger of Sanofi and Synthélabo, a dispute arose between Sanofi-Synthélabo and the other shareholders of the
Yves Rocher Group, who challenged the registration in the name of Sanofi-Synthélabo of the shares in the companies Financière
des Laboratoires de Cosmétologie Yves Rocher and Laboratoires de Biologie Végétale Yves Rocher held prior to that date by
Sanofi. The dispute relates to an alleged breach of a pact between the shareholders.
Legal action was brought. An appeal court ruling of January 10, 2001, ordered:
–  the reinstatement of Sanofi-Synthélabo's rights in Financière des Laboratoires de Cosmétologie Yves Rocher;
–  the appointment of an expert to value the direct interest of Sanofi in Laboratoires de Biologie Végétale Yves Rocher as of the
date of the merger. On completion of this expert valuation, Yves Rocher may exercise its option to buy out the shares held by
Sanofi-Synthélabo at the price set by the expert or, if it does not exercise the option, must register the shares in the name of
Sanofi-Synthélabo.
Following the delivery of the expert's findings in November 2001 and in line with the court ruling, Laboratoires de Biologie Végétale
Yves Rocher arranged for the acquisition of Sanofi-Synthélabo's interest in its capital.
This acquisition took place at end December 2001, at a price of 316 million euros. The pre-tax capital gain in the Sanofi-
Synthélabo parent company financial statements was 308 million euros.
In line with the Rennes Appeal Court ruling of January 10, 2001, Sanofi-Synthélabo remains a shareholder of Financière 
des Laboratoires de Cosmétologie Yves Rocher.
During the first half of 2001, Sanofi-Synthélabo and Financière des Laboratoires de Cosmétologie Yves Rocher both entered
appeals against the aforementioned orders in the French Supreme Court.
After this sale, Sanofi-Synthélabo, based on available information, owns 39.1% of Financière des Laboratoires de Cosmétologie
Yves Rocher. This holding company owns a 51.3% interest in Laboratoires de Biologie Végétale Yves Rocher. Consequently,
Sanofi-Synthélabo held an indirect interest of 20.1% in the Yves Rocher Group as of December 31, 2002.
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Note 19: List of subsidiaries and participating interests
Summary information on all subsidiaries and participating interests held by Sanofi-Synthélabo
Subsidiaries Participating interests
(in millions of euros) French Foreign French Foreign
Gross book value of shares held 1,306 1,764 4 24
Net book value of shares held 1,297 1,679 4 24
Loans and advances made 40 455 – –
Guarantees given 57 244 1 14
Dividends received 396 267 10 1
Subsidiaries and participating interests of which the net book value of
the shares held exceeds 1% of the share capital of Sanofi-Synthélabo
Capital Equity 
other than
capital
(in millions of euros)
Subsidiaries more than 10% held
French subsidiaries 
Laboratoires IREX – 6
S.A. N° SIREN 380663914 – 22, Avenue Galilée – 92350 Le Plessis-Robinson
Sanofi-Chimie (ex.Sasy.1) 271 198
S.A. N° SIREN 428706204 – 9, rue du Président Allende – 94250 Gentilly
Sanofi-Synthélabo France (ex. Sanofi Winthrop) 13 (10)
S.A. N° SIREN 403335904 – 174, Avenue de France – 75013 Paris
Sanofi Winthrop Industrie 159 136
S.A. N° SIREN 775662257 – 82, Avenue Raspail – 94250 Gentilly
Secipe 39 202
S.A. N° SIREN 722019965 – 174, Avenue de France – 75013 Paris
Synthélabo Biomédical 27 5
S.A. N° SIREN 319740726 – 22, Avenue Galilée – 92350 Le Plessis Robinson
Sanofi-Synthélabo Recherche 2 30
S.A. N° SIREN 713002269 – 1, Avenue P.Brossolette – 91380 Chilly-Mazarin
Sanofi-Synthélabo Groupe 26 38
S.A. N° SIREN 403335938 – 174, Avenue de France – 75013 Paris
Foreign subsidiaries
Chinoin Pharmaceutical and Chemical Works Co Ltd – Budapest, Hungary 17 180
Sanofi-Synthélabo do Brasil Ltda – Rio de Janeiro, Brazil 16 3
Sanofi-Synthélabo Holding GmbH – Berlin, Germany 61 31
Sanofi-Synthélabo Inc – New York, United States – 259
Sanofi-Synthélabo SA – Barcelona, Spain 1 82
Sanofi-Synthélabo SpA – Milan, Italy 85 23
Sanofi-Synthélabo UK Ltd – Guildford, UK –    169
Sanofi-Synthélabo de Colombia S.A. – Cali, Colombia 3 15
Sanofi-Synthélabo Polholding BV – Maassluis, Netherlands – 28
Sanofi-Synthélabo Produtos Farmaceuticos SA – Alcabideche, Portugal 18 –
Sanofi-Synthélao AE – Peania, Greece 18 (7)
Sanofi-Synthélabo AB – Bromma, Sweden – 9
Sanofi-Synthélabo Koréa Co. Ltd – Seoul, South Korea 27 (15)
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Share of Book value of Outstanding Guarantees Net sales for Net income/ Dividends
capital held shares held loans given by the last financial loss for last received by 
(%) and advances company year financial the company
receivable year during 
Gross Net the year
100 18 18 15 – 41 (6) –
100 430 430 17 – 370 22 –
100 73 73 – – 1 383 74 126
100 400 400 – 55 2 722 326 218
100 235 235 – – – 2 21
100 36 33 – – – 1 25
95 26 26 – 2 810 8 6
93 47 47 – – 397 3 –
99 157 157 – 35 239 45 –
100 65 65 – – – (5) –
100 80 80 – 2 – 32 30
100 608 608 432 38 363 419 139
100 104 104 – 8 344 39 7
100 116 116 – – 314 20 12
100 161 161 – 12 – – 10
90 16 16 – 17 26 2 –
100 88 88 7 – – – 4
86 22 22 – – 66 5 –
100 38 38 – – 85 8 –
100 36 36 – 2 52 1 1
100 38 38 – 5 66 4 –
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Five-year financial summary: Sanofi-Synthélabo parent company
(In millions of euros) 2002 2001 2000 1999 (2) 1998 (2)
Capital at period-end
Share capital 1,465 1,464 1,463 1,462
Number of shares in issue 732,367,507 732,005,084 731,441,746 731,143,218 5,000
Income statement data
Net sales 273 176 194 301
Net income before tax, depreciation, 
amortization and provisions 1,391 1,525 908 538
Income taxes 193 222 50 29
Employee profit-sharing 
charge for the period(1) – (1) 6 7
Net income after tax, depreciation, 
amortization and provisions 1,323 1,442 630 488
Dividend paid 473 317 231
Per share data (in euros)
Net income after tax but before 
depreciation, amortization 
and provisions
– based on actual number of shares 1.64 1.78 1.17 0.70 3.87
– based on adjusted number of shares* 1.64 1.78 1.17 0.70 15.48
Net income after tax, depreciation, 
amortization and provisions
– based on actual number of shares 1.81 1.97 0.86 0.67 3.87
– based on adjusted number of shares* 1.81 1.97 0.86 0.67 15.48
Dividend per share (net)
– based on actual number of shares 0.66 0.44 0.32 –
Employees
Average number of 
employees during the period 22 22 26 1,160 –
Wages and salaries for the period 9 10 12 69 –
Social security and other benefits paid  5 5 5 30 –
* Adjusted to take account of the 4-for-1 stock split that took place on May 18, 1999.
(1) Provision for statutory and voluntary employee profit-sharing schemes
(2) On May 18, 1999, Sanofi and Synthélabo were merged into a shell company, which took the name Sanofi-Synthélabo. On January 25, 2000,
Sanofi-Synthélabo transferred its support activities to the 100% directly and indirectly owned subsidiary Sanofi-Synthélabo Groupe, with 
retrospective effect from January 1, 2000.
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Parent company/subsidiary relations 
The group comprising Sanofi-Synthélabo and its subsidiaries is focused on a single business: pharmaceuticals.
The Sanofi-Synthélabo parent company directly owns most of its subsidiaries and the main industrial property rights.
Sanofi-Synthélabo assumes responsibility for research and development within the Group. It defines strategic priorities, co-
ordinates the work, and takes out industrial property rights in its own name and at its own expense. In order to fulfil this role,
Sanofi-Synthélabo subcontracts research and development work to those of its subsidiaries that have the necessary resources.
Sanofi-Synthélabo licenses its patents, manufacturing know-how and trademarks to certain French and foreign subsidiaries. The
licensee subsidiaries manufacture and distribute the Group's products, either directly or indirectly via local distribution subsidiaries. 
In certain countries, in particular Japan, the Sanofi-Synthélabo Group carries on some of its activities through joint ventures with
local partners. In addition, the company has signed worldwide agreements whereby some of its strategic products are 
marketed through alliances with Bristol Myers Squibb and Organon (cf pages 36-37 of the 2002 Financial report).
Sanofi-Synthélabo meets the financing needs of most of its subsidiaries and manages their cash surpluses. The company also
operates a centralized foreign exchange risk management system, which takes out the necessary hedges to protect its main 
subsidiaries from such risks.
Note 15 "Transactions with related undertakings" provides summary financial data concerning relations between the Sanofi-
Synthélabo parent company and other Group companies.
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Risk factors for the issuer  
LEGAL RISKS
Product approval 
Sanofi-Synthélabo must obtain and maintain regulatory approval for its pharmaceutical products in the European Union, the
United States and other countries before a product may be sold in these markets. Filing an application with the regulatory
authority in a particular country or in the European Union does not guarantee that a license to market the product will be granted.
Each authority may impose its own requirements, including requiring clinical studies in its own country, and may delay or refuse
approval, even though a product has already been approved in another country.
In Sanofi-Synthélabo's main markets, the approval process for one or more indications of a new product is complex and lengthy
(six months to two years from the date of application). Approvals may be limited to certain indications. A product which is
already marketed is also subject to continual review after regulatory approval. Problems may result in marketing restrictions or
withdrawal of the product, as well as possible legal penalties.
In addition, Sanofi-Synthélabo is subject to strict government controls on the manufacture, labeling, distribution and marketing
of its products.
All these factors affect the probability of a product being launched or remaining on the market, and also affect the cost of
developing new products.
Industrial property rights
The success of Sanofi-Synthélabo's operations depends on our ability to protect our industrial property rights effectively by
obtaining, maintaining and enforcing patents and other rights. Patent law in the pharmaceutical field is continually evolving,
and hence is a source of uncertainty. It is never certain that:
- a new invention will be patentable;
- patents applied for will be granted;
- the scope of patent protection will be sufficient to exclude competitors.
In addition, third parties may claim ownership of patents or other industrial property rights owned by or licensed to 
Sanofi-Synthélabo, which could result in the cancellation or unenforceability of these rights.
Sanofi-Synthélabo currently has over 9,000 patents and patent applications worldwide, and licenses for more than 30 additional
patents. We cannot be certain how much protection these will provide. Early in 2002, two pharmaceutical companies, Apotex
and Dr. Reddy's Laboratories, each filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration
(FDA), seeking to market a generic form of Plavix® in the United States, and challenging certain American patents relating to
Plavix® (see "Legal Proceedings", page 90 of this report). The Plavix® patents are material to Sanofi-Synthélabo's business,
and if we were unsuccessful in asserting them or they were deemed invalid, any resulting introduction in the United States of
a generic version of Plavix® would reduce the price that we receive for this product and the volume of the product that we would
be able to sell. 
Certain national governments have recently responded to healthcare crises by taking measures which have the effect of 
eroding the patent protection enjoyed by pharmaceutical companies. These measures include the threat of imposing compul-
sory licenses for products they view as essential. 
Sanofi-Synthélabo supports the efforts of national governments to combat major healthcare crises. However, if such efforts are
at the expense of effective patent protection, they will impair the ability of Sanofi-Synthélabo and other pharmaceutical 
companies to recover research and development expenditure, thereby inducing them to curtail such expenditure and develop
fewer new products.
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Risk of patent infringement
There is a risk that competitors may infringe Sanofi-Synthélabo's patents or attempt to circumvent them by making innovations.
To prevent infringement, Sanofi-Synthélabo may file infringement claims, which are lengthy and expensive. It is difficult to
monitor the illegal use of industrial property rights, and Sanofi-Synthélabo may not always be able to prevent the fraudulent
use of its industrial property rights. This risk is increased by the rapid growth in patents filed and granted in the pharmaceuticals
industry.
Legal proceedings 
Refer also to the notes to the consolidated financial statements D.14  and D.19, pages 48 and 54 of this report.
In February 2002, Sanofi-Synthélabo was informed that Apotex, a generic drug manufacturer, had filed an Abbreviated New
Drug Application (ANDA) with the FDA challenging two American patents relating to Plavix® listed in the Orange Book. In
April 2002, Sanofi-Synthélabo was informed that another generic drug manufacturer, Dr. Reddy’s Laboratories, had also filed
an ANDA with the FDA challenging the three American patents relating to Plavix® listed in the Orange Book as of that date.
An ANDA is an application made by a drug manufacturer for authorization to market a generic version of an approved product,
by demonstrating that it has the same properties as the original product. Generally, an ANDA may not be filed until the expi-
ration of the five-year market exclusivity period that applies to the original product following its initial market authorization.
However, if the product is protected by a patent owned by or licensed to the manufacturer of the original version, the ANDA
cannot be approved until the patent expires unless the ANDA applicant challenges the validity of the patent. In that case, 
the ANDA may be filed four years following the initial market authorization of the original product.
One of the patents challenged by Apotex and by Dr. Reddy’s Laboratories expires in 2011, and the other in 2014. The third
patent, challenged by Dr. Reddy’s Laboratories, expires in 2003. 
Two additional American patents expiring in 2019 were listed in the Orange Book by Sanofi-Synthélabo in September 2002 and
January 2003. These patents are not included in the proceedings.
On March 21, 2002, Sanofi-Synthélabo filed suit in the U.S. District Court for the Southern District of New York against Apotex
for infringement of our patents. On May 14, 2002, Sanofi-Synthélabo filed suit against Dr. Reddy's Laboratories in the same
court for infringement of our patents. If either of these challenges is successful, the prevailing party would have the right to 
produce a generic version of Plavix® and market it in the United States in competition with Sanofi-Synthélabo and our alliance
partner, BMS. Under American law, the FDA will not be able to approve the ANDAs filed by Apotex or Dr. Reddy's Laboratories
until the earlier of May 17, 2005 or the issuance of a court decision that is adverse to the Plavix® patents. However, Sanofi-
Synthélabo believes its patents to be valid. If the courts support this view, Plavix® will continue to enjoy patent protection.
Sanofi-Synthélabo intends to defend its interests vigorously in this matter.
In March 2003, Sanofi-Synthélabo was informed that Apotex (as referred to above) had filed an application for marketing
authorization with the Canadian authorities for a generic version of Plavix®, challenging the Canadian patent for clopidogrel.
Sanofi-Synthélabo believes that this patent is valid, and that it protects Plavix® in Canada until August 2012. Sanofi-Synthélabo
intends to defend its interests vigorously in this matter.
As far as Sanofi-Synthélabo is aware, there are no exceptional facts or legal proceedings, other than the cases described above,
that have not been provided for and that could have a material effect on the Group's financial position, net income, assets
and liabilities or prospects.
Pricing of products 
The performance of Sanofi-Synthélabo depends in part on the price at which drugs are reimbursed to patients. There is strong
pressure on prices, due in particular to:
- the current tendency of government and private healthcare providers to favor generic drugs;
- the price controls imposed by governments in many countries; and
- parallel imports, a practice whereby intermediaries exploit price differentials between markets by purchasing products 
in lower-priced markets for resale in higher-priced markets.
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Price pressure is very strong in Europe and the United States, which in 2002 accounted for 57.7% and 22.7% respectively of
consolidated net sales. Changes in pricing policies in these two markets are liable to have a material effect on Sanofi-Synthélabo's
net sales and net income.
Dependency on third parties 
Sanofi-Synthélabo markets some of its products in collaboration with other pharmaceutical companies. We have signed major
collaboration agreements with Bristol-Myers Squibb for the marketing of Plavix® and Aprovel®, and with Organon, a
subsidiary of Akzo Nobel, for the marketing of Arixtra®. Sanofi-Synthélabo has also entered into alliances with several Japanese
companies for the marketing of its products in Japan. When Sanofi-Synthélabo markets its products under collaboration 
agreements, certain decisions, such as the preparation of budgets and promotional strategies, are under the control of our
partners. Deadlock may arise and adversely affect the activities conducted through these collaboration agreements. For example,
our alliances with Bristol-Myers Squibb are subject to the operational management of Bristol-Myers Squibb in some countries,
including the United States, where from March 2002 Bristol-Myers Squibb implemented a policy of reducing the level of Plavix®
and Avapro® inventories towards American wholesalers.
We cannot be certain that Sanofi-Synthélabo's partners will perform their obligations as expected. Our partners may favor
their own existing or alternative technologies, or pursue other products than those developed or marketed in collaboration
with Sanofi-Synthélabo.
Sanofi-Synthélabo's general policy is to manufacture the active ingredients for its products itself. However, Sanofi-Synthélabo
subcontracts the manufacture of the active ingredients for some of its products to third parties, and consequently is exposed
to a risk of interruptions to supply in the event that its suppliers experience financial difficulties or are unable to meet demand.
At present, Sanofi-Synthélabo subcontracts part of the manufacture of the active ingredients for Stilnox® and Xatral®, two of
its six strategic* products, to Dynamit Nobel, which bought the factory that manufactures these ingredients from 
Sanofi-Synthélabo in February 2001. Although Sanofi-Synthélabo has not experienced any problems in the past, any inter-
ruption in the supply of raw materials as a result of difficulties with subcontractors may adversely affect the ability of 
Sanofi-Synthélabo to supply the market, and damage its reputation and customer relations. Although we make efforts to secure
alternative sources of supply wherever possible, including by manufacturing active ingredients at two or even three production
sites (double/triple sourcing policy), there can be no certainty that this would prove adequate if the main source of supply
were to be temporarily unavailable.
Collaborations with third parties expose Sanofi-Synthélabo to the risk that these third parties may assert intellectual or industrial
property rights to our inventions or fail to keep our unpatented technology confidential.
Sanofi-Synthélabo may provide information and materials to research collaborators in universities or to other public or private
entities, and may commission them to conduct tests to investigate these materials. In all cases, Sanofi-Synthélabo enters into
adequate confidentiality agreements with the entities. However, these entities may assert industrial property rights over the results
of the tests conducted by their staff, and may refuse to license these rights to Sanofi-Synthélabo on acceptable terms.
Our business also relies on unpatented technology, manufacturing processes, know-how and data which we regard as trade
secrets, and which we protect in part by entering into confidentiality agreements with our employees and consultants and with
certain joint contractors. We cannot be certain that these agreements or any other available form of protection of trade secrets
will afford sufficient protection, or that we will have adequate remedies if they are breached (see section “A crucial issue: indus-
trial property” page 65 of the 2002 Business report).   
*Plavix®/Iscover®, Stilnox®/Ambien®/Myslee®, Aprovel®/Avapro®/Karvéa®, Eloxatine®, Xatral®, Arixtra®.
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RISKS RELATING TO SANOFI-SYNTHÉLABO'S ACTIVITIES 
Sanofi-Synthélabo must invest heavily in research and development to remain competitive. 
To be successful in the highly competitive pharmaceutical industry, Sanofi-Synthélabo must commit substantial resources to research
and development every year in order to develop new products. Our efforts may be undermined if our competitors gain an
advantage. In 2002, Sanofi-Synthélabo spent 1,218 million euros, or around 16% of consolidated net sales, on research and
development. The increase in expenditure associated with current investment in the launch of new products and the research
and development of future products may not necessarily result in an increase in Sanofi-Synthélabo's net sales.
The research and development process is lengthy and carries a significant risk of failure.
The research and development process generally takes 10-15 years from discovery of the compound to commercial product launch. 
The process involves various phases, and at each phase there is a significant risk that the objectives will not be met and that 
Sanofi-Synthélabo will abandon a product in which substantial amounts have been invested. For example, in order to develop
a commercially viable product Sanofi-Synthélabo must demonstrate via large-scale pre-clinical and clinical trials on humans
that the compound is safe and effective for use in humans. There can be no assurance that successful pre-clinical trials will be
confirmed by subsequent clinical trials, or that clinical trials will provide sufficient efficacy and product safety data to secure
approval from regulatory authorities. As of December 31, 2002, Sanofi-Synthélabo had 52 compounds in pre-clinical and 
clinical development in its four main therapeutic fields, including 23 in phase II or phase III of clinical trials. For further 
information on clinical trials and the definition of clinical trial phases, refer to page 33 of the 2002 Business report. There can
be no guarantee that these compounds will prove effective or safe, or that they will result in successfully marketable products.
Expansion in the United States
To meet its growth targets, Sanofi-Synthélabo must profitably expand its business in the United States, the world's largest
pharmaceuticals market. The United States, which accounted for 22.7% of 2002 consolidated net sales, is a major potential source
of future growth for Sanofi-Synthélabo, and we plan to expand significantly our direct presence in the United States in the
coming years. For example, in April 2002 Sanofi-Synthélabo acquired Pharmacia's interest in the joint venture which markets
Stilnox® (under the name Ambien®) and Kerlone® in the United States. A number of obstacles need to be overcome to secure
profitable expansion in the United States, in particular:
- the implementation of organizational structures compatible with the size of this vast market;
- the targeting of new markets;
- the domination of the U.S. market by the major American pharmaceutical companies;
- the risks associated with pricing and healthcare reimbursement policies, which are constantly under discussion as a result of
the high level of healthcare spending in the United States.
INDUSTRIAL AND ENVIRONMENTAL RISKS
See also section “The dynamics of continuous progress: a methodology for our HSE policy”, pages 74-77 of the 2002 
Business report. 
General overview
Use of hazardous substances 
The manufacture of pharmaceutical products, and in particular of active ingredients (including storage and transportation of raw
materials, products and waste), gives rise to the risk of: 
- fires from inflammable subtances:
- leaks from storage tanks;
- emission or disposal of toxic substances.
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These operating risks may, if they crystallize, cause personal injury, property damage or environmental pollution. Consequences
may include:
- the closure of the sites involved;
- the imposition of civil or criminal penalties on Sanofi-Synthélabo. 
The occurrence of any such event could therefore have an adverse effect on the operating profits of Sanofi-Synthélabo.
Site remediation
Sanofi-Synthélabo is obliged to remediate contaminated sites. These may include sites that we currently own or operate, or sites
that we owned or operated in the past. They may also include sites where waste generated by Sanofi-Synthélabo's activities
has been discharged. As for any company involved in the pharmaceutical industry, soil or groundwater contamination has
occurred at certain sites in the past, and may also recur or be discovered at other sites. 
In addition:
- Sanofi-Synthélabo is currently involved in claims, lawsuits and administrative proceedings relating to environmental matters,
and others may arise;
- environmental regulations are constantly changing, and the introduction of stricter health, safety and environmental rules 
is liable to increase the costs and liabilities incurred by the company.
Significant factors liable to impact the company's assets and liabilities or results
Sanofi-Synthélabo's manufacturing and research activities are subject to increasingly stringent laws and regulations on health,
safety and the environment. These laws and regulations are complex and rapidly evolving. Sanofi-Synthélabo has incurred and
will continue to incur the necessary expenditure to ensure compliance. Our investment in health, safety and the environment
varies from year to year: the total amount invested was 11 millions euros in 2001 and 23 millions euros in 2002. It is not 
possible to predict with certainty future expenditure in this area.
Provisions booked for environmental risks are adequate, based on information available as of the date they were booked. Given
the uncertainties inherent in anticipating industrial and environmental liabilities, the company cannot warrant that it will not need
to incur additional expense beyond the amounts provided. Any shortfall in provisions to meet such risks could have a material
impact on operating profits.
In addition, although Sanofi-Synthélabo has taken out property, liability and business interruption insurance cover in line with
industry practice, there can be no guarantee that such insurance will fully cover all the consequences of potential dangers
affecting its business. For more information, see the "Insurance and risk coverage" section, page 96 of this report.
Subject to these reservations, the company is not currently aware of any industrial or environmental risk that might 
significantly affect the assets and liabilities or results of the company.
Policy of prevention in the environmental field and risk assessment
Sanofi-Synthélabo's health, safety and environment policy is designed to promote the health and well-being of its employees
and respect for the environment. Sanofi-Synthélabo regards this policy as an integral part of its commitment to social 
responsibility. The key points of the policy are summarized below.
Environment. The core objectives of Sanofi-Synthélabo's environment policy are to implement clean manufacturing 
techniques, minimize the use of natural resources and reduce the environmental impact of our business. In order to optimize
and improve our environmental performance, Sanofi-Synthélabo has undertaken to obtain ISO 14001 certification. 
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Two sites are certified in 2002 and three others are expected to be certified in 2003. This move is part of the rolling improve-
ment strategy practiced at all Sanofi-Synthélabo establishments through annual implementation of progress plans in health, safety
and the environment, known as PASS. Sanofi-Synthélabo believes that this strategy reflects the genuine involvement of 
management and individuals in health, safety and the environment.
Health. From the development of compounds to the launch of new drugs, Sanofi-Synthélabo's research scientists are constantly
assessing the impact of products on human health. Their expertise is made available to Sanofi-Synthélabo employees via two
committees responsible for chemical and biological risk assessment. The COVALIS committee classifies all chemical and 
pharmaceutical substances handled within Sanofi-Synthélabo and sets workplace exposure limits for each of them. To date, 
659 active pharmaceutical ingredients and 435 synthesis intermediates have been assessed. The TRIBIO committee classifies all
biological agents according to their degree of pathogenicity and makes decisions on confinement rules and preventive measures
to be implemented within Sanofi-Synthélabo.
Safety. Sanofi-Synthélabo has a rigorous policy designed to identify and assess risks, and to develop preventive measures and
methods to monitor the effectiveness of these measures. Sanofi-Synthélabo also invests in training programs designed to ensure
that a safety culture is built into all workplace activities. Such policies are implemented worldwide in order to ensure the safety
of all employees and protect their health. All projects, whether in research, development or manufacturing, are subject to
evaluation procedures incorporating data on substances and chemical processes obtained from the COVALIS and TRIBIO 
committees described above. The preventive measures primarily aim to reduce the number and seriousness of workplace 
accidents for permanent and temporary staff, and for employees of outside contractors. We believe that our efforts are 
succeeding, given the significant improvements in safety performance since the merger.
The Sisteron site mentioned above is one of the sites that has been subject to an upgraded inspection regime, given the safety
issues inherent in its manufacturing processes, which include the use of toxic and inflammable substances.
MARKET RISKS
Liquidity
Sanofi-Synthélabo expects that its current operating cash flows will be sufficient to finance its ongoing activities and investments
for the coming years. Sanofi-Synthélabo does not expect to increase its level of investment significantly in 2003 relative to
recent years, and has no current plan that would lead to a substantial rise in the next few years.
Sanofi-Synthélabo does not expect any significant change in its sources of liquidity in the future; our operating cash flows are
likely to remain substantial as long as consolidated profits continue to grow. Sanofi-Synthélabo does not expect to need to
increase debt significantly, unless it makes a major acquisition requiring a change to its financing strategy. Sanofi-Synthélabo
cannot be sure that its profits will continue to rise as in the past. However, there is currently no reason to anticipate a fall in conso-
lidated profits in the near future. Moreover, a substantial drop in profits or a very sizeable increase in expenditure would be requi-
red before cash flows became insufficient to finance ongoing liquidity requirements. Even then, the low level of debt would provide
a major source of potential liquidity.
Impact of interest rates
Sanofi-Synthélabo's operations generate substantial cash flows. Investment is financed mainly out of operating cash flow, and
Sanofi-Synthélabo pays regular dividends. Debt is limited and there was a positive net cash position as of December 31, 2002.
At that date, the net cash position was not hedged against interest rate risk. However, a deterioration in yields following any
fall in interest rates could impact the Group's net income.
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Impact of exchange rates
The financial statements are denominated in euros. Given that a substantial proportion of net sales is generated in non 
euro-zone countries, operating profits may be significantly impacted by exchange rate fluctuations between the euro and other
currencies, mainly the US dollar and, to a lesser extent, the Japanese yen. Sanofi-Synthélabo's policy is not to set up specific
hedges of net investments in foreign currencies, but to carry out a variety of foreign currency hedging transactions designed
to reduce our foreign currency risk exposure and protect operating margins. Hedging instruments relate to assets and liabilities
existing as of the balance sheet date and, in some cases, to commitments in respect of future transactions, determined when
annual forecasts are made. As of December 31, 2002, virtually all such assets and liabilities were hedged against foreign 
currency risk. As a result, such transactions will have no impact on the 2003 accounts. In 2002, 22.7% of net sales were from
the United States and 4.2% from Japan. As it was the case in 2002, a fall in the dollar relative to the euro in 2003 would have
a negative impact on Sanofi-Synthélabo's net sales which would be unlikely to be offset by a parallel reduction in expense, 
and would therefore negatively impact operating profits.
Stock market risk
Sanofi-Synthélabo has a policy of not trading in the markets for speculative purposes. Surplus cash is invested in money-
market mutual funds and term deposits with bank counterparties having high credit ratings.
Sanofi-Synthélabo does not own material equity interests in listed companies. 
As of December 31, 2002, the Sanofi-Synthélabo Group owned:
- 16,411,795 treasury shares, representing 2.24% of the share capital. These shares, bought under a share repurchase program,
were recorded in the consolidated financial statements as a deduction from shareholders' equity (see note D12.5 to the conso-
lidated financial statements, page 44 of this report). Movements in the Sanofi-Synthélabo share price will have no impact 
on consolidated net income.  
- 13,964,580 treasury shares, classified under "Short-term investments" at a net value of 623 million euros (see note D10 to
the consolidated financial statements, page 43 of this report). Of these shares, which represent 1.91% of the share capital, 
a total of 13,836,580 are allocated to stock option plans granted to employees. A provision for impairment of 46 million euros
was taken against these shares in 2002. This provision equates to the shortfall, valued on a plan by plan basis, between the 
average acquisition price of the shares and their average listed stock market price during December 2002 (57.10 euros). 
In the case of this second group of treasury shares, movements in the Sanofi-Synthélabo share price will have an impact on 
consolidated net income in the future. The table below shows the impact for a range of movements in the share price:
Movement relative to the listed Net impact
price of 57.10 euros in millions of euros
+20% +27
+10% +15
-10% -23
-20% -45
-30% -69
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OTHER RISKS 
As of December 31, 2002, the two main shareholders, L’Oréal and TotalFinaElf, held 19.5% and 24.5% of the share capital
respectively, representing 26.9% and 33.7% of the voting rights respectively. They are party to a shareholders' agreement
which runs to December 2004 and may be renewed; this agreement enables them to exercise significant influence over the choice
of board members and officers and over other company decisions requiring the approval of shareholders. While the agree-
ment continues in force, these factors may discourage bids for the shares of Sanofi-Synthélabo and deter a change in control.
INSURANCE AND RISK COVERAGE    
The Group has set up two worldwide insurance programs covering general and product liability, property damage and business
interruption, plus damage to goods in transit. Virtually all subsidiaries have subscribed to these insurance programs, which have
been taken out with top international insurance firms. Other insurance policies have been taken out for specific risks or to take
account of local constraints.
Despite a tougher market, we managed to maintain the limit of liability insurance at a sufficient level in 2002; however, the cover
was reduced by insurers' forced introduction of numerous new exclusions aimed specifically at certain products. This trend,
which began in 2002 and affected the industry as a whole, has continued in 2003 with the exclusion of other products and 
the raising of the level of deductibles.
Property cover and business interruption cover were less affected by market trends, though they were subject to reductions and
even some significant exclusions, particularly in relation to terrorism and natural events. In addition to insurance cover, 
the Group is implementing a double sourcing and storage policy for strategic products, designed to reduce our risks and 
ultimately our dependence on the insurance market.
Product liability is a major commercial risk which could grow, given the expansion of the business in the United States, where
compensation claims for defective products can be very high. In some countries, pharmaceutical companies have been ordered
to pay substantial damages following claims alleging injury caused by using their products. Some pharmaceutical companies have
even withdrawn products from the market recently after major product liability claims. Sanofi-Synthélabo is not currently 
involved in significant litigation alleging liability for injury caused by our products, but such litigation could arise in the future.
The insurance policies taken out are of the highest standard, the best available on the market and in line with industry practice;
however, they cannot totally rule out the possibility that a major event with unforeseeable or uninsurable consequences might
materially affect Sanofi-Synthélabo's assets and liabilities, financial condition or results.
97
F i n a n c i a l ,  a d m i n i s t r a t i v e  a n d  l e g a l  a d d i t i o n a l  i n f o r m a t i o n
General information concerning the company and the capital 
GENERAL INFORMATION CONCERNING THE COMPANY 
Sanofi-Synthélabo (the "Company") was formed as a result of the 1999 merger of two companies, Sanofi and Synthélabo, into
a shell company (previously named DGFP Delta) which took the name of Sanofi-Synthélabo. This company was a 100%-
owned subsidiary of Elf-Aquitaine, itself subsequently merged into TotalFinaElf, which had sold 50% of the capital of DGFP Delta
to L'Oréal on December 15, 1998. The mergers of Sanofi and of Synthélabo into Sanofi-Synthélabo were approved by the
General Meetings of Sanofi, Synthélabo and Sanofi-Synthélabo shareholders on May 18, 1999, with retrospective effect from
January 1, 1999.
Corporate name and registered office 
Sanofi-Synthélabo 174, avenue de France – 75013 Paris, France. Telephone number: +33 (0)1.53.77.40.00
The name Sanofi-Synthélabo was adopted by the Combined General Meeting of December 18, 1998, replacing the name DGFP Delta.
Legal form
The Company is a French limited liability company (société anonyme), administered by a Board of Directors and governed 
by the French Commercial Code and decree no. 67-236 of March 23, 1967.
Legislation
The Company is governed by French legislation.
Date of incorporation and duration of the Company
The Company was incorporated on April 28, 1994 and first registered in the Nanterre Register of Commerce and Companies
on May 18, 1994. The Company will expire on May 18, 2093 unless it is dissolved or extended prior to that date.
Corporate objects
Under article 3 of the bylaws, the Company's corporate objects, in France and abroad, are:
– acquiring interests and holdings, in any form whatsoever, in any company or enterprise, in existence or to be created, connected
directly or indirectly with the health and fine chemicals, human and animal therapeutics, nutrition or bio-industries sectors;
in the above areas:
– purchase and sale of all raw materials and products necessary for these activities;
– research, study, and development of new products, techniques and processes;
– manufacture and sale of all chemical, biological, dietary and sanitary products;
– obtaining or acquiring all industrial property rights related to results obtained and, in particular, filing all patents, trademarks
and models, processes or inventions;
– operating directly or indirectly, purchasing, and transferring for free or for consideration, pledging or securing all industrial 
property rights, particularly all patents, trademarks and models, processes or inventions;
– obtaining, operating, holding and granting all licenses;
– participating, as part of a Group-wide policy, in treasury management transactions in compliance with applicable legal 
provisions, whether as lead company or not, in the form of cash pooling, centralized exchange risk management, netting 
of intra-Group balances, or in any form authorized by applicable legislation;
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and, more generally:
– all commercial, industrial, real or personal property, financial or other transactions connected directly or indirectly, totally or 
partially, with the activities described above and with all similar or related objects or with any other objects likely to promote or
develop the Company’s activities.
Registration
The Company is registered in the Paris Register of Commerce and Companies as number 395 030 844. Its "APE" activity code is 741 J.
Consultation of corporate documents
Corporate documents and information concerning the Company may be consulted at the registered office.
Financial year
The financial year starts on January 1 and ends on December 31 of each year.
Allocation of profits under the bylaws
Under articles 24 and 25 of the bylaws, the profit or loss for the financial year is the difference between the income and
expenses for the financial year, after deducting depreciation, amortization and provisions, as shown in the statement of income.
From the profit of the financial year, less any losses brought forward, at least 5% is transferred to a reserve fund known as the
"legal reserve". This deduction ceases to be compulsory when the amount of the legal reserve reaches one-tenth of the share
capital, but resumes if the legal reserve falls below the said fraction for any reason.
The balance, plus any retained earnings carried forward, constitutes the distributable profit.
On the Board’s proposal, the ordinary general shareholders' meeting may decide that some or all of the distributable profit
will be carried forward or appropriated to one or more general or special reserve funds.
Dividends are distributed to the shareholders in proportion to the share in the capital held by each.
The general shareholders' meeting voting on the accounts for the financial year may give each shareholder the option of receiving
some or all of the dividend in cash or shares.
Subject to prevailing legal or regulatory provisions, the Board of Directors may pay interim dividends in cash or shares, even during
the course of the financial year.
General meetings
Notice of meetings
Meetings are convened by the Board of Directors under the conditions and within the time limits prescribed by law. They are
held at the registered office or at any other place indicated in the notice of the meeting.
Decisions are taken by shareholders at ordinary, general or extraordinary meetings, depending on the nature of the resolution
on which they are asked to vote.
Participation in meetings
Under articles 9, 19 and 20 of the bylaws, all shareholders are entitled to attend meetings personally or by proxy, on presentation
of proof of identity and share ownership, in the form and at the places indicated in the notice of the meeting, no less than 
5 days before the date of the General Meeting. The Board of Directors shall always have the option of reducing this period, but
only if it does so for all shareholders.
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All shareholders may be represented by their spouse or by another shareholder at all meetings. They may also vote by mail 
on the conditions stipulated by law.
The Company's bylaws state that all shareholders may also, if the Board of Directors so decides at the time the meeting is called,
participate in and vote at meetings by video-conference link or by any means of telecommunication that enables shareholders
to be identified on the conditions and using the methods stipulated by the legal provisions in force.
Voting rights
Each shareholder has as many votes as the number of shares he owns subject to the provisions below.
Under article 9 of the bylaws, double voting rights are assigned to each registered share that is fully paid and that has been 
registered in the name of the same shareholder for at least two years.
Double voting rights cease automatically for any share converted into a bearer share or transferred from one owner to another,
subject to exceptions laid down by law.
Bonus shares arising from an increase of share capital by incorporation of reserves, profits or share premium are entitled to
double voting rights as from the time of their issue if they are allotted on the basis of shares already benefiting from this entitlement.
Form and transfer of shares
Under articles 7 and 8 of the bylaws, the shares are registered or bearer shares, at the shareholder's discretion, under the conditions
established by applicable legal provisions.
The shares are freely negotiable.
Transfer of shares occurs by transfer from one account to another in accordance with the conditions laid down by law and regulations.
Identification of shareholders
The Company may at any time, in accordance with the law and regulations in force, request information from the securities clearing
body (name, date of birth or incorporation, nationality and address) that will identify holders of securities giving immediate or
future access to the right to vote at shareholders' meetings, together with the quantity of securities held by each and any restrictions
attached to such securities. 
Share ownership thresholds
Under article 7 of the bylaws, any individual or entity, acting alone or in concert, who acquires a number of shares representing
a proportion of the capital or of voting rights equal to or exceeding 1% of the share capital, or any multiple of this percentage,
in addition to the declaration thresholds laid down by legal and regulatory provisions, must inform the Company of the total number
of shares and voting rights held by such individual or entity and of any securities giving future access to the capital or voting rights
potentially attached to those shares. Notification is to be made by registered mail with advice of delivery within five stock
exchange days of the date on which the threshold was reached. The obligation to notify the Company also applies when the 
shareholder's interest in the capital or voting rights falls to a level below each of the above thresholds.
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GENERAL INFORMATION CONCERNING THE CAPITAL
Changes to the capital and to shareholders' rights
Changes to the share capital and to voting rights attached to the securities comprising the share capital are subject only to
legal provisions, the bylaws containing no specific provisions in this respect.
Share capital
As of December 31, 2002, the share capital was 1,464,735,014 euros, divided into 732,367,507 shares with a par value of 2 euros
each, fully paid and entitled to the same rights. Of these shares, 30,376,375 (i.e. 4.15% of the capital) were held by the Company
itself as treasury shares.
Capital authorized but not issued
Authorizations to increase the capital
The Combined General Meeting of Sanofi-Synthélabo shareholders held on May 22, 2002 authorized the Company, for a period
of 26 months, to increase its share capital by issuance of shares or other securities giving immediate or future access, at any time
or on a fixed date, to new shares in the Company by subscription, conversion, exchange, redemption, presentation of a warrant
or any other means, up to a maximum aggregate par value of 750 million euros.
Such issues may be made with shareholders' preemptive rights either maintained or canceled.
The General Meeting of May 22, 2002 authorized the Board of Directors to use these authorizations to increase the share capital
in the event of one or more public tender offers or public exchange offers for securities issued by the Company, during the period
of said offer. This authorization was granted for a period expiring at the end of the General Meeting held to approve the financial
statements for the year ended December 31, 2002. The shareholders will be asked to approve renewal of this authorization at
the Combined General Meeting to be held on May 19, 2003.
The General Meeting of May 22, 2002 also authorized the Board of Directors to increase the share capital on one or more
occasions by the incorporation of share premium, reserves, profits or other items, in the form of a bonus issue or an increase
in the par value of the existing shares or by a combination of these two methods. This authorization is valid for a period of 
26 months and for a maximum aggregate par value of 500 million euros.
The General Meeting of May 22, 2002 also authorized the Board of Directors to increase the Company's share capital on one
or more occasions by issuance of new shares or allotment of bonus shares or other securities giving access to the Company's
capital to the employees, early retirees or retirees of Sanofi-Synthélabo or of those French or foreign companies that are 
related to the Company under the law, where such employees, early retirees or retirees are members of a company or Group
employee savings plan or a long-term employee savings plan set up under article L.443-1-2 of the Labor Code, up to a limit
of 2% of the share capital as of the date of the said meeting, and for a period of 26 months with effect from the date of said
meeting. The preemptive rights of shareholders have been waived in favor of the aforementioned beneficiaries and the 
shareholders have also waived any rights to bonus shares or other securities giving access to the capital issued under the terms
of this authorization.
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The table below summarizes the current authorizations granted by the General Meeting of Sanofi-Synthélabo shareholders of
May 22, 2002 to issue securities giving access to the Company's capital.
Maximum Maximum Shareholders' Priority Period
aggregate aggregate preemptive subscription of
par value of par value of rights rights validity
immediate or issues
Nature of authorization future capital of debt
increases securities
potentially giving
resulting from access to
the issue the capital
(euros) (euros)
Issuance of shares and/or any  
other securities, including stand-alone
warrants, giving immediate or future 
access to the Company's capital by  
subscription, conversion, exchange,   
redemption, presentation of  (a) (c) yes – 26 months
a warrant or any other means (3) 750,000,000 (1) 7,000,000,000 (2)
Issuance of shares and/or any other 
securities, including stand-alone warrants, 
giving immediate or future access to 
the Company's capital by subscription,
conversion, exchange, redemption,  
presentation of a warrant or any
other means (3) / Issuance of shares
or securities representing a proportion  
of the Company's capital subsequent 
to the issuance by certain Group   
subsidiaries of bonds with attached 
warrants to subscribe for shares in the
Company or of other composite As decided
securities giving immediate or (b) (d) No by the Board
future access to shares in the Company  750,000,000 (1) 7,000,000,000 (2) of Directors 26 months
Capital increase by incorporation 
of reserves, profits or share premium, 
by allotment of bonus shares (e) 26 months
and/or an increase in par value 500,000,000 (4) – – –
Issuance of new shares reserved 
for employees belonging
to a company or Group employee 
savings plan or to a long-term (f) No 26 months
employee savings plan 29,284,259 (5) – –
(1) (a) and (b) are not cumulative: the maximum aggregate par value of immediate or future capital increases potentially arising from issues
that may be made with or without preemptive rights is 750,000,000 euros or the equivalent value of this sum in any other currency or 
currency unit established by reference to more than one currency.
(2) (c) and (d) are not cumulative: the maximum aggregate par value of debt securities giving immediate or future access to shares in the
Company that may be made with or without preemptive rights is 7,000,000,000 euros or the equivalent value of this sum in any other
currency or currency unit established by reference to more than one currency. However, this sum is cumulative with the maximum 
aggregate par value of 7,000,000,000 euros of ordinary bonds that may be issued under the authorization granted by the General Meeting
of May 22, 2001.
(3) The Board of Directors may make full or partial use, within the scope of the law, of this authorization in the event of one or more public
tender offers or public exchange offers for securities issued by the Company. Renewal of this authorization in the event of one or more public
tender offers or public exchange offers for securities issued by the Company will be put to the Combined General Meeting to be held on
May 19, 2003.
(4) (e) is cumulative with (a) and (b).
(5) (f) is cumulative with (a), (b) and (e).
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Other securities giving access to the capital
Stock options
The Combined General Meeting of Sanofi-Synthélabo shareholders held on May 18, 1999 authorized the Board of Directors for 
a 5-year period, to grant to members of the salaried staff and corporate officers of Sanofi-Synthélabo and of French or foreign
companies or groupings related to Sanofi-Synthélabo according to the definition contained in article 208-4 of the law of July 24,
1966 (now codified under article L.225-180 of the Commercial Code), as such members are designated by the Board of Directors,
options to subscribe for new Sanofi-Synthélabo shares to be issued by way of capital increases or options to buy existing shares 
acquired by Sanofi-Synthélabo as permitted by law. 
The total number of options granted may not result in the subscription or purchase of a quantity of shares exceeding 2% of the share
capital as of May 18, 1999, i.e. 14,611,740 shares.
The authorization entails express waiver, in favor of grantees of options to subscribe for shares, of the preemptive rights of 
shareholders in respect of shares issued as and when options are exercised.
The Board of Directors sets the terms on which options are granted and the arrangements as regards the dividend entitlement of
the shares and (where appropriate) payment for the shares.
The same meeting also approved the assumption of the undertakings made by Sanofi and Synthélabo respectively to grantees 
of options to subscribe for or purchase shares granted by these companies prior to the May 1999 merger.
This substitution automatically entails the unconditional waiver, in favor of the grantees of options to subscribe for shares, of the
preemptive rights of shareholders in respect of shares issued as and when options are exercised.
As of December 31, 2002, the potential number of shares liable to be issued as a result of the exercise of options to subscribe for
shares was 514,925.
The number of options still to be granted by the Board of Directors under the twenty-ninth resolution of the Combined General Meeting
of May 18, 1999 authorizing the Company to grant stock options is 4,271,390.
Full disclosures concerning the granting and exercise of stock options are provided on page 21 of the 2002 Business report, pages
109-111 of this report and in note D.12.6 to the consolidated financial statements on page 45 of this report.
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Changes in share capital through February 28, 2003
Date Capital Additional Number Transaction
paid-in capital of shares
As of Dec 31, 94 FRF 250,000 2,500 Incorporation
As of Dec 18, 98 250,000 F 5,000 2-for-1 stock split 
(FRF 50 shares)
As of Dec 31, 98 250,000 F 5,000 
As of May 18, 99 FRF 5,993,275,950
FRF 3,138,811,650 FRF 16,055,191,046 119,865,519 Sanofi capital contribution
FRF 1,906,786,645 62,776,233 Synthélabo capital  contribution
FRF (7,853,487,116) Deduction from share 
premium on merger
FRF 9,132,337,600 FRF 10,108,490,575 182,646,752 Sub-total post merger
730,587,008 4-for-1 stock split 
FRF 452,335,640 FRF (452,335,640) 730,587,008 Conversion into euros
FRF 9,584,673,240 FRF 9,656,154,935 Sub-total in French francs
EUR 1,461,174,016 EUR 1,472,071,330 Sub-total in euros
EUR 1,112,420 EUR 4,700,035 556,210 Capital increase by 
exercise of options to  
subscribe for shares
As of Dec 31, 99 EUR 1,462,286,436 EUR 1,476,771,365 731,143,218
EUR 597,056 EUR 2,439,128 298,528 Capital increase by 
exercise of options to  
subscribe for shares
As of Dec 31, 00 EUR 1,462,883,492 EUR 1,479,210,493 731,441,746
EUR 1,126,676 EUR 5,342,269 563,338 Capital increase by 
exercise of options to  
subscribe for shares
EUR (1,838) Deduction from merger  
premium (Laboratoires 
Synthélabo merger)
As of Dec 31, 01 EUR 1,464,010,168 EUR 1,484,550,924 732,005,084
EUR 724,846 EUR 3,495,454 362,423 Capital increase by 
exercise of options to 
subscribe for shares
EUR 90,104,605 Merger surplus  
(SaSy 3 merger)
As of Dec 31,02 EUR 1,464,735,014 EUR 1,578,150,983 732,367,507
EUR 77,182 EUR 484,703 38,591 Capital increase by 
exercice of options to
subscribe for shares
As of Feb 28,03 EUR 1,464,812,196 EUR 1,578,635,686 732,406,098
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OWNERSHIP OF SHARE CAPITAL AND VOTING RIGHTS
Changes in share ownership over the last three years
Situation as of Dec 31, 2002
Shareholder Number of shares % of capital % of voting rights*
TotalFinaElf 179,586,513 24.52 33.74
L’Oréal 143,041,202 19.53 26.87
Treasury shares 30,376,375 4.15 0
Employees 7,659,036 1.05 1.36
Public 371,704,381 50.75 38.03
Total 732,367,507 100 100
Situation as of Dec 31, 2001
Shareholder Number of shares % of capital % of voting rights**
TotalFinaElf 190,800,756 26.07 34.90
L’Oréal 143,041,202 19.54 26.17
Treasury shares 11,419,291 1.56 0
Employees 7,004,436 0.96 1.28
Public 379,739,399 51.87 37.65
Total 732,005,084 100 100
Situation as of Dec 31, 2000
Shareholder Number of shares % of capital % of voting rights***
TotalFinaElf 239,400,756 32.73 41.60
L’Oréal 143,041,202 19.55 26.35
Treasury shares 8,946,924 1.22 0
Employees 7,340,673 1.00 0.68
Public 332,712,191 45.50 31.37
Total 731,441,746 100 100
* Based on the total number of voting rights published subsequent to the Ordinary General Meeting of May 22, 2002, i.e. 1,064,540,103.
** Based on the total number of voting rights published subsequent to the Ordinary General Meeting of May 22, 2001, i.e. 1,093,320,462.
*** Based on the total number of voting rights published subsequent to the Ordinary General Meeting of May 24, 2000, i.e. 1,082,361,505.
The difference between the percentage of capital held and the percentage of voting rights held is due firstly to the existence 
of double voting rights and secondly to the existence of treasury shares which do not have voting rights.
During the year ended December 31, 2002, Sanofi-Synthélabo was informed by shareholders that the following share ownership
declaration thresholds had been passed: 
 Between November 22 and December 16, 2002 State Street Bank and Trust declared on several occasions that it had alternately
passed above and then below the legal threshold of 5% of the Company's capital on behalf of its clients. On December 16, 2002,
State Street Bank and Trust declared that as of that date it held 36,638,351 of the Company's shares, representing 
5.00% of the capital.
 After a number of declarations that it had passed below and above the thresholds of 2% and 1% of the share capital, Caisse des
Dépôts et Consignations (CDC) finally informed Sanofi-Synthélabo on December 10, 2002, that it had passed above the threshold
of 1% of voting rights, disclosure of which is required under the Company's bylaws. CDC declared that as of that date it held
11,184,536 of the Company's shares and voting rights, i.e. 1.52% of the capital and 1.05% of the voting rights issued.
 On June 7, 2002, Citigroup Inc. declared that companies belonging to its group had passed above the threshold of 
1% of the capital, disclosure of which is required under the Company's bylaws. As of that date, these companies held a 
combined total of 8,019,296 shares, i.e. 1.09% of the capital.
105
F i n a n c i a l ,  a d m i n i s t r a t i v e  a n d  l e g a l  a d d i t i o n a l  i n f o r m a t i o n
On February 13, 2003, Capital Group International, Inc., the American-registered parent company of a group of investment
management companies, filed a 13G declaration as required by the Securities and Exchange Commission (SEC) stating that it
held 6.7% of the Company's capital on behalf of clients.
The Company itself passed above the threshold of 5% of its own capital on February 20, 2003. As of February 28, 2003, it held
38,560,314 of its own shares, i.e. 5.26% of the capital.
As far as the Company is aware, no other shareholder owns 5% or more of the capital or voting rights. The identifiable 
bearer shares inquiry (“Titres au porteur identifiable”) carried out on December 31, 2002 revealed approximately 
28,000 shareholders. As far as we are aware, no Sanofi-Synthélabo shares have been pledged.
Shareholders' agreement 
L’Oréal and TotalFinaElf (the latter indirectly via Elf-Aquitaine) owned in concert 44.05% of the Company's capital and 
60.61% of its voting rights as of December 31, 2002. 
A shareholders' agreement between L'Oréal and Elf-Aquitaine was signed on April 9, 1999 for an initial term of six years with
effect from December 2, 1998. This agreement is described in the prospectus approved by the Commission des Opérations de
Bourse on April 15, 1999 as number 99-399. The Conseil des Marchés Financiers, in decisions dated November 27, 1998 (SBF
opinion no.98-4707 of December 7, 1998) and March 16, 1999 (SBF opinion no. 99-1083 of March 18, 1999) exempted 
Elf-Aquitaine and L'Oréal from the requirement to file a draft public tender offer for Sanofi-Synthélabo shares.
The main terms of this agreement are as follows:
Elf-Aquitaine and L'Oréal agreed not to sell during the entire term of the agreement any of the shares covered (19.4% of the
current share capital for each of the two companies). However, in the event of a public offer for the capital of Sanofi-Synthélabo,
Elf-Aquitaine and L'Oréal may together contribute all their shares covered by the agreement to such offer, or to any competing
or higher offer. If they fail to agree to contribute their shares together, either company may contribute the shares it owns which
are covered by the agreement subject to the prior written consent of the other, which will have preemptive rights over some or
all of the shares involved.
Disposals of shares covered by the agreement are exempted from the agreement not to sell provided such disposals do not
exceed 0.5% of the capital or voting rights of Sanofi-Synthélabo over a rolling 12-month period. Elf-Aquitaine and L'Oréal also
agreed to mutual preemptive rights applicable to all disposals to third parties of shares covered by the agreement during the
entire term of the agreement.
Elf-Aquitaine and L'Oréal agreed to ensure that the Board of Directors of Sanofi-Synthélabo be composed of twelve or eleven
members, split as follows:
– four or three members chosen from among candidates proposed by Elf-Aquitaine, depending on whether or not the 
Elf Aquitaine group's interest in the capital remains more than 3% greater than that of L'Oréal;
– three members chosen from among candidates proposed by L'Oréal;
– two executive directors;
– three independent members.
In practice, there has been a slight change in the composition of the Board of Directors with the full consent between 
Elf-Aquitaine and l’Oréal. (see page 16 of the 2002 Business report).
Elf-Aquitaine and L'Oréal agreed to consult one another in advance of any meeting of the Board of Directors and any General
Meeting of the shareholders of Sanofi-Synthélabo, and in advance of any important decision affecting the future prospects of
Sanofi-Synthélabo, with a view to establishing a common position or policy.
Elf-Aquitaine and L'Oréal have declared that they are acting in concert within Sanofi-Synthélabo. The two companies have
agreed not to increase their interest, either alone or acting in concert, in such a proportion that would require them to make 
a public offer for the capital of Sanofi-Synthélabo (currently 2% per rolling 12-month period).
Elf-Aquitaine and L'Oréal agreed not to put themselves in a position where they were acting in concert with a third party.
Shares held by the Elf-Aquitaine group which are unrestricted (i.e. they are not covered by the agreement) may be freely 
disposed of subject to certain conditions. 
The agreement is for an initial term of six years expiring December 2, 2004, and is automatically renewable.
The Conseil des Marchés Financiers has taken the view that in the event that the interest in the capital or voting rights held by
L'Oréal is likely to become greater than that held by Elf-Aquitaine due to the acquisition of shares by L'Oréal, including by the use
of its preemptive rights, it would be necessary to examine the consequences of such change in the balance of the concert-party
as regards the requirement to file a draft public offer.
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For a description of the L'Oréal and TotalFinaElf groups, refer to the registration documents (“documents de référence”) issued
by each of the two groups.
During the financial year, the interest held by the TotalFinaElf group, both directly and indirectly via Elf Aquitaine and its subsidiary
Valorisation et Gestion Financière, fell from 26.07% of the capital and 34.90% of the voting rights as of December 31, 2001
to 24.52% of the capital and 33.74% of the voting rights as of December 31, 2002.
Since the merger of Sanofi and Synthélabo into Sanofi-Synthélabo on May 18, 1999, TotalFinaElf, via Elf Aquitaine, 
has disposed of 10.8% of its holdings not covered by the agreement: 2.5% in September 2000, 2.3% in April 2001, 
and 6% between April 2001 and December 2002.  
Share repurchase program
During the year ended December 31, 2002, the Board of Directors used the authorization granted by the Combined General
Meetings of Sanofi-Synthélabo shareholders held on May 22, 2001 and May 22, 2002, in conformity with articles L.225-209 
et seq of the Commercial Code, to buy shares in the Company (prospectuses approved by the Commission des Opérations de Bourse
on April 19, 2001 as no. 01-402 and on April 19, 2002 as no. 02-421) in order to allocate shares to the stock purchase options of
the plan date May 22, 2002 and in the light of market conditions.
A total of 19,550,679 shares were bought at an average price of 60.57 euros per share. Of these, 16,520,795 were bought in the
light of market conditions and 3,029,884 to allocate shares to the stock purchase options plan dated May 22, 2002. During the
same period, 484,595 shares were sold to grantees of stock purchase options at an average price of 14.49 euros per share, and
109,000 shares were sold on the market at an average price of 59.29 euros.
At end December 2002, the Company held 30,376,375 of its own shares, representing 4.15% of the share capital. Of these,
13,836,580 shares were allocated to pre-existing stock purchase options plans.
Since the start of the 2003 financial year, Sanofi-Synthélabo has continued its share repurchase program in the light of market 
conditions. Under this program, the Company acquired 8,269,109 shares between January 1, 2003 and February 28, 2003, at an
average price of 49.56 euros. At the same time, it sold 85,170 shares to grantees of stock purchase option, at an average price of
21.36 euros. This took the number of treasury shares as of February 28, 2003 to 38,560,314 (5.26% of the capital), of which
13,711,760 are allocated to existing stock purchase options plans.
The Combined General Meeting of May 19, 2003 will be asked to renew the authorization to purchase, hold or transfer the
Company's shares for a period of eighteen months. Under this authorization, the quantity of shares purchased by the Company
may not exceed 10% of the shares comprising the capital of the Company, up to a maximum amount of 5,858,940,080 euros.
The quantity of shares held by the company at any time may not exceed 10% of the shares comprising the share capital of the
company. The maximum purchase price would be 80 euros per share, and the minimum selling price of treasury shares would be
20 euros, with the exception of shares resold to beneficiaries of certain stock purchase options plans, which may be sold at prices
between 6.01 euros and 69.94 euros. 
The objectives of this repurchase program would be the implementation of any stock purchase options plan, the purchase or sale
of the Company's shares in the light of market conditions, the regulation of the share price by systematic intervention in the 
market to counter price movements,  the implementation of any employee share purchase plan, the delivery of shares in connec-
tion with mergers or acquisitions, the delivery of shares on the exercise of rights attached to securities, the implementation of 
a capital and financial management policy (see pages 116-117 of this report).
Employee share ownership
The sums derived from voluntary and statutory employee profit-sharing schemes and from voluntary payments made by 
Sanofi-Synthélabo Group employees are invested in mutual funds established under the Sanofi-Synthélabo Group employee savings
scheme agreement signed on December 2, 1999 (see also “schemes for involving staff in the capital” below, page 112 of this
report). This plan is open to all employees. The profit-sharing entitlement of employees under voluntary and statutory schemes
can be paid into this plan. Employees may also make voluntary contributions to the plan. Of the five mutual funds set up under
the plan, one is wholly invested in Sanofi-Synthélabo shares in order to give all employees a greater stake in the Group's
growth. As of December 31, 2002, this fund owned 7,659,036 shares, i.e. 1.05% of Sanofi-Synthélabo's share capital.
107
F i n a n c i a l ,  a d m i n i s t r a t i v e  a n d  l e g a l  a d d i t i o n a l  i n f o r m a t i o n
Options to subscribe for shares and options to purchase shares have been granted to certain employees and corporate officers
of the Group (see page 21 of the 2002 Business report, pages 109-111 of this report and note D.12.6 to the consolidated
financial statements on page 45 of this report). 
Shareholder’s structure by geographic origin 
According to the identifiable bearer shares inquiry (“Titres au porteur identifiable”) and share ownership inquiry as of December
31, 2002, and after taking account of the 3% of unidentified bearers, French shareholders, excluding the reference 
shareholders TotalFinaElf and L'Oréal, Group employees and treasury shares represent about 14% of Sanofi-Synthélabo's share
capital ; mainly formed by institutional investors. Foreign shareholders represents about 32% of the capital; mainly 
formed by American institutional investors (16% of the capital) and English (6% of the capital).
MARKET IN SANOFI-SYNTHÉLABO SHARES
Places of listing
Sanofi-Synthélabo shares have been listed on the Premier Marché  of Euronext Paris since May 25, 1999.
Sanofi-Synthélabo shares are included in the CAC 40 index. As of December 31, 2002, Sanofi-Synthélabo had a weighting 
of 3.72% in this index, and a market capitalization of 42,660 million euros, the third largest on the Paris Bourse.
Since March 2, 2001, only 50% of the market capitalization of Sanofi-Synthélabo has been included in the calculation of the
CAC 40 index, as opposed to 100% previously. This change was made in order to limit the weighting of Sanofi-Synthélabo to
the portion of the capital not held by the Sanofi-Synthélabo’s reference shareholders also included in the CAC 40 index. Starting
from October 2003, only the free float will be taken into account when calculating the share's weighting in the CAC 40 index.
The Company's ordinary shares are traded under Sicovam code 12057.
Shares identified under Sicovam code 18197 are those arising from options to subscribe for shares exercised between January
1 of any one year and the payment date of the previous year's dividend. These shares are not entitled to the previous year's
dividend. After the payment date of the previous year's dividend (for example, June 2, 2003 for the 2002 dividend), shares with
Sicovam code 18197 are assimilated with those which have Sicovam code 12057.
Sanofi-Synthélabo shares have been included in the Dow Jones Euro Stoxx 50 index since September 20, 1999.
With effect from September 18, 2000, only the free float of Sanofi-Synthélabo's capital has been taken into account when
calculating the share's weighting in the Dow Jones Euro Stoxx 50 index, against 100% of the capital previously.
Sanofi-Synthélabo shares are an underlying asset for options traded on the Monep, the negotiable options market of 
the Paris Bourse.
With effect from July 1, 2002, Sanofi-Synthélabo shares have been listed on the New York Stock Exchange (NYSE) in the form
of American Depositary Receipts (ADRs). Sanofi-Synthélabo ADRs are listed under the "SNY" symbol and each represents
one-half of an ordinary share. No new shares were issued as a result of this listing. The Bank of New York acts as depositary
of the ADRs. 
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Stock market data - Euronext Paris
Transactions Price
Dates Number of Average  Share price in euros Closing share 
shares traded capital price of month
traded daily High Low in euros
(thousands 
of euros)
2001
July 43,967,660 143,176.9 78.10 66.50 71.80
August 44,189,006 138,108.2 75.80 65.80 72.05
September 52,353,808 188,083.8 77.40 65.15 71.50
October 45,259,025 145,944.3 80.40 69.25 73.25
November 41,610,991 143,711.8 79.20 71.10 77.40
December 31,172,347 135,461.0 86.50 73.80 83.80
2002
January 42,625,956 155,128.3 84.30 76.30 77.80
February 72,126,236 263,929.9 78.30 69.15 75.90
March 39,651,646 144,367.6 76.00 70.15 73.60
April 44,971,872 150,296.5 73.95 66.90 71.05
May 46,416,891 143,435.7 72.30 64.20 64.95
June 78,698,782 230,726.1 65.00 53.00 61.60
July 66,095,812 164,412.8 64.00 49.78 60.20
August 52,931,515 150,179.5 65.85 57.10 61.15
September 53,760,985 145,481.8 62.75 50.50 57.05
October 59,213,345 155,563.8 65.90 56.30 61.75
November 43,294,167 121,778.7 63.10 55.05 59.40
December 39,434,063 112,412.0 59.70 54.25 58.25
2003
January 62,195,736 145,467.6 59.50 44.60 48.65
February 57,305,226 134,036.4 49.90 41.60 49.62
Stock market data – New York Stock Exchange (ADRs*)
Transactions Price
Dates Number of Average ADR price in US dollars Closing ADR 
ADRs traded capital price of month
traded daily High Low in US dollars
(US dollars)
2002
July 2,430,590 3,164,656 31.55 24.90 29.30
August 1,795,689 2,521,329 32.80 28.50 30.40
September 2,187,991 3,103,498 30.55 25.35 28.50
October 1,707,892 2,225,523 31.58 28.05 30.40
November 991,091 1,469,447 31.65 27.94 29.30
December 1,079,091 1,507,484 30.70 27.72 30.40
2003
January 2,544,200 3,216,648 32.00 24.38 26.54
February 1,521,100 2,138,670 27.00 22.53 26.70
* Each ADR represents one-half of one ordinary share
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Administrative and management bodies
SHARES OWNED BY MEMBERS OF THE BOARD OF DIRECTORS AND OF THE EXECUTIVE
COMMITTEE
As of December 31, 2002, members of the Board of Directors(1) (other than corporate members) and members of the 
Sanofi-Synthélabo Executive Committee between them owned 329,464 shares, i.e. 0.04% of the capital, and 178,820 voting
rights for an ordinary general meeting (0.02%)(2) and 378,820 voting rights for an extraordinary general meeting (0.03%).
STOCK OPTIONS
Stock options granted to and exercised by corporate officers(3)
Stock options granted to Number of options Price Expires
and exercised by each granted/shares (in euros)
corporate officer subscribed for or bought 
Options granted to each corporate officer  
during the year by the issuer  
and any other Group company:
– Mr Jean-François Dehecq 145,000 69.94 May 22, 2012
– Mr Gérard Le Fur 70,000 69.94 May 22, 2012
Options exercised during the year 
by each corporate officer:
– Mr Jean-François Dehecq 60,000 21.46 Sept 22, 2004
– Mr Hervé Guérin 90,000 8.50 Dec 15, 2015
Stock options granted to the ten employees (other than corporate officers(3)) 
receiving the highest number of stock options, and stock options exercised by the
ten employees (other than corporate officers) exercising the highest number of options
Stock options granted to the 10 employees (other Total number of Weighted Expires
than corporate officers) receiving the highest number options granted/ average
of stock options, and stock options exercised by shares subscribed price
the 10 employees (other than corporate officers) for or bought (in euros)
exercising the highest number of options
Options granted during the year by the issuer   
(no options were granted by any other  
Group company), to the ten* employees  
of the issuer or of any other company included
in the scope of the stock option plans receiving
the highest number of stock options  273,000 69.94 May 22, 2012
Options relating to the shares of the issuer  
or of the aforementioned  companies exercised 
during the period by the ten employees of the issuer 
or of the aforementioned companies who bought 
or subscribed for the highest number of shares 101,580 11.44 –
*14 employees (due to some employees ranking equally)
(1)  Includes permanent representatives and observers
(2)  Takes account of shares subject to usufruct
(3)  Corporate officers comprises members of the Board of Directors, the Chairman and Chief Executive Officer and the Senior Executive Vice
President.
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History of stock options granted – outstanding plans
The table below shows all plans under which options were exercised in 2002, including those which ended during the year
either because the plan expiration date was reached or because all the options granted under the plan had been exercised.
However, plans which ended prior to 2002 are not shown.
Source Date of   Date of Options of which  of which 
General Board granted corporate  10 employees
Meeting Meeting officers* granted most 
options**
Synthélabo 06/28/90 12/15/93 364,000 130,000 104,000
Synthélabo 06/28/90 10/18/94 330,200 0 200,200
Synthélabo 06/28/90 12/15/94 49,400 0 49,400
Sanofi 05/21/92 09/20/95 1,056,000 44,000 167,640
Synthélabo 06/28/90 12/15/95 442,000 130,000 312,000
Synthélabo 06/28/90 01/12/96 208,000 0 52,000
Synthélabo 06/28/90 04/05/96 228,800 0 67,600
Sanofi 05/21/92 09/18/96 1,056,000 44,000 194,720
Sanofi 07/04/97 09/22/97 1,120,000 60,000 204,000
Synthélabo 06/28/90 10/14/97 262,080 0 165,360
Synthélabo 06/28/90 06/25/98 296,400 148,200 117,000
Sanofi 06/04/97 12/10/98 1,200,000 80,000 220,800
Synthélabo 06/23/98 03/30/99 716,040 0 176,800
Sanofi-Synthélabo 05/18/99 05/24/00 4,292,000 310,000 325,000
Sanofi-Synthélabo 05/18/99 05/10/01 2,936,500 145,000 286,000
Sanofi-Synthélabo 05/18/99 05/22/02 3,111,850 145,000 268,000
* Holding office as of the date of grant."Corporate officers" comprises members of the Board of Directors, the Chairman 
and Chief Executive Officer, and the Senior Executive Vice President
** Calculated as of the date of grant
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Start date Expiration Exercise price Options Options Options
of vesting date (in euros) exercised canceled outstanding
period as of in 2002
Dec. 31, 2002 
12/15/98 12/15/13 6.36 348,400 0 10,400
10/18/99 10/18/14 6.01 305,200 0 25,000
12/15/99 12/15/14 5.86 49,400 0 0
09/21/96 09/20/02 10.26 1,025,640 29,040 0
12/15/00 12/15/15 8.5 378,400 0 63,600
01/12/01 01/12/16 8.56 133,630 0 74,370
04/05/01 04/05/16 10.85 114,040 0 114,760
09/19/97 09/18/03 14.56 539,675 0 514,925
09/23/99 09/22/04 21.46 194,020 0 925,980
10/14/02 10/14/17 19.73 49,760 0 207,120
06/26/03 06/25/18 28.38 – 0 296,400
12/11/00 12/10/05 34.95 24,720 800 1,172,480
03/31/04 03/30/19 38.08 – 1,560 710,320
04/25/04 05/24/10 43.25 – 17,900 4,225,600
05/11/05 05/10/11 64.5 – 12,800 2,907,900
05/23/06 05/22/12 69.94 – 9,200 3,102,650
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RELATED-PARTY AGREEMENTS
Refer to the Special Report of the Statutory Auditors on page 65 of this report.
No new agreements relating to the current financial year have been entered into since January 1st, 2003.
SCHEMES FOR INVOLVING STAFF IN THE CAPITAL
Statutory and voluntary profit-sharing agreements
All employees of the French companies within the Sanofi-Synthélabo Group belong to voluntary and statutory profit-sharing
schemes.
Voluntary scheme (“Intéressement des salariés”):
These schemes are optional for the employer. The aim is to give employees an interest in the growth of the business and 
improvements in its performance. It must be a collective scheme and must be contingent upon performance.
On March 18, 2000, Sanofi-Synthélabo signed a 3-year Group-wide agreement covering the years 2000, 2001 and 2002, and
based on growth in the Group's consolidated net income. This Group-based component may be supplemented by a component
linked to the performance or activities of individual subsidiaries.
In 2002, the Group-based component amounted to 14,054,538 euros, compared with 23,687,288.30 euros for 2001 and
24,853,024 euros for 2000.
Statutory scheme (“Participation des salariés aux résultats de l’Entreprise”):
This scheme is a French legal obligation for businesses with more than 50 employees which made a profit during the previous
year. Employees are entitled to a share of the profit for the year based on the relevant provisions of the Labor Code.
On June 28, 2001, Sanofi-Synthélabo signed a 2-year Group-wide agreement covering the years 2001 and 2002. For 2002, 
the gross amount of the special statutory profit-sharing reserve was 49,376,009 euros, compared with 50,615,617 euros in
2001 and 33,673,804 euros in 2000.
Combined General Meeting of May 19, 2003
AGENDA
Ordinary business
 Approval of the individual company financial statements for the year ended December 31, 2002.
 Approval of the consolidated financial statements for the year ended December 31, 2002.
 Appropriation of profits; declaration of dividend.
 Approval of transactions covered by the Statutory Auditors' Special Report prepared in accordance with article L.225-40 
of the Commercial Code.
 Appointment of member of Board of Directors.
 Authorization to the Board of Directors to purchase, hold and transfer the company's own shares.
Extraordinary business
 Delegation to the Board of Directors to increase the share capital by issuance of shares and/or other securities giving imme-
diate or future access to the company's shares in the event of public offers for the company's securities.
 Amendments to the bylaws.
 Powers for the accomplishment of formalities.
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REPORT OF THE BOARD OF DIRECTORS 
Resolutions submitted to the General Meeting of May 19, 2003
(This text is a free translation from the French language and is supplied solely for information purposes. Only the original
version in the French language has legal force.)
A. Ordinary business
Approval of financial statements  
(1st and 2nd resolutions)
The 1st resolution requests your approval of the individual
company financial statements.
In accordance with law 2001-420 of May 15, 2001 (article
L.225-100 paragraph 3 of the Commercial Code), we are
requesting in the 2nd resolution that you approve the 
consolidated financial statements for the year ended
December 31, 2002.
Appropriation of profits; 
declaration of dividend (3rd resolution)
The profit for the year amounts to 1,322,602,139.11 euros.
We propose deducting from this profit the sum of 72,484.60
euros, corresponding to a portion of the long-term capital gains
arising in the year, and transferring it to the legal reserve.
The distributable profit for the year of 1,322,529,654.51 euros,
plus retained earnings brought forward of 369,262,618.92 euros,
gives total distributable profits of 1,691,792,273.43 euros, which
it is proposed to appropriate as follows:
 to the long-term capital 
gains reserve 878,169,310.13 euros
 to the payment of dividend 615,188,705.88 euros
 to be carried forward as 
retained earnings 198,434,257.42 euros
If you accept these proposals, each of the 732,367,507 shares
comprising the share capital as at December 31, 2002 will
receive a net dividend of 0.84 euros accompanied by a tax
credit of 0.42 euros (50% rate) taking the total income per
share to 1.26 euros, or of 0.08 euros (10% rate) taking the
total income per share to 0.92 euros.
This dividend will be paid on June 2, 2003.
The per share amount of dividend, tax already paid to the
French Treasury (tax credit) and total income for the
previous three financial years is as follows:
Year Net dividend Tax already income Tax already paid Total
paid paid total (tax credit) income
(euros) (tax credit) (euros) (Rate: 40% in 1999, (euros)
(Rate: 50%) 25% in 2000,
(euros) 15% in 2001)
(euros)
1999 0.32 0.16 0.48 0.13 0.45
2000 0.44 0.22 0.66 0.11 0.55
2001 0.66 0.33 0.99 0.10 0.76
The Meeting is also requested to authorize the company to
transfer to retained earnings the amount of 2002 dividend
relating to shares owned by the company itself as of the
payment date of the dividend.
Appointment of a member of the Board of Directors 
(5th resolution)
We propose that you appoint Mr Gérard Van Kemmel as 
a member of the Board of Directors to serve for a period of 
five years in accordance with article 11 of the bylaws.
Authorization to the Board of Directors to purchase,
hold and transfer the company's own shares 
(6th resolution)
You are also requested to authorize the company to purchase,
hold and transfer its own shares in accordance with articles
L.225-209 et seq of the Commercial Code.
The conditions under which such purchases and transfers
may be made are described in the prospectus submitted to
the Commission des Opérations de Bourse for approval, 
a copy of which has been available to the shareholders at
the registered office for the period required by law.
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Delegation to the Board of Directors of powers to
increase the share capital by the issuance of shares
and/or other securities giving immediate or future
access to shares in the company in the event of a
public offer for the company's shares (7th resolution)
This resolution proposes that you allow the Board of Directors,
as permitted by law, to continue making use of the powers
to issue securities with or without preemptive rights as granted
by the 8th and 9th resolutions of the Combined General
Meeting of May 22, 2002 in the event that one or more
public tender offers or public exchange offers for securities
issued by the company occurs between the date of the 
present Meeting and the Meeting held to approve the 
financial statements for the year ending December 31, 2003.
The Board is resubmitting this resolution to you this year
because the similar resolution passed at the General Meeting
of May 22, 2002 lapses by law at the present Meeting (article
L.225-129 of the Commercial Code).
In accordance with the regulations governing capital increases,
the Board of Directors has reported to you on the company's
affairs since the start of the current accounting period in its
management report covered in the ordinary business of 
this Meeting.
If the Board of Directors were to use the delegation to be
granted by the 7th resolution, it would prepare as required
and in accordance with the law, at the time of its decision,
a supplementary report describing the final terms of the issue
and indicating the impact of the issue on the position of the
shareholder, and in particular on the shareholder's interest in
the company's net assets. This report, together with that of
the Statutory Auditors, would be made available to 
shareholders immediately, and then brought to their atten-
tion at the next General Meeting.
Amendments to the bylaws (8th resolution)
You are asked, as regards the offices of Chairman or
Chairman and Chief Executive Officer, to approve the raising
of the age limit to 68 and the consequent amendment 
of article 12 paragraph 1 and article 16 paragraph 3 of 
the bylaws.
B. Extraordinary business
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First resolution
Approval of the individual company financial statements
for the year ended December 31, 2002.
The General Meeting, voting on the quorum and majority
conditions for Ordinary Meetings, having reviewed the
Directors' Report and the Statutory Auditors' report, approves
all parts of these reports and the individual company financial
statements for the year ended December 31, 2002 as presen-
ted and closed, showing a profit of 1,322,602,139.11 euros.
Second resolution
Approval of the consolidated financial statements for
the year ended December 31, 2002.
The General Meeting, voting on the quorum and majority
conditions for Ordinary Meetings, having reviewed the
Directors' Report and the Statutory Auditors' report, approves
all parts of these reports and the consolidated financial state-
ments for the year ended December 31, 2002 as presented
and closed.
Third resolution
Appropriation of profits; declaration of dividend.
The General Meeting, voting on the quorum and majority
conditions for Ordinary Meetings, resolves to deduct from 
the profit for the year of 1,322,602,139.11 euros the sum of
72,484.60 euros corresponding to a fraction of the long-term
capital gains arising in the year and to transfer this sum to 
the legal reserve.
The Meeting notes that:
 distributable profits for the year of €1,322,529,654.51
 plus retained earnings of €369,262,618.92
gives total distributable profits of €1,691,792,273.43
and resolves to appropriate this sum as follows:
 to the long-term capital gains reserve €878,169,310.13
 to the payment of dividend €615,188,705.88
 to be carried forward as retained earnings €198,434,257.42
Consequently, each of the 732,367,507 shares comprising the
share capital as at December 31, 2002 will receive a net dividend
of 0.84 euros. To this will be attached, under the conditions
stipulated by the legislation in force, a right to reimbursement
of the tax already paid to the French Treasury (tax credit) of
0.42 euros (50% rate), taking the total income per share to
1.26 euros, or of 0.08 euros (10% rate) taking the total income
per share to 0.92 euros.
This dividend will be paid on June 2, 2003.
If the company holds any of its own shares as of the payment
date of the dividend, the proportion of distributable profits not
distributed as a result of the company holding its own shares will
be appropriated to retained earnings.
PROPOSED RESOLUTIONS
Ordinary business
(This text is a free translation from the French language and is supplied solely for information purposes. Only the original 
version in the French language has legal force.)
The per share amount of dividend, tax already paid to the French Treasury (tax credit) and total income for the previous three
financial years is as follows:
Year Net dividend Tax already paid Total Tax already paid Total
paid (tax credit) income (tax credit) income
(euros) (Rate: 50%) (euros) (Rate: 40% in 1999 (euros)
(euros) 25% in 2000,
15% in 2001)
(euros)
1999 0.32 0.16 0.48 0.13 0.45
2000 0.44 0.22 0.66 0.11 0.55
2001 0.66 0.33 0.99 0.10 0.76
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Fourth resolution
Approval of transactions covered by the Statutory
Auditors' Special Report prepared in accordance with
article L.225-40 of the Commercial Code.
The General Meeting, voting on the quorum and majority condi-
tions for Ordinary Meetings, having reviewed the Statutory
Auditors' Special Report on agreements covered by articles
L.225-38 et seq of the Commercial Code entered into and 
performed during the year, approves all parts of this report and
the agreements described therein.
Fifth resolution
Appointment of member of Board of Directors.
The General Meeting, voting on the quorum and majority
conditions for Ordinary Meetings, and in accordance with
article 11 of the bylaws, appoints Mr Gérard Van Kemmel as
a member of the Board of Directors to serve for a period 
of five years, in other words until the General Meeting held
to approve the financial statements for the year ending
December 31, 2007.
Sixth resolution
Authorization to the Board of Directors to purchase,
hold, and transfer the company's own shares.
The General Meeting, voting on the quorum and majority 
conditions for Ordinary Meetings, having reviewed the 
Directors' Report and the prospectus approved by the
Commission des Opérations de Bourse, authorizes the Board of
Directors, in accordance with articles L.225-209 et seq of the
Commercial Code, to buy and sell the company's shares; the
objectives of this program would be, in the following order of
priority: 
 the implementation of any stock option plan under the terms
of the twenty-ninth resolution of the Combined General Meeting 
of May 18, 1999, which set the number of shares that could 
be bought as a result of employees exercising options to
purchase shares at 2% of the capital as of May 18, 1999,
i.e. 14,611,740 shares, of which 10,340,350 have already 
been utilized;
 the purchase or sale of the company's shares in the light of
market conditions; 
 the regulation of the share price by systematic intervention in
the market to counter price movements; 
 the implementation of any employee share purchase plan under
the conditions stipulated by law, in particular articles L.443-1 et
seq of the Labor Code;
 the delivery of shares (in exchange, as payment, or otherwise)
in connection with mergers or acquisitions;
 the delivery of shares on the exercise of rights attached to 
securities giving entitlement to the allotment of shares in the
company, whether by redemption, conversion, exchange, 
presentation of a warrant or any other means;
 the implementation of a capital and financial management
policy to include the holding, sale and more generally transfer
of such shares, together with the possibility of canceling some
or all of the shares repurchased in this way, on the terms set by
the thirteenth resolution of the Combined General Meeting of
May 22, 2002. 
The quantity of its own shares purchased by the company will be
subject to the following restrictions:
 the quantity of shares acquired by the company during the
repurchase program may not exceed 10% of the shares 
comprising the share capital, which, as an indication, represents
73,236,751 shares as at December 31, 2002;
 the quantity of shares held by the company at any time may not
exceed 10% of the shares comprising the share capital of the
company.
Acquisitions, sales and transfers of shares may be accomplished
at any time (including during a public offer period) by any
means, on the stock market or over the counter, including by
block purchases or sales (with no limit on the portion of the
share repurchase program that can be carried out by this
means), the use of options or other derivatives traded on a
regulated or over the counter market, or the implementation
of options strategies. The Board of Directors shall ensure that
mechanisms are not used that increase significantly the 
volatility of the share. 
The maximum purchase price would be 80 euros per share (or
the equivalent value of this amount as at the same date in any
other currency), such maximum price being applicable only to
acquisitions on which a decision is taken on or after the date
of the present Meeting and not to forward deals concluded
by virtue of an authorization given by a previous General
Meeting in anticipation of share acquisitions subsequent to
the date of the present Meeting.
In the event of a resale on the market, the minimum selling
price of treasury shares acquired in connection with share
repurchase programs authorized by the present or previous
General Meetings would be 20 euros per share (or the 
equivalent value of this amount as at the same date in any
other currency), with the exception of shares resold to 
beneficiaries of certain stock option plans, which may be sold
at prices between 6.01 and 69.94 euros, such price being 
applicable both to transfers on which a decision is taken on or
after the date of the present Meeting and to forward deals
concluded previously in anticipation of share transfers 
subsequent to the present Meeting.
117
F i n a n c i a l ,  a d m i n i s t r a t i v e  a n d  l e g a l  a d d i t i o n a l  i n f o r m a t i o n
The maximum amount that the company is authorized to pay
for the purchase of its own shares is 5,858,940,080 euros. 
This authorization voids with effect from this day any unused
portion of any previous delegation to the Board of Directors by
virtue of the seventh resolution of the General Meeting of May
22, 2002 of authority to purchase, hold and transfer the shares
of the company. It is granted for a period of eighteen months
from this day.
The General Meeting delegates to the Board of Directors powers
to adjust the aforementioned purchase and selling prices in
the event of a change in the par value of the shares, increase
in share capital by incorporation of reserves, bonus issue of
shares, consolidation of shares, distribution of reserves or of
any other assets, redemption of capital, or any other transaction
affecting shareholders' equity, so as to take account of the
impact on the value of the shares. The General Meeting confers
full powers on the Board of Directors, with authority to sub-
delegate within the law, to decide on and implement the 
present authorization and if necessary to specify the conditions
and determine the terms thereof, with authority to delegate,
within the law, the execution of the share repurchase program,
and in particular to place stock market orders, enter into agree-
ments, arrange for the keeping of registers of purchases and
sales of shares, make declarations to the Commission des
Opérations de Bourse, the Conseil des Marchés Financiers or
any other authority that may substitute for them, accomplish
all formalities and generally do all that is necessary. 
Extraordinary business
Seventh resolution
Delegation to the Board of Directors to increase the share
capital by issuance of shares and/or other securities giving
immediate or future access to the company's shares in the
event of public offers for the company's securities.
The General Meeting, voting on the quorum and majority 
conditions for Extraordinary Meetings, having reviewed the
Directors' Report , authorizes the Board of Directors to make full
or partial use, within the scope of the law, of the authorizations
given to the Board of Directors by the eighth and ninth resolu-
tions of the Combined General Meeting of May 22, 2002 to
increase the share capital by issuance of the shares or other 
securities mentioned in said resolutions in the event of one or
more public tender offers, public exchange offers, or any other
form of public offer in compliance with the applicable law and
regulations, for securities issued by the company, during the
period of said offer.
The present authorization is given for a period expiring at the end
of the Meeting held to approve the financial statements for the
year ending December 31, 2003.
Eighth resolution
Amendments to the bylaws.
The General Meeting, voting on the quorum and majority condi-
tions for Extraordinary Meetings, having reviewed the Directors'
Report, resolves that as regards the offices of Chairman 
or Chairman and Chief Executive Officer, the age limit should 
be raised to 68, and that article 12 paragraph 1 and article 
16 paragraph 3 of the bylaws should be amended accordingly.
Article 12 – Chairman and Vice-Chairman of the Board
of Directors
Paragraph 1 
The Board of Directors shall elect from among its members 
a Chairman, who must be a natural person less than 68 years 
of age.
Article 16 - Management 
Paragraph 3
If the executive management of the company is conducted 
by the Chairman, the provisions contained in the law and 
regulations and in the bylaws relating to the Chief Executive
Officer shall apply to him except for those concerning the age
limit. He shall take the title of Chairman and Chief Executive
Officer and shall hold office until the age of 68.
Ninth resolution
Powers for the accomplishment of formalities.
The General Meeting, voting on the quorum and majority 
conditions for Extraordinary Meetings, confers full powers on
the bearer of an original, copy or extract of the minutes of its 
deliberations to carry out any filings or formalities required by law.
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Persons responsible and declarations 
Persons responsible for the registration document (“document de référence”)
Jean-François Dehecq, Chairman and Chief Executive Officer of Sanofi-Synthélabo.
Declaration
"To the best of my knowledge, the data contained in the present registration document are accurate and include all the 
information necessary for investors to form a judgement on the net assets, operations, financial position, results and prospects
of Sanofi-Synthélabo; they do not contain any omission liable to alter the import of the document".
Paris, April 22, 2003
Jean-François Dehecq
Chairman and Chief Executive Officer of Sanofi-Synthélabo
Persons responsible for the audit of the financial statements
Statutory auditors
1) Ernst & Young Audit, represented by Mr Dominique Thouvenin and Mrs Valérie Quint 
4, rue Auber – 75009 Paris
– appointed April 28, 1994
– reappointed at the General Meeting of May 24, 2000
– term of office expires at the end of the General Meeting held to approve the financial statements for the year ended 
December 31, 2005
2) PricewaterhouseCoopers Audit, represented by Mr Jacques Denizeau and Mr Jean-Christophe Georghiou
32, rue Guersant – 75017 Paris
– appointed March 12, 1999
– term of office expires at the end of the General Meeting held to approve the financial statements for the year ended 
December 31, 2004
Deputy statutory auditors
1) Mr Bruno Perrin
100 rue Raymond Losserand – 75014 Paris
– appointed March 12, 1999(1)
– reappointed at the General Meeting of May 24, 2000
– term of office expires at the end of the General Meeting held to approve the financial statements for the year ended
December 31, 2005
2) Mr Pierre Coll
11 rue Marguerite – 75017 Paris
– appointed May 22, 2001(2)
– term of office expires at the end of the General Meeting held to approve the financial statements for the year ended 
December 31, 2004
(1) Mr Bruno Perrin was appointed to replace the previous deputy statutory auditor to Ernst & Young Audit for the previous deputy statutory
auditor's remaining term of office.
(2) Mr Pierre Coll was appointed to replace the previous deputy statutory auditor to PricewaterhouseCoopers Audit for the previous deputy
statutory auditor's remaining term of office.
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Opinion of the statutory auditors on the registration document (“document de référence”).
In our capacity as statutory auditors of Sanofi-Synthelabo and in compliance with the COB Regulation n° 98-01, we have 
verified, in accordance with French professional standards, the information in respect of the financial position and historic 
financial statements included in the accompanying registration document (“document de référence”).
This registration document is the responsibility of the Chairman-Chief Executive Officer. Our responsibility is to issue an opinion
on the fairness of the information contained therein with respect to the financial position and financial statements. 
We conducted our review in accordance with French professional standards. This review consisted in assessing the fairness of the
information on the financial position and financial statements and to verify their consistency with the audited accounts. We also
reviewed other financial information contained in the registration document in order to identify any significant inconsistency
with information in respect of the financial position and financial statements and to bring to your attention any obvious 
misstatements we noted based on our general understanding of the company gained through our audit. As the prospective
information has been properly prepared, our review took into account Management's assumptions on which the prospective
information is based.
We conducted an audit in accordance with French professional standards on the annual and consolidated accounts for the years
ended December 31, 2002, 2001 and 2000, drawn up by the Board of Directors.
We issued an unqualified opinion on the annual and consolidated accounts for the years ended December 31, 2001 and 2000.
Without qualifying our opinion on the annual and consolidated accounts for the year ended December 31, 2002, we drawn the
attention to note B2 to the consolidated financial statements, which present the impact on the consolidated financial statements
of the change in accounting method resulting from the application, with effect from January 1, 2002, of the new CRC rule 
2000-06 on liabilities.
We have nothing to report with respect to the fairness of the information on the financial position and financial statements
contained in the registration document (“document de référence”).
Paris, April 22, 2003 
The Statutory Auditors
Ernst & Young Audit PricewaterhouseCoopers Audit
Dominique Thouvenin Valérie Quint Jacques Denizeau Jean-Christophe Georghiou
Person responsible for financial information 
Individual and institutional shareholders, and financial analysts, are welcome to contact the Investor Relations Department with
any questions.
Contact: Mr Philippe Goupit
Investor Relations Department
Tel.: +33 (0)1.53.77.45.45
Toll-free (France): 0800.07.58.76
e-mail: investor-relations@sanofi-synthelabo.com
Address: 174, avenue de France - 75013 Paris, France
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Registration document (“document de référence”) checklist
The registration document checklist below sets out the main headings specified in the Instruction of December 2001, issued
in application of regulation 98-01 of the Commission des Opérations de Bourse, and refers users to the corresponding pages
of the "Business report 2002" and "Financial report 2002" brochures, together constituting the Annual Report, which has 
registration document status.
Items required under COB regulation 98-01 Relevant page of annual report 
with registration document status
2002 Business 2002 Financial 
report report
Chapter I 
Person responsible for the registration document and persons responsible 
for the audit of the financial statements
1.1 Name and position of the person responsible for the registration document - 118
1.2 Declaration by the person responsible for the registration document - 118
1.3 Persons responsible for the audit of the financial statements - 118
1.4 Opinion of the statutory auditors on the registration document - 119
1.5 Information policy 14-15 119
Chapter III 
General information concerning the Company and its capital
3.1 General information concerning the Company - 97-99
3.2 General information concerning the capital - 100-103
3.3 Current ownership of capital and voting rights - 104-107
3.4 Market in the Company's securities 10-13 107-108
3.5 Dividends 13 12
Chapter IV 
Information concerning the Company's activities
4.1 Presentation of the Company and the Group 22-88 87
4.2 Dependency of the Company - 16, 91
4.3 Employees 79 14-15
4.4 Investment policy 67 41
4.5 Risk factors for the issuer and Insurance - 89-96
Chapter V
Assets and liabilities – Financial position – Profits and losses - 1-86
5.1 Financial statements of the issuer - 25-86
5.2 Fees charged to the Group for services provided by the statutory auditors - 23
Chapter VI 
Administrative and management bodies
6.1 Composition and operation of administrative  and management bodies, corporate governance 16-20
6.2 Interest of members of administrative and management bodies 16, 21 13, 14, 109-111
in the issuer's capital, compensation of corporate officers and stock options plans
6.3 Description of schemes for involving staff in the capital - 102, 106, 109
Chapter VII
Recent developments and prospects
7.1 Recent developments * -
7.2 Prospects 5, 13 11
COB

The present registration document was filed with the Commission des Opérations de Bourse on 04/23/2003, in accordance with regulation 
98-01. It may be used to support a financial operation if supplemented by a prospectus registered with the Commission des Opérations 
de Bourse.
* Interleaf at the start of the 2002 Business report.
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